source_id@collection_memberships.#1@collection_memberships.#2@collection_memberships.#3@collection_memberships.#4@collection_memberships.#5@subscription.#1@subscription.#2@subscription.#3@subscription.#4@subscription.#5@Acronym@Administration@Asset_Classification@ONCO_ATC_Code@ATC_Level3@Black_Box@Company_HQ@Completion_Date@Current_Status@Drug_Description@Drug_Type@DynamicObjectID@ONCO_Full_Indication@Gender@ONCO_Hospital_Status@HTA_Decision_Date.RawValue@HTA_Decision_Date.Value@ICER_QALYs@Intervention@Intervention_Type@Length_Of_Trial@Level_Of_Reimbursement@Licensing_Status@Line_Of_Therapy@NCT_Code@No_Of_Patients@Official_Dosage@ONCO_Approval_Date.RawValue@ONCO_Approval_Date.Value@ONCO_Marketing_Date@ONCO_Orphan_Drug@Breakthrough_Therapy@ONCO_Start_Date@ONCO_Warnings@Other_IDs@ONCO_Parallel_Import@Patent_Expiration@Patient_Description@Patient_Profile@Patient_Profile_Age_Groups@Phase_Of_Trial@Portfolio_Pipeline_Status@ONCO_Regulatory_Submission_Date@Reimbursement_Guidance@Reimbursement_Plan@Results_Efficacy@Results_Safety_and_Adverse_Events@Sponsors@Study_Funded_By@ONCO_Therapeutic_Class@Type_Of_Therapy@API.#1@API.#2@API.#3@API.#4@API.#5@API_KEY@ONCO_Company.#1@ONCO_Company.#2@ONCO_Company.#3@ONCO_Company.#4@ONCO_Company.#5@ONCO_Company_KEY@Country_Clinical_Trial.#1@Country_Clinical_Trial.#2@Country_Clinical_Trial.#3@Country_Clinical_Trial.#4@Country_Clinical_Trial.#5@Country_Clinical_Trial_KEY@Disease_Area.#1@Disease_Area.#2@Disease_Area.#3@Disease_Area.#4@Disease_Area.#5@Disease_Area_KEY@Drug.#1@Drug.#2@Drug.#3@Drug.#4@Drug.#5@Drug_KEY@Drug_Class.#1@Drug_Class.#2@Drug_Class.#3@Drug_Class.#4@Drug_Class.#5@Drug_Class_KEY@Primary_Endpoint.#1@Primary_Endpoint.#2@Primary_Endpoint.#3@Primary_Endpoint.#4@Primary_Endpoint.#5@Secondary_Endpoints.#1@Secondary_Endpoints.#2@Secondary_Endpoints.#3@Secondary_Endpoints.#4@Secondary_Endpoints.#5@Stage_Of_Disease.#1@Stage_Of_Disease.#2@Stage_Of_Disease.#3@Stage_Of_Disease.#4@Stage_Of_Disease.#5@Trial_Design.#1@Trial_Design.#2@Trial_Design.#3@Trial_Design.#4@Trial_Design.#5@Assumption_value@Assumption_unit@ATC_Calculation_attempt@Average_Annual_Cost@Average_Cost_Per_Treatment_Cycle@Average_Duration_of_Use.Value@Average_Duration_of_Use.Unit@Average_Duration_of_Use.Comment@Average_Treatment_Cost.RawValue@Average_Treatment_Cost.Value@Cost_Per_Day@Number_of_Units@ONCO_Exchange_Rate@Factory_Price@Retail_Price@Wholesale_Price@PriceTimestamps.ManufacturerPriceDelta.TimeStamp@PriceTimestamps.ManufacturerPriceDelta.ValueChange@PriceTimestamps.ManufacturerPriceDelta.PercentageChange@PriceTimestamps.WholesalerPriceDelta.TimeStamp@PriceTimestamps.WholesalerPriceDelta.ValueChange@PriceTimestamps.WholesalerPriceDelta.PercentageChange@PriceTimestamps.RetailerPriceDelta.TimeStamp@PriceTimestamps.RetailerPriceDelta.ValueChange@PriceTimestamps.RetailerPriceDelta.PercentageChange@Price_Per_MG@Treatment_Phase_1.Cycle_Duration@Treatment_Phase_1.Cycle_Repetition@Treatment_Phase_1.Dosage_Unit@Treatment_Phase_1.Dosage_Value@Treatment_Phase_1.Treatment_Duration@Treatment_Phase_2.Cycle_Duration@Treatment_Phase_2.Cycle_Repetition@Treatment_Phase_2.Dosage_Unit@Treatment_Phase_2.Dosage_Value@Treatment_Phase_2.Treatment_Duration@Treatment_Phase_3.Cycle_Duration@Treatment_Phase_3.Cycle_Repetition@Treatment_Phase_3.Dosage_Unit@Treatment_Phase_3.Dosage_Value@Treatment_Phase_3.Treatment_Duration@Price_Date@ONCO_Price_per_Unit.RawValue@ONCO_Price_per_Unit.Value@Import_Id@Form@Currency@Active_Ingredients.Original.Active_Ingredient@Active_Ingredients.Original.Input_Language@Active_Ingredients.Original.Active_Ingredient_Translated@Active_Ingredients.Original.Volume@Active_Ingredients.Original.Volume_Unit@Active_Ingredients.Original.Dose@Active_Ingredients.Original.Dose_Unit@Active_Ingredients.Original.Strength@Active_Ingredients.Original.Strength_Unit@Active_Ingredients.Original.Strength_Comment@Active_Ingredients.Original.DDD@Active_Ingredients.Original.DDD_Unit@Active_Ingredients.Original.DDD_Comment@Active_Ingredients.Extracted.Active_Ingredient_Item.#1@Active_Ingredients.Extracted.Active_Ingredient_Item.#2@Active_Ingredients.Extracted.Active_Ingredient_Item.#3@Active_Ingredients.Extracted.Active_Ingredient_Item.#4@Active_Ingredients.Extracted.Active_Ingredient_Item.#5@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#1@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#2@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#3@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#4@Active_Ingredients.Extracted.Active_Ingredient_Item_Translated.#5@Active_Ingredients.Extracted.Strength_Item.#1@Active_Ingredients.Extracted.Strength_Item.#2@Active_Ingredients.Extracted.Strength_Item.#3@Active_Ingredients.Extracted.Strength_Item.#4@Active_Ingredients.Extracted.Strength_Item.#5@Active_Ingredients.Extracted.Strength_CALC@Active_Ingredients.Extracted.Strength_unit@Active_Ingredients.Extracted.Strength_value@Active_Ingredients.Extracted.DDD@TimeStamp@geographic_location.#1.row_id@geographic_location.#1.name@geographic_location.#2.row_id@geographic_location.#2.name@geographic_location.#3.row_id@geographic_location.#3.name@geographic_location.#4.row_id@geographic_location.#4.name@geographic_location.#5.row_id@geographic_location.#5.name
14923503@Onco@@@@@@@@@@@The patients receive the IVIG calculated as 1g/kg/bodyweight per cycle (defined as every 21 days) until progression disease is noted. All patients are being followed for a period of 6 months after patient's withdrawal. SOURCE: clinical.trials.gov@@-@-@-@-@@@@@14923503@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00294476@30@-@-@@@-@@7/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GAMMACAN@@@@@GAMMACAN||||@Israel@@@@@Israel|||||||||@Melanoma / Skin Cancer@Prostate Cancer@Colorectal Cancer@@@Melanoma / Skin Cancer|Prostate Cancer|Colorectal Cancer|||||||@GCAN-01@@@@@GCAN-01||||@Immunotherapy@@@@@Immunotherapy||||@RECIST@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924833@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924833@-@@-@-@@NO REVIEW@@@@-@Macrochem acquired Virium. SOURCE: Virium, 28 April 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@MACROCHEM CORP@VIRIUM PHARMACEUTICAL@@@@MACROCHEM CORP|VIRIUM PHARMACEUTICAL|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@VP-101@EL-532@@@@VP-101|EL-532|||@HDAC@@@@@HDAC||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15041413@Onco@@@@@300f1020ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15041413@@@NO@@@NO REVIEW@@@@100%@@@@@@N/A@@@@@@@@No@@@@@@APPROVED@@@SSN@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMACEUTICALS@@@@@CHUGAI PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@79.39@131.02@82.96@@@@@@@@@@@@@@@@@@@@@@@@@@6/7/2017@79.39@79.39@28686044@INJECTABLE PREPARATION, 1 ML@EURO@@@@@@@@263@MCG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14916500@Onco@@@@@300f1018ntsdm@@@@@@Administered as Five Daily Intravenous Infusions Every 28 Days@@-@-@-@BRENTFORD, UNITED KINGDOM@@@@@14916500@Previously untreated@@-@-@@NO REVIEW@@@@-@Licensed from Ligand@-@NCT00107718@64@-@-@@@-@@11/1/2004@-@SB-485232006@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@IBOCTADEKIN@@@@@IBOCTADEKIN||||@GSK@@@@@GSK||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@SB-485232@@@@@SB-485232||||@Interleukin@@@@@Interleukin||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@RANDOMISED@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14921643@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@G207 followed by radiation@@-@-@-@-@@@@@14921643@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00157703@18@-@-@@@-@@5/1/2005@-@CT2001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MEDIGENE@@@@@MEDIGENE||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@G-207@@@@@G-207||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916720@Onco@@@@@@@@@@@Larotaxel versus 5-FU continuous administration@@-@-@-@PARIS, FRANCE@9/1/2007@@@@14916720@Patients previously treated with Gemzar-containing regiment@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00417209@400@-@Submission of regulatory application for larotaxel for second-line treatment of metastatic pancreatic cancer in 2009@@@-@@12/1/2006@-@PAPRIKA@@-@-@@@EFC6596, XRP9881; @III@@-@-@RESULTS PENDING@-@@@@MONO@LAROTAXEL@@@@@LAROTAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@XRP-9881@@@@@XRP-9881||||@Taxane@@@@@Taxane||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918978@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14918978@Uterine Cancer@@-@-@@NO REVIEW@@@@-@-@-@-@300@-@-@@@-@@12/1/2004@-@N/A@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@ARZOXIFENE@@@@@ARZOXIFENE||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@LY-353381@@@@@LY-353381||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924173@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924173@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@ATVOGEN@@@@@ATVOGEN||||@HEMISPHERX BIOPHARMA@@@@@HEMISPHERX BIOPHARMA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@AMPLIGEN@@@@@AMPLIGEN||||@Immunotherapy@Interferon@@@@Immunotherapy|Interferon|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919051@Onco@@@@@@@@@@@N/A@@-@-@-@PARIS, FRANCE@@@@@14919051@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@III@III@@-@-@Trial design still in progress@-@@@@-@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVE-8062@AC-7700@@@@AVE-8062|AC-7700|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@N/A@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16623702@Onco@@@@@@@@@@@@@@@@UNITED STATES@@@@@16623702@Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion@Both@@@@@Open-label expanded access, capsules or liquid formulation@@@@@@NCT03025360@@@@@@@@@@Larotrectinib (LOXO-101) EAP@@@-  Diagnosis of cancer with a NTRK1, NTRK2, or NTRK3 gene fusion  -  Are unable to participate in an ongoing larotrectinib (LOXO-101) clinical trial  -  Willing and able to provide written, signed informed consent  -  Medically suitable for treatment with@NTRK Gene Fusion@N/A - N/A@N/A@-@@@@@@@@@MONO@LAROTRECTINIB@@@@@LAROTRECTINIB||||@LOXO ONCOLOGY@@@@@LOXO ONCOLOGY||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LOXO-101@@@@@LOXO-101||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922971@Onco@@@@@@@@@@@-@@-@-@-@SHENZEN, CHINA@@@@@14922971@Primary liver cancer@@-@-@@NO REVIEW@@@@-@-@-@-@300@-@NDA filing expected within 2 years. SOURCE: CMS, 17 January 2008@1/17/2008@@-@@@-@-@@-@-@@@III@III@@-@-@Completion due in Q4 2009. SOURCE: CMS, 17 January 2008@-@@@@-@-@@@@@-||||@CHINA MEDICAL SYSTEMS@@@@@CHINA MEDICAL SYSTEMS||||@China@@@@@China|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@CMS-024@@@@@CMS-024||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922947@Onco@@@@@300f1014ntsdm@@@@@@-@@-@-@-@MONTREAL, CANADA@@@@@14922947@-@@-@-@@NO REVIEW@@@@-@-@-@-@300@-@PHASE III DUE TO START IN 2Q08@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@SP1049C@@@@@SP1049C||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14919039@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14919039@Reverse resistance to Temodar@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@N/A@-@-@@@-@@2/1/2008@-@N/A@@-@-@@@I@I@@-@-@First-patient-in. SOURCE: Tracon, 25 February 2008@-@@@@MONO@METHOXYAMINE@@@@@METHOXYAMINE||||@TRACON PHARMACEUTICALS@@@@@TRACON PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TRC-102@@@@@TRC-102||||@Other@@@@@Other||||@SAFETY@TOLERABILITY@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924636@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Combining PancAtak with standard of care chemoradiation and surgery@@-@-@-@BOSTON, MASSACHUSETTS@@@@@14924636@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ADVANTAGENE@@@@@ADVANTAGENE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@PANCATAK@@@@@PANCATAK||||@Immunotherapy@@@@@Immunotherapy||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924642@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LONDON, UNITED KINGDOM@@@@@14924642@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@DISCONTINUED@@-@-@Discontinued in October 2007@-@@@@-@LOMEGUATRIB@@@@@LOMEGUATRIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@Melanoma / Skin Cancer@@@@Solid Tumours|Melanoma / Skin Cancer||||||||@PATRIN@AZD-5896@@@@PATRIN|AZD-5896|||@AGT Inhibitor@@@@@AGT Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919088@Onco@@@@@@@@@@@-@@-@-@-@-@@@-@@14919088@-@@-@-@@NO REVIEW@@@July 2008-July 2009@-@-@-@NCT00734305@40@-@-@@@-@@@-@MM-121-01-100@@-@Patients must have histologically or cytologically confirmed advanced solid tumors that have recurred or progressed following standard therapy, or that have not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy @@@I@I@@-@-@FPI started. SOURCE: Merrimack, 12 August 2008@-@@@@-@-@@@@@-||||@MERRIMACK PHARMACEUTICALS@@@@@MERRIMACK PHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@MM-121@@@@@MM-121||||@mAb@Human@@@@mAb|Human|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924023@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@-@@@@@14924023@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@SPA agreement with FDA. SOURCE: Cougar, 1 April 2008@4/1/2008@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@LYTIX BIOPHARMA@@@@@LYTIX BIOPHARMA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LTX-400@@@@@LTX-400||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923717@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@JAPAN@@@-@@14923717@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@@RESULTS PENDING@-@@@@-@-@@@@@-||||@ZERIA@@@@@ZERIA||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@Z-100@@@@@Z-100||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14922977@Onco@@@@@@@@@@@Different intramuscular dosages of ozarelix@@-@-@-@QUEBEC, QUEBEC@@@@@14922977@Hormone-dependent prostate cancer@@-@-@@NO REVIEW@@@-@-@Ozarelix rights for all indications have been licensed by 'terna Zentaris  to Spectrum Pharmaceuticals for North America and India and oncology rights have been licensed to Nippon Kayaku for Japan. 'terna Zentaris has kept the rest of the world rights.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@Achieved its primary end-point of defining a tolerable dosage regimen of ozarelix that would ensure continuous suppression of testosterone at castration level (0.5 ng/ml) for a three month test period. A secondary efficacy end-point of the study aimed at assessing tumour response as determined by a 50% or greater reduction of serum PSA levels, compared to baseline, was also achieved. @-@@@@MONO@OZARELIX@@@@@OZARELIX||||@AETERNA ZENTARIS@@@@@AETERNA ZENTARIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@@@@@-||||@LH-RH Analog@@@@@LH-RH Analog||||@MAXIMUM TOLERATED DOSE@PSA@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920146@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01BC05@L01B@@@@@@@14920146@@@@@@NO REVIEW@@@@@@@@@@FDA, 25 July 2011@7/25/2011@@@@@@@No@NOVEMBER 2007 (PAEDIATRIC); JULY 2009 (OVERIAN CANCER); EXTENSIONS TO 2013@@@@@APPROVED@@@@RESULTS PENDING@@@@@@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@SUN PHARMACEUTICAL@@@@@SUN PHARMACEUTICAL||||@@@@@@|||||||||@NSCLC@Breast Cancer@Ovarian Cancer@@@NSCLC|Breast Cancer|Ovarian Cancer|||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@US$@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921910@Onco@@@@@@@@@@@BMS-663513 0.1MG/KG every 3 weeks or 1MG/KG every 3 weeks or 1MG/KG every 6 weeks or 5MG/KG every 3 weeks@@-@-@-@NEW YORK, NEW YORK@9/1/2010@@@@14921910@-@@-@-@@NO REVIEW@@@@-@Medarex receives part-royalties and milestones.@SECOND-LINE@NCT00612664@168@-@-@@@-@@3/1/2008@-@CA186-006@@-@-@@@II@II@@-@-@Endpoint over 6 weeks starting at week 12 after randomisation@-@@@@MONO@-@@@@@-||||@BMS@@@@@BMS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@BMS-663513@@@@@BMS-663513||||@mAb@@@@@mAb||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918846@Onco@@@@@@@@@@@N/A@@-@-@-@-@@@@@14918846@Stage III and IV melanoma@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@FDA orphan drug for Stage IIB-IV melanoma. SOURCE: GammaCan, 7 August 2008@8/7/2008@@FDA orphan drug for Stage IIB-IV melanoma. SOURCE: GammaCan, 7 August 2008@@@-@N/A@@-@-@@@I/II@II@@-@-@Trial to commence in 2008. SOURCE: GammaCan@-@@@@MONO@-@@@@@-||||@GAMMACAN@@@@@GAMMACAN||||@Israel@@@@@Israel|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@VITIGAM@@@@@VITIGAM||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924235@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14924235@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Filings expected in 2011. SOURCE: Antisoma, 13 April 2008@4/13/2008@@-@@@-@-@@-@-@@@II@II@@-@-@Trial to commence in 2008. SOURCE: CG, 7 April 2008@-@@@@-@-@@@@@-||||@CG THERAPEUTICS@@@@@CG THERAPEUTICS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@CG-201@@@@@CG-201||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918840@Onco@@@@@300f1012ntsdm@@@@@@Sabarubicin with cisplatin@@-@-@-@FLORENCE, ITALY@@@@@14918840@Combo with cisplatin for extended disease@@-@-@@NO REVIEW@@@@-@Drug available for partnering.@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@SABARUBICIN@CISPLATIN@@@@SABARUBICIN|CISPLATIN|||@MENARINI@@@@@MENARINI||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@MEN-10755@@@@@MEN-10755||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@MAXIMUM TOLERATED DOSE@RESPONSE RATE@@@@@@@@@-@@@@@OPEN-LABEL@NON-RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924513@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924513@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@TRAGEN PHARMACEUTICALS@@@@@TRAGEN PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@ISF-154@@@@@ISF-154||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921604@Onco@@@@@@@@@@@ZD4054  10mg oral tablet, once daily with pemetrexed 500mg2/m IV infusion versus Alimta alone@@-@-@-@LONDON, UNITED KINGDOM@8/1/2010@@@@14921604@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00745875@64@-@-@@@-@@8/1/2008@-@D4320C00035@@-@>> Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy     >> Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy@@@II@II@@-@-@Trial registered. [AstraZeneca, 02.09.2008]@-@@@@COMBO@-@PEMETREXED@@@@-|PEMETREXED|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZD-4054@ALIMTA@@@@ZD-4054|ALIMTA|||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@OVERALL SURVIVAL@@@@@PROGRESSION-FREE SURVIVAL@SAFETY@@@@RELAPSED@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921492@Onco@@@@@@@@@@@Larotaxel every 3 weeks versus Xeloda tablets twice daily for 2 weeks in 3-week cycles@@-@-@-@PARIS, FRANCE@@@@@14921492@Male or female patients with advanced breast cancer progressed after taxanes and anthracycline@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00081796@800@-@-@@@-@@4/1/2004@-@EFC6089@@-@-@@@; Trial 305; @III@@-@-@RESULTS PENDING@-@@@@MONO@LAROTAXEL@@@@@LAROTAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XRP-9881@@@@@XRP-9881||||@Taxane@@@@@Taxane||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918959@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AUSTIN, TEXAS@@@@@14918959@Combined with radiation therapy@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@III@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@INGN-241@@@@@INGN-241||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924488@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@FREDERICK, MARYLAND@@@@@14924488@-@@-@-@@NO REVIEW@@@@-@Xenova terminated its licensing agreement with Intracel in October 2004.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@VOTUMUMAB@@@@@VOTUMUMAB||||@INTRACEL@XENOVA@@@@INTRACEL|XENOVA|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@HUMASPECT@@@@@HUMASPECT||||@mAb@Human@Radiolabeled@@@mAb|Human|Radiolabeled||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923011@Onco@@@@@@@@@@@Patients will receive weekly intravenous infusions of Symadex for 3 weeks, followed by 1 week of rest for a total of 4 weeks. Responding patients will be subjected to additional cycles with regular tumor assessments until progressive disease or death. @@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14923011@Second-line therapy @@-@-@@NO REVIEW@@@STARTED IN JANUARY 2006@-@Antisoma acquired Xanthus in an all-share deal of GB£26.8 mil. SOURCE: Antisoma, 16 May 2008@SECOND-LINE@-@49@-@-@@@-@@@-@-@@-@49 PATIENTS AFTER FAILURE OF TREATMENT WITH OXALIPLATIN AND/OR IRINOTECAN @@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@XANTHUS PHARMACEUTICALS@ANTISOMA@@@@XANTHUS PHARMACEUTICALS|ANTISOMA|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@SYMADEX@C-1311@@@@SYMADEX|C-1311|||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918897@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PHILIPSBURG, NEW JERSEY@@@@@14918897@-@@-@-@@NO REVIEW@@@@-@Alteris acquired by Celldex in October 2005@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@CELLDEX THERAPEUTICS@ALTERIS THERAPEUTICS@@@@CELLDEX THERAPEUTICS|ALTERIS THERAPEUTICS|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@ALT-110@@@@@ALT-110||||@Vaccine@TK Inhibitor@EGFR@@@Vaccine|TK Inhibitor|EGFR||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924199@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arry-543 in combination with Erbitux cetuximab.@@-@-@-@BOULDER, COLORADO@@@@@14924199@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@1/1/2008@-@-@@-@-@@@I/II@II@@-@-@-@-@@@@COMBO@-@CETUXIMAB@@@@-|CETUXIMAB|||@ARRAY BIOPHARMA@@@@@ARRAY BIOPHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ARRY-543@ERBITUX@@@@ARRY-543|ERBITUX|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921197@Onco@@@@@@@@@@@Sample Size - 20 patients in Stage I and up to 20 patients in Stage II. Dosage Form - IV solution of sterilized lyophilized powder in Sodium Chloride (NaCl) for Injection, USP (0.9%). Doses - 140 mg/m2 GPX-100 with escalation to 170 mg/m2 and de-escalation to 105 mg/m2 depending upon clinical response and toxicity. Administration - One IV infusion every 3 weeks for up to 8 doses.@@-@-@-@-@11/1/2005@@@@14921197@Newly diagnosed metastatic breast cancer@@-@-@@NO REVIEW@@@@-@Licensed to Access Oncology (Keryx)@-@NCT00123877@40@-@-@@@-@@3/1/2005@-@GPX-100-003@@-@-@@@II@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GEM PHARMACEUTICALS@@@@@GEM PHARMACEUTICALS||||@Bulgaria@@@@@Bulgaria|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GPX-100@@@@@GPX-100||||@Other@@@@@Other||||@RECIST@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921799@Onco@@@@@@@@@@@Larotaxel with cisplatin versus Gemzar with cisplatin@@-@-@-@PARIS, FRANCE@@@@@14921799@Locally advanced, metastatic urothelial tract or bladder cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00625664@900@-@Submit regulatory application (2012)@@@-@@2/1/2008@-@CILABEFC6668@@-@-@@@III@III@@-@-@Phase III start 4Q07; confirmed February 2008. SOURCE: sanofi-aventis, February 2008@-@@@@COMBO@LAROTAXEL@CISPLATIN@@@@LAROTAXEL|CISPLATIN|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@XRP-9881@@@@@XRP-9881||||@Taxane@@@@@Taxane||||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924020@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@-@@@@@14924020@Trial versus Neupogen@@YES@-@@NO REVIEW@@@@-@Arrowhead merged its two subsidiaries Calando and Insert Therapeutics in February 2008; now known as Calando Pharmaceuticals.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial started. Results expected in H2 2008, with plans for a US-based Phase III trial therafter. SOURCE: Insmed, 16 April 2008@-@@@@MONO@-@@@@@-||||@INSMED@@@@@INSMED||||@@@@@@|||||||||@Anaemia@@@@@Anaemia|||||||||@INS-19@@@@@INS-19||||@G-CSF@@@@@G-CSF||||@BIOEQUIVALENCE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923725@Onco@@@@@@@@@@@Patients will receive Xeloda 1250mg/m² p.o. twice daily as intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week without treatment). @@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14923725@Adjuvant treatment @@-@6-Dec@@NO REVIEW@@@@-@-@-@NCT00502671@>500@-@-@@@-@@@-@-@@-@-@-@@IV@IV@@-@-@Not yet available.@-@@@@ADJUVANT@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@Russia@@@@@Russia|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@ADVERSE EVENTS@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922992@Onco@@@@@@@@@@@-@@A04AD12@A04A@-@WHITEHOUSE STATION, NEW JERSEY@@@@@14922992@-@@-@-@@NO REVIEW@@@-@-@Japanese rights with Ono.@-@-@-@-@Chemotherapy-induced nausea and vomiting:CHMP positive opinion. SOURCE: Merck & Co, 16 November 2007.MAA accepted in May 2006@11/16/2007@@-@@@-@-@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@FOSAPREPITANT MEGLUMINE@@@@@FOSAPREPITANT MEGLUMINE||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@EMEND FOR INJECTION@@@@@EMEND FOR INJECTION||||@NK1 Antagonist@@@@@NK1 Antagonist||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@115@MG@115 MG@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921226@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@-@@@@@14921226@Surgically resectable pancreatic cancer patients in combination with adjuvant gemcitabine@@-@-@@NO REVIEW@@@@-@-@-@NCT00300950@100@-@-@@@-@@1/1/2006@-@GI-4000-02@@-@-@-@@II@II@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@GLOBEIMMUNE@@@@@GLOBEIMMUNE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@GI-4000@TARMOGEN@@@@GI-4000|TARMOGEN|||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924972@Onco@@@@@@@@@@@Dose escalation of dHER2 protein with AS15 adjuvant; 6 intramuscular vaccinations over a 14-week period@@-@-@-@BRENTFORD, UNITED KINGDOM@@@@@14924972@High-risk breast cancer@@-@-@@NO REVIEW@@@MARCH 2005-OCTOBER 2008@-@-@MULTIPLE@NCT00140738@40@-@-@@@-@@@-@100633@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@GSK@@@@@GSK||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@HER2 RECOMBINANT PHARMACCINE@@@@@HER2 RECOMBINANT PHARMACCINE||||@Vaccine@HER2@@@@Vaccine|HER2|||@TOXICITY@COMPLETE RESPONSE@PARTIAL RESPONSE@@@PARTIAL RESPONSE@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15046564@Onco@@@@@300f1015ntsdm@@@@@@@@@@@PETACH TIKVA, ISRAEL@@@Lonquex (lipegfilgrastim) is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) based on novel GlycoPEGylation technology. Lipegfilgrastim is a novel, pegylated and glycosylated long-acting form of filgrastim, intended for once-per-cycle fixed dose, subcutaneous injection for neutrophil support in patients receiving myelosuppressive chemotherapy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). [Teva]@@15046564@@@@@@NO REVIEW@@@@@@@@@@EMA, 8 August 2013@8/8/2013@@@@@@@No@@@@@@APPROVED@@@@NO LABELLED TRIAL@@@@@@LIPEGFILGRASTIM@@@@@LIPEGFILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@LONQUEX@@@@@LONQUEX||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14916648@Onco@@@@@@@@@@@N/A@@-@-@-@FOSTER CITY, CALIFORNIA@@@DC Bead is an embolic agent with the capability of also targeting a chemotherapeutic agent directly to the tumor site.@@14916648@-@@-@-@@NO REVIEW@@@NOVEMBER 2005-@-@-@-@NCT00261378@-@-@-@@@-@@@-@PRECISION V@@-@-@@@CA1008; @II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SCICLONE PHARMACEUTICALS@@@@@SCICLONE PHARMACEUTICALS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@DC BEAD@@@@@DC BEAD||||@Other@@@@@Other||||@RECIST@@@@@@@@@@-@@@@@RANDOMISED@SINGLE-ARM@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921654@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Pasireotide LAR versus octreotide LAR@@-@-@-@BASEL, SWITZERLAND@@@@@14921654@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00600886@330@-@-@@@-@@11/1/2007@-@CSOM230C2305@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@PASIREOTIDE@@@@@PASIREOTIDE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Acromegaly@@@@@Acromegaly|||||||||@SOM-230@@@@@SOM-230||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@GROWTH HORMONE LEVEL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922506@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ZD-4054 alone@@-@-@-@LONDON, UNITED KINGDOM@@@@@14922506@Metastatic prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00055471@-@-@-@@@-@@@-@4054IL0004  @@-@PATIENTS WITH METASTATIC PROSTATE CANCER@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ZD-4054@@@@@ZD-4054||||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@N/A@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923364@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@PARIS, FRANCE@@@@@14923364@Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.@@@@@NO REVIEW@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@@RESULTS PENDING@@@@@@CHLOROTRIANISENE@@@@@CHLOROTRIANISENE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TACE@@@@@TACE||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923096@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@@@@@@14923096@@@@@@NO REVIEW@@@@@Nippon Kayaku@@@@@@@@@@@@@No@@@@@@APPROVED@@@@@@@@@@OXYCODONE HYDROCHLORIDE@@@@@OXYCODONE HYDROCHLORIDE||||@SHIONOGI@@@@@SHIONOGI||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@S-8116@@@@@S-8116||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@IMMEDIATE RELEASE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918939@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918939@Discontinued in Phase II trials in July 2007 due to slow enrolment.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II@DISCONTINUED@@-@-@Trial failed in July 2007 due to slow enrolment.@-@@@@-@SQUALAMINE LACTATE@@@@@SQUALAMINE LACTATE||||@GENAERA@@@@@GENAERA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@EVIZON@@@@@EVIZON||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@RESPONSE RATE@SAFETY@PSA@@@PSA@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922137@Onco@@@@@@@@@@@3 different dose levels@@-@-@-@KJELSAS, NORWAY@@@Algeta's lead product based on the alpha emitter technology is Alpharadin, a product being developed as a new treatment for skeletal metastases in patients with late-stage, hormone refractory prostate cancer (HRPC). Alpharadin (radium-223 chloride) is a unique targeted therapeutic in phase III clinical trials for the treatment for HRPC that has metastasized to the skeleton.@@14922137@Palliation@@-@-@@NO REVIEW@@@-@-@-@-@-@N/A@-@-@@@-@@@-@BCI-04@@-@-@@@II@II@@-@-@Preliminary results expected in Q3 2008@-@@@@MONO@-@@@@@-||||@ALGETA@@@@@ALGETA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ALPHARADIN@@@@@ALPHARADIN||||@Other@@@@@Other||||@PSA@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922342@Onco@@@@@@@@@@@Dose escalation study of PF-03814735 capsules administered orally once a day for 5 consecutive days (schedule A) or 10 consecutive days (schedule B) out of 21-day cycles. Starting dose 5 mg/day. Treatment continues up to disease progression, untolerable toxicity, or consent withdrawal. @@-@-@-@NEW YORK, NEW YORK@9/1/2008@@@@14922342@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00424632@60@-@-@@@-@@11/1/2006@-@A9491001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@Belgium@@@@@Belgium|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-3814735@@@@@PF-3814735||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15041411@Onco@@@@@300f1015ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15041411@@@NO@@@@@@@@@@@@@@@9/13/2004@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@@@@@@||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@39.79@50.55@42.45@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@39.79@39.79@3.40E+12@POWDER AND SOLVANT FOR INJECTABLE SOLUTION PREFILLED SYRINGE - 1 ML@EURO@@@@@@@@105@MCG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14920928@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@GVAX alone@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@10/1/2004@@@@14920928@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00116441@22@-@-@@@-@@10/1/2000@-@K-0007@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CELL GENESYS@@@@@CELL GENESYS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@GVAX@@@@@GVAX||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918831@Onco@@@@@300f1012ntsdm@@@@@@N/A@@-@-@-@HEIDELBERG, GERMANY@@@@@14918831@GVHD@@-@-@@NO REVIEW@@@@-@-@-@-@30@-@EMEA Orphan designation. SOURCE: Apogenix, March 2008@@@EMEA Orphan designation. SOURCE: Apogenix, March 2008@@@-@N/A@@-@-@@@I@I@@-@-@Phase I trial to start in Q2 2008. Data expected in Q2 2009. SOURCE: Apogenix, March 2008@-@@@@MONO@-@@@@@-||||@APOGENIX@@@@@APOGENIX||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@APG-101@@@@@APG-101||||@mAb@@@@@mAb||||@SAFETY@@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924605@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@ONTARIO, CANADA@@@@@14924605@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@YM BIOSCIENCES@@@@@YM BIOSCIENCES||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@NORELIN@@@@@NORELIN||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924568@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924568@Palliative therapy of advanced inoperable or metastatic carcinoma of the breast in post-menopausal women (withdrawn)@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@-@CALUSTERONE@@@@@CALUSTERONE||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@METHOSARB@@@@@METHOSARB||||@Sex Hormone@@@@@Sex Hormone||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924236@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14924236@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Filings expected in 2011. SOURCE: Antisoma, 13 April 2008@4/13/2008@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@CG THERAPEUTICS@@@@@CG THERAPEUTICS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@CG-201@@@@@CG-201||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916781@Onco@@@@@300f1015ntsdm@@@@@@Two doses of SR31747A (75 mg and 125 mg) @@-@-@-@PARIS, FRANCE@@@@@14916781@Non-metastatic AIPC@@-@-@@NO REVIEW@@@@-@-@-@-@255@-@-@@@-@@11/1/2003@-@ODYSSEY@@-@-@@@EFC5378; @DISCONTINUED@@-@-@Discontinued in April 2007. SOURCE: sanofi-aventis@-@@@@MONO@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@SR-31747@@@@@SR-31747||||@Immunosuppressive@@@@@Immunosuppressive||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924696@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924696@Phase II discontinued and suspension of rNAPc2 for all indications@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@DISCONTINUED@@-@-@Phase II trial discontinued and development suspended.@-@@@@-@-@@@@@-||||@NUVELO@@@@@NUVELO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RNAPC2@@@@@RNAPC2||||@RNA@@@@@RNA||||@SAFETY@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924129@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@UNITED STATES@@@@@14924129@Studies expected to commence in H2 2007@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING; studies commencing in H2 2007.@-@@@@-@17AAG NANOPARTICLE ALBUMIN-BOUND@@@@@17AAG NANOPARTICLE ALBUMIN-BOUND||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ABI-010@@@@@ABI-010||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@1Onco1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@4549@Northern America@@@@@@@@
14924805@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WILMINGTON, DELAWARE@@@Incyte has discovered multiple potent, selective and orally bioavailable JAK inhibitors from multiple distinct chemical scaffolds. A lead follow-on compound is scheduled to begin Phase I trials this month.@@14924805@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@I@@-@-@Trial of new follow-on JAK inhibitor to start in Q2. SOURCE: Incyte, 2 June 2008@-@@@@-@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@Other@@@@@Other|||||||||@UNKNOWN@@@@@UNKNOWN||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924022@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@-@@@@@14924022@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@SPA agreement with FDA. SOURCE: Cougar, 1 April 2008@4/1/2008@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@LYTIX BIOPHARMA@@@@@LYTIX BIOPHARMA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LTX-300@@@@@LTX-300||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14924219@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LEVERKUSEN, GERMANY@@@@@14924219@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@MAY 2005 APPROVABLE LETTER REQUIRING FURTHER TRIAL DATA.@@@-@@@-@-@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@CLODRONIC ACID@@@@@CLODRONIC ACID||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@BONEFOS@@@@@BONEFOS||||@Bisphosphonate@@@@@Bisphosphonate||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918918@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEOUL, SOUTH KOREA@@@@@14918918@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@UNKNOWN@-@@@@-@BELOTECAN@@@@@BELOTECAN||||@CHONG KUN DANG@@@@@CHONG KUN DANG||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@CAMTOBELL@@@@@CAMTOBELL||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918961@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SUMMIT, NEW JERSEY@@@@@14918961@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@Status unclear@II@@-@-@Presently in Phase II trials (SEC 10-K March 2006)@-@@@@-@-@@@@@-||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@JNK-401@CC-401@@@@JNK-401|CC-401|||@TK Inhibitor@@@@@TK Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924966@Onco@@@@@300f1012ntsdm@@@@@@N/A@@-@-@-@LEVERKUSEN, GERMANY@@@@@14924966@Stage IIIB or IV NSCLC@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00160069@N/A@-@First Phase III trials planned for 2008.@@@-@@7/1/2005@-@307971@@-@-@@@II@II@@-@-@First Phase III trials planned for 2008.@-@@@@MONO@SAGOPILONE@@@@@SAGOPILONE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZK-EPO@ZK-219477@@@@ZK-EPO|ZK-219477|||@Epothilone@@@@@Epothilone||||@RECIST@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14918938@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918938@Discontinued in Phase II trials in July 2007 after failure of prostate cancer trial.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II@DISCONTINUED@@-@-@Trial discontinued after failure of prostate cancer trial.@-@@@@-@SQUALAMINE LACTATE@@@@@SQUALAMINE LACTATE||||@GENAERA@@@@@GENAERA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@EVIZON@@@@@EVIZON||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921580@Onco@@@@@@@@@@@Patients receive DX-8951f IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for survival.@@-@-@-@TOKYO, JAPAN@@@@@14921580@Stage IIIB or IV NSCLC@@-@-@@NO REVIEW@@@FEBRUARY 1999-@-@-@-@NCT00005091@37@-@-@@@-@@@-@DAIICHI-8951E-PRT017, @@-@-@@@EU-99044; @II@@-@-@RESULTS PENDING@-@@@@MONO@EXATECAN MESYLATE@@@@@EXATECAN MESYLATE||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@DX-8951F@@@@@DX-8951F||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TUMOUR RESPONSE@@@@@@@@@@-@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923502@Onco@@@@@@@@@@@-@@-@-@-@-@@@@@14923502@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial to start in 2009. SOURCE: Compugen, 17 July 2008@-@@@@MONO@-@@@@@-||||@COMPUGEN@@@@@COMPUGEN||||@Israel@@@@@Israel|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CGEN-50001@@@@@CGEN-50001||||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918850@Onco@@@@@300f1020ntsdm@@@@@@N/A@@-@-@-@MILAN, ITALY@@@@@14918850@-@@-@-@@NO REVIEW@@@@-@-@-@-@5@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@Endpoint according to IWG response criteria for Hodgkin's Lymphoma. Completion is due December 2008. SOURCE: Italfarmaco@-@@@@MONO@-@@@@@-||||@ITALFARMACO@@@@@ITALFARMACO||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Solid Tumours@@@Haematological Malignancy|Hodgkin's Lymphoma|Solid Tumours|||||||@ITF-2357@@@@@ITF-2357||||@HDAC@@@@@HDAC||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14918974@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918974@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@4/1/2008@-@N/A@@-@-@@@II@II@@-@-@Trial to commence in Q2 08. SOURCE: Ligand Q4 Call, 20 February 2008@-@@@@-@-@@@@@-||||@LIGAND PHARMACEUTICALS@@@@@LIGAND PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@LGD-4665@@@@@LGD-4665||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924664@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@-@@14924664@-@@-@-@@NO REVIEW@@@@-@Ligand acquires Pharmacopeia in US$70 million deal. [Ligand, 24.09.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@-@-@@@@MONO@-@@@@@-||||@PHARMACOPEIA@BMS@LIGAND PHARMACEUTICALS@@@PHARMACOPEIA|BMS|LIGAND PHARMACEUTICALS||@@@@@@|||||||||@Supportive Care@Cachexia@@@@Supportive Care|Cachexia||||||||@PS-178990@@@@@PS-178990||||@Other@@@@@Other||||@-@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920129@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BG03@L02B@@@@@@@14920129@@@@@@@@@@@@@@@@FDA, 29 April 2008@4/29/2008@@@@@@@No@@@@@@APPROVED@@@@@@@@@@ANASTROZOLE@@@@@ANASTROZOLE||||@ZYDUS PHARMA@@@@@ZYDUS PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@US$@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15299755@Onco@@@@@300f1010ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15299755@@@NO@@@@@@@100%@@@@@@@@@@@@@@No@@@@@@APPROVED@@@NHS@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMACEUTICALS@@@@@CHUGAI PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@200.55@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@40.11@40.11@4.52E+15@INJECTION POWDER FOR RECONSTITUTION (VIAL)@GB£@@@@@@@@105@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14924021@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@-@@@LC-1 can block Rel A protein, resulting in the targeted killing of leukemia cells from CLL patients. Tests in the laboratory show the new drug is equally effective in treating the cells of patients that respond poorly to the current treatment, Fludarabine. @@14924021@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial commenced [CombiMatrix, 28.01.2009]@-@@@@MONO@-@@@@@-||||@LEUCHEMIX@COMBIMATRIX@@@@LEUCHEMIX|COMBIMATRIX|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@LC-1@@@@@LC-1||||@Other@@@@@Other||||@@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14916467@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@BOSTON, MASSACHUSSETTS@@@@@14916467@-@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00423306@60@-@-@@@-@@@-@SGL2005@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@DARINAPARSIN@@@@@DARINAPARSIN||||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@ZIO-101@@@@@ZIO-101||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924105@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924105@Chemotherapy-induced nausea and vomiting@@-@-@@NO REVIEW@@@@-@Full rights licensed from Roche in June 2005@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@NETUPITANT@@@@@NETUPITANT||||@HELSINN@@@@@HELSINN||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@-@@@@@-||||@NK1 Antagonist@@@@@NK1 Antagonist||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412597@Onco@@@@@@@@@@@Routine clinical practice group (NSCLC ALK+), , Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+@@L01XE16@L01X@@NEW YORK, NEW YORK@2/1/2019@@@@15412597@Prospective Observational Study To Identify Patients With Advanced/Metastatic NSCLC And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)@Both@@@@@Treatment with crizotinib following routine clinical practice@@@@@@NCT02679170@1@@@@@@@3/1/2016@@A8081057@@@Patients with Advanced or metastatic non-small cell lung cancer  -  Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement  -  Age > 18 years  -  For the patients that will be recruited prospectively: Patients must have a signed informed consent document.  -  For the treatment sub-study, patients must also meet the following criteria  -  Confirmed anaplastic lymphoma kinase (ALK)-positive tumour  -  Patients treated with crizotinib under routine clinical practice  -  Patients with a minimum data registered at the medical history@@ADULTS@N/A@-@@@@@@@@@@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@INCIDENCE OF ALK-POSITIVE NSCLC@Progressioni Free Survival@@@@@@@@@@@@@@Cohort@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923022@Onco@@@@@@@@@@@-@@-@-@-@JAPAN@@@Gastrin CCK2 inhibitor@@14923022@Cancer pain related to pancreatic cancer@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial started. SOURCE: Zeria, 11 August 2008@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@ZERIA@@@@@ZERIA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@Pancreatic Cancer@@@Supportive Care|Cancer Pain|Pancreatic Cancer|||||||@Z-360@GEMZAR@@@@Z-360|GEMZAR|||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924247@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14924247@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Covx in December 2007@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@COVX@PFIZER@@@@COVX|PFIZER|||@@@@@@|||||||||@Other@@@@@Other|||||||||@CVX-045@@@@@CVX-045||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924174@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@UNITED STATES@@@@@14924174@-@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@IND accepted by FDA; trial to begin enrolment during 2008. SOURCE: Alexion, 30 April 2008@-@@@@MONO@-@@@@@-||||@ALEXION PHARMACEUTICAL@@@@@ALEXION PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ANTI-CD200 MAB@@@@@ANTI-CD200 MAB||||@mAb@@@@@mAb||||@SAFETY@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924205@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, UNITED KINGDOM@@@AT-13387 is a small molecule inhibitor of Hsp90, which acts as a molecular chaperone.@@14924205@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@IND approved and trial commenced. [Astex, January 2008]@-@@@@MONO@-@@@@@-||||@ASTEX THERAPEUTICS@@@@@ASTEX THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AT-13387@@@@@AT-13387||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@SAFETY@TOLERABILITY@@@@@@@@@ADVANCED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918803@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918803@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924606@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924606@Uterine myoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@CETRORELIX ACETATE@@@@@CETRORELIX ACETATE||||@SHIONOGI@@@@@SHIONOGI||||@@@@@@|||||||||@Myoma@@@@@Myoma|||||||||@NS-75A@@@@@NS-75A||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924271@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@TOKYO, JAPAN@@@@@14924271@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Other@@@@@Other|||||||||@E-6201@@@@@E-6201||||@MEK Inhibitor@@@@@MEK Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924803@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924803@-@@-@-@@NO REVIEW@@@@-@Keryx receives notice from Nasdaq that the company is not in compliance with the US$1 minimum bid price for continued listing and most reach this within 180 days. SOURCE: Keryx, 28 April 2008Licensed from Kyowa Hakko@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@-@@@@@-||||@KERYX BIOPHARMACEUTICALS@@@@@KERYX BIOPHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@UCN-01@KW-2401@@@@UCN-01|KW-2401|||@PKC Inhibitor@@@@@PKC Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924835@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924835@Adjuvant combo with oxaliplatin@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@ADJUVANT@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924588@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AMSTERDAM, NETHERLANDS@@@@@14924588@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@KIADIS PHARMA@@@@@KIADIS PHARMA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@NB-1011@@@@@NB-1011||||@TS Inhibitor@@@@@TS Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916011@Onco@@@@@@@@@@@ZD-4054 alone@@-@-@-@LONDON, UNITED KINGDOM@@@@@14916011@Pain-free or mildly symptomatic prostate cancer and bone metastases who have rising serum PSA@@-@-@@NO REVIEW@@@@-@-@-@NCT00090363@260@-@-@@@-@@8/1/2004@-@ZD4054@@-@-@@@D4320C00006; TRIAL 6;@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@Bone Metastases@@@@Prostate Cancer|Bone Metastases||||||||@ZD-4054@@@@@ZD-4054||||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924440@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@-@@14924440@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@I@@-@-@Trial to begin Q1 2009 [Tigris, 5 March 2009]@-@@@@MONO@-@@@@@-||||@TIGRIS@@@@@TIGRIS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@GGTI-2418@@@@@GGTI-2418||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@-@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924474@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924474@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@Phase I/II trial to start H1 2008@-@@@@MONO@-@@@@@-||||@HOLLIS-EDEN PHARMACEUTICALS@@@@@HOLLIS-EDEN PHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@HE3235@@@@@HE3235||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924867@Onco@@@@@@@@@@@-@@-@-@-@-@@@@@14924867@-@@-@-@@NO REVIEW@@@@-@Licensed from Schering AG@-@-@-@-@-@@@-@@@-@-@@-@-@@@III@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@-@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@INTARCIA THERAPEUTICS@@@@@INTARCIA THERAPEUTICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@-@@@@@-||||@Hormone Antagonist@@@@@Hormone Antagonist||||@-@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924882@Onco@@@@@@@@@@@-@@-@-@-@FREDERICK, MARYLAND@@@@@14924882@Stage II colon cancer; adjuvant@@-@-@@NO REVIEW@@@@-@Vaccinogen licensed exclusive rights from Intracel. SOURCE: Vaccinogen, 6 February 2008@-@-@560@-@OncoVax to be launched in Switzerland, Hungary, Czech Republic, Slovakia, Poland, Romania, Bulgaria and Slovenia starting June 2008. SOURCE: Vaccinogen, 27 February 2008Confirmatory trial will be used to support BLA in the U.S.SPA (FDA; stage II colon carcinoma adjuvant). SOURCE: Intracel, 19 July 2006Fast-track (FDA; stage II colon carcinoma adjuvant). SOURCE: Intracel, July 2006@2/27/2008@@-@@4/1/2006@-@-@@-@-@-@@III@III@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@INTRACEL@@@@@INTRACEL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ONCOVAX@@@@@ONCOVAX||||@Vaccine@@@@@Vaccine||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@MULTI-CENTRE@PIVOTAL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916654@Onco@@@@@@@@@@@PR-104 with prophylactic G-CSF@@-@-@-@-@8/1/2008@@@@14916654@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00616213@21@-@-@@@-@@1/1/2008@-@PR-104-1004@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@G-CSF@@@@-|G-CSF|||@PROACTA@@@@@PROACTA||||@New Zealand@@@@@New Zealand|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PR-104@@@@@PR-104||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924504@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924504@-@@-@-@@NO REVIEW@@@@-@Licensed from Aphton in July 2006 after Aphton filed for bankrupcty.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@G17DT IMMUNOGEN@@@@@G17DT IMMUNOGEN||||@RECEPTOR BIOLOGIX@@@@@RECEPTOR BIOLOGIX||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@INSEGNIA@@@@@INSEGNIA||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923680@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@-@@@@@14923680@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@@RESULTS PENDING@-@@@@-@NOGITECAN HYDROCLORIDE@@@@@NOGITECAN HYDROCLORIDE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@NK-211@HYCAMTIN@@@@NK-211|HYCAMTIN|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14924794@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924794@Unresectable pancreatic cancer@@-@-@@NO REVIEW@@@@-@-@-@-@65@-@-@@@-@@10/1/2007@-@-@@-@-@@@II@II@@-@-@-@-@@@@MONO@-@@@@@-||||@TAPESTRY@@@@@TAPESTRY||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@TPI-287@@@@@TPI-287||||@Taxane@@@@@Taxane||||@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917687@Onco@@@@@300f1015ntsdm@@@@@@@@P02CE01@P02C@@NEW BRUNSWICK, NEW JERSEY@@@@@14917687@Palliative treatment of advanced prostatic cancer@@@temporary use in France@@NO REVIEW@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@LEVAMISOLE HYDROCHLORIDE@@@@@LEVAMISOLE HYDROCHLORIDE||||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ERGAMISOL@@@@@ERGAMISOL||||@Anthelminitic@@@@@Anthelminitic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922499@Onco@@@@@@@@@@@Gemzar/cisplatin with two doses of LY-293111 or placebo@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922499@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00069875@195@-@-@@@-@@@-@4842H6H-MC-JEAM  @@-@-@@@II@II@@-@-@Trial stopped recruitment, but results RESULTS PENDING@-@@@@COMBO@-@GEMCITABINE@CISPLATIN@@@-|GEMCITABINE|CISPLATIN||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@LY-293111@GEMZAR@@@@LY-293111|GEMZAR|||@LTB4 Receptor Antagonist@@@@@LTB4 Receptor Antagonist||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918804@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918804@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918808@Onco@@@@@@@@@@@600 mcg/m2 q4–6w@@-@-@-@-@@@@@14918808@-@@-@-@@NO REVIEW@@@N/A@-@-@-@-@N/A@-@On 27 July 2005, orphan designation (EU/3/05/300) was granted by the European Commission for nemorubicin hydrochloride for the treatment of hepatocellular carcinoma.@7/27/2005@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@ASCO 2006; there were 11/57 confirmed liver CR/PRs (RR = 19.3%) lasting 1–54+ months. Stable disease  3 months was observed in 17/57 (29.8%) pts, most with AJCC Stage III, IIIA and IVA. @-@@@@MONO@NEMORUBICIN@@@@@NEMORUBICIN||||@NERVIANO@@@@@NERVIANO||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@-@@@@@-||||@Topoisomerase I Inhibitor@Anthracycline@@@@Topoisomerase I Inhibitor|Anthracycline|||@RESPONSE RATE@STABLE DISEASE@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924841@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924841@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@RESULTS PENDING@-@@@@-@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15413010@Onco@@@@@@@@@@@TK216 treatment, Experimental, Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.@@@@@@12/1/2017@@@@15413010@A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma@Both@@@@@Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein@@@@@@NCT02657005@45@@@@@@@3/1/2016@@TK216-01@@@Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT) in subjects with relapsed or refractory disease who have failed standard therapy@MONO@@Phase 1@I@@@@@@@@@@-@@@@@-||||@TOKALAS@@@@@TOKALAS||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@TK216@@@@@TK216||||@TK Inhibitor@@@@@TK Inhibitor||||@Dose-limiting toxicities (DLTs)@Maximum tolerated dose (MTD)@Biologically effective and recommended Phase 2 dose (RP2D)@@@ADVERSE EVENTS@Antitumor activity as measured by Overall Response Rate (ORR)@@@@RELAPSED@REFRACTORY@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924115@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@IRVINE, CALIFORNIA@@@@@14924115@Taxane-refractory solid tumours@@-@-@@NO REVIEW@@@@-@Spectrum licensed global rights to ortataxel from Indena in July 2007 for regulatory and sales milestones as well as double-digit royalties.@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@February 2008 (U.S.)@-@The drug was previously discontinued at Bayer.@-@@@@-@ORTATAXEL@@@@@ORTATAXEL||||@SPECTRUM PHARMACEUTICALS@INDENA@@@@SPECTRUM PHARMACEUTICALS|INDENA|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Taxane@@@@@Taxane||||@-@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918981@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@FLORENCE, ITALY@@@@@14918981@-@@-@-@@NO REVIEW@@@@-@Drug available for partnering.@-@-@N/A@-@-@@@-@@1/1/2007@-@N/A@@-@-@@@III@III@@-@-@Trial to commence in 2007.@-@@@@-@SABARUBICIN@@@@@SABARUBICIN||||@MENARINI@@@@@MENARINI||||@@@@@@|||||||||@NSCLC@SCLC@@@@NSCLC|SCLC||||||||@MEN-10755@@@@@MEN-10755||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@-@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918779@Onco@@@@@300f1018ntsdm@@@@@@-@@-@-@-@VICTORIA, AUSTRALIA@@@@@14918779@-@@-@-@@NO REVIEW@@@-@-@Celltrion will manufacture the supplies to the drug for CSL according to a January 2008 licensing deal.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Final data expected by year-end. SOURCE: CSL, January 2008@-@@@@MONO@-@@@@@-||||@CSL@CELLTRION@@@@CSL|CELLTRION|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CSL-360@@@@@CSL-360||||@mAb@@@@@mAb||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14922366@Onco@@@@@300f1012ntsdm@@@@@@@@L01XX22@L01X@@FRAZER, PENNSYLVANIA@@@@@14922366@@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@@@@@@@@@@No@@@@@@APPROVED@@@GKV@RESULTS PENDING@@@@@@TRETINOIN@@@@@TRETINOIN||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@PANRETIN@@@@@PANRETIN||||@Retinoid@@@@@Retinoid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@1254.3@1594.71@1292.8@@@@@@@@@@20.91@@@@@@@@@@@@@@@@8/1/2017@1254.3@1254.3@2260679@GEL 60 G@EURO@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924614@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@FREDERICK, MARYLAND@@@@@14924614@Renal cell carcinoma@@-@-@@NO REVIEW@@@@-@Vaccinogen licensed exclusive rights from Intracel. SOURCE: Vaccinogen, 6 February 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@INTRACEL@@@@@INTRACEL||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@ONCOVAX@@@@@ONCOVAX||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918815@Onco@@@@@@@@@@@10, 30, 60 or 100 µg/kg of MAXY-G34 versus 6 mg of Neulasta pegfilgrastim after each 21-day cycle of chemotherapy.@@-@-@-@-@@@@@14918815@Chemotherapy-induced neutropaenia in patients with Stage I-IIIa breast cancer@@-@-@@NO REVIEW@@@-@-@-@-@-@30@-@-@@@-@@@-@N/A@@-@-@@@IIA@II@@-@-@Met primary endpoint of safety in severe neutropaenia which last five days or under for the 10 µg/kg of MAXY-G34 dose. There were no serious adverse events or immunogenicity. The DSMB recommended increase dose to 30 µg/kg@-@@@@MONO@-@@@@@-||||@MAXYGEN INC.@@@@@MAXYGEN INC.||||@@@@@@|||||||||@Supportive Care@Neutropaenia@Breast Cancer@@@Supportive Care|Neutropaenia|Breast Cancer|||||||@MAXY-G34@@@@@MAXY-G34||||@G-CSF@@@@@G-CSF||||@SAFETY@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921631@Onco@@@@@@@@@@@N/A@@-@-@-@SCHLIEREN, GERMANY@@@@@14921631@HLA-A2 positive patients with Stage II malignant melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00306566@N/A@-@-@@@-@@@-@CYT004-MelQbG10 02@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@IMEXON@@@@@IMEXON||||@CYTOS BIOTECHNOLOGY@@@@@CYTOS BIOTECHNOLOGY||||@Switzerland@@@@@Switzerland|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CYT-004-MELQBG10@@@@@CYT-004-MELQBG10||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925037@Onco@@@@@@@@@@@Increasing doses of AS-1409 combined with IL-12@@-@-@-@LONDON, UNITED KINGDOM@2/1/2009@@@@14925037@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00625768@20@-@-@@@-@@2/1/2008@-@101@@-@-@@@I@I@@-@-@Final results expected in 2009@-@@@@COMBO@-@@@@@-||||@ANTISOMA@@@@@ANTISOMA||||@New Zealand@@@@@New Zealand|||||||||@Kidney Cancer@Renal Cell Carcinoma@Melanoma / Skin Cancer@@@Kidney Cancer|Renal Cell Carcinoma|Melanoma / Skin Cancer|||||||@AS-1409@@@@@AS-1409||||@mAb@@@@@mAb||||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924570@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intratumoural administration.@@-@-@-@OXFORD, UNITED KINGDOM@@@@@14924570@-@@-@-@@NO REVIEW@@@@-@Commercial partners sought to co-develop and market the drug. @-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@Treated tumours reduced in size. SOURCE: Oxford BioMedica, March 2002@-@@@@MONO@-@@@@@-||||@OXFORD BIOMEDICA@@@@@OXFORD BIOMEDICA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@METXIA@@@@@METXIA||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924842@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924842@Adjuvant with Avastin@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@RESULTS PENDING@-@@@@ADJUVANT@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923005@Onco@@@@@@@@@@@SC dose of Neugranin prior to myelosuppressive chemo; in the phase II portion, the drug will be compared with Neulasta@@-@-@-@ROCKVILLE, MARYLAND@@@@@14923005@Treatment of neutropaneia in patients with breast cancer receiving doxorubicin and taxotere@@-@-@@NO REVIEW@@@MARCH 2007-@-@Teva acquired CoGenesys for US$400 million. SOURCE: CoGenesys, 22 January 2008@FIRST-LINE@-@60@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@LONG-ACTING G-CSF@@@@@LONG-ACTING G-CSF||||@COGENESYS@TEVA PHARMACEUTICAL@@@@COGENESYS|TEVA PHARMACEUTICAL|||@@@@@@|||||||||@Supportive Care@Neutropaenia@Breast Cancer@@@Supportive Care|Neutropaenia|Breast Cancer|||||||@NEUGRANIN@@@@@NEUGRANIN||||@G-CSF@@@@@G-CSF||||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918868@Onco@@@@@300f1010ntsdm@@@@@@Combo with cyclophosphamide@@-@-@-@OXFORD, UNITED KINGDOM@@@@@14918868@Non-resectable@@-@-@@NO REVIEW@@@@-@Commercial partners sought to co-develop and market the drug. @-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@CYCLOPHOSPHAMIDE@@@@-|CYCLOPHOSPHAMIDE|||@OXFORD BIOMEDICA@@@@@OXFORD BIOMEDICA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@METXIA@@@@@METXIA||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923681@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@-@@@@@14923681@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@@RESULTS PENDING@-@@@@-@-@@@@@-||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NK-292@@@@@NK-292||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14923494@Onco@@@@@@@@@@@Patients will receive an IV 6mg Bondronat on days 1, 2 and 3.@@-@-@-@BASEL, SWITZERLAND@@@@@14923494@-@@-@-@@NO REVIEW@@@@-@Licensed from SmithKline Beecham in January 2001 in exchange for North American rights to Coreg@-@NCT00478270@<100@-@-@@@-@@@-@-@@-@<100 patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain.@@@II@II@@-@-@Not yet available@-@@@@MONO@IBANDRONATE@@@@@IBANDRONATE||||@ROCHE@@@@@ROCHE||||@Greece@@@@@Greece|||||||||@Bone Metastases@Breast Cancer@@@@Bone Metastases|Breast Cancer||||||||@BONDRONAT@@@@@BONDRONAT||||@Bisphosphonate@@@@@Bisphosphonate||||@PAIN RELIEF@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919009@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14919009@-@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Trial to commence in H2 2008. SOURCE: Ardea, 24 March 2008@-@@@@-@-@@@@@-||||@ARDEA BIOSCIENCES@@@@@ARDEA BIOSCIENCES||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@RDEA-436@@@@@RDEA-436||||@MEK Inhibitor@@@@@MEK Inhibitor||||@N/A@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918805@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918805@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15412803@Onco@@@@@@@@@@@@@@@@@9/1/2018@@@@15412803@The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring@Both@@@@@@@@@@@NCT02647164@360@@@@@@@1/1/2016@@CTC2015-01@@@Age 18-80 years old  -  Patients with histologically documented (stage Ⅰ/Ⅱ/ⅢA ) non-small cell lung cancer.  -  Patients will undergo surgery.  -  Patients with preoperative CTCs ≥8.5 Units / 3 ml  -  Informed consent must be obtained from all patients prior to beginning therapy. Patients should have the ability to understand and the willingness to sign a written informed consent document.@@ADULTS@N/A@-@@@@@@@@@@-@@@@@-||||@GENOSABER@@@@@GENOSABER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Other@@@@@Other||||@Circulating tumor cells will be detected by Immunomagnetic negative screening and targeted PCR method.@@@@@carcinoembryonic antigen(CEA) concentration will be detected by electrochemical luminescence.@Liconography using conventional CT examination results.@@@@@@@@@Case-Only@PROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924535@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924535@-@@-@-@@NO REVIEW@@@@-@Keryx receives notice from Nasdaq that the company is not in compliance with the US$1 minimum bid price for continued listing and most reach this within 180 days. SOURCE: Keryx, 28 April 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@-@@@@@-||||@KERYX BIOPHARMACEUTICALS@@@@@KERYX BIOPHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@KRX-0601@@@@@KRX-0601||||@PKC Inhibitor@@@@@PKC Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918921@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SUMMIT, NEW JERSEY@@@@@14918921@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@Status unclear@II@@-@-@In Phase I/II (SEC 10-K March 2005)@-@@@@-@-@@@@@-||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@CC-8490@@@@@CC-8490||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924218@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924218@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@UNKNOWN@-@@@-@@@-@-@@-@-@@@-@II@@-@-@UNKNOWN@-@@@@-@-@@@@@-||||@BMS@@@@@BMS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BMS-214662@@@@@BMS-214662||||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921520@Onco@@@@@@@@@@@E7070 with capecitabine versus capecitabine alone@@-@-@-@TOKYO, JAPAN@@@@@14921520@Combo with Xeloda following prior anthracycline and taxane therapy@@-@-@@NO REVIEW@@@DECEMBER 2004-SEPTEMEBER 2006@-@Global rights licensed from Ligand in September 2006@THIRD-LINE@NCT00165880@180@-@-@@@-@@@-@E7070-E044-213@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@INDISULAM@@@@@INDISULAM||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@E-7070@@@@@E-7070||||@Cytotoxic Antibiotic@Sulfonamide@@@@Cytotoxic Antibiotic|Sulfonamide|||@RECIST@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15041414@Onco@@@@@300f1037ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15041414@@@YES@@@@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@SNS@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMACEUTICALS@@@@@CHUGAI PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.1511@284.94@349.28@292.48@@@@@@@@@@@@@@@@@@@@@@@@@@8/4/2017@56.99@56.99@694430@INJECTION (VIAL + AMPOULE), 1 ML@EURO@@@@@@@@263@MCG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14916736@Onco@@@@@@@@@@@Lonafarnib plus anastrazole versus anastrazole alone.@@-@-@-@KENILWORTH, NEW JERSEY@@@@@14916736@with anastrazole@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Organon in 2007@-@NCT00081510@124@-@-@@@-@@@-@P03480  @@-@-@@@II@II@@-@-@Completion expected in April 2008.@-@@@@COMBO@LONAFARNIB@ANASTRAZOLE@@@@LONAFARNIB|ANASTRAZOLE|||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SARASAR@ARIMIDEX@@@@SARASAR|ARIMIDEX|||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923504@Onco@@@@@@@@@@@-@@-@-@-@JAMISON, PENNSYLVANIA@@@@@14923504@-@@-@-@@NO REVIEW@@@@-@-@-@-@80@-@-@@@FDA orphan drug designation. SOURCE: Hy@@@-@-@@-@-@@@III@III@@-@-@Trial to begin. SOURCE: Hy, 27 May 2008@-@@@@MONO@HYPERICIN@@@@@HYPERICIN||||@HY BIOPHARMA@@@@@HY BIOPHARMA||||@Israel@@@@@Israel|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@HBP-347@@@@@HBP-347||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@N/A@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922493@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@-@12/1/2008@@-@@14922493@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00758407@66@-@-@@@-@@8/1/2006@-@6520-9959-02@@-@-@@@II/III@III@@-@-@Trial registered. [Medice, 24.09.2008]@-@@@@-@METHYLPHENIDATE@@@@@METHYLPHENIDATE||||@MEDICE@@@@@MEDICE||||@@@@@@|||||||||@Supportive Care@Cancer Fatigue@@@@Supportive Care|Cancer Fatigue||||||||@-@@@@@-||||@Other@@@@@Other||||@GENERAL FATIGUE@@@@@QUALITY OF LIFE@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
15413044@Onco@@@@@@@@@@@Nivolumab(Opdivo)+Ipilimumab(Yervoy), Experimental,@@@@@NEW YORK, NEW YORK@1/1/2017@@@@15413044@An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab as First Line-therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)@Both@@@@@@@@@@@NCT02659059@170@@@@@@@2/1/2016@@CA209-568@@@Men and Women ≥ 18 years of age  -  Diagnosed with stage IV Non-Small Cell Lung Cancer  -  Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.@@ADULTS@Phase 2@II@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@Other@@@@@Other||||@The objective response rate (ORR)@@@@@Progression free survival (PFS)@Progression free survival (PFS) at 6 months@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924118@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924118@Post-surgery renal cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@IND submitted to begin Phase III trial@@@-@@@-@-@@-@-@@@II@II@@-@-@-@-@@@@-@RENIALE@@@@@RENIALE||||@LIPONOVA@@@@@LIPONOVA||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@-@@@@@-||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924544@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924544@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II/III@III@@-@-@Received NIH grant to conduct trial. SOURCE: NovaRx, 12 May 2004@-@@@@-@BELEGENPUMATUCEL-L@@@@@BELEGENPUMATUCEL-L||||@NOVARX@@@@@NOVARX||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@LUCANIX@@@@@LUCANIX||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@PIVOTAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924465@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924465@-@@-@-@@NO REVIEW@@@@-@Neose is selling substantially all of its assets to BioGeneriX and Novo Nordisk. [Neose, 18.09.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@BIOGENERIX@NEOSE TECHNOLOGIES@@@@BIOGENERIX|NEOSE TECHNOLOGIES|||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GLYCO-PEG-GCSF@@@@@GLYCO-PEG-GCSF||||@G-CSF@@@@@G-CSF||||@-@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918813@Onco@@@@@@@@@@@-@@-@-@-@ABINGDON, UNITED KINGDOM@@@@@14918813@First (and only)-in-class aminopeptidase inhibitor; Phase II commenced in March 2007@@-@-@@NO REVIEW@@@-@-@Licensed from Vernalis@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@CHROMA THERAPEUTICS@@@@@CHROMA THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CHR-2797@@@@@CHR-2797||||@Enzyme@@@@@Enzyme||||@-@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919053@Onco@@@@@@@@@@@-@@-@-@-@MONTVALE, NEW JERSEY@@@@@14919053@-@@-@-@@NO REVIEW@@@@-@Teva announces acquisition of Barr. SOURCE: Teva, 21 July 2008Pliva (Barr) and Mayne Pharma (Hospira) finalised an agreement on biosimilar G-CSF for the European, South East Asian, Middle Eastern and Asia-Pacific markets in July 2006.@-@-@-@-@Expected to be launched 2010@@@-@@@-@N/A@@-@-@@@-@III@@-@-@UNKNOWN@-@@@@-@-@@@@@-||||@BARR PHARMACEUTICALS@PLIVA@HOSPIRA@MAYNE PHARMA@TEVA PHARMACEUTICAL@BARR PHARMACEUTICALS|PLIVA|HOSPIRA|MAYNE PHARMA|TEVA PHARMACEUTICAL@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@G-CSF@@@@@G-CSF||||@G-CSF@@@@@G-CSF||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923500@Onco@@@@@@@@@@@-@@-@-@-@-@@@@@14923500@Long-acting formulation of EPO@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@The drug has been approved in the Philippines for use as a first-line and adjuvant therapy for pancreatic and breast cancer and a second-line therapy for all other solid tumors that are refractory to standard chemotherapy.@@@-@@@-@-@@-@-@@@I@I@@-@-@Interim data showed that it was well tolerated. SOURCE: Lipoxen, 23 April 2008@-@@@@-@-@@@@@-||||@LIPOXEN@@@@@LIPOXEN||||@India@@@@@India|||||||||@Other@@@@@Other|||||||||@EREPOXEN@@@@@EREPOXEN||||@EPO@@@@@EPO||||@SAFETY@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918847@Onco@@@@@300f1020ntsdm@@@@@@-@@-@-@-@-@@@@@14918847@Hepatocellular carcinoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@11/1/2003@-@N/A@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@PHOENIX PHARMACOLOGICS@@@@@PHOENIX PHARMACOLOGICS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@ADI-PEG20@@@@@ADI-PEG20||||@Enzyme@@@@@Enzyme||||@N/A@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14922684@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@LY-573636-sodium once every 21 days.@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922684@Soft tissue sarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00490451@50@-@-@@@-@@@-@10408H8K-MC-JZAD  @@-@-@@@II@II@@-@-@Completion expected in August 2009.@-@@@@MONO@-@@@@@-||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@LY-573636@@@@@LY-573636||||@Sulfonamide@@@@@Sulfonamide||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924158@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924158@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@-@@I@I@@-@-@Trial started. SOURCE: Albany Molecular, 19 August 2008@-@@@@-@-@@@@@-||||@ALBANY MOLECULAR RESEARCH@@@@@ALBANY MOLECULAR RESEARCH||||@@@@@@|||||||||@Other@@@@@Other|||||||||@ALB-109564(A)@@@@@ALB-109564(A)||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@-@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15299754@Onco@@@@@300f1010ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15299754@@@NO@@@@@@@100%@@@@@@@@@@@@@@No@@@@@@APPROVED@@@NHS@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMACEUTICALS@@@@@CHUGAI PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@40.11@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@40.11@40.11@1.64E+16@INJECTION POWDER FOR RECONSTITUTION (VIAL)@GB£@@@@@@@@105@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923148@Onco@@@@@300f1015ntsdm@@@@@@-@@-@-@-@MARSEILLE, FRANCE@@@@@14923148@-@@-@-@@NO REVIEW@@@@-@Novo Nordisk exited this partnership after discontinuing all of its oncology interests in February 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@INNATE PHARMA@@@@@INNATE PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@IPH-2101@NN-1975@@@@IPH-2101|NN-1975|||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
15409677@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@@@@@@15409677@Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma@Both@@@@@@@@@@@NCT02666209@@@@@@@@@@16-002@@@Must be currently participating on protocol 11-240 (DFCI)/ CA 212-002(BMS), tolerating therapy, and still receiving benefit from treatment.@@ADULTS@N/A@-@@@@@@@@@@ULOCUPLUMAB@@@@@ULOCUPLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@United States@@@@@United States|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@-@@@@@-||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@N/A@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924943@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-102 alone@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@@@14924943@Advanced renal cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00422019@80@-@-@@@-@@11/1/2006@-@20060100@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@AMG-102@@@@@AMG-102||||@mAb@Human@@@@mAb|Human|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918915@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@IRVINE, CALIFORNIA@@@@@14918915@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@IDM PHARMA@@@@@IDM PHARMA||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@BEXIDEM@@@@@BEXIDEM||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923506@Onco@@@@@300f1020ntsdm@@@@@@-@@-@-@-@-@@@@@14923506@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial started. SOURCE: Sigma Tau, 24 August 2007@-@@@@-@ADAROTENE@@@@@ADAROTENE||||@SIGMA TAU@@@@@SIGMA TAU||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924587@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AMSTERDAM, NETHERLANDS@@@@@14924587@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@KIADIS PHARMA@@@@@KIADIS PHARMA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@NB-1011@@@@@NB-1011||||@TS Inhibitor@@@@@TS Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924210@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924210@-@@-@-@@NO REVIEW@@@@-@"Seeking to sell off this ""non-core"" asset. SOURCE: Supergen Q2 Earnings Call, 2 August 2007Licensed from AVI in April 2000"@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPERGEN@@@@@SUPERGEN||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AVICINE@@@@@AVICINE||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924804@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@UNBS-5162 is a pan-agonist of CXCL chemokines@@14924804@-@@-@-@@NO REVIEW@@@@-@Drais has licensed full rights to develop the drug for all indications for US$31 million upfront plus milestones and royalties. [Drais, 17.09.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@DRAIS PHARMACEUTICALS@UNIBIOSCREEN@@@@DRAIS PHARMACEUTICALS|UNIBIOSCREEN|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@UNBS-5162@@@@@UNBS-5162||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924893@Onco@@@@@@@@@@@Patients receive capecitabine dose of 1,000 mg/m2 twice daily for 24 weeks as neoadjuvant therapy @@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924893@NeoAdjuvant treatment for women with newly diagnosed locally advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00347438 @48@-@-@@@-@@9/1/2006@-@-@@-@-@@@II@II@@-@-@Not yet available.@-@@@@NEOADJUVANT@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@PARTIAL RESPONSE@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920483@Onco@@@@@300f1015ntsdm@@@@@@@@L01XX03@L01X@@GALASHIELS, UNITED KINGDOM@@@@@14920483@@@NO@@@NO REVIEW@@@@@@@@@@@@2/5/2001@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@@ALTRETAMINE@@@@@ALTRETAMINE||||@PROSTRAKAN@@@@@PROSTRAKAN||||@@@@@@|||||||||@Ovarian Cancer@SCLC@@@@Ovarian Cancer|SCLC||||||||@HEXASTAT@@@@@HEXASTAT||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1511@15.34@20.49@16.36@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@0.61@0.61@3.40E+12@CAPSULE@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924545@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@IRVINE, CALIFORNIA@@@@@14924545@Radiation sensitisier in brain tumour and brain metastases@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@THIAXANTHENONE@@@@@THIAXANTHENONE||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@LUCANTHONE@@@@@LUCANTHONE||||@Plant Alkaloid@Topoisomerase II Inhibitor@@@@Plant Alkaloid|Topoisomerase II Inhibitor|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924237@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14924237@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Filings expected in 2011. SOURCE: Antisoma, 13 April 2008@4/13/2008@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@CG THERAPEUTICS@@@@@CG THERAPEUTICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CG-201@@@@@CG-201||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921003@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AUSTIN, TEXAS@12/1/2006@@@@14921003@Transit melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00116363@25@-@-@@@-@@3/1/2005@-@INT 241-004@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@INGN-241@@@@@INGN-241||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921188@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intratumoural injections of TNFerade plus radiation as a 4-week treatment followed by 3-year follow-up@@-@-@-@-@@@@@14921188@Stage III or IV metastatic melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00261404@N/A@-@-@@@-@@@-@GV-001.008@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GENVEC@@@@@GENVEC||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TNFERADE@@@@@TNFERADE||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924214@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924214@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@Trial to commence in 2008. SOURCE: NatImmune@-@@@@-@-@@@@@-||||@NATIMMUNE@@@@@NATIMMUNE||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@BAMLET@@@@@BAMLET||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@LIQUID@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920130@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BG03@L02B@@CORONA, CALIFORNIA@@@@@14920130@@@@@@@@@@@@@@@@FDA, 24 April 2008@4/24/2008@@@@@@@No@@@@@@APPROVED@@@@@@@@@@ANASTROZOLE@@@@@ANASTROZOLE||||@WATSON PHARMACEUTICALS@@@@@WATSON PHARMACEUTICALS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@US$@@@@@@@@1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918945@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918945@In patients with terminal cancers and psoriasis@@-@-@@NO REVIEW@@@@-@Licensed to Access Oncology (Keryx)@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@-@-@@@@-@-@@@@@-||||@GEM PHARMACEUTICALS@@@@@GEM PHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@GPX-150@@@@@GPX-150||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922487@Onco@@@@@@@@@@@Gemzar/cisplatin with concomitant thoracic radiotherapy@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922487@Inoperable Stage III SCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00192036@N/A@-@-@@@-@@@-@8984B9E-BX-JHSQ@@-@-@@@II@II@@-@-@Completion expected February 2008.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@CISPLATIN@@@@GEMCITABINE HYDROCHLORIDE|CISPLATIN|||@LILLY@@@@@LILLY||||@Belgium@@@@@Belgium|||||||||@SCLC@@@@@SCLC|||||||||@GEMZAR@@@@@GEMZAR||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@N/A@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924800@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924800@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TSU-68@SU-6668@@@@TSU-68|SU-6668|||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@FGF@PDGF@TK Inhibitor|Angiogenesis Inhibitor|VEGF|FGF|PDGF@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412296@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@NEW YORK, NEW YORK@@@@@15412296@Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma@Both@@@@@@@@@@@NCT02666209@@@@@@@@@@16-002@@@Signed informed consent document, Must be currently participating on protocol 11-240 (DFCI)/ CA 212-002(BMS), tolerating therapy, and still receiving benefit from treatment.@@ADULTS@N/A@-@@@@@@@@@@ULOCUPLUMAB@@@@@ULOCUPLUMAB||||@BRISTOL-MEYERS SQUIBB@@@@@BRISTOL-MEYERS SQUIBB||||@United States@@@@@United States|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@-@@@@@-||||@Other@@@@@Other||||@@@@@@@@@@@REFRACTORY@RELAPSED@@@@N/A@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923025@Onco@@@@@@@@@@@Patients will receive an IV 6mg Bondronat in 3 consecutive days. @@-@-@-@BASEL, SWITZERLAND@@@@@14923025@-@@-@-@@NO REVIEW@@@@-@Licensed from SmithKline Beecham in January 2001 in exchange for North American rights to Coreg@-@NCT00381368@60@-@-@@@-@@10/1/2006@-@-@@-@60 female patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain.@@@II@II@@-@-@Not yet available@-@@@@MONO@IBANDRONATE@@@@@IBANDRONATE||||@ROCHE@@@@@ROCHE||||@Finland@@@@@Finland|||||||||@Bone Metastases@Breast Cancer@@@@Bone Metastases|Breast Cancer||||||||@BONDRONAT@@@@@BONDRONAT||||@Bisphosphonate@@@@@Bisphosphonate||||@BONE PAIN@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924709@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14924709@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@SGN-30@@@@@SGN-30||||@mAb@Chimeric@CD30@@@mAb|Chimeric|CD30||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918927@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@8 dose levels of CNDO-101@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14918927@Advanced cancers with bone metastases@@-@-@@NO REVIEW@@@@-@-@-@-@30@-@-@@@-@@1/1/2008@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CORONADO BIOSCIENCES@@@@@CORONADO BIOSCIENCES||||@@@@@@|||||||||@Other@@@@@Other|||||||||@CNDO-101@@@@@CNDO-101||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@DOSE RANGE@@@@@@@@@@ADVANCED@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922478@Onco@@@@@300f1012ntsdm@@@@@@LY-573636 IV day 1 of 21 day cycle@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922478@Unresectable, metastatic NSCLC@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00363766@50@-@-@@@-@@@-@9813H8K-MC-JZAC  @@-@-@@@II@II@@-@-@Completion expected in February 2008.@-@@@@MONO@-@@@@@-||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@LY-573636@@@@@LY-573636||||@Sulfonamide@@@@@Sulfonamide||||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14916784@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive oral aminolevulinic acid* 3-4 hours before photodynamic therapy using pulsed dye laser on day 1.@@-@-@-@-@@@@@14916784@Leukoplakia@@-@-@@NO REVIEW@@@@-@-@-@NCT00571558@35@-@-@@@-@@5/1/2008@-@NU-NWU05-5-01@@-@-@@@I@I@@-@-@Trial started. SOURCE: DUSA, 30 May 2008@-@@@@MONO@AMINOLEVULINIC ACID@@@@@AMINOLEVULINIC ACID||||@DUSA@@@@@DUSA||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@-@@@@@-||||@Other@@@@@Other||||@TOXICITY@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918957@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AUSTIN, TEXAS@@@@@14918957@Mouth cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@MOUTH WASH@@@@@MOUTH WASH||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@INGN-234@@@@@INGN-234||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919022@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@@@14919022@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@-@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SP-1049C@@@@@SP-1049C||||@Other@@@@@Other||||@N/A@@@@@@@@@@REFRACTORY@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922972@Onco@@@@@@@@@@@-@@-@-@-@CHINA@@@First recombinant human endostatin injection approved in China.@@14922972@Endu with platinum chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@IV@IV@@-@-@Overall response rate and clinical benefit rate were 24% and 81% respectively, while the response rates of the newly trated and previously treated groups were 31% and 17% respectively. [Simcere, 8.09.2008]@-@@@@COMBO@ENDOSTATIN@@@@@ENDOSTATIN||||@SIMCERE@@@@@SIMCERE||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@ENDU@ENDOSTAR@@@@ENDU|ENDOSTAR|||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1Onco2@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@gtestCountry_Clinical_Trial11@gtestCountry_Clinical_Trial21@gtestCountry_Clinical_Trial31@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@LEVOCARNITINE@En@Active_Ingredient_Translated@20@ML@3.141592741@Dose UnitTest@300@MG@300 MG@2000@MG@DDD CommentTest@Active_Ingredient_Item1@Active_Ingredient_Item2@Active_Ingredient_Item3@Active_Ingredient_Item4@@Active_Ingredient_Item_Translated1@Active_Ingredient_Item_Translated2@Active_Ingredient_Item_Translated3@@@Strength_Item1@Strength_Item2@Strength_Item3@@@Strength_CALCtest@Strength_unitTST@63.62@DDDtest@@@@@@@@@@@
14924604@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BA01@L02B@@LONDON, UNITED KINGDOM@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14924604@@@@@@NO REVIEW@@@@@@@@@@@@@@@@@@@@@@@@DISCONTINUED@@@@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NOLVADEX@@@@@NOLVADEX||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924211@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924211@-@@-@-@@NO REVIEW@@@@-@"Seeking to sell off this ""non-core"" asset. SOURCE: Supergen Q2 Earnings Call, 2 August 2007Licensed from AVI in April 2000"@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@-@-@@@@-@-@@@@@-||||@SUPERGEN@@@@@SUPERGEN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@AVICINE@@@@@AVICINE||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922343@Onco@@@@@300f1018ntsdm@@@@@@Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles. Number of Cycles: Until Progression or unacceptable toxicity develops. @@-@-@-@NEW YORK, NEW YORK@2/1/2010@@@@14922343@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00557505@60@-@-@@@-@@12/1/2007@-@A9301001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-3732010@@@@@PF-3732010||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14921812@Onco@@@@@@@@@@@Patupilone versus pegylated liposomal doxorubicin@@-@-@-@BASEL, SWITZERLAND@@@Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel.@@14921812@Recurrent ovarian, primary fallopian or primary peritoneal cancer refractory or resistant to taxane/platinum therapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00262990@810@-@-@@@-@@11/1/2005@-@CEPO906A2303@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@PATUPILONE@@@@@PATUPILONE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@EPO-906@@@@@EPO-906||||@Epothilone@@@@@Epothilone||||@RECIST@OVERALL SURVIVAL@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922776@Onco@@@@@300f1018ntsdm@@@@@@-@@-@-@-@-@@@@@14922776@-@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@SOLASONINE AND SOLAMARGINE@@@@@SOLASONINE AND SOLAMARGINE||||@SOLBEC PHARMACEUTICALS@@@@@SOLBEC PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CORAMSINE@@@@@CORAMSINE||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14923505@Onco@@@@@@@@@@@-@@-@-@-@JAMISON, PENNSYLVANIA@@@@@14923505@Cutaneous T-cell lymphoma@@-@-@@NO REVIEW@@@@-@-@-@-@80@-@-@@@FDA orphan drug designation. SOURCE: Hy@@@-@-@@-@-@@@III@III@@-@-@Trial to begin. SOURCE: Hy, 27 May 2008@-@@@@MONO@HYPERICIN@@@@@HYPERICIN||||@HY BIOPHARMA@@@@@HY BIOPHARMA||||@Israel@@@@@Israel|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@HBP-347@@@@@HBP-347||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@N/A@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924126@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive 2 5-day treatments applied to the perianal/anal areas, each on a 28-day cyle (months 1 and 2). @@-@-@-@-@@@@@14924126@Anal high grade squamous intraepithelial lesions@@-@-@@NO REVIEW@@@@-@-@-@-@15@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TIGRIS PHARMACEUTICALS@@@@@TIGRIS PHARMACEUTICALS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@A-007@@@@@A-007||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923002@Onco@@@@@@@@@@@80MG/M2 of alvespimycin given weekly for 3 weeks@@-@-@-@HAYWARD, CALIFORNIA@@@@@14923002@HER2-POSITIVE METASTATIC BREAST CANCER not treated by Herceptin except as adjuvant@@-@-@@NO REVIEW@@@4 repeated cycles@-@BMS acquires Kosan Biosciences for US$190 million. SOURCE: BMS, 29 May 2008@-@-@25@-@-@@@-@@@-@-@@-@-@@@II@DISCONTINUED@@-@-@Candidate withdrawn in favour of development of tanespimycin. SOURCE: Kosan, 28 February 2008Trial started. SOURCE: Kosan, 15 January 2008.@-@@@@MONO@ALVESPIMYCIN@@@@@ALVESPIMYCIN||||@KOSAN BIOSCIENCES@BMS@@@@KOSAN BIOSCIENCES|BMS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@KOS-1022@DMAG@@@@KOS-1022|DMAG|||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923013@Onco@@@@@@@@@@@Patients treated with cisplatin and paclitaxel every 3 weeks were given dimesna@@-@-@-@SAN ANTONIO, TEXAS@@@@@14923013@Chemotherapy-associated neuropathy in NSCLC@@-@-@@NO REVIEW@@@-@-@Licensing and development deal with Takeda terminated in October 2006.@-@-@-@-@-@@@-@@@-@-@@-@-@@@III; European Lung Cancer Trial@III@@-@-@July 2006; trial failed primary endpoint in total incidence of sever chemotherapy-associated neuropathy and difference in tumour response rates.@-@@@@MONO@DIMESNA@@@@@DIMESNA||||@BIONUMERIK@TAKEDA PHARMACEUTICAL@@@@BIONUMERIK|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Supportive Care@NSCLC@@@@Supportive Care|NSCLC||||||||@TAVOCEPT@BNP-7787@@@@TAVOCEPT|BNP-7787|||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@NEUROPATHY@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924885@Onco@@@@@@@@@@@-@@-@-@-@MADISON, NEW JERSEY@@@@@14924885@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@-@60@-@-@@@-@@4/1/2006@-@-@@-@60 PATIENTS WITH STAGE IIIB, IIIC OR IV BREAST CANCER AND PATIENTS WHO HAVE PROGRESSED WITH UP TO THREE YEARS PRIOR TO CHEMOTHERAPY REGIMENS.@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BOSUTINIB@@@@@BOSUTINIB||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@SKI-606@@@@@SKI-606||||@TK Inhibitor@bcr-abl@HER2@@@TK Inhibitor|bcr-abl|HER2||@-@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924645@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BRISBANE, AUSTRALIA@@@@@14924645@Hormone refractory prostate cancer; delay disease progression@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@P53 GENE@@@@@P53 GENE||||@AVANTOGEN@@@@@AVANTOGEN||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@PENTRYS VACCINE@@@@@PENTRYS VACCINE||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921140@Onco@@@@@@@@@@@Weekly alvocidib@@-@-@-@PARIS, FRANCE@@@@@14921140@Previously treated CLL@@-@-@@NO REVIEW@@@APRIL 2007-@-@-@-@NCT00464633@165@-@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@-@HMR1275@@-@-@@@EFC6663, @II@@-@-@RESULTS PENDING@-@@@@MONO@ALVOCIDIB@@@@@ALVOCIDIB||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@HMR-1275@@@@@HMR-1275||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924811@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924811@Adjuvant to cancer vaccines@@-@-@@NO REVIEW@@@@-@Coley licensed to GSK and Novartis for oncology vaccines; Pfizer bought Coley in November 2007@-@-@-@-@-@@@-@@@-@-@@-@-@-@@-@II@@-@-@-@-@@@@ADJUVANT@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Other@@@@@Other|||||||||@VAXIMMUNE@@@@@VAXIMMUNE||||@TLR-targeted@Vaccine@@@@TLR-targeted|Vaccine|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924505@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924505@Gastric cancer@@-@-@@NO REVIEW@@@@-@Licensed from Aphton in July 2006 after Aphton filed for bankrupcty.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@G17DT IMMUNOGEN@@@@@G17DT IMMUNOGEN||||@RECEPTOR BIOLOGIX@@@@@RECEPTOR BIOLOGIX||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@INSEGNIA@@@@@INSEGNIA||||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924649@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924649@Gastric cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@WELLSTAT BIOLOGICS@@@@@WELLSTAT BIOLOGICS||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@PN-401@@@@@PN-401||||@Nucleoside Analogue@@@@@Nucleoside Analogue||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918867@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@-@@@@@14918867@Leukaemia@@-@-@@NO REVIEW@@@@-@ImmuPharma licensed exclusive rights from the Centre National de la Recherche Scientifique (France) in January 2008.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Trial to start by year-end. SOURCE: ImmuPharma, January 2008.@-@@@@MONO@-@@@@@-||||@IMMUPHARMA@@@@@IMMUPHARMA||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@IPP-204106@@@@@IPP-204106||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14921607@Onco@@@@@@@@@@@Zactima versus Tarceva@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14921607@Versus Tarceva@@-@-@@NO REVIEW@@@@-@-@-@NCT00364351@1150@-@-@@@-@@8/1/2006@-@D4200C00057@@-@-@@@III; EUDRACT NO. 2006-000259-16 / @III@@-@-@RESULTS PENDING@-@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919052@Onco@@@@@@@@@@@N/A@@-@-@-@PARIS, FRANCE@@@@@14919052@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@III@III@@-@-@Trial design still in progress@-@@@@-@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@AVE-8062@AC-7700@@@@AVE-8062|AC-7700|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@N/A@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924501@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WILMINGTON, DELAWARE@@@@@14924501@Mono@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial to begin in 2008@-@@@@MONO@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@INCB-7839@@@@@INCB-7839||||@Other@HER2@@@@Other|HER2|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921681@Onco@@@@@@@@@@@Mycobacterium with paclitaxel and cisplatin versus paclitaxel and cisplatin@@-@-@-@-@12/1/2010@@@@14921681@Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer @@-@-@@NO REVIEW@@@@-@-@-@NCT00680940@220@-@-@@@-@@6/1/2008@-@CR-60/7260@@-@Histologically or cytologically confirmed Non-Small Cell Cancer, Stage IIIB or IV. Age should be 18 years or above. ECOG should be in 0-1 range.@@@II@II@@-@-@Trial registered. SOURCE: Cadila, 16 May 2008@-@@@@COMBO@MYCOBACTERIUM@PACLITAXEL@CISPLATIN@@@MYCOBACTERIUM|PACLITAXEL|CISPLATIN||@CADILA PHARMACEUTICALS@@@@@CADILA PHARMACEUTICALS||||@India@@@@@India|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Immunotherapy@@@@@Immunotherapy||||@OVERALL SURVIVAL@QUALITY OF LIFE@@@@RESPONSE RATE@TOXICITY@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921168@Onco@@@@@@@@@@@-@@-@-@-@SOUTH KOREA@@@-@@14921168@Advanced Hepatocellular Carcinoma.@@-@-@@NO REVIEW@@@November 2006-April 2008@-@KAEL Co, through its subsidiary VaxOnco, will acquire GemVax from Pharmexa, including GV-1001. Financial details not disclosed. [KAEL, 31.10.2008]@-@NCT00444782@41@-@-@@@-@@@-@HEPTOVAX@@-@-@@@II@II@@-@-@Trial registered [Gemvax, 7.03.2007]@-@@@@-@-@@@@@-||||@KAEL CO.@PHARMEXA@@@@KAEL CO.|PHARMEXA|||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@GV-1001@@@@@GV-1001||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RECIST@@@@@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924685@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14924685@@@@@@NO REVIEW@@@@@-@@@@@@@@@@@@@@@@@@@II@@@@RESULTS PENDING@@@@@@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922338@Onco@@@@@@@@@@@Zoladex 10.8mg every 12 weeks versus Zoladex 3.6mg every 4 weeks@@L02AE03@L02A@-@LONDON, UNITED KINGDOM@@@Zoladex (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Zoladex results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Zoladex, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.@@14922338@ER-positive advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00322348@260@-@-@@@-@@@-@ABC STUDY  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZOLADEX@@@@@ZOLADEX||||@LH-RH Analog@@@@@LH-RH Analog||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918864@Onco@@@@@300f1010ntsdm@@@@@@-@@L01XX19@L01X@-@FARNHAM, UNITED KINGDOM@@@@@14918864@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@MONO@IRINOTECAN, DRUG-ELUTING BEAD@@@@@IRINOTECAN, DRUG-ELUTING BEAD||||@BIOCOMPATIBLES INTERNATIONAL@@@@@BIOCOMPATIBLES INTERNATIONAL||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@DEB@@@@@DEB||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14921164@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@C01BA02@C01B@@@@@@@14921164@@@@@@NO REVIEW@@@@@Mundipharma@@@@@@@@@@@@@No@@@@@@APPROVED@@@@@@@@@@PROCARBAZINE HYDROCHLORIDE@@@@@PROCARBAZINE HYDROCHLORIDE||||@SIGMA TAU@@@@@SIGMA TAU||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@MATULANE@@@@@MATULANE||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1@8160.6@@@@@@@@@@@@1.63@@@@@@@@@@@@@@@@8/2/2017@81.61@81.61@54482-0053-01@CAPSULE@US$@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918956@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AUSTIN, TEXAS@@@@@14918956@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@INGN-225@@@@@INGN-225||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919041@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14919041@Reverse resistance to Alimta@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Trial to begin in 2008. SOURCE: Tracon, 25 February 2008@-@@@@MONO@METHOXYAMINE@@@@@METHOXYAMINE||||@TRACON PHARMACEUTICALS@@@@@TRACON PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TRC-102@@@@@TRC-102||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918762@Onco@@@@@@@@@@@-@@-@-@-@TROMSO, NORWAY@@@@@14918762@Oral mucositis@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@"Biotec Pharmacon ""maintains an optimistic objective"" to file in Europe in 2009. Orphan drug in Europe."@@@-@@@-@NA@@-@-@@@III@III@@-@-@June 2007; EMEA confirmed that the company may be in a position to file for marketing authorisation based on two positive, confirmatory phase III studies, and the company is now in preparation for one of these. @-@@@@-@-@@@@@-||||@BIOTEC PHARMACON@@@@@BIOTEC PHARMACON||||@@@@@@|||||||||@Supportive Care@Mucositis@@@@Supportive Care|Mucositis||||||||@SBG@@@@@SBG||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919057@Onco@@@@@@@@@@@100MG dose daily@@-@-@-@NEW YORK, NEW YORK@@@@@14919057@-@@-@-@@NO REVIEW@@@@-@-@-@-@66@-@-@@@-@@4/1/2006@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SU-14813@@@@@SU-14813||||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@PDGF@@TK Inhibitor|Angiogenesis Inhibitor|VEGF|PDGF|@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919021@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@@@14919021@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@-@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@SP-1049C@@@@@SP-1049C||||@Other@@@@@Other||||@N/A@@@@@@@@@@REFRACTORY@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924074@Onco@@@@@300f1014ntsdm@@@@@@@@L01XX14@L01X@@BASEL, SWITZERLAND@@@@@14924074@@@@@@NO REVIEW@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@RAMQ@RESULTS PENDING@@@@@@TRETINOIN@@@@@TRETINOIN||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@VESANOID@@@@@VESANOID||||@Retinoid@@@@@Retinoid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@0.7881@1638.63@@@@@@@@@@@@1.64@@@@@@@@@@@@@@@@7/19/2017@16.39@16.39@2145839100@CAPSULE@C$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14924571@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@TOKYO, JAPAN@@@@@14924571@-@@-@-@@NO REVIEW@@@@-@Eisai acquired through takeover of MGI Pharma. MGI Pharma licensed North American rights from British Biotech in 2000@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@-@-@@@@-@-@@@@@-||||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@MG-98@@@@@MG-98||||@Antisense@@@@@Antisense||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918941@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918941@Anaemia of chronic disease@@-@-@@NO REVIEW@@@@-@Astellas has licensed global rights after an extended agreement in April 2006.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@FIBROGEN@ASTELLAS PHARMA@@@@FIBROGEN|ASTELLAS PHARMA|||@@@@@@|||||||||@Supportive Care@Anaemia@@@@Supportive Care|Anaemia||||||||@FG-4592@@@@@FG-4592||||@HIF-targeting@@@@@HIF-targeting||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15064835@Onco@@@@@@@@@@@MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per dayPlacebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@-@@15064835@-@@-@-@@NO REVIEW@@@JUNE 2010 - JUNE 2014@-@-@@NCT01151046@130@-@-@@@-@@@-@MM-121-02-02-03@@-@Locally advanced or metastatic breast cancerHistologically or cytologically confirmed ER+ and/or PgR+ and Her2 negative breast cancer@@@II@II@@-@-@Trial registered [Merrimack, 24 June 2010]@-@@@@-@-@EXEMESTANE@@@@-|EXEMESTANE|||@MERRIMACK PHARMACEUTICALS@@@@@MERRIMACK PHARMACEUTICALS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MM-121@AROMASIN@@@@MM-121|AROMASIN|||@mAb@Human@@@@mAb|Human|||@EFFICACY@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924487@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@FREDERICK, MARYLAND@@@@@14924487@-@@-@-@@NO REVIEW@@@@-@Xenova terminated its development and licensing agreement.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@INTRACEL@XENOVA@@@@INTRACEL|XENOVA|||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@HUMARAD-HN@@@@@HUMARAD-HN||||@mAb@Human@Radiolabeled@@@mAb|Human|Radiolabeled||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923628@Onco@@@@@300f1020ntsdm@@@@@@-@@-@-@-@-@@@@@14923628@-@@YES@-@@NO REVIEW@@@@100%@-@-@-@-@-@N/A@@@-@@@-@-@@-@-@@@I@I@@1@SSN@Trial started. SOURCE: Sigma Tau, 24 August 2007@-@@@@-@-@@@@@-||||@SIGMA TAU@@@@@SIGMA TAU||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ST-1926@@@@@ST-1926||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924502@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WILMINGTON, DELAWARE@@@@@14924502@Combo with Herceptin@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@INCB-7839@@@@@INCB-7839||||@Other@HER2@@@@Other|HER2|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924650@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924650@Adjuvant to fluorouracil therapy and will be tested against gemcitabine.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@-@@III@III@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@WELLSTAT BIOLOGICS@@@@@WELLSTAT BIOLOGICS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@PN-401@@@@@PN-401||||@Nucleoside Analogue@@@@@Nucleoside Analogue||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924077@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01XX14@L01X@@BASEL, SWITZERLAND@@@@@14924077@@@@@@NO REVIEW@@@@@@@@@@FDA, 22 November 1995@11/22/1995@@@@@@@No@@@@@@APPROVED@@@@RESULTS PENDING@@@@@@TRETINOIN@@@@@TRETINOIN||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@VESANOID@@@@@VESANOID||||@Retinoid@@@@@Retinoid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00004-0250-01@CAPSULE@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924215@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14924215@-@@-@-@@NO REVIEW@@@@-@Biogen Idec licensed exclusive rights to maytansinoid TAP technology with antibodies that target Cripto from ImmunoGen in 2004.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BIIB-015@@@@@BIIB-015||||@mAb@@@@@mAb||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16078588@Onco@@@@@@@@@@@Experimental: ARM A :Carboplatin plus PF-01367338 Experimental: ARM A EXPANSION : Carboplatin plus PF-01367338@@@@@@4/1/2014@@@@16078588@A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens@Both@@@@@Experimental: ARM ACarboplatin plus PF-01367338@@@@@@NCT01009190@85@@@@@@@2/1/2010@@CO-338-1014@@@Patients with histologically confirmed solid tumors, Eastern Cooperative Oncology Group (ECOG) 0 or 1 - Patients with acceptable renal, hepatic, and bone marrow function@COMBO@Adult@Phase 1@I@@@@@@@@@@RUCAPARIB@CARBOPLATIN@@@@RUCAPARIB|CARBOPLATIN|||@CLOVIS ONCOLOGY@@@@@CLOVIS ONCOLOGY||||@France@Italy@@@@France|Italy||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-01367338@GENERIC@@@@PF-01367338|GENERIC|||@PARP Inhibitor@@@@@PARP Inhibitor||||@Safety and tolerability of escalating doses of PF-01367338 in combination with chemotherapy@@@@@Pharmacokinetics and pharmacodynamics@@@@@ADVANCED@@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15409686@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@@12/1/2016@@@@15409686@Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy@Both@@@@@@@@@@@NCT02665299@200@@@@@@@1/1/2016@@Pathway Genomics 005@@@18 years of age or older who are scheduled to undergo a screening or diagnostic colonoscopy by Dr. Phillip Fleshner@@ADULTS@N/A@-@@@@@@@@@@-@@@@@-||||@@@@@@||||@United States@@@@@United States|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@Utility of plasma ctDNA measurements to detect colon cancer or precancerous conditions.@@@@@Determination of incident rate of new colon or other cancers in patients who underwent initial measurement of ctDNA@@@@@@@@@@Cohort@PROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921655@Onco@@@@@@@@@@@Monthly doses of pasireotide I.M. LAR injection@@-@-@-@BASEL, SWITZERLAND@@@@@14921655@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00446082@60@-@-@@@-@@6/1/2006@-@CSOM230C2110@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@PASIREOTIDE@@@@@PASIREOTIDE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Acromegaly@Carcinoid / Neuroendocrine Tumour@@@@Acromegaly|Carcinoid / Neuroendocrine Tumour||||||||@SOM-230@@@@@SOM-230||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@PHARMACOKINETICS@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924683@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AMSTERDAM, NETHERLANDS@@@@@14924683@Eliminating cancer cells from autologous graft in bone marrow transplantations for end-stage blood cancer patients@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@SPA granted. SOURCE: Kiadis, 22 February 2008@2/22/2008@@-@@@-@-@@-@-@@@III@III@@-@-@Trial to begin early 2008. SOURCE: Kiadis, 22 February@-@@@@-@-@@@@@-||||@KIADIS PHARMA@@@@@KIADIS PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Supportive Care@@@@Haematological Malignancy|Supportive Care||||||||@REVIROC@@@@@REVIROC||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14925093@Onco@@@@@@@@@@@@@@@@@@@@@14925093@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@III@@@@@@@@@@-@@@@@-||||@@@@@@||||@@@@@@|||||||||@Other@@@@@Other|||||||||@GSK-2118436@GSK-1120212@@@@GSK-2118436|GSK-1120212|||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924234@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SEATTLE, WASHINGTON@@@@@14924234@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Filings expected in 2011. SOURCE: Antisoma, 13 April 2008@4/13/2008@@-@@@-@-@@-@-@@@II@II@@-@-@Trial to commence in 2008. SOURCE: CG, 7 April 2008@-@@@@-@-@@@@@-||||@CG THERAPEUTICS@@@@@CG THERAPEUTICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CG-201@@@@@CG-201||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918865@Onco@@@@@300f1010ntsdm@@@@@@-@@L01DB01@L01D@-@FARNHAM, UNITED KINGDOM@@@@@14918865@Glioma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@MONO@DOXORUBICIN, DRUG-ELUTING BEAD@@@@@DOXORUBICIN, DRUG-ELUTING BEAD||||@BIOCOMPATIBLES INTERNATIONAL@@@@@BIOCOMPATIBLES INTERNATIONAL||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@DEB@@@@@DEB||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14924130@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@UNITED STATES@@@@@14924130@Studies expected to commence in 2008.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING; studies commencing in 2008.@-@@@@-@THIOCOLCHICINE NANOPARTICLE ALBUMIN-BOUND@@@@@THIOCOLCHICINE NANOPARTICLE ALBUMIN-BOUND||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ABI-011@@@@@ABI-011||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922350@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single-agent testing@@-@-@-@NEW YORK, NEW YORK@@@@@14922350@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00557856@60@-@-@@@-@@11/1/2007@-@A8471001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-3446962@@@@@PF-3446962||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@RP2D@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923629@Onco@@@@@300f1020ntsdm@@@@@@-@@-@-@-@-@@@@@14923629@-@@YES@-@@NO REVIEW@@@@100%@-@-@-@-@-@N/A@@@-@@@-@-@@-@-@@@I@I@@1@SSN@Trial started. SOURCE: Sigma Tau, 24 August 2007@-@@@@-@-@@@@@-||||@SIGMA TAU@@@@@SIGMA TAU||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ST-1968@@@@@ST-1968||||@Camptothecin@@@@@Camptothecin||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14921614@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@LONDON, UNITED KINGDOM@11/1/2009@@@@14921614@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00454090@60@-@-@@@-@@3/1/2007@-@D1536C00001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-8330@@@@@AZD-8330||||@MEK Inhibitor@@@@@MEK Inhibitor||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922101@Onco@@@@@@@@@@@Arm I: Patients receive brostallicin IV over 10 minutes on day 1. Arm II: Patients receive doxorubicin hydrochloride IV over 10 minutes on day 1. In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity@@-@-@-@-@@@@@14922101@METASTATIC SOFT TISSUE SARCOMA@@-@-@@NO REVIEW@@@@-@Inherited from Pharmacia & Upjohn/Pfizer merger@-@NCT00410462@108@-@-@@@-@@10/1/2006@-@BRTA-0100-015@@-@-@@@EORTC-62061, EUDRACT-2006-001861-40, @II@@-@-@EORTC completes enrollment. SOURCE: Cell Therapeutics, 13 August 2008PREVIOUSLY DISCONTINUED AT PHARMACIA & UPJOHN.@-@@@@MONO@BROSTALLICIN@@@@@BROSTALLICIN||||@NERVIANO@@@@@NERVIANO||||@Netherlands@@@@@Netherlands|||||||||@Sarcoma@@@@@Sarcoma|||||||||@(PNU-166196)@@@@@(PNU-166196)||||@Anthracycline@@@@@Anthracycline||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923000@Onco@@@@@@@@@@@-@@-@-@-@-@@@@@14923000@-@@-@-@@NO REVIEW@@@-@-@-@-@-@90@-@EMEA ORPHAN DRUG STATUS GRANTED FOR RENAL CELL CANCER IN MARCH 2007.@@@EMEA ORPHAN DRUG STATUS GRANTED FOR RENAL CELL CANCER IN MARCH 2007.@@@-@-@@-@-@@@I/II@II@@-@-@Trial started. SOURCE: Immatics, 22 April 2008@-@@@@-@-@@@@@-||||@IMMATICS@@@@@IMMATICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@IMA-910@@@@@IMA-910||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@SAFETY@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924248@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14924248@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Covx in December 2007@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@COVX@PFIZER@@@@COVX|PFIZER|||@@@@@@|||||||||@Other@@@@@Other|||||||||@CVX-060@@@@@CVX-060||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918851@Onco@@@@@300f1020ntsdm@@@@@@-@@-@-@-@MILAN, ITALY@@@@@14918851@-@@-@-@@NO REVIEW@@@@-@Takara Bio holds the Asian market rights. MolMed is looking to out-license other rights.@-@-@17@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@Preliminary results in 17 patients; objective response seen in 3 patients with little toxic side-effects@-@@@@MONO@-@@@@@-||||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@M3TK@@@@@M3TK||||@Vaccine@@@@@Vaccine||||@SAFETY@RESPONSE RATE@@@@@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@MULTI-CENTRE@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
15041410@Onco@@@@@300f1018ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15041410@@@YES@@@@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@PBS@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@10@0.779@1219.42@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/1/2017@121.94@121.94@1654-1424-HB-PF@POWDER FOR INJECTION@A$@@@@@@@@263@MCG@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14924742@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924742@-@@-@-@@NO REVIEW@@@@-@Japanese rights licensed from Abraxis in November 2005@-@NCT00166543@180@-@-@@@-@@5/1/2004@-@-@@-@POSTMENOPAUSAL PATIENTS@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TAS-108@SR-16234@@@@TAS-108|SR-16234|||@SERMs@@@@@SERMs||||@TIME TO PROGRESSION@@@@@@@@@@RELAPSED@@@@@RANDOMISED@DOUBLE-BLIND@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924162@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@UNITED STATES@@@@@14924162@Cutaneous metastatic melanoma@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@"Trial due to commence ""end of the summer"" in 2008. SOURCE: ALS, 14 May 2008"@-@@@@MONO@-@@@@@-||||@ADVANCED LIFE SCIENCES@@@@@ADVANCED LIFE SCIENCES||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ALS-357@@@@@ALS-357||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@METASTATIC@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921509@Onco@@@@@@@@@@@Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm @@-@-@-@FRAZER, PENNSYLVANIA@@@@@14921509@-@@-@-@@NO REVIEW@@@NOVEMBER 2007-JUNE 2009@-@-@-@NCT00572637@55@-@-@@@-@@@-@E-CEP\I\01@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@Solid Tumours|Haematological Malignancy|Non-Hodgkin's Lymphoma|||||||@CEP-18770@@@@@CEP-18770||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919040@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14919040@Combo with Alimta@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Trial to begin in 2008. SOURCE: Tracon, 25 February 2008@-@@@@COMBO@METHOXYAMINE@@@@@METHOXYAMINE||||@TRACON PHARMACEUTICALS@@@@@TRACON PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TRC-102@@@@@TRC-102||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924201@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BOULDER, COLORADO@@@P38 Tie2 inhibitor @@14924201@P38 Tie2 inhibitor in healthy volunteers@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@I@@-@-@Trial started. SOURCE: Array, 25 March 2008@-@@@@MONO@-@@@@@-||||@ARRAY BIOPHARMA@@@@@ARRAY BIOPHARMA||||@@@@@@|||||||||@Other@@@@@Other|||||||||@ARRY-614@@@@@ARRY-614||||@Other@@@@@Other||||@SAFETY@TOLERABILITY@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921521@Onco@@@@@@@@@@@Patients receive E7070 IV over 1 hour. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks.@@-@-@-@TOKYO, JAPAN@@@@@14921521@Stage IV melanoma@@-@-@@NO REVIEW@@@N/A@-@Global rights licensed from Ligand in September 2006@-@NCT00014625@19-24@-@-@@@-@@@-@E7070-E044-205@@-@-@@@EORTC-16005, EORTC-18002@II@@-@-@RESULTS PENDING@-@@@@MONO@INDISULAM@@@@@INDISULAM||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@E-7070@@@@@E-7070||||@Cytotoxic Antibiotic@Sulfonamide@@@@Cytotoxic Antibiotic|Sulfonamide|||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@DURATION OF RESPONSE@@@DURATION OF RESPONSE@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924075@Onco@@@@@300f1020ntsdm@@@@@@-@@L01XX14@L01X@-@BASEL, SWITZERLAND@@@@@14924075@-@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@-@N/A@@@-@@@-@-@No@-@-@@@-@APPROVED@@@SSN@RESULTS PENDING@-@@@@-@TRETINOIN@@@@@TRETINOIN||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@VESANOID@@@@@VESANOID||||@Retinoid@@@@@Retinoid||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1229@315.87@521.32@330.09@@@@@@@@@@0.32@@@@@@@@@@@@@@@@6/7/2017@3.16@3.16@29838024@CAPSULE@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14923683@Onco@@@@@300f1008ntsdm@@@@@@-@@L01DB01@L01D@-@-@@@-@@14923683@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@@RESULTS PENDING@-@@@@-@DOXORUBICIN HYDROCHLORIDE, MICELLE@@@@@DOXORUBICIN HYDROCHLORIDE, MICELLE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@NK-911@@@@@NK-911||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14918832@Onco@@@@@300f1012ntsdm@@@@@@N/A@@-@-@-@DREIEICH, GERMANY@@@@@14918832@-@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@FDA orphan drug designation. SOURCE: Biotest, March 2008@@@FDA orphan drug designation. SOURCE: Biotest, March 2008@@@-@N/A@@-@-@@@I@I@@-@-@Phase I trial to start H1 2008. SOURCE: Biotest@-@@@@MONO@-@@@@@-||||@BIOTEST AG@@@@@BIOTEST AG||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@BT-062@@@@@BT-062||||@mAb@@@@@mAb||||@SAFETY@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14923147@Onco@@@@@300f1015ntsdm@@@@@@-@@-@-@-@MARSEILLE, FRANCE@@@@@14923147@-@@-@-@@NO REVIEW@@@@-@Novo Nordisk exited this partnership after discontinuing all of its oncology interests in February 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@INNATE PHARMA@@@@@INNATE PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@IPH-2101@NN-1975@@@@IPH-2101|NN-1975|||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14918776@Onco@@@@@300f1018ntsdm@@@@@@N/A@@-@-@-@THEBARTON, AUSTRALIA@@@@@14918776@Advanced cancer@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIONOMICS@@@@@BIONOMICS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@BNC-105@@@@@BNC-105||||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@PHARMACOKINETICS@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14916160@Onco@@@@@300f1008ntsdm@@@@@@UFT versus observation@@-@-@-@DARMSTADT, GERMANY@9/1/2014@@@@14916160@Curatively resected Stage II colon cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00392899@2000@-@-@@@-@@10/1/2006@-@TMDU-BRI-CC-05-01@@-@-@@@III@III@@-@@RESULTS PENDING@-@@@@ADJUVANT@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFTORAL@@@@@UFTORAL||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14919001@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@NEW YORK, NEW YORK@@@@@14919001@Advanced cancer@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@7/1/2007@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-562271@@@@@PF-562271||||@Other@@@@@Other||||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15413040@Onco@@@@@@@@@@@PF-06671008, Experimental,@@@@@NEW YORK, NEW YORK@6/1/2019@@@@15413040@A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of PF-06671008 In Patients With Advanced Solid Tumors@Both@@@@@Dose Escalation Phase - Part 1@@@@@@NCT02659631@110@@@@@@@3/1/2016@@B7831001@@@Diagnosis of tumor type with the potential to have P-cadherin expression that is resistant to standard therapy or for which no standard therapy is available  -  Performance status of 0 or 1  -  Adequate bone marrow, kidney and liver function@MONO@ADULTS@Phase 1@I@@@@@@@@@@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-06671008@@@@@PF-06671008||||@Other@@@@@Other||||@Number of participants with Dose-Limiting Toxicities (DLT) [Part 1]@Number of participants with objective response@@@@Maximum Observed Plasma Concentration (Cmax)@Time to Reach Maximum Observed Plasma Concentration (Tmax)@@@@ADVANCED@@@@@NON-RANDOMIZED@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924834@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924834@-@@-@-@@NO REVIEW@@@@-@Macrochem acquired Virium. SOURCE: Virium, 28 April 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@MACROCHEM CORP@VIRIUM PHARMACEUTICAL@@@@MACROCHEM CORP|VIRIUM PHARMACEUTICAL|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@VP-101@EL-532@@@@VP-101|EL-532|||@HDAC@@@@@HDAC||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923934@Onco@@@@@@@@@@@Patients will receive Xeloda 1000mg/m² po twice daily, D1-D10 every 2 weeks (10 days treatment followed by 4 days rest period) plus oxaliplatin 85 mg/m²/day IV, D1 every 2 weeks@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14923934@Xeloda in combination with standard chemotherapy regimens@@-@6-Dec@@NO REVIEW@@@@-@-@-@NCT00436241 @<100@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Not yet available.@-@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@Taiwan@@@@@Taiwan|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924810@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924810@Adjuvant to cancer vaccines@@-@-@@NO REVIEW@@@@-@Coley licensed to GSK and Novartis for oncology vaccines; Pfizer bought Coley in November 2007@-@-@-@-@-@@@-@@@-@-@@-@-@-@@-@II@@-@-@-@-@@@@ADJUVANT@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Other@@@@@Other|||||||||@VAXIMMUNE@@@@@VAXIMMUNE||||@TLR-targeted@Vaccine@@@@TLR-targeted|Vaccine|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922136@Onco@@@@@@@@@@@-@@-@-@-@KJELSAS, NORWAY@@@Algeta's lead product based on the alpha emitter technology is Alpharadin, a product being developed as a new treatment for skeletal metastases in patients with late-stage, hormone refractory prostate cancer (HRPC). Alpharadin (radium-223 chloride) is a unique targeted therapeutic in phase III clinical trials for the treatment for HRPC that has metastasized to the skeleton.@@14922136@HRPC@@-@-@@NO REVIEW@@@STARTED JULY 2007@-@-@-@-@10@-@-@@@-@@@-@BCI-05@@-@-@@@I/II@II@@-@-@Patient enrolment is expected to be complete during Q1 2008. @-@@@@MONO@-@@@@@-||||@ALGETA@@@@@ALGETA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ALPHARADIN@@@@@ALPHARADIN||||@Other@@@@@Other||||@BIODISTRIBUTION@@@@@@@@@@REFRACTORY@@@@@DOSIMETRY@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924646@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SWITERLAND@@@@@14924646@Uterine myoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@Trial started. SOURCE: PregLem, 20 August 2008@-@@@@MONO@ULIPRISTAL@@@@@ULIPRISTAL||||@PREGLEM@@@@@PREGLEM||||@@@@@@|||||||||@Other@@@@@Other|||||||||@PGL-4001@@@@@PGL-4001||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921694@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@@@@BASEL, SWITZERLAND@2/1/2006@@@@14921694@AML or MDS with either wild-type or mutated FLT3@@@@@NO REVIEW@@@@@@@NCT00045942@20@@@@@@@6/1/2004@@CPKC412 2104@@@@@@II@II@@@@@@@@@MONO@MIDOSTAURIN@@@@@MIDOSTAURIN||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Myelodysplastic Syndrome@@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Myelodysplastic Syndrome|||||||@PKC-412@@@@@PKC-412||||@PKC Inhibitor@@@@@PKC Inhibitor||||@SAFETY@PHARMACOKINETICS@@@@@@@@@@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918806@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918806@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916499@Onco@@@@@@@@@@@SBG in combination with standard therapy@@-@-@-@TROMSO, NORWAY@@@@@14916499@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00062478@12@-@-@@@-@@1/1/2007@-@SBG-2-01@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@BIOTEC PHARMACON@@@@@BIOTEC PHARMACON||||@Norway@@@@@Norway|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SBG@@@@@SBG||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921493@Onco@@@@@@@@@@@Tirapazamine versus concomitant radiation and cisplatin@@-@-@-@-@@@@@14921493@-@@-@-@@NO REVIEW@@@OCTOBER 2002-@-@Available for licensing. sanofi-aventis returned all rights to the drug after discontinuation of drug. SOURCE: SRI, 7 May 2007@-@NCT00094081@850@-@-@@@-@@@-@EFC4690@@-@-@@@III@DISCONTINUED@@-@-@Trial discontinued before results were due year-end 2007. SOURCE: sanofi-aventis, 13 February 2007@-@@@@MONO@TIRAPAZAMINE@@@@@TIRAPAZAMINE||||@SRI INTERNATIONAL@@@@@SRI INTERNATIONAL||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@TIRAZONE@SR-259075@@@@TIRAZONE|SR-259075|||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924543@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924543@-@@-@-@@NO REVIEW@@@@-@-@-@-@75@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@"Demonstrated two year-survival more than four times that of individuals treated with the current standard of care. NovaRx is in ""final stages"" of 400-patient pivotal phase III trial. SOURCE: NovaRx/ASCO, 5 June 2006"@-@@@@-@BELEGENPUMATUCEL-L@@@@@BELEGENPUMATUCEL-L||||@NOVARX@@@@@NOVARX||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@LUCANIX@@@@@LUCANIX||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924227@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LONDON, UNITED KINGDOM@@@@@14924227@-@@-@-@@NO REVIEW@@@@-@CAT licensed it in July 2006 from Enzon, which had acquired it from the NCI@-@-@-@-@-@@@-@@@-@-@@-@-@@@Expected to move into Phase II in 2008.@II@@-@-@Expected to move into Phase II in 2008.@-@@@@-@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@CAT-5001@SS-1P@@@@CAT-5001|SS-1P|||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924076@Onco@@@@@300f1037ntsdm@@@@@@@@L01XX14@L01X@@BASEL, SWITZERLAND@@@@@14924076@@@YES@@@NO REVIEW@@@@90%@@@@@@10-Jul-03@7/10/2003@5/12/2004@@@@@@No@@@@@@APPROVED@@NO REVIEW@SNS@RESULTS PENDING@@@@@@TRETINOIN@@@@@TRETINOIN||||@KERN PHARMA@@@@@KERN PHARMA||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@VESANOID@@@@@VESANOID||||@Retinoid@@@@@Retinoid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1.1511@226.95@288.97@234.49@@@@@@@@@@0.23@@@@@@@@@@@@@@@@8/4/2017@2.27@2.27@700610@SOFT CAPSULE IN BOTTLE@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14923159@Onco@@@@@300f1015ntsdm@@@@@@-@@-@-@-@-@@@@@14923159@Acute graft versus host disease in allogeneic bone marrow transplant recipients@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Orphan Drug International in March 2007@-@-@-@-@EMEA orphan designation for GVHD. SOURCE: EMEA, 5 March 2001@3/5/2001@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@INOLIMOMAB@@@@@INOLIMOMAB||||@EUSA PHARMA@@@@@EUSA PHARMA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@LEUKOTAC@@@@@LEUKOTAC||||@mAb@Murine@CD25@@@mAb|Murine|CD25||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14923682@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@-@@@@@14923682@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@@RESULTS PENDING@-@@@@-@-@@@@@-||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@NK-314@@@@@NK-314||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14923716@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@JAPAN@@@-@@14923716@-@@-@-@@NO REVIEW@@@@-@Kissei licenses Japanese rights to YSCMA. [Kissei, 12.09.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@@Trial to start in February 2009. [Kissei, 12.09.2008]@-@@@@-@-@@@@@-||||@KISSEI PHARMACEUTICAL@@@@@KISSEI PHARMACEUTICAL||||@@@@@@|||||||||@Mesothelioma@@@@@Mesothelioma|||||||||@YSCMA@YS-110@@@@YSCMA|YS-110|||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14918812@Onco@@@@@@@@@@@-@@-@-@-@CAMBRIDGE, UNITED KINGDOM@@@@@14918812@Mucositis in solid tumour patients@@-@-@@NO REVIEW@@@-@-@-@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Trial to start in H2 2008. SOURCE: Alizyme, January 2008.@-@@@@MONO@-@@@@@-||||@ALIZYME@@@@@ALIZYME||||@@@@@@|||||||||@Supportive Care@Mucositis@Solid Tumours@@@Supportive Care|Mucositis|Solid Tumours|||||||@ATL-104@@@@@ATL-104||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924493@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924493@-@@-@-@@NO REVIEW@@@@-@Licensing status unclear after bankruptcy of Aphton.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@Development status unclear after bankruptcy of Aphton.@-@@@@-@-@@@@@-||||@APHTON@@@@@APHTON||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@IGN-101@@@@@IGN-101||||@Vaccine@mAb@Human@@@Vaccine|mAb|Human||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922311@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Autologous therapy@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14922311@Newly diagnosed resectable pancreatic cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00664482@1@-@-@@@-@@5/1/2007@-@AGS-006-001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ARGOS THERAPEUTICS@@@@@ARGOS THERAPEUTICS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@AGS-006@@@@@AGS-006||||@Immunotherapy@@@@@Immunotherapy||||@CTCAE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923685@Onco@@@@@300f1008ntsdm@@@@@@BMS@@-@-@-@-@@@@@14923685@Hysteromyoma@@-@-@@NO REVIEW@@@@-@Joint development with Shionogi and Kayaku Zentaris@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@@-@-@@@@-@CETRORELIX ACETATE@@@@@CETRORELIX ACETATE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@NS-75A@@@@@NS-75A||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14918960@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918960@-@@-@-@@NO REVIEW@@@@-@The GI Co. is looking for a global partner@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Data expected in H1 08. SOURCE: The GI Co, January 2008@-@@@@MONO@-@@@@@-||||@THE GI CO@@@@@THE GI CO||||@@@@@@|||||||||@Supportive Care@Mucositis@@@@Supportive Care|Mucositis||||||||@ITF@@@@@ITF||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921813@Onco@@@@@@@@@@@Patupilone plus prednisone versus docetaxel with prednisone@@-@-@-@BASEL, SWITZERLAND@@@Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel.@@14921813@Men over 17 years old@@-@-@@NO REVIEW@@@@-@-@-@NCT00411528@150@-@-@@@-@@9/1/2006@-@CEPO906A2229@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@PATUPILONE@PREDNISONE@@@@PATUPILONE|PREDNISONE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@EPO-906@@@@@EPO-906||||@Epothilone@@@@@Epothilone||||@PSA@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922699@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Acyline 20MG oral dose daily for 7 days@@-@-@-@-@6/1/2008@@@@14922699@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00603187@4@-@-@@@-@@2/1/2008@-@07-7973-W@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@ACYLINE@@@@@ACYLINE||||@MERRION PHARMACEUTICALS@@@@@MERRION PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@MER-104@@@@@MER-104||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15041415@Onco@@@@@300f1010ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15041415@@@NO@@@@@@@100%@@@@@@@@@@@@@@No@@@@@@APPROVED@@@NHS@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMACEUTICALS@@@@@CHUGAI PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@62.54@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@62.54@62.54@1.64E+16@INJECTION POWDER FOR RECONSTITUTION (VIAL)@GB£@@@@@@@@263@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923935@Onco@@@@@@@@@@@Patients will receive an IV 6mg Bondronat on days 1, 2 and 3.@@-@-@-@BASEL, SWITZERLAND@@@@@14923935@-@@-@-@@NO REVIEW@@@@-@Licensed from SmithKline Beecham in January 2001 in exchange for North American rights to Coreg@-@NCT00502736@<100@-@-@@@-@@10/1/2007@-@-@@-@<100 female patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain.@@@II@II@@-@-@Not yet available@-@@@@MONO@IBANDRONATE@@@@@IBANDRONATE||||@ROCHE@@@@@ROCHE||||@Turkey@@@@@Turkey|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@BONDRONAT@@@@@BONDRONAT||||@Bisphosphonate@@@@@Bisphosphonate||||@PAIN RELIEF@CONSUMPTION OF ANALGESICS@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916170@Onco@@@@@@@@@@@-@@-@-@-@MILAN, ITALY@@@@@14916170@Haplo-HSCT@@-@-@@NO REVIEW@@@JANUARY 2008-@-@Takara Bio holds the Asian market rights. MolMed is looking to out-license other rights.@-@-@N/A@-@EMEA Orphan drug 2003.FDA orphan drug 2005.@@@EMEA Orphan drug 2003.FDA orphan drug 2005.@@@-@TK007@@-@-@@@III@III@@-@-@Another Phase I/II trial is also planned for 2008.@-@@@@MONO@-@@@@@-||||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@TK@@@@@TK||||@Gene Therapy@@@@@Gene Therapy||||@OVERALL SURVIVAL@SAFETY@@@@@@@@@-@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921008@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients apply Regenecare to the face over 3 times daily for 4 weeks@@N01BB02@N01B@-@-@@@@@14921008@Cancer rash secondary to Erbitux or other EGFRs@@-@-@@NO REVIEW@@@@-@-@-@NCT00498992@20@-@-@@@-@@7/1/2006@-@ING-100@@-@-@@@IV@IV@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@LIDOCAINE@@@@@LIDOCAINE||||@MPM MEDICAL@@@@@MPM MEDICAL||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@REGENECARE@@@@@REGENECARE||||@Other@@@@@Other||||@INCIDENCE OF RASH@@@@@@@@@@-@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924353@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924353@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@TRAGEN PHARMACEUTICALS@@@@@TRAGEN PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@GENE THERAPY@@@@@GENE THERAPY||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921630@Onco@@@@@@@@@@@CYT-004 with montanide, imiquimod or a combination of all three, or CYT-004 alone@@-@-@-@SCHLIEREN, GERMANY@12/1/2009@@@@14921630@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00651703@20@-@-@@@-@@4/1/2008@-@CYT004-MelQbG10 04@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@ADJUVANT@IMEXON@@@@@IMEXON||||@CYTOS BIOTECHNOLOGY@@@@@CYTOS BIOTECHNOLOGY||||@Switzerland@@@@@Switzerland|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CYT-004-MELQBG10@@@@@CYT-004-MELQBG10||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916040@Onco@@@@@300f1015ntsdm@@@@@@@@A14AA08@A14A@@@@@@@14916040@Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections or severe trauma, and in some patients who withough definite pathophysiologic reasons fail to gain or to maintain normal weight.@@YES@@@NO REVIEW@@@@@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@@@@@@@@@@@@@No@@@@@@APPROVED@@COMPASSIONATE USE@HAUTE AUTORITÉ DE SANTÉ@@@@@@ADJUVANT@OXANDROLONE@@@@@OXANDROLONE||||@SOCIETA PRODOTTI ANTIBIOTICI@@@@@SOCIETA PRODOTTI ANTIBIOTICI||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@OXANDROLONE@@@@@OXANDROLONE||||@Anabolic Steroid@@@@@Anabolic Steroid||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@30@1.1807@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+12@TABLET@EURO@@@@@@@@2.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14918801@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918801@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918802@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918802@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916429@Onco@@@@@@@@@@@Patients receive 6, 3, 2 or 1 over up to 2 weeks@@-@-@-@-@@@@@14916429@-@@-@-@@NO REVIEW@@@JUNE 2005-JULY 2008@-@-@-@NCT00285103@46@-@-@@@-@@@-@SPC2996-101@@-@-@@@I/II@II@@-@-@Endpoint over 13 days.@-@@@@MONO@-@@@@@-||||@SANTARIS PHARMA@@@@@SANTARIS PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@SPC-2996@@@@@SPC-2996||||@TK Inhibitor@Bcl-2 Inhibitor@@@@TK Inhibitor|Bcl-2 Inhibitor|||@BCL-2 M-RNA LEVELS@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924169@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 745 targets inhibition of myostatin and is being investigated for its potential to inhibit muscle loss associated with a variety of diseases/conditions. @@14924169@Muscle wasting@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@Cachexia@@@@Supportive Care|Cachexia||||||||@AMG-745@@@@@AMG-745||||@Other@@@@@Other||||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14998797@Onco@@@@@@@@@@@-@@-@-@-@PETACH TIKVA, ISRAEL@@@Lonquex (lipegfilgrastim) is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) based on novel GlycoPEGylation technology. Lipegfilgrastim is a novel, pegylated and glycosylated long-acting form of filgrastim, intended for once-per-cycle fixed dose, subcutaneous injection for neutrophil support in patients receiving myelosuppressive chemotherapy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). [Teva]@@14998797@-@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@CHMP recommends market approval.[Teva, 3 June 2013, http://www.tevapharm.com/Media/News/Pages/2013/1826090.aspx?year=2013 ]@6/3/2013@@-@@@-@-@@-@-@@@-@FILED@@-@-@NO LABELLED TRIAL@-@@@@-@LIPEGFILGRASTIM@@@@@LIPEGFILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@LONQUEX@@@@@LONQUEX||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916679@Onco@@@@@300f1010ntsdm@@@@@@ATN-224 in combo with letrozole versus letrozole alone@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14916679@Post-menopausal women with recurrent, oestrogen and/or progresterone receptor positive breast cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@PH2053@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@LETROZOLE@@@@-|LETROZOLE|||@ATTENUON@@@@@ATTENUON||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ATN-224@FEMARA@@@@ATN-224|FEMARA|||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@PDGF@@TK Inhibitor|Angiogenesis Inhibitor|VEGF|PDGF|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14924172@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924172@Renal cell carcinoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@ATVOGEN@@@@@ATVOGEN||||@HEMISPHERX BIOPHARMA@@@@@HEMISPHERX BIOPHARMA||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@AMPLIGEN@@@@@AMPLIGEN||||@Immunotherapy@Interferon@@@@Immunotherapy|Interferon|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15299753@Onco@@@@@300f1010ntsdm@@@@@@@@L03AA10@L03A@@@@@@@15299753@@@NO@@@@@@@100%@@@@@@@@@@@@@@No@@@@@@APPROVED@@@NHS@@@@@@@LENOGRASTIM@@@@@LENOGRASTIM||||@CHUGAI PHARMACEUTICALS@@@@@CHUGAI PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@GRANOCYTE@@@@@GRANOCYTE||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@312.69@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@62.54@62.54@4.52E+15@INJECTION POWDER FOR RECONSTITUTION (VIAL)@GB£@@@@@@@@263@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923937@Onco@@@@@@@@@@@Kaletra/Truvada versus efavirenz/Truvada@@-@-@-@UNITED STATES@@@@@14923937@HIV/AIDS-related Kaposi's sarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00444379@224@-@-@@@-@@4/1/2007@-@-@@-@-@@@IV@IV@@-@-@RESULTS PENDING- this is a ten-year trial.@-@@@@COMBO@LOPINAVIR@RITONAVIR@@@@LOPINAVIR|RITONAVIR|||@ABBOTT@@@@@ABBOTT||||@Uganda@@@@@Uganda|||||||||@Sarcoma@Kaposi's Sarcoma@@@@Sarcoma|Kaposi's Sarcoma||||||||@KALETRA@@@@@KALETRA||||@Protease Inhibitor@@@@@Protease Inhibitor||||@LESIONS@@@@@@@@@@-@@@@@RANDOMISED@SINGLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14920145@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01BC05@L01B@@@@@@@14920145@@@@@@NO REVIEW@@@@@@@@@@FDA, 25 July 2011@7/25/2011@@@@@@@No@NOVEMBER 2007 (PAEDIATRIC); JULY 2009 (OVERIAN CANCER); EXTENSIONS TO 2013@@@@@APPROVED@@@@RESULTS PENDING@@@@@@GEMCITABINE HYDROCHLORIDE@@@@@GEMCITABINE HYDROCHLORIDE||||@SUN PHARMACEUTICAL@@@@@SUN PHARMACEUTICAL||||@@@@@@|||||||||@NSCLC@Breast Cancer@Ovarian Cancer@@@NSCLC|Breast Cancer|Ovarian Cancer|||||||@GENERIC@@@@@GENERIC||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@US$@@@@@@@@1@G@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412797@Onco@@@@@@@@@@@Patients advanced NSCLC EGFR mutated, , This is an observational study, there is no intervention.@@@@@@11/1/2018@@@@15412797@Epidermal Growth Factor Receptor (EGFR) Mutation Detection From Advanced Non-small Cell Lung Cancer Tissue and Plasma in Tyrosine Kinase Inhibitor (TKI) Treatment@Both@@@@@@@@@@@NCT02644889@100@@@@@@@1/1/2016@@EGFR2015-02@@@Age older than 18 years and under 75 years  -  Histologically and cytologically proven non-small Cell Lung Cancer  -  Clinical stages Ⅲ ~ Ⅳ  -  Not receive any anti-tumor treatment  -  Eastern cooperative oncology group performance status (ECOG PS) =1~2  -  Estimated survival time more than 3 months  -  EGFR-TKI treatment for first-line or second-line  -  Voluntary to participate in this clinical trial and sign the consent form@@ADULTS@N/A@-@@@@@@@@@@-@@@@@-||||@GENOSABER@@@@@GENOSABER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Other@@@@@Other||||@EGFR Mutation Detection of FFPE and plasma samples@EGFR Mutation Detection of plasma samples for the following-up patients who take TKI.@@@@@@@@@@@@@@Cohort@RETROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924589@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AMSTERDAM, NETHERLANDS@@@@@14924589@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@KIADIS PHARMA@@@@@KIADIS PHARMA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@NB-1011@@@@@NB-1011||||@TS Inhibitor@@@@@TS Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922158@Onco@@@@@@@@@@@Multiple-ascending doses@@-@-@-@LONDON, UNITED KINGDOM@11/1/2008@@@@14922158@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00637039@30@-@-@@@-@@2/1/2008@-@AZD8931 Study 002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Russia@@@@@Russia|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-8931@@@@@AZD-8931||||@TK Inhibitor@@@@@TK Inhibitor||||@ADVERSE EVENTS@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921611@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AZD-4877 administered weekly@@-@-@-@LONDON, UNITED KINGDOM@10/1/2009@@@@14921611@Cell cycle inhibitor@@-@-@@NO REVIEW@@@@-@-@-@NCT00661609@50@-@-@@@-@@5/1/2008@-@D2782C00010@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@AZD-4877@@@@@AZD-4877||||@Other@@@@@Other||||@RECIST@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924631@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WALTHAM, MASSACHUSSETTS@@@@@14924631@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@COMBRETASTATIN A4 PRODRUG@@@@@COMBRETASTATIN A4 PRODRUG||||@OXIGENE@@@@@OXIGENE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OXI-4503@@@@@OXI-4503||||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@-@@@@@@@@@@ADVANCED@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919005@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@-@@@@@14919005@Trial I healthy volunteers@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@3/1/2008@-@N/A@@-@-@@@I@I@@-@-@Trial started. SOURCE: Polyphor, 27 March 2008@-@@@@MONO@-@@@@@-||||@POLYPHOR@@@@@POLYPHOR||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@POL-6326@@@@@POL-6326||||@CXCR4 Antagonist@@@@@CXCR4 Antagonist||||@SAFETY@TOLERABILITY@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916186@Onco@@@@@@@@@@@E10A 1*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles with cisplatin 25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles and paclitaxel 160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles; versus placebo/cisplatin and paclitaxel  SOURCE: clinicaltrials.gov@@-@-@-@-@12/1/2010@@@@14916186@E10A with cisplatin and paclitaxel for head and neck squamous carcinoma or nasopharyngeal carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00634595@116@-@-@@@-@@3/1/2008@-@TG0717E10A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@CISPLATIN@@@@-|CISPLATIN|||@DOUBLLE BIOPRODUCT@@@@@DOUBLLE BIOPRODUCT||||@China@@@@@China|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@E10A@@@@@E10A||||@Angiogenesis Inhibitor@Gene Therapy@@@@Angiogenesis Inhibitor|Gene Therapy|||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918807@Onco@@@@@@@@@@@-@@-@-@-@HANGZHOU, CHINA@@@@@14918807@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@AIDA PHARMACEUTICAL@@@@@AIDA PHARMACEUTICAL||||@China@@@@@China|||||||||@Sarcoma@@@@@Sarcoma|||||||||@RH-AP2L@@@@@RH-AP2L||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916091@Onco@@@@@@@@@@@Injected directly into tumour@@-@-@-@PARIS, FRANCE@@@@@14916091@Neoadjuvant breast cancer@@-@-@@NO REVIEW@@@N/A@-@Diatos licensed exclusive rights to develop and commercialise OncoGel worldwide except for North America and Korea from Protherics. Diatos also received rights to sublicense OncoGel and to develop and commercialise second generation OncoGel products.@-@-@N/A@-@-@@@-@@@-@UKNOWN@@-@-@@@N/A@II@@-@-@RESULTS PENDING@-@@@@NEOADJUVANT@PACLITAXEL POLYMER GEL REGEL@@@@@PACLITAXEL POLYMER GEL REGEL||||@DIATOS@@@@@DIATOS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@DTS-301@@@@@DTS-301||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923677@Onco@@@@@300f1008ntsdm@@@@@@-@@-@-@-@-@@@@@14923677@Preventing recurrence of bladder cancer@@-@-@@NO REVIEW@@@@-@Pasteur Merieux Connaught (now Sanofi Pasteur) and Nippon Kayaku developed PMCJ together. Sanofi Pasteur is a subsidiary of sanofi-aventis.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@@RESULTS PENDING@-@@@@-@CONNAUGHT STRAIN BCG@@@@@CONNAUGHT STRAIN BCG||||@NIPPON KAYAKU@SANOFI PASTEUR@SANOFI-AVENTIS@@@NIPPON KAYAKU|SANOFI PASTEUR|SANOFI-AVENTIS||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@IMMUCYST PMCJ-9@@@@@IMMUCYST PMCJ-9||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
12345678@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916045@Onco@@@@@@@@@@@Low versus high dose VT-122 versus no intervention@@-@-@-@-@2/1/2008@@@@14916045@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00527319@60@-@-@@@-@@1/1/2007@-@VT-1 CAX-001@@-@-@@@II@II@@-@-@Enrolment completed. SOURCE: Vicus, 30 April 2008@-@@@@MONO@-@@@@@-||||@VICUS THERAPEUTICS@@@@@VICUS THERAPEUTICS||||@India@@@@@India|||||||||@Supportive Care@Cachexia@NSCLC@@@Supportive Care|Cachexia|NSCLC|||||||@VT-122@@@@@VT-122||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@FACTORIAL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924152@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@QUEBEC, QUEBEC@@@@@14924152@To treat LHRH-positive ovarian cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Phase II to commence year-end 2007@-@@@@-@-@@@@@-||||@AETERNA ZENTARIS@@@@@AETERNA ZENTARIS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@AEZS-108@@@@@AEZS-108||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922777@Onco@@@@@300f1018ntsdm@@@@@@Coramsine infusion over 12-week cycle@@-@-@-@-@@@@@14922777@-@@-@-@@NO REVIEW@@@@-@-@-@-@40-50@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING; trial suspended in November 2006 but  new development plan approved with TGA in May 2007@-@@@@-@SOLASONINE AND SOLAMARGINE@@@@@SOLASONINE AND SOLAMARGINE||||@SOLBEC PHARMACEUTICALS@@@@@SOLBEC PHARMACEUTICALS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@Melanoma / Skin Cancer@@@Kidney Cancer|Renal Cell Carcinoma|Melanoma / Skin Cancer|||||||@CORAMSINE@@@@@CORAMSINE||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14921619@Onco@@@@@@@@@@@AZD-1152 in ascending doses@@-@-@-@LONDON, UNITED KINGDOM@@@@@14921619@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00497991@70@-@-@@@-@@5/1/2006@-@D1531C0007  @@-@-@@@I/II@II@@-@-@RESULTS PENDING (recruiting). Several Phase I trials in progress.@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AZD-1152@@@@@AZD-1152||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921399@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01DC01@L01D@-@-@9/1/2008@@@@14921399@Cutaneous and sub-cutaneous cancers@@-@-@@NO REVIEW@@@@-@-@-@NCT00198276@100@-@-@@@-@@2/1/2004@-@EU-CCBE-2003@@-@-@@@IV@IV@@-@-@RESULTS PENDING@-@@@@MONO@BLEOMYCIN @@@@@BLEOMYCIN ||||@INOVIO BIOMEDICAL@@@@@INOVIO BIOMEDICAL||||@@@@@@|||||||||@Other@@@@@Other|||||||||@MEDPULSER@@@@@MEDPULSER||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923992@Onco@@@@@300f1037ntsdm@@@@@@@@@@@DARMSTADT, GERMANY@@@@@14923992@First-line treatment of metastatic colorectal cancer with calcium folinate.@@NO@@@NO REVIEW@@@@90%@@@@@@EMA, 1 February 1993@2/1/1993@@@@@@@No@@@@@@APPROVED@@NO REVIEW@SNS@@@@@@@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFT@@@@@UFT||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@60@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@EURO@@@@@@@@@@224/100MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14924484@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924484@Cervical intraepithelial neoplasia@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@Patients with high-grade cervical dysplasia (CIN2/3)@@@II@II@@-@-@Nventa has finalised trial protocol. SOURCE: Nventa, 18 July 2008@-@@@@MONO@-@@@@@-||||@NVENTA BIOPHARMACEUTICAL@@@@@NVENTA BIOPHARMACEUTICAL||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@HSPE7@@@@@HSPE7||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@MULTI-CENTRE@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921919@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Brivanib 800MG with Erbitux 400MG/M2 followed by 250MG/M2 up to 48 weeks@@-@-@-@NEW YORK, NEW YORK@3/1/2008@@@@14921919@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00207051@50@-@-@@@-@@1/1/2006@-@CA182-003@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@BRIVANIB ALANINATE@CETUXIMAB@@@@BRIVANIB ALANINATE|CETUXIMAB|||@BMS@@@@@BMS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@BMS-582664@ERBITUX@@@@BMS-582664|ERBITUX|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@SAFETY@@@SAFETY@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15370432@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX42@L01X@@BASEL,SWITZERLAND@@@@@15370432@Treatment of relapsed and/or refractory multiple myeloma@@NA@31-Aug-15@8/31/2015@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@THIRD-LINE@@@20 mg, taken orally once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, and 12) of Weeks 1 and 2 of each 21-day cycle for 8 cycles@MHLW, 31 August 2015@8/31/2015@@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@COMBO@PANOBINOSTAT@BORTEZOMIB@DEXAMETHASONE@@@PANOBINOSTAT|BORTEZOMIB|DEXAMETHASONE||@NOVARTIS@@@@@NOVARTIS||||@World@@@@@World|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@FARYDAK@VELCADE@@@@FARYDAK|VELCADE|||@HDAC@@@@@HDAC||||@@@@@@@@@@@RELAPSED@@@@@@@@@@1@1@5956444.8@@@48@week@48 week@5956444.8@5956444.8@17727.51@1@0.0091@31023.15@36583.9@@@@@@@@@@@3102.32@21@@mg@20@6@@@@@@@@@@@8/30/2017@31023.15@31023.15@4291040M1023@CAPSULE@YEN@@@@@@@@10@MG@10 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14922581@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@10 mg capsules by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles, with standard-of-care steroid treatment@@L04AX04@L04A@@SUMMIT, NEW JERSEY@4/1/2010@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14922581@GVHD@@@@@NO REVIEW@@@@@-@SECOND-LINE@NCT00675441@46@@@@@@@4/1/2008@@20060321@@@@@@II@II@@@@RESULTS PENDING@@@@@COMBO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@RESPONSE RATE@@@@@@@@@@@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924499@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WILMINGTON, DELAWARE@@@INCB18424 is Incyte's lead internally developed JAK inhibitor. The compound is a potent JAK inhibitor that is greater than 100 fold selective against a broad panel of kinases and is being developed as an oral treatment for MF, PV and ET, multiple myeloma, hormone refractory prostate cancer, and rheumatoid arthritis and as an oral and topical treatment for psoriasis.@@14924499@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@Trial to start in Q1 08@-@@@@-@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@INCB-18424@@@@@INCB-18424||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922119@Onco@@@@@@@@@@@Erlotinib 100mg po daily escalating to a maximum of 250mg po daily with gemcitabine 1000mg/m2 iv on days 1,8 and 15 of each 4 week cycle versus erlotinib 100mg po daily with gemcitabine 1000mg/m2 iv on days 1,8 and 15 of each 4 week cycle. [clinicaltrials.gov]@@L01XE03@L01X@-@BASEL, SWITZERLAND@8/1/2010@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14922119@-@@-@-@@NO REVIEW@@@@-@>> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]@-@NCT00652366@400@-@-@@@-@@5/1/2008@-@BO21128@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@ERLOTINIB HYDROCHLORIDE@GEMCITABINE@@@@ERLOTINIB HYDROCHLORIDE|GEMCITABINE|||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@TARCEVA@GEMZAR@@@@TARCEVA|GEMZAR|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922534@Onco@@@@@@@@@@@Patients are randomised to receive SNX-111 or placebo (AS PER AMENDMENT 1/22/98: with randomisation weighted 2:1 in favor of SNX-111) via external pump and an intrathecal catheter (thin tube inserted into the spinal canal). (AS PER AMENDMENT 1/22/98: the dose is increased every 24 hours, in the absence of onset of analgesia or adverse events. After 2-5 days, patients who respond to their medication continue treatment at home for 5-8 days. Patients who do not respond will be switched to the other regimen (i.e., placebo to SNX-111, or SNX-111 to placebo). After 10 days, responding patients are unblinded and asked to enroll in the long-term, open-label extension protocol. Patients remain on a fixed dose at the therapeutic level found in the previous study. The dose may be increased or decreased at the discretion of the investigator. Patients may continue therapy on a long-term basis until the drug is approved.@@-@-@-@ATHLONE, IRELAND@@@@@14922534@Sever chronic pain in opioid-resistant patient populations with neuropathic pain and pain related to cancer and HIV/AIDS@@-@-@@NO REVIEW@@@-@-@-@-@-@100@-@-@@@-@@@-@256A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@ZICONOTIDE@@@@@ZICONOTIDE||||@ELAN@@@@@ELAN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@PRIALT@@@@@PRIALT||||@Other@@@@@Other||||@PAIN RELIEF@@@@@@@@@@-@@@@@PLACEBO-CONTROLLED@DOUBLE-BLIND@RANDOMISED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924441@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@Octreotide is a synthetic octapeptide analog of naturally occurring somatostatin with similar pharmacological effects, but with a longer duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the gastroenteropancreatic (GEP) endocrine system, stomach, intestine and pancreas (for example, gastrin, insulin and glucagon). @@14924441@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@QLT is submitting information to the FDA and expects to enter the clinic in H1 2007. SOURCE: QLT, 22 February 2007@-@@@@-@OCTREOTIDE ACETATE@@@@@OCTREOTIDE ACETATE||||@QLT@@@@@QLT||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@GHRP-1@ATRIGEL@@@@GHRP-1|ATRIGEL|||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916647@Onco@@@@@@@@@@@N/A@@L02BG04@L02B@-@BASEL, SWITZERLAND@@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14916647@Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR) @@-@-@@NO REVIEW@@@@-@-@-@NCT00237133@N/A@-@-@@@-@@3/1/2003@-@PREDICT@@-@-@@@CFEM345EBR01;@IV@@-@-@Trial registered. [Novartis, 9.10.2005]@-@@@@NEOADJUVANT@LETROZOLE@@@@@LETROZOLE||||@NOVARTIS@@@@@NOVARTIS||||@Brazil@@@@@Brazil|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@@@@@FEMARA||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@N/A@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921814@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@@@Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel.@@14921814@NSCLC metastatic to the brain@@-@-@@NO REVIEW@@@@-@-@-@NCT00219297@50@-@-@@@-@@9/1/2005@-@CEPO906A2227@@-@-@@@II@II@@-@-@In a previous Phase I/II trial in NSCLC patupilone was administered as a 5 min infusion once every three weeks starting at a dose of 6.5 mg/m2 and was increased in 0.5 mg/m2 increments until the MTD was reached; of 20 evaluable patients, two showed partial responses and six had stable disease. SOURCE: Novartis/European Society for Medical Oncology Congress, 1 November 2004@-@@@@MONO@PATUPILONE@@@@@PATUPILONE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@NSCLC@Brain Cancer@@@@NSCLC|Brain Cancer||||||||@EPO-906@@@@@EPO-906||||@Epothilone@@@@@Epothilone||||@RECIST@@@@@@@@@@METASTATIC@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921598@Onco@@@@@300f1008ntsdm@@@@@@AZD-2171 combo with FOLFOX@@-@-@-@LONDON, UNITED KINGDOM@8/1/2011@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921598@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00494221@171@-@-@@@-@@6/1/2007@-@D8480C00039@@-@-@@@I/II@II@@-@@RESULTS PENDING@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14923063@Onco@@@@@300f1015ntsdm@@@@@@E-7070 700mg/m2 in 3-weekly doses until disease progression or toxicity@@-@-@-@TOKYO, JAPAN@@@@@14923063@Metastatic relapsed RCC@@-@-@@NO REVIEW@@@@-@Global rights licensed from Ligand in September 2006@-@-@30@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@ASCO June 2004; 1 (3.3%), 14 (43.3%) and 12 (40%) achieved PR, SD and progressive disease respectively. 6-month and 1-year survival rates were 67% and 37% respectively. 12-week PFS was 29% and median survival was 10.7 months.@-@@@@MONO@INDISULAM@@@@@INDISULAM||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@E-7070@@@@@E-7070||||@Cytotoxic Antibiotic@Sulfonamide@@@@Cytotoxic Antibiotic|Sulfonamide|||@PARTIAL RESPONSE@STABLE DISEASE@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
16159514@Onco@@@@@@@@@@@inecalcitol, Experimental, placebo, Placebo Comparator,@@-@-@@PARIS, FRANCE@6/1/2018@@@@16159514@Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy@Both@@@@@vitamin D receptor agonist@@@@@FIRST-LINE@NCT02802267@110@@@@@@@6/1/2016@@ICT8@@@- Patients aged 65 to < 75 years with at least one non severe comorbidity ie disease or syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities which could increase the risk of toxicity and/or early death of intensive chemo@@ADULTS@Phase 2@II@@@@@@@@@COMBO@INECALCITOL@DECITABINE@@@@INECALCITOL|DECITABINE|||@HYBRIGENICS@@@@@HYBRIGENICS||||@France@United States@@@@France|United States||||||||@Acute Myeloid Leukaemia@@@@@Acute Myeloid Leukaemia|||||||||@-@DACOGEN@@@@-|DACOGEN|||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@@@@@@@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16446194@Onco@@@@@@@@@@@"Quizartinib, Experimental, Once-daily repeated oral administration until there is no longer clinical benefit from therapy, or until unacceptable toxicity occurs."@@@@@TOKYO, JAPAN@4/1/2018@@@@16446194@Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia@Both@@@@@A novel second-generation FLT3 inhibitor@@@@@FIRST-LINE@NCT02984995@41@@@@@@@12/1/2016@@AC220-A-J201@@@-  AML patients in first relapse or refractory after all prior therapy  -  Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood  -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2@FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation@ADULTS@Phase 2@II@@@@@@@@@MONO@QUIZARTINIB@@@@@QUIZARTINIB||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Acute Myeloid Leukaemia@@@@@Acute Myeloid Leukaemia|||||||||@-@@@@@-||||@Other@@@@@Other||||@Composite complete remission (CRc) rate@@@@@Number of participants achieving best response@Percentage of participants achieving best response@@@@RELAPSED@REFRACTORY@@@@Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919059@Onco@@@@@@@@@@@All subjects received initial loading doses of Teverelix LA and then a single repeat dose on Day 28 and every 28 days thereafter up to Week 24; using a one month dosing regime repeated every four weeks up to the twenty fourth week. SOURCE: Ardana@@-@-@-@EDINBURGH, UNITED KINGDOM@@@@@14919059@-@@-@-@@NO REVIEW@@@@-@Development costs are assumed by Ardana Biosciences from 'terna Zentaris. As part of the agreement, Zentaris will provide certain development services and supply clinical samples to Ardana. On April 2, 2004, Ardana extended its agreement and acquired full@-@-@40@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Testosterone levels at baseline were 3.74 ng/ml.  Suppression in testosterone was attained within two days of dosing to a median value of 0.40 ng/ml.  Median testosterone values remained at or below the castration threshold of 0.5 ng/ml from two weeks following the first injection of Teverelix LA until the end of the study at week 28. Mean PSA levels were reduced by approximately 75% within 4 weeks of the first injection of Teverelix  LA.  The suppression of PSA follows the suppression of testosterone in patients and also appears to be maintained throughout the 28 week study. Steady state Teverelix LA plasma levels were achieved within four weeks of dosing. The product appears to continue to be well tolerated and there was no evidence of immunogenicity. SOURCE: Ardana, 9 April 2008@-@@@@MONO@TEVERELIX@@@@@TEVERELIX||||@ARDANA BIOSCIENCE@@@@@ARDANA BIOSCIENCE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TEVERELIX LA@@@@@TEVERELIX LA||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@-@@@@@RANDOMISED@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918764@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ADH-1 in three separate combinations (Taxotere, carboplatin and Xeloda)@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14918764@Combo with either docetaxel, carboplatin or capecitabine@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@NA@@-@-@@@II@II@@-@-@ASCO June 2007;  ADH-1 was well-tolerated and prolonged stable disease@-@@@@COMBO@-@@@@@-||||@ADHEREX TECHNOLOGIES@@@@@ADHEREX TECHNOLOGIES||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@EXHERIN@ADH-1@@@@EXHERIN|ADH-1|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918953@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single dose after surgery@@-@-@-@MORRIS PLAINS, NEW JERSEY@@@Radiolabeled humanized antibody targeting CEA-expressing tumors.  Primarily use for the treatment of inoperable metastatic solid tumors.  Every year there are 140,000 newly diagnosed and 65,000 deaths due to colorectal cancer; 180,000 new cases and 45,000 deaths due to breast cancer; 172,000 new case and 160,000 deaths due to lung cancer; 25,000 new case and 15,000 deaths due to ovarian cancer; and 29,000 new cases and 28,000 deaths due to pancreatic cancer.  Phase I clinical trials of yttrium-90-labeled labetuzumab have been completed as well as Phase II clinical trials of iodine-131-labeled labetuzumab for the treatment of patients with colorectal cancer that has metastasized to the liver.@@14918953@-@@-@-@@NO REVIEW@@@@-@-@-@-@19@-@-@@@-@@@-@N/A@@-@-@@@-@II@@-@-@JCO September 2005; 5-year survival was 51% on antibody versus 7% in conventional therapy group. Median OS from first surgery was 68.0 months versus 31 months in control group.@-@@@@-@LABETUZUMAB@@@@@LABETUZUMAB||||@IMMUNOMEDICS@@@@@IMMUNOMEDICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@IMMU-100@IMMU-101@@@@IMMU-100|IMMU-101|||@mAb@Humanised@Radiolabeled@@@mAb|Humanised|Radiolabeled||@OVERALL SURVIVAL@5-YEAR SURVIVAL@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924756@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly Taxoprexin with carboplatin versus paclitaxel plus carboplatin@@L01CD01@L01C@-@TOKYO, JAPAN@@@Taxoprexin is a conjugate of paclitaxel and the fatty acid docosahexaenoic acid (DHA). Preclinical studies have shown increased activity and an improved therapeutic ratio relative to paclitaxel. @@14924756@-@@-@-@@NO REVIEW@@@@-@Luitpold is a subsidiary of Daiichi Sankyo.@FIRST-LINE@NCT00243867@512@-@-@@@-@@@-@-@@-@-@@@III@III@@-@-@Study completion due in April 2008.@-@@@@COMBO@PACLITAXEL, DHI@CARBOPLATIN@@@@PACLITAXEL, DHI|CARBOPLATIN|||@DAIICHI SANKYO@LUITPOLD PHARMACEUTICALS@@@@DAIICHI SANKYO|LUITPOLD PHARMACEUTICALS|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAXOPREXIN@@@@@TAXOPREXIN||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922615@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CEP-701 (80mg daily for up to 113 days) administered in sequence with standard chemotherapy (cytarabine, etoposide, mitoxantrone) @@-@-@-@FRAZER, PENNSYLVANIA@@@@@14922615@AML-expressing FLT-3 mutations@@-@-@@NO REVIEW@@@@-@Licensed from Kyowa Hakko; supplied by Abbott/TAP. Original licensing agreement with Schwarz Pharma terminated.@SECOND-LINE@NCT00483340@220@-@-@@@-@@12/1/2003@-@2003-0719@@-@-@@@II@II@@-@-@December 2005 preliminary update on 44 patients; complete response seen in 10 of 22 (45%) of patients in the CEP-701 + chemo group versus 6 of 22 (27%) in the chemo-only group.@-@@@@COMBO@LESTAURTINIB@CYTARABINE@ETOPOSIDE@MITOXANTRONE@@LESTAURTINIB|CYTARABINE|ETOPOSIDE|MITOXANTRONE|@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CEP-701@@@@@CEP-701||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@OVERALL SURVIVAL@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920989@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are stratified according to disease stage (II vs III). Beginning 28-35 days after total surgical resection, patients receive adjuvant autologous tumor cell vaccine intradermally once weekly for 3 vaccinations. The first 2 vaccinations also contain BCG. Patients with stage II disease receive a fourth vaccination 6 months after surgical resection. Beginning 10-17 days after the third vaccination, patients with stage III disease receive adjuvant leucovorin calcium IV and fluorouracil IV on days 1-5. Chemotherapy continues every 28-35 days for a total of 6 courses. These patients also receive a fourth vaccination 1 month after the completion of chemotherapy. Patients are followed at 90 days and 6 months.@@-@-@-@FREDERICK, MARYLAND@@@@@14920989@Stage II or III@@-@-@@NO REVIEW@@@@-@Vaccinogen licensed exclusive rights from Intracel. SOURCE: Vaccinogen, 6 February 2008@-@NCT00016133@30@-@-@@@-@@3/1/2001@-@INTRACEL-ASI-2002@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@INTRACEL@@@@@INTRACEL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ONCOVAX@@@@@ONCOVAX||||@Vaccine@@@@@Vaccine||||@SAFETY@IMMUNE RESPONSE@@@@@@@@@-@@@@@NON-RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922314@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm I: Chemoprevention. Lotion composed of T4 endonuclease V protein encapsulated in liposomes and suspended in phosphate-buffered saline in a hydrogel base, T4N5 Liposome Lotion, T4N5. Arm II: Control. Liposomes suspended in phosphate-buffered saline in a hydrogel base, Placebo, PLCB.@@-@-@-@FREEPORT, NEW YORK@@@@@14922314@Xeroderma Pigmentosa@@-@February 1998 (FDA)@@NO REVIEW@@@@-@-@-@NCT00002811@30@-@On 5 September 2007 AGI Dermatics announced that T4N5 (DIMERICINE) has been granted Fast Track status by the US FDA for the treatment of solar and ultraviolet photosensitivity in patients with xeroderma pigmentosum (XP).@9/5/2007@@-@@7/1/1996@-@AGI-007, @@-@-@@@AGI-FDR000992, NCI-V96-0953; @III@@-@-@RESULTS PENDING@-@@@@MONO@DIMERICINE@@@@@DIMERICINE||||@AGI DERMATICS@@@@@AGI DERMATICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@T4N5@@@@@T4N5||||@Enzyme@@@@@Enzyme||||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@PREVENTION@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924770@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924770@Myelodysplastic syndrome (MDS)@@-@-@@NO REVIEW@@@@-@-@-@NCT00280631@85@-@PARTIAL HOLD ON TELCYTA ARMS IMPOSED IN JUNE 2007; ASSIST-3 AND ASSIST-5 PATIENTS WILL CONTINUE TO RECEIVE TREATMENT.@@@-@@1/1/2006@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TELIK@@@@@TELIK||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@TELINTRA@@@@@TELINTRA||||@Enzyme@@@@@Enzyme||||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922707@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Two dose levels of AdV-tk will be evaluated: 1x1011 vp per injection or 3x1011 vp per injection. Dose escalation will be performed according to the dose escalation and stopping rules in section 7.4 of the protocol with 3-6 patients per dose level. The prodrug valacyclovir, at a fixed dose, will be started 1-3 days after AdV-tk injection and continue for 14 days. Radiation throught radiotherapy will be determined and administered as per standard of care for the patient's disease. It will start 3-7 days after AdV-tk injection.@@-@-@-@BOSTON, MASSACHUSETTS@12/1/2009@@@@14922707@Paediatric patients with malignant glioma@@-@-@@NO REVIEW@@@@-@-@-@NCT00634231@12@-@-@@@-@@4/1/2008@-@07-098@@-@-@PAEDIATRIC@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@ADVANTAGENE@@@@@ADVANTAGENE||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@ADV-TK@@@@@ADV-TK||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@IMMUNE RESPONSE@@@@@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16382368@Onco@@@@@300f1014ntsdm@@@@@@@@M05BX04@M05B@@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@16382368@XGEVA is indicated for the treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate@@NO@@@@@@@@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@@@@@Health Canada@@3/16/2012@@@@@@No@@@@@@APPROVED@@@RAMQ@@@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Hypercalcaemia of Malignancy@@@@@Hypercalcaemia of Malignancy|||||||||@XGEVA@@@@@XGEVA||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@@@@@@@@@@@REFRACTORY@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@0.7881@538.45@@@@@@@@@@@@4.49@@@@@@@@@@@@@@@@7/19/2017@538.45@538.45@23681531@SOLUTION FOR INJECTION@C$@@@@@@@@120@MG@120 MG/1.7 ML@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
15409679@Onco@@@@@@@@@@@Iomab-B, Experimental, Iomab-B prior to HCTConventional Care, Active Comparator, Azacitidine (not allowed as a single agent), Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent), Doxorubicin, Etoposide, Fludarabine, Hydroxyurea (not allowed as a single agent), Idarubicin, L-Asparaginase, Mitoxantrone, Thioguanine@@@@@@4/1/2018@@@@15409679@A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia@Both@@@@@@@@@@@NCT02665065@150@@@@@@@6/1/2016@@Iomab-01@@@Be 55 years and older with active, relapsed or refractory Acute Myeloid Leukemia ; Have 8/8 HCT donor match (related and unrelated); Karnofsky score ≥ 70@@ADULTS@Phase 3@III@@@@@@@@@@IOMAB-B@@@@@IOMAB-B||||@Actinium Pharmaceuticals@@@@@Actinium Pharmaceuticals||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@-@@@@@-||||@Other@@@@@Other||||@Durable Complete Remission (dCR)@@@@@OVERALL SURVIVAL@@@@@@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924339@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@IRVINE, CALIFORNIA@@@Fusilev is a novel folate analog. It is the pharmacologically active isomer of leucovorin. Fusilev rescue is indicated after high-dose methotrexate therapy in osteosarcoma, and is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.@@14924339@It is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists.@@-@-@@NO REVIEW@@@@-@Acquired through takeover of oncology assets of Targent, which licensed it from Merck KGaA in 2004, in March 2006.@-@-@-@-@Filed with FDA. SOURCE: Spectrum, 5 June 2008@6/5/2008@@-@@@-@-@@-@-@@@-@FILED@@-@-@-@-@@@@-@LEVOLEUCOVORIN@@@@@LEVOLEUCOVORIN||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@FUSILEV@(ISO-VORIN)@@@@FUSILEV|(ISO-VORIN)|||@Detoxifying Agent@@@@@Detoxifying Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917957@Onco@@@@@300f1015ntsdm@@@@@@@@V03AF03@V03A@@@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14917957@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@Mar-00@@NO REVIEW@@@@65%@@@@@@@@3/8/2000@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@THERABEL LUCIEN PHARMA@@@@@THERABEL LUCIEN PHARMA||||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@FOLINORAL@@@@@FOLINORAL||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@14@1.1511@10.45@13.89@11.15@@@@@@@@@@0.03@@@@@@@@@@@@@@@@8/1/2017@0.75@0.75@3.40E+12@CAPSULE@EURO@@@@@@@@25@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14916732@Onco@@@@@@@@@@@SCH-61974 versus placebo@@-@-@-@KENILWORTH, NEW JERSEY@@@@@14916732@-@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00394966@450@-@-@@@-@@9/1/2006@-@P04352AM1@@-@-@@@P04351; CLIN DOC NUMBER =3047522 / @II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@-@@@@@-||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@SCH-619734@@@@@SCH-619734||||@Other@@@@@Other||||@N/A@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923750@Onco@@@@@300f1037ntsdm@@@@@@Oxaliplatin combined with cisplatin and 5FU.@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14923750@-@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@NCT00259402@43@-@-@@@-@@2/1/2000@-@-@@-@43 patients aged between 18 and 75 years @@@II@II@@-@-@-@-@@@@MONO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@OVERALL SURVIVAL@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14922455@Onco@@@@@@@@@@@Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2. Prednisone is administered at a dose of 5 mg twice daily. CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).  [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@1/1/2010@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922455@CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00313781@120@-@-@@@-@@5/1/2006@-@A4021011@@-@-@@@II@II@@-@-@Trial registered. [Pfizer, 10.04.2006]@-@@@@COMBO@FIGITUMUMAB@DOCETAXEL@PREDNISONE@@@FIGITUMUMAB|DOCETAXEL|PREDNISONE||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@CP-751,871@TAXOTERE@@@@CP-751,871|TAXOTERE|||@mAb@Human@@@@mAb|Human|||@PSA@RECIST@@@@SAFETY@PHARMACOKINETICS@PROGRESSION-FREE SURVIVAL@@@REFRACTORY@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923145@Onco@@@@@300f1015ntsdm@@@@@@-@@-@-@-@MARSEILLE, FRANCE@@@"IPH 1101 is the most advanced drug candidate of the ?d T cell platform - one of Innate Pharma's three platforms currently under development. This platform is constituted by a familyof agonists of V?9Vd2 T lymphocytes, a non-conventional T cell population. IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the V?9Vd2 T cell subset. The compound has been developed for intravenous delivery in association with subcutaneous, low-dose IL-2, since the latter enables the expansion of the V?9Vd2 T cell population. IPH 1101 potentiates the direct cytotoxic activity of V?9Vd2 T cells against a large number of tumor cell lines and triggers the synthesis of pro-inflammatory cytokines - inducing the recruitment of other cell effectors and facilitating implementation of an adaptive response. It"@@14923145@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@PHOSPHOSTIM@@@@@PHOSPHOSTIM||||@INNATE PHARMA@@@@@INNATE PHARMA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@IPH-1101@@@@@IPH-1101||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14920890@Onco@@@@@300f1012ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920890@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@Waldenstrom's Macroglobulinaemia: Leukeran is the treatment of choice in this indication. Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.@@@@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Waldenstrom's Macroglobinaemia@@@@Haematological Malignancy|Waldenstrom's Macroglobinaemia||||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@25@1.1511@55@80.52@57.43@@@@@@@@@@1.1@@@@@@@@@@@@@@@@8/1/2017@2.2@2.2@1263954@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14916018@Onco@@@@@300f1008ntsdm@@@@@@S-1 or UFT@@-@-@-@DARMSTADT, GERMANY@3/1/2012@@@@14916018@Previously treated Stage III or IV locally advanced squamous cell carcinoma of the head and neck cancer; S-1 versus UFT@@-@-@@NO REVIEW@@@@-@-@-@NCT00336947@500@-@-@@@-@@4/1/2006@-@YCU-BRI-HN-05-01@@-@-@@@III@III@@-@@RESULTS PENDING@-@@@@ADJUVANT@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@UFTORAL@S-1@@@@UFTORAL|S-1|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@DISEASE-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@@@@@RANDOMISED@ACTIVE CONTROL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14916297@Onco@@@@@@@@@@@All patients received Cerepro plus standard care (surgical removal of the tumour followed by radiotherapy of primary tumours only or chemotherapy. @@-@-@-@LONDON, UNITED KINGDOM@@@@@14916297@Malignant glioma; filed in Europe in October 2005.@@-@-@@NO REVIEW@@@-@-@-@-@-@250@-@-@@@ORPHAN DRUG IN EMEA AND FDA@@@-@STUDY 904@@-@-@@@III@III@@-@-@Cerepro demonstrated an 81% increase in mean survival (from 39 weeks to 71 weeks) compared to standard care in 70 patients. The difference between the groups was statistically significant even when study results were adjusted for the main disease prognostic factors of age, gender, tumour type, histology and Karnofski score. DSMB recommended continuation of Phase III trial in July 2007.@-@@@@COMBO@SITIMAGENE CERADENOVEC@@@@@SITIMAGENE CERADENOVEC||||@ARK THERAPEUTICS@@@@@ARK THERAPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@CEREPRO@@@@@CEREPRO||||@Gene Therapy@@@@@Gene Therapy||||@OVERALL SURVIVAL@KARNOFSKY SCALE@@@@@@@@@MALIGNANT@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922066@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive intratumor BG00001 by stereotactic injection on day 1. Patients undergo tumor resection and receive the second injection of BG00001 into the tumor bed and remaining tumor on day 8 in the absence of unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of BG00001 until the maximum tolerated dose (MTD) is determined. The MTD is defined as one dose level below that at which either 2 of 3 or 2 or more of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 14-17 additional patients receive treatment as above with the MTD of BG00001. Patients are followed on days 9, 10, 11, 12, 15, 22, and 29; weeks 8, 17, 26, and 52; and then every 6 months thereafter. SOURCE: clinicaltrials.gov@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14922066@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00036725@3/1/1950@-@-@@@-@@1/1/2002@-@C-1502@@-@-@@@UARIZ-HSC-01197, NCI-V02-1696; @I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@BG-00001@@@@@BG-00001||||@Gene Therapy@@@@@Gene Therapy||||@TOXICITY@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924230@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@Ceplene is EpiCept's registration-stage compound for the treatment of AML.Ceplene is based on the naturally occurring molecule histamine, and isdesigned to prevent or inhibit oxidative stress, thus protecting criticalimmune cells.  Research has demonstrated that oxidative stress suppresses theimmune system's ability to destroy cancer cells, including malignant AMLcells.@@14924230@Advanced malignant melanoma patients with liver metastases.@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Maxim Pharmaceuticals in January 2006.@-@-@-@-@Maxim withdrew NDA in November 2004 following the failure of the confirmatory M0104 trial.@@@-@@@-@-@@2018 [Orphan exclusivity]@-@@@-@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@-@HISTAMINE DIHYDROCHLORIDE@@@@@HISTAMINE DIHYDROCHLORIDE||||@EPICEPT@@@@@EPICEPT||||@@@@@@|||||||||@Melanoma / Skin Cancer@Liver Cancer@@@@Melanoma / Skin Cancer|Liver Cancer||||||||@CEPLENE@@@@@CEPLENE||||@Other@@@@@Other||||@-@@@@@@@@@@METASTATIC@ADVANCED@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412801@Onco@@@@@@@@@@@DC-CIK, Experimental, After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.Chemotherapy, Sham Comparator, After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.@@@@@@12/1/2018@@@@15412801@Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection@Both@@@@@Experimental: DC-CIK. After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.Interventions:◦Drug: Paclitaxel/Biological: DC-CIK/Drug: CisplatinComparator: Chemotherapy. After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.Interventions:◦Drug: Paclitaxel/Drug: Cisplatin@@@@@@NCT02644863@60@@@@@@@12/1/2015@@HYK-esophageal cancer@@@18-75 years old;  -  Clinical diagnosis of esophageal cancer patients,tumor TNM stageII-III;  -  Patients who can accept curative operations;  -  Patients who have a life expectancy of at least 3 months; .Eastern Cooperative Oncology Group (ECOG) performance status was 0-2.@COMBO@ADULTS@Phase 2@II@@@@@@@@@@-@PACLITAXEL@CISPLATIN@@@-|PACLITAXEL|CISPLATIN||@@@@@@||||@China@@@@@China|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@DC-CIK@GENERIC@@@@DC-CIK|GENERIC|||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@Progress-free survival@QUALITY OF LIFE@@@@@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924984@Onco@@@@@300f1008ntsdm@@@@@@Nexavar 400mg versus placebo@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14924984@-@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00494299@414@-@-@@@-@@4/1/2006@-@11721@@-@-@@@III@III@@-@@RESULTS PENDING (recruiting)@-@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14922535@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Somatuline Autogel 120mg injection every 28 days with pegvisomant 40 to 120mg per week.@@-@-@-@PARIS, FRANCE@@@@@14922535@With pegvisomant@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00383708@68@-@-@@@-@@10/1/2006@-@2-55-52030-727  @@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@LANREOTIDE@@@@@LANREOTIDE||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Acromegaly@@@@@Acromegaly|||||||||@SOMATULINE AUTOGEL@@@@@SOMATULINE AUTOGEL||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916714@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Insegnia in combination with chemotherapy@@-@-@-@-@@@@@14916714@-@@-@-@@NO REVIEW@@@@-@Licensed from Aphton in July 2006 after Aphton filed for bankrupcty.@-@NCT00044031@N/A@-@-@@@-@@2/1/2001@-@PC4@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@G17DT IMMUNOGEN@@@@@G17DT IMMUNOGEN||||@RECEPTOR BIOLOGIX@@@@@RECEPTOR BIOLOGIX||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@INSEGNIA@@@@@INSEGNIA||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922138@Onco@@@@@@@@@@@4 different dose levels from 5-100kBq/kg@@-@-@-@KJELSAS, NORWAY@@@Algeta's lead product based on the alpha emitter technology is Alpharadin, a product being developed as a new treatment for skeletal metastases in patients with late-stage, hormone refractory prostate cancer (HRPC). Alpharadin (radium-223 chloride) is a unique targeted therapeutic in phase III clinical trials for the treatment for HRPC that has metastasized to the skeleton.@@14922138@Palliation@@-@-@@NO REVIEW@@@-@-@-@-@-@N/A@-@-@@@-@@@-@BCI-03@@-@-@@@II@II@@-@-@Primary objective of BC1-03 was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. Full results will be released in a peer-reviewed journal. [Algeta, 28.08.2008]>Results expected in Q2 2008.@The study has further confirmed the safety of Alpharadin and shown its benign side-effect profile; the higher the dose of Alpharadin that patients received, the fewer adverse events were experienced.@@@@MONO@-@@@@@-||||@ALGETA@@@@@ALGETA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ALPHARADIN@@@@@ALPHARADIN||||@Other@@@@@Other||||@PALLIATION@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923183@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@@@NO@@@@@@14923183@The principal use of Sodium Phosphate P 32 is for the treatment of polycythemia vera, and it is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia.Sodium Phosphate P 32 is also used in palliative treatment of selected patients with multiple areas of skeletal metastases.@@NO@@@NO REVIEW@@@@@Part of Tyco Healthcare@@@@The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Oral administration of high-specific-activity Sodium Phosphate P 32 in the fasting state may equal intravenous administration.@@@@@@@NONE@NO LABELLED TRIAL@No@N/A@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@SODIUM PHOSPHATE@@@@@SODIUM PHOSPHATE||||@MALLINCKRODT@@@@@MALLINCKRODT||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Chronic Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia|||||||@SODIUM PHOSPHATE P32 SOLUTION@@@@@SODIUM PHOSPHATE P32 SOLUTION||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@5@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@0.67@MCI@0.67 MCI/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921602@Onco@@@@@@@@@@@Patients receive Iressa@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14921602@First-line adenocarcinoma with EGFR mutation@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00344773@145@-@-@@@-@@3/1/2006@-@D7913L00056  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@South Korea@@@@@South Korea|||||||||@Other@@@@@Other|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@RESPONSE RATE@RECIST@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15260721@Onco@@@@@300f1008ntsdm@@@@@@@@L01XC17@L01X@@OSAKA, JAPAN@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@15260721@Indicated for the treatment of patients with unresectable melanoma@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@35@@MHLW, 1 September 2014@9/1/2014@9/1/2014@Yes@@@@@No@@@@@III@APPROVED@@@NHI@@@@@@@NIVOLUMAB@@@@@NIVOLUMAB||||@ONO PHARMACEUTICALS@@@@@ONO PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@@@@@@@@@@76.5@kg@7543387.013@@@11@month@11 month@7543387.01@7543387.01@22546.11@1@0.0091@309456.4@364925@@@@@@@@@@@3094.56@21@@mg/kg@2@1@@@@@@@@@@@8/30/2017@309456.4@309456.4@4291427A2020@INTRAVENOUS INFUSION 10 ML@YEN@@@@@@@@100@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14916719@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@KVISTGARD, DENMARK@@@@@14916719@Androgen-independent prostate cancer (AIPC) but no measurable metastatic disease@@-@-@@NO REVIEW@@@@-@The drug was initially developed by Therion Biologics, but after failing to meet its primary endpoint in June 2006, the firm was liquidated, and Prostvac was returned to the US government. Bavarian Nordic and the NCI are currently co-developing the drug.@-@-@-@-@-@@@-@@12/1/2006@-@PARADIGM STUDY@@-@PATIENTS WITH LESS ADVANCED DISEASE COMPARED TO PHASE II @@@III@III@@-@-@In June 2006, Therion reported the trial did not meet its primary efficacy endpoint of improving progression free survival with PROSTVAC-VF treament. But preliminary data suggests the vaccine is linked with a potential reduction in mortality compared to placebo.   @-@@@@-@-@@@@@-||||@BAVARIAN NORDIC@@@@@BAVARIAN NORDIC||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PROSTVAC@@@@@PROSTVAC||||@Vaccine@@@@@Vaccine||||@TIME-TO-OVERT METASTATIC DISEASE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924122@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@10 and 25 mg tablets of asoprisnil was administered daily for 12 months to women with abnormal uterine bleeding associated with uterine fibroids after an initial 12 months@@-@-@-@-@1/1/2007@@@@14924122@Benign uterine tumours; myoma@@-@-@@NO REVIEW@@@@-@Abbott/Takeda joint venture TAP Pharmaceuticals dissolved. Abbott received rights to Lupron franchise; Takeda received the remaining organisation and pipeline - though Abbott receives payments based on TAP's current and future products. SOURCE: Takeda, 19@-@NCT00156195@523@-@-@@@-@@9/1/2003@-@-@@-@-@@@III@III@@-@-@As a result of some subjects receiving asoprisnil developing endometrial changes, dosing was prematurely discontinued for all participants.In most subjects, endometrial changes reversed after asoprisnil discontinuation. @-@@@@-@ASOPRISNIL@@@@@ASOPRISNIL||||@BAYER HEALTHCARE@TAKEDA PHARMACEUTICAL@TAP PHARMACEUTICALS@@@BAYER HEALTHCARE|TAKEDA PHARMACEUTICAL|TAP PHARMACEUTICALS||@@@@@@|||||||||@Myoma@@@@@Myoma|||||||||@-@@@@@-||||@Hormone Antagonist@@@@@Hormone Antagonist||||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922518@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Rituximab 375 mg/m2 q4wls and dose escalation of inotuzumab ozogamicin in combination with rituximab, MTD = 1.8 mg/mg. SOURCE: clinicaltrials.gov@@-@-@-@MADISON, NEW JERSEY@12/1/2012@@@@14922518@Follicular or diffuse large B-cell NHL@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@NCT00299494@100@-@-@@@-@@3/1/2006@-@3129K3-101@@-@-@@@I/II@III@@-@-@RESULTS PENDING@-@@@@COMBO@INOTUZUMAB OZOGAMICIN@RITUXIMAB@@@@INOTUZUMAB OZOGAMICIN|RITUXIMAB|||@WYETH@PFIZER@@@@WYETH|PFIZER|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@DLBCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|DLBCL||||||@CMC-544@RITUXAN@MABTHERA@@@CMC-544|RITUXAN|MABTHERA||@mAb@@@@@mAb||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919024@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@@@14919024@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@SP-1049C@@@@@SP-1049C||||@Other@@@@@Other||||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16614938@Onco@@@@@@@@@@@Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped  -  Patients should participate in the study voluntarily and sign informed consent@@@@@CHINA@12/1/2018@@@@16614938@Phase I Study of Tolerance and Pharmacokinetics of TQ-B3101 in Patients With Advanced Cancer@Both@@@@@TQ-B3101 p.o. qd@@the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating@@@FIRST-LINE@NCT03019276@20@@@@@@@2/1/2017@@TQ-B3101-1-0001@@@-  Histological documentation of Advanced solid tumors  -  Lack of the standard treatment or treatment failure  -  18-70years,ECOG PS:0-1,Life expectancy of more than 3 months  -  Main organs function is normal  -  Women of childbearing potential should a@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@JIANGSU CHIA-TAI TIANQING PHARMACEUTICAL@@@@@JIANGSU CHIA-TAI TIANQING PHARMACEUTICAL||||@China@@@@@China|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TQ-B3101@@@@@TQ-B3101||||@Other@@@@@Other||||@"TQ-B3101, Experimental, TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"@The maximum tolerated dose (MTD) of TQ-B3101@The type of dose-limiting toxicity(ies) (DLT[s]) of TQ-B3101@@@Objective Response Rate (ORR)@@@@@ADVANCED@@@@@Pharmacokinetics/Dynamics Study@Single Group Assignment@Open Label@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924703@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@A04AA02@A04A@-@GALASHIELS, UNITED KINGDOM@@@Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. Radioligand binding studies have demonstrated that Granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites. Granisetron is effective orally prophylactically in abolishing the retching and vomiting evoked by cytostatic therapy.@@14924703@-@@-@-@@NO REVIEW@@@@-@Prostrakan license rights to Japan, China and some Southeast Asian rights for transdermal granisteron to JapanBridge. SOURCE: ProStrakan, 26 May 2008@-@-@-@-@Due to resource constraints, action date amended to 10 June 2008. ProStrakan notes there appears to be no outstanding questions regarding the NDA. SOURCE: ProStrakan, 2 June 2008NDA filed with FDA; action date on 2 May 2008. SOURCE: Prostrakan, June 2007@5/2/2008@@-@@@-@-@@-@-@@@-@FILED@@-@-@-@-@@@@-@GRANISETRON HYDROCHLORIDE@@@@@GRANISETRON HYDROCHLORIDE||||@PROSTRAKAN@@@@@PROSTRAKAN||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@SANCUSO@@@@@SANCUSO||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@PATCH, TRANSDERMAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922495@Onco@@@@@@@@@@@Zactima versus Iressa@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14922495@NSCLC after failure of prior platinum-based chemo@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00059722@160@-@-@@@-@@4/1/2005@-@6474IL0003  @@-@-@@@II@II@@-@-@ASCO June 2006 Final Results; in Part A, median PFS was 11.0 weeks for ZD-6474 and 8.1 weeks for gefitinib (statistically significant); disease control >8 weeks was achieved in 37/83 (45%) patients receiving ZD-6474 and in 29/85 (34%) receiving gefitinib. The adverse event profile of ZD-6474 in Part A was similar to that seen in previous trials, and included diarrhea (CTC grade 3/4, 8.4%), rash (CTC grade 3/4, 4.8%) and asymptomatic QTc prolongation (all CTC grade 1, 20.5%). In Part B, disease control >8 weeks was achieved in 16/37 patients who switched to ZD-6474 (from gefitinib) and in 7/29 who switched to gefitinib (from ZD6474). Overall survival was not significantly different (median 6.1 and 7.4 months, respectively).@-@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@TIME TO PROGRESSION@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@CROSSOVER@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16161175@Onco@@@@@@@@@@@Experimental Arm 1, Experimental, BMS-986012/Cisplatin/EtoposideExperimental Arm 2, Experimental, BMS-986012/Carboplatin/EtoposideExperimental Arm 3A, Experimental, BMS-986012/Platinum/EtoposideActive Comparator Arm 3B, Active Comparator, Platinum/Etoposide@@@@@NEW YORK, NEW YORK@7/1/2019@@@@16161175@A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer@Both@@@@@@@@@@FIRST-LINE@NCT02815592@120@@@@@@@9/1/2016@@CA001-044@@@For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  -  Male and Females 18 years of age or older  -  Pulmonary SCLC documented by histology or cytology  -  Extensive disease (Stage IV) SCLC  -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@-@CISPLATIN@ETOPOSIDE@CARBOPLATIN@@-|CISPLATIN|ETOPOSIDE|CARBOPLATIN|@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@BMS-986012@GENERIC@GENERIC@PARAPLATIN@@BMS-986012|GENERIC|GENERIC|PARAPLATIN|@Other@@@@@Other||||@Number of participants with Adverse Events (AEs)@Number of participants with serious adverse events (SAEs )@Discontinuations due to AEs@@@Maximum observed serum concentration(Cmax)@Time of maximum observed serum concentration(Tmax)@@@@EXTENSIVE@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@TREATMENT@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922159@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Carboplatin/paclitaxel with or without AZD-0530@@-@-@-@LONDON, UNITED KINGDOM@12/1/2009@@AZD0530 is an orally available, dual-specific, Src/Abl kinase inhibitor that is being evaluated to determine its effects as an anti-invasive agent. AZD0530 is being studied in a variety of clinical settings in solid tumors and leukemias.@@14922159@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00610714@200@-@-@@@-@@4/1/2008@-@AZD0530 Study 15@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@CARBOPLATIN@PACLITAXEL@@@-|CARBOPLATIN|PACLITAXEL||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@AZD-0530@@@@@AZD-0530||||@TK Inhibitor@@@@@TK Inhibitor||||@RECIST@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920263@Onco@@@@@300f1014ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@NEW YORK, NEW YORK@@@@@14920263@@@@@@NO REVIEW@@@-@@@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@1-Dec-67@12/1/1967@@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@RAMQ@NO LABELLED TRIAL@@@@@@HYDROXYUREA@@@@@HYDROXYUREA||||@GENPHARM@@@@@GENPHARM||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@GEN-HYDROXYUREA@GENERIC@@@@GEN-HYDROXYUREA|GENERIC|||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@100@0.7881@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@C$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
15004597@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental: Arm I (temozolomide):Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may crossover to arm II.Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.@@@@-@LONDON, UNITED KINGDOM@5/1/2015@@@@15004597@Randomized Phase II Trial of Temozolomide Versus Hyd-sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT01143402@159@-@-@@@-@@6/1/2010@-@@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting). ASCO June 2007; genotyping of EGFR CAn is a predictive marker for skin rashes in Iressa use. @-@@@@COMBO@SELUMETINIB@TEMOZOLOLOMIDE@@@@SELUMETINIB|TEMOZOLOLOMIDE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TEMODAL@@@@@TEMODAL||||@MEK Inhibitor@@@@@MEK Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@SAFETY@RESPONSE RATE@@@METASTATIC@@@@@RANDOMISED@PARALLEL ASSIGNMENT@OPEN-LABEL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921620@Onco@@@@@@@@@@@Experimental (AZD1152): 1200 mg, iv, 7 day infusion  Active Comparator (LDAC):  20 mg, sc, bd, 10 days  Experimental (AZD1152 + LDAC): Dose dependant upon parallel study D1531C00018@@-@-@-@LONDON, UNITED KINGDOM@12/1/2012@@@@14921620@A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged = 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)@@-@-@@NO REVIEW@@@@-@-@-@NCT00952588@417@-@-@@@-@@7/1/2009@-@D1531C00009@@-@Newly diagnosed male or female patients aged 60 and over De Novo or Secondary AML@@@II@II@@-@-@TRIAL REGISTERED [AZ 4 AUG 2009]@-@@@@COMBO@-@CYTOSINE ARABINOSIDE@@@@-|CYTOSINE ARABINOSIDE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AZD-1152@CYTOSINE ARABINOSIDE@@@@AZD-1152|CYTOSINE ARABINOSIDE|||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@RESPONSE RATE@@@@@SAFETY@OVERALL SURVIVAL@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918888@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@IRVINE, CALIFORNIA@@@@@14918888@-@@-@-@@NO REVIEW@@@@-@Available for out-licensing outside the U.S.@-@-@-@-@EMEA has agreed that data from these two Phase III trials will suffice to make a decision on approval for non-invasive bladder cancer. SOURCE: Spectrum, January 2008@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@ELSAMITRUCIN@@@@@ELSAMITRUCIN||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@(BMY-28090)@@@@@(BMY-28090)||||@Topoisomerase II Inhibitor@Topoisomerase I Inhibitor@@@@Topoisomerase II Inhibitor|Topoisomerase I Inhibitor|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15051155@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@INGELHEIM, GERMANY@12/1/2010@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051155@Tovok and BSC versus placebo/BSC in patients failing Tarceva or Iressa@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00656136@400@-@-@@@-@@4/1/2008@-@1200.23@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BIBW-2992@TOVOK@@@@BIBW-2992|TOVOK|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918898@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalating doses of ALT-801@@-@-@-@MIRAMAR, FLORIDA@@@@@14918898@Progressive metastatic malignancies@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@12/1/2007@-@N/A@@-@-@@@I/II@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ALTOR BIOSCIENCE@@@@@ALTOR BIOSCIENCE||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ALT-801@@@@@ALT-801||||@Interleukin@@@@@Interleukin||||@SAFETY@MAXIMUM TOLERATED DOSE@PHARMACOKINETICS@@@PHARMACOKINETICS@@@@@METASTATIC@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922256@Onco@@@@@@@@@@@Patients receive a once-weekly infusion of Rencarex or placebo for 24 weeks. Those on Rencarex receive a loading dose of 50 mg WX-G250 in week 1, and weekly doses of 20mg during weeks 2-24. @@-@-@-@-@@@@@14922256@adjuvant monotherapy@@-@-@@NO REVIEW@@@@-@Wilex obtained option to own full marketing rights to Rencarex from Centocor in October 2004. Wilex inked a marketing partnership with Spanish firm Esteve for Southern Europe in April 2004.  @-@-@856@-@-@@@-@@7/1/2004@-@ARISER @@-@856 PATIENTS (428 PER TREATMENT ARM) WITH CLEAR CELL RCC AND HIGH RISK OF RECURRENCE AFTER SURGERY (NEPHRECTOMY). @@@III@III@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@WILEX@CENTOCOR@JOHNSON & JOHNSON@@@WILEX|CENTOCOR|JOHNSON & JOHNSON||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@RENCAREX@WX-G250@@@@RENCAREX|WX-G250|||@mAb@Chimeric@@@@mAb|Chimeric|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@THREE-ARM@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@MULTI-CENTRE@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919589@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@BEERSE, BELGIUM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919589@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@@@@@@October 2006 (renewal)@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14921581@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@TOKYO, JAPAN@@@@@14921581@Relapsed or refractory Ewing's sarcoma or peripheral primitive neuroectodermal tumour or desmoplastic small cell tumour@@-@-@@NO REVIEW@@@@-@-@-@NCT00055952@27@-@-@@@-@@1/1/2003@-@DAIICHI-8951A-PRT034,@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@EXATECAN MESYLATE@@@@@EXATECAN MESYLATE||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@DX-8951F@@@@@DX-8951F||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@OVERALL SURVIVAL@@PARTIAL RESPONSE@OVERALL SURVIVAL@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919054@Onco@@@@@@@@@@@258 randomised to observation whilst 257 received five experimental vaccinations 2.5MG on weeks 0,2,4,6 ad 10.@@-@-@-@DARMSTADT, GERMANY@@@@@14919054@Limited disease@@-@-@@NO REVIEW@@@@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]     >> ImClone licensed co-development and co-promotion rights to BMS in North America and Japan, and to Merck KGaA in Europe.@MULTIPLE@-@515@-@-@@@-@@@-@N/A@@-@-@@@III@DISCONTINUED@@-@-@Did not meet primary endpoint; development discontinued. SOURCE: ImClone/Merck/ASCO, June 2004 and February 2005@-@@@@MONO@MITUMOMAB@@@@@MITUMOMAB||||@MERCK SERONO@IMCLONE@@@@MERCK SERONO|IMCLONE|||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@IMC-BEC2@@@@@IMC-BEC2||||@mAb@Murine@@@@mAb|Murine|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919050@Onco@@@@@@@@@@@Axitinib versus placebo@@-@-@-@NEW YORK, NEW YORK@@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14919050@Adriamycin-refractory thyroid cancer@@-@-@@NO REVIEW@@@@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@SECOND-LINE@-@-@-@-@@@-@@@-@N/A@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@AXITINIB@@@@@AXITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@N/A@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921622@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AZD-7762 administered either alone or with Gemzar@@-@-@-@LONDON, UNITED KINGDOM@1/1/2010@@@@14921622@CHK1 Inhibitor@@-@-@@NO REVIEW@@@@-@-@-@NCT00413686@60@-@-@@@-@@12/1/2006@-@D1040C00002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@BOTH@-@GEMCITABINE@@@@-|GEMCITABINE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-7762@GEMZAR@@@@AZD-7762|GEMZAR|||@Other@@@@@Other||||@SAFETY@PHARMACOKINETICS@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15409683@Onco@@@@@@@@@@@Nivolumab + Temozolomide + Radiotherapy, Experimental, Nivolumab: specified dose on specified days; IV (intravenous) infusion Temozolomide: 75 mg (milligram)/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units (joule of radiation energy per kilogram) 5 times per week for 6 weeksNivolumab placebo + Temozolomide + Radiotherapy, Placebo Comparator, Nivolumab Placebo: specified dose on specified days; IV infusion Temozolomide: 75 mg/meter squared daily during Radiotherapy, 4 week treatment break, 150 mg/meter squared Day 1-5 for Cycle 1 and increased to 200 mg/meter squared Day 1-5 for Cycle2-Cycle 6 as tolerated; orally (additional cycles may be permitted with approval of sponsor) Radiotherapy: 2 gray units 5x/week x 6 weeks@@@@@@9/1/2020@@@@15409683@A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548@Both@@@@@@@@@@@NCT02667587@320@@@@@@@3/1/2016@@CA209-548@@@Males and Females, age ≥ 18 years old ; Newly diagnosed brain cancer or tumor called glioblastoma or GBM; Karnofsky performance status of ≥ 70 (able to take care of self); Full recovery from surgical resection; Tumor test result shows MGMT methylated, partially methylated, or indeterminate tumor subtype@@ADULTS@Phase 2@II@@@@@@@@@@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@ONO PHARMACEUTICALS@@@@BRISTOL-MYERS SQUIBB|ONO PHARMACEUTICALS|||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@-@@@@@-||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Overall survival defined as time from the date of randomization to the date of death.@@@@@PROGRESSION FREE SURVIVAL@@@@@@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@Double Blind (Subject,  Caregiver,  Investigator)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15409678@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Standard NCCN counseling, Placebo Comparator, National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.Standard NCCN counseling and Oncotype DX results, Experimental, National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor."@@@@@@8/1/2022@@@@15409678@The Impact of a Gene Expression Profile on Treatment Choice and Outcome Among Minority Men Newly Diagnosed With Prostate Cancer: A Randomized Trial@Male@@@@@@@@@@@NCT02668276@300@@@@@@@3/1/2016@@2015-1294@@@Men with newly diagnosed prostate cancer who are categorized as Very Low, Low, or Intermediate risk by NCCN criteria;  Are age 76 or younger@@ADULTS@N/A@-@@@@@@@@@@STANDARD NCCN COUNSELING@@@@@STANDARD NCCN COUNSELING||||@@@@@@||||@United States@@@@@United States|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@Effect of adding Oncotype DX prostate cancer assay to usual counseling on the proportion of men adopting Active Surveillance (AS).@@@@@@@@@@@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921072@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@10 patients were given the agent at 34 mg/m2 iv over 30 min daily for five consecutive days every three weeks and 55 patients were treated at the 28 mg/m2/day dose.@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@9/1/2006@@@@14921072@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Ilex in 2004@-@NCT00068211@N/A@-@-@@@-@@8/1/2003@-@ILX651-211@@-@-@@@II@II@@-@-@Dose limiting toxicity (neutropaenia) was seen in 4 out of the 10 patients in the 34 mg/m2/day group. At 28 mg/m2, the drug was well tolerated. Overall, 5 patients had a response (one complete response and four partial responses), and 38 patients achieved stable disease. Median progression free survival time for all patients was 43 days, and median overall survival time has not yet been reached. SOURCE: ASCO May 2005.@-@@@@MONO@TASIDOTIN@@@@@TASIDOTIN||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ILX-651@@@@@ILX-651||||@Depsipeptide@@@@@Depsipeptide||||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916270@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Docetaxel and prednisone with or without Xinlay.@@-@-@-@UNITED STATES@@@@@14916270@Stage IV HRPC and bone metastases@@-@-@@NO REVIEW@@@@-@-@-@NCT00134056@-@-@NDA FILED IN DECEMBER 2004; ODAC RECOMMENDED AGAINST APPROVAL IN SEPTEMBER 2005 CITING LACK OF EFFICACY DATA; DEVELOPMENT DISCONTINUED IN EARLY 2007.@@@-@@8/1/2006@-@SWOG-S0421 @@-@PATIENTS WITH HRPC@@@III@DISCONTINUED@@-@-@Phase III trials halted in February 2003 due to failure to stop disease progression; but lack of interaction with testosterone led to mitigated side-effects.@-@@@@MONO@ATRASENTAN@@@@@ATRASENTAN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Prostate Cancer@Bone Metastases@@@@Prostate Cancer|Bone Metastases||||||||@XINLAY@@@@@XINLAY||||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@MULTI-CENTRE@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921308@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@2 doses of ERA-923 in patients who have failed tamoxifen therapy@@-@-@-@-@@@@@14921308@Postmenopausal women with metastatic breast cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00006369@UP TO 100 @-@-@@@-@@6/1/2000@-@GENE-C9944-33@@-@-@@@MCC-IRB-5757; W-AR-3077A1-200-US; NCI-G00-1871 / @II@@-@-@RESULTS PENDING@-@@@@-@PIPENDOXIFENE @@@@@PIPENDOXIFENE ||||@LIGAND PHARMACEUTICALS@WYETH@@@@LIGAND PHARMACEUTICALS|WYETH|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ERA-923@@@@@ERA-923||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923905@Onco@@@@@300f1037ntsdm@@@@@@Patients will receive Xeloda in combination with one of 4 standard chemotherapy regimens; the dose of Xeloda will be from 625mg/m² - 1000mg/m² bid orally, depending on the chemotherapy regimen used.#@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14923905@Xeloda in combination with standard chemotherapy regimens@@-@6-Dec@@NO REVIEW@@@@-@-@-@NCT00454636@100-500 @-@-@@@-@@3/1/2007@-@-@@-@-@@@II@II@@-@-@Not yet available.@-@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@SAFETY@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14918906@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918906@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@30-40@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FPI due in Q2 08. SOURCE: Genentech, 10 April 2008@-@@@@COMBO@-@BORTEZOMIB@@@@-|BORTEZOMIB|||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ANTI-CD40@VELCADE@@@@ANTI-CD40|VELCADE|||@mAb@CD40@@@@mAb|CD40|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918980@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918980@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MEK INHIBITOR@@@@@MEK INHIBITOR||||@MEK Inhibitor@@@@@MEK Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16076433@Onco@@@@@300f1037ntsdm@@@@@@Participants treated with eribulin for at least 7 months, ,@@L01XX41@L01X@@TOKYO, JAPAN@6/1/2014@@@@16076433@Long-term Eribulin Treatment in Metastatic Breast Cancer: A Multicenter, Case-study Analysis@Female@@@@@@@@@@@NCT02769364@45@@@@@@@11/1/2013@@OBU-SW-H-05@@@Participants with Advanced or Metastatic Breast Cancer on Eribulin for at least 7 months@@-@N/A@-@@@@@@@@@@ERIBULIN@@@@@ERIBULIN||||@EISAI@@@@@EISAI||||@Spain@@@@@Spain|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@HALAVEN@@@@@HALAVEN||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@OVERALL SURVIVAL@Progression Free Survival (PFS)@Objective response rate@@@Number of participants with adverse events/serious adverse events/toxic deaths as a measure of safety@@@@@METASTATIC@@@@@Case-Only@RETROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14921656@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Twice-daily dosing of SOM-230@@-@-@-@BASEL, SWITZERLAND@@@@@14921656@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00088595@36@-@-@@@-@@11/1/2003@-@CSOM230B2202@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PASIREOTIDE@@@@@PASIREOTIDE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@SOM-230@@@@@SOM-230||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@BOWEL MOVEMENTS@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921627@Onco@@@@@300f1008ntsdm@@@@@@AZD2281 following single and multiple oral doses [clinicaltrials.gov]@@-@-@-@LONDON, UNITED KINGDOM@3/1/2009@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14921627@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00572364@18@-@-@@@-@@11/1/2007@-@D0810C00001@@-@Histologically or cytologically confirmed malignant solid tumour and refractory to standard therapy or for which no suitable effective standard therapy exists. @@@I@I@@-@@Trial registered. [AstraZeneca, 12.12.2007]@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-2281@@@@@AZD-2281||||@PARP Inhibitor@@@@@PARP Inhibitor||||@SAFETY@TOLERABILITY@@@@MAXIMUM TOLERATED DOSE@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14919120@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Irofulven with fluorouracil versus fluorouracil alone@@-@-@-@TOKYO, JAPAN@4/1/2002@@@@14919120@Gemzar-refractory@@-@-@@NO REVIEW@@@@-@Eisai acquired through takeover of MGI Pharma.@SECOND-LINE@NCT00033735@350@-@-@@@-@@1/1/2000@-@MGI-IROF-003@@-@-@@@III@DISCONTINUED@@-@-@Irofulven failed to demonstrate statistical significance. SOURCE: MGI, April 2002@-@@@@COMBO@IROFULVEN@FLUOROURACIL@@@@IROFULVEN|FLUOROURACIL|||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@MGI-114@@@@@MGI-114||||@Alkylating Agent@@@@@Alkylating Agent||||@RESPONSE RATE@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922545@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@@@NO@@@@@@14922545@Phosphocol P 32 is employed by intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer.@@YES@@@NO REVIEW@@@@@Part of Tyco Healthcare@@@@The suggested dose range employed in the average patient (70 kg) is: Intraperitoneal instillation: 370 to 740 megabecquerels (10 to 20 millicuries); Intrapleural instillation: 222 to 444 megabecquerels (6 to 12 millicuries). Doses for interstitial use should be based on estimated gram weight of tumor, about 3.7 to 18.5 MBq/gm (0.1 to 0.5 mCi/gm).@FDA, 23 September 1974@9/23/1974@@@@@Not for intravascular use. This radiopharmaceutical should not be administered to patients who are pregnant or during lactation unless the therapeutic benefits outweigh the potential hazards.@NO LABELLED TRIAL@No@NOT AVAILABLE@@@@@APPROVED@@@MEDICARE@NO LABELLED TRIAL@@@@@@CHROMIC PHOSPHATE P32 SUSPENSION@@@@@CHROMIC PHOSPHATE P32 SUSPENSION||||@MALLINCKRODT@@@@@MALLINCKRODT||||@@@@@@|||||||||@Other@@@@@Other|||||||||@PHOSPHOCOL P32@@@@@PHOSPHOCOL P32||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@150000@IU@7 MIL/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921352@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@The cyclic peptide structure of romidepsin is unique among members of a new class of cancer drugs known as histone deacetylase, or HDAC, inhibitors. HDAC inhibition has been shown to increase acetylation of histones and other proteins, which is associated with anti-tumor activity including chromatin remodeling, tumor suppressor gene transcription, growth inhibition, and apoptosis. Preclinical studies suggest that romidepsin is among the most potent inhibitors of both Class I and Class II HDACs. @@14921352@Progressed following or during immunotherapy@@-@-@@NO REVIEW@@@@-@Global rights licensed from Fujisawa (Astellas) in April 2004@-@NCT00106613@N/A@-@-@@@-@@@-@FJ-228-0001@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@ROMIDEPSIN@@@@@ROMIDEPSIN||||@GLOUCESTER PHARMACEUTICALS@@@@@GLOUCESTER PHARMACEUTICALS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@ISTODAX@@@@@ISTODAX||||@HDAC@@@@@HDAC||||@SAFETY@RESPONSE RATE@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921100@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day with erlotinib taken at 150 mg every morning with food. @@-@-@-@BOSTON, MASSACHUSSETTS@@@@@14921100@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00591383@20@-@-@@@-@@1/1/2008@-@IBL1004@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@INDIBULIN@ERLOTINIB@@@@INDIBULIN|ERLOTINIB|||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ZIO-301@TARCEVA@@@@ZIO-301|TARCEVA|||@Other@@@@@Other||||@TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16406115@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@16406115@XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).@@NA@16-Mar-17@3/16/2017@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@53@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) takencontinuously.@EMA, 25 August 2016@8/25/2016@11/15/2012@No@@@@Study 1001@No@@@ROS1-positive@@@APPROVED@@No additional benefit [16 March 2017, G-BA, https://www.g-ba.de/downloads/39-261-2879/2017-03-16_AM-RL-XII_Crizotinib_D-261.pdf]@GKV@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@ADVANCED@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@96272.91809@@@19.3@month@19.3 month@96272.92@96272.92@164@60@1.1511@4920.01@6087.77@4958.51@@@@@@@@@@0.33@1@@mg@500@1@@@@@@@@@@@8/1/2017@82@82@9884710@HARD CAPSULE@EURO@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
16388207@Onco@@@@@@@@@@@"Part A: prexasertib + ralimetinib, Experimental, Prexasertib given intravenously (IV) and ralimetinib given orally.Part B1: prexasertib + ralimetinib (colorectal cancer), Experimental, Prexasertib given IV and ralimetinib given orally.Part B2: prexasertib + ralimetinib (NSCLC), Experimental, Prexasertib given IV and ralimetinib given orally."@@@@@INDIANAPOLIS, INDIANA@7/1/2018@@@@16388207@A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer@Both@@@@@Administered IV@@@@@-@NCT02860780@70@@@@@@@8/1/2016@@16379@@@#NAME?@KRAS and/or BRAF@ADULTS@Phase 1@I@@@@@@@@@COMBO@PREXASERTIB@RALIMETINIB@@@@PREXASERTIB|RALIMETINIB|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Colorectal Cancer@NSCLC@@@@Colorectal Cancer|NSCLC||||||||@LY2606368@LY2228820@@@@LY2606368|LY2228820|||@Other@@@@@Other||||@Maximum Tolerated Dose (MTD) of Prexasertib and Ralimetinib@@@@@Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib@PK: Area Under the Curve (AUC) of Prexasertib@@@@ADVANCED@METASTATIC@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921025@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@20 minute IV infusion, low dose (2mg) 4-5 times per years@@-@-@-@-@12/1/2007@@@@14921025@Stage III/IV; Shows high specificity against tumour-associated antigen CA-125 which is over-expressed in many late-stage ovarian cancer patients@@-@-@@NO REVIEW@@@@-@ViRexx partners the drug with United in the U.S. and Canada (via subsidiary United's subsidiary Unither Pharmaceuticals).@-@NCT00050375,@177@-@-@@@-@@12/1/2002@-@IMPACT I@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@OREGOVOMAB@@@@@OREGOVOMAB||||@UNITED THERAPEUTICS@VIREXX@@@@UNITED THERAPEUTICS|VIREXX|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@OVAREX@@@@@OVAREX||||@Immunotherapy@mAb@Murine@@@Immunotherapy|mAb|Murine||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@REFRACTORY@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917746@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N02AB03@N02A@@CORONA, CALIFORNIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14917746@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@Authorised generic of Actiq@@@@@FDA, 6 September 2006@9/6/2006@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@WATSON PHARMACEUTICALS@CEPHALON@@@@WATSON PHARMACEUTICALS|CEPHALON|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@2177@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@72.57@72.57@63459-0504-30@LOZENGE@US$@@@@@@@@400@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922467@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@15 mg/kg every 90 days @@-@-@-@NEW YORK, NEW YORK@11/1/2008@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922467@-@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@-@NCT00254579@215@-@-@@@-@@12/1/2005@-@A3671008@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916772@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@One dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.  [clinicaltrials.gov]@@-@-@-@MONTREAL, CANADA@3/1/2009@@-@@14916772@Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Folinic Acid, 5-Fluorouracil, or Capecitabine and Oxaliplatin Chemotherapy as Second-Line and/or Third-Line Treatment@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00809796@15@-@-@@@-@@3/1/2008@-@OP-103@@-@Histologically or cytologically proven diagnosis of adenocarcinoma of the colon or rectum with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease Failure of first-line or second-line therapy for colorectal cancer.@@@I/II@II@@-@-@Trial registered. [Oncozyme, 15.12.2008]@-@@@@COMBO@PENTAMIDINE@5-FU@CAPECITABINE@OXALIPLATIN@@PENTAMIDINE|5-FU|CAPECITABINE|OXALIPLATIN|@ONCOZYME PHARMA@@@@@ONCOZYME PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@SEVERE ADVERSE EVENTS@CEA MARKER@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14922071@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Given as IV infusion at a dose of 60 mg/m2 weekly for 4 weeks followed by 2 weeks safety follow-up. @@-@-@-@-@6/1/2009@@@@14922071@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00065429@35@-@-@@@FDA grants orphan drug designation for SCLC.[ImmunoGen 18 August 2010 http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=1461311&highlight= ]@@4/1/2003@-@C10IVB001@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@IMMUNOGEN@@@@@IMMUNOGEN||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@BB-10901@IMGN-901@@@@BB-10901|IMGN-901|||@mAb@Humanised@CD56@@@mAb|Humanised|CD56||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920204@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BA01@L02B@YES@PETACH TIKVA, ISRAEL@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920204@@@NO@@@NO REVIEW@@@@@Via takeover of Ivax@@@@@@@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@500@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00093-0784-05@FILM-COATED TABLET@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916529@Onco@@@@@@@@@@@Secondary adjuvant endocrine Arimidex therapy for 2 further years versus 5 further years.@@L02BG03@L02B@-@LONDON, UNITED KINGDOM@@@Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. Estrone is subsequently converted to estradiol. Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. In postmenopausal women, Arimidex at a daily dose of 1 mg produced estradiol suppression of greater than 80% using a highly sensitive assay. Arimidex does not possess any progestogenic, androgenic or oestrogenic activity. Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard ACTH challenge testing. Corticoid supplements are therefore not needed.@@14916529@Secondaruy adjuvant endocrine Arimidex for HR-positive breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00295620@3500@-@-@@@-@@3/1/2004@-@SALSA@@-@-@-@@III; 1033AU/0003; ABCSG 16; D5392L00016 / @III@@-@-@RESULTS PENDING (recruiting)@-@@@@ADJUVANT@ANASTROZOLE@@@@@ANASTROZOLE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Austria@@@@@Austria|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ARIMIDEX@@@@@ARIMIDEX||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922133@Onco@@@@@@@@@@@Single agent forodesine@@-@-@-@BIRMINGHAM, ALABAMA@@@Forodesine HCl is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in clinical trials for indications including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). @@14922133@CTCL@@-@-@@NO REVIEW@@@JULY 2007-@-@In February 2006, BioCryst announced an exclusive licensing agreement with Mundipharma to develop and commercialise forodesine HCL for use in the treatment of oncology in markets across Europe, Asia, Australia and certain neighbouring countries.@-@NCT00501735@120@-@-@@@-@@@-@BCX1777-203@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@FORODESINE@@@@@FORODESINE||||@BIOCRYST PHARMACEUTICALS@MUNDIPHARMA@@@@BIOCRYST PHARMACEUTICALS|MUNDIPHARMA|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@CTCL@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|CTCL|||||||@FODOSINE@BCX-1777@@@@FODOSINE|BCX-1777|||@PNP Inhibitor@@@@@PNP Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15051139@Onco@@@@@300f1015ntsdm@@@@@@-@@-@-@-@INGELHEIM, GERMANY@2/1/2011@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051139@Dose Escalation Study of Concomitant BIBF 1120 + BIBW 2992 in Patients With Advanced Solid Tumours.@@-@-@@NO REVIEW@@@@-@-@-@NCT00998296@24@-@-@@@-@@10/1/2009@-@EUDRACT2009-011321-14@@-@"Patients with confirmed histological or cytological diagnosis of advanced solid tumours and for whom no proven therapy exists or who are not amenable to established treatments. Life expectancy of at least three months."@@@I@I@@-@-@Trial registered. [BI, 19 October 2009 ]@-@@@@COMBO@AFATINIB@@@@@AFATINIB||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BIBW-2992@BIBW-1120@@@@BIBW-2992|BIBW-1120|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@MAXIMUM TOLERATED DOSE@@@@@RESPONSE RATE@@@@@ADVANCED@@@@@SAFETY@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924682@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Inhaled Doxorubicin with IV Docetaxel and Cisplatin@@L01DB01@L01D@-@-@@@Although not completely elucidated, the mechanism of action of doxorubicin is related to its ability to bind to DNA and inhibit nucleic acid synthesis. Cell culture studies have demonstrated rapid cell penetration and perinucleolar chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, mutagenesis and chromosomal aberrations. The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.@@14924682@with docetaxel and cisplatin@@-@-@@NO REVIEW@@@@-@Battelle is the parent company of Zivena@FIRST-LINE@NCT00082472@30@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@DOXORUBICIN@DOCETAXEL@CISPLATIN@@@DOXORUBICIN|DOCETAXEL|CISPLATIN||@ZIVENA@BATTELLE@@@@ZIVENA|BATTELLE|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@RESMYCIN@TAXOTERE@@@@RESMYCIN|TAXOTERE|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@-@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INHALED@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922088@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will continue with the same dosing regimen and schedule of CPG 7909 Injection with which they were treated in the Coley sponsored CPG 7909 Injection trial that they recently completed.@@-@-@-@NEW YORK, NEW YORK@1/1/2008@@@@14922088@Continuation study@@-@-@@NO REVIEW@@@@-@In May 2005, Pfizer licensed global rights for NSCLC and breast cancer from Coley; Pfizer subsequently bought Coley in November 2007. @-@NCT00043368@50@-@-@@@-@@7/1/2002@-@C016@@-@-@@@I/II@II@@-@-@Designed to analyse safety data.@-@@@@BOTH@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Other@@@@@Other|||||||||@PF-3512676@CPG-7909@@@@PF-3512676|CPG-7909|||@TLR-targeted@Immunotherapy@Vaccine@@@TLR-targeted|Immunotherapy|Vaccine||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921106@Onco@@@@@@@@@@@Single-agent zalutumab dose escalation@@-@-@-@COPENHAGEN, DENMARK@@@Zalutumumab is a fully human, high-affinity antibody targeted at the Epidermal Growth Factor receptor (EGFr) and is in clinical development to treat head and neck cancer, non small cell lung cancer (NSCLC) and colorectal cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells. @@14921106@-@@-@-@@NO REVIEW@@@@-@No licensing partner@-@NCT00093041@N/A@-@-@@@-@@@-@Hx-EGFr-001@@-@-@@@I/II@III@@-@-@RESULTS PENDING@-@@@@MONO@ZALUTUMUMAB@@@@@ZALUTUMUMAB||||@GENMAB@@@@@GENMAB||||@Denmark@@@@@Denmark|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@HUMAX-EGFR@@@@@HUMAX-EGFR||||@mAb@Human@TK Inhibitor@EGFR@@mAb|Human|TK Inhibitor|EGFR|@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16382370@Onco@@@@@300f1008ntsdm@@@@@@120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@@M05BX04@M05B@@@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma.@@16382370@Prevention of skeletal related events in patients with bone metastases from solid tumours.@@NA@@@NO REVIEW@@@@100%@@@@2862@The recommended dose of XGEVA for the prevention of skeletal related events is 120 mg administered as a single subcutaneous injection once every 4 weeks into the thigh, abdomen or upper arm.@MHLW, 1 April 2012@4/1/2012@@@@@@@No@@@@@III@APPROVED@@@NHI@@@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Supportive Care@Bone Loss@@@@Supportive Care|Bone Loss||||||||@RANMARK@@@@@RANMARK||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@@@@@@@@@@@@@@@@@@@@@1@1@1186933.44@@@27.6@month@27.6 month@1186933.44@1186933.44@1413.89@1@0.0091@39588.88@46685@@@@@@@@@@@329.91@28@@mg@120@1@@@@@@@@@@@8/30/2017@39588.88@39588.88@3999435A1020@SUBCUTANEOUS INJECTION@YEN@@@@@@@@120@MG@120 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14918976@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@TORONTO, CANADA@@@@@14918976@-@@-@-@@NO REVIEW@@@@-@Global rights available for partnering@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Phase I trial to start in Q4 08, results in 2009. SOURCE: Lorus, 31 March 2008@-@@@@MONO@-@@@@@-||||@LORUS THERAPEUTICS@@@@@LORUS THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LOR-253 / LT-253@@@@@LOR-253 / LT-253||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@TOXICITY@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16061300@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX17@L01X@@@@@Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double strand breaks.@@16061300@Pediatric malignant solid tumors in combination with other anti-neoplastic agents@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@0.75mg / m2 (body surface area) for 5 days dispensed daily drip infusion, with a 3 week interval between the start of each course.@MHLW, 1 June 2007@6/1/2007@@@@@@@No@@@PAEDIATRIC@@@APPROVED@@@NHI@@@@@@COMBO@TOPOTECAN HYDROCHLORIDE@@@@@TOPOTECAN HYDROCHLORIDE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@HYCAMTIN@@@@@HYCAMTIN||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@@@@@@@@@@@MALIGNANT@@@@@@@@@@1.2@m²@Invalid Average Duration of Use@@@@@@@@@1@0.0091@7301.28@8610@@@@@@@@@@@6637.53@21@@mg/m²@0.75@5@@@@@@@@@@@8/30/2017@7301.28@7301.28@4240408D1037@POWDER FOR INJECTION@YEN@@@@@@@@1.1@MG@1.1 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
16389714@Onco@@@@@@@@@@@Nivolumab in combination with Ipilimumab, Experimental,@@L01XC17@L01X@@NEW YORK, NEW YORK@2/1/2018@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16389714@A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination With Ipilimumab in Participants With Advanced Malignancies@Both@@@@@Specified dose on specified days@@@@@FIRST-LINE@NCT02869789@700@@@@@@@9/1/2016@@CA209-817@@@Histologically confirmed Stage 4 or recurrent non-small cell lung cancer  -  Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)  -  No prior systemic anticancer therapy (including EGFR and ALK inhibitors)  -  Tissue or Programmed death-ligand 1 (PD-L1) results available@@ADULTS@Phase 3@III@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BMS@@@@@BMS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Number of participants who experience high grade AEs (Adverse Events)@Percentage of participants who experience high grade AEs@@@@Progression-Free Survival (PFS)@Objective Response Rate (ORR)@@@@ADVANCED@@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916010@Onco@@@@@@@@@@@Zactima with Alimta versus Alimta alone@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14916010@Combo with Alimta@@-@-@@NO REVIEW@@@@-@-@-@NCT00418886@508@-@Filing due in 2008@@@-@@1/1/2007@-@ZEAL @@-@-@@@III; EUDRACT NO. 2006-003695-35 / @III@@-@-@Enrolment completed. Filing due in 2008. SOURCE: AstraZeneca, March 2008@-@@@@COMBO@VANDETANIB@PEMETREXED@@@@VANDETANIB|PEMETREXED|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZACTIMA@ALIMTA@@@@ZACTIMA|ALIMTA|||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15046567@Onco@@@@@300f1010ntsdm@@@@@@@@L03AA14@L03A@@PETACH TIKVA, ISRAEL@@@Lonquex (lipegfilgrastim) is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) based on novel GlycoPEGylation technology. Lipegfilgrastim is a novel, pegylated and glycosylated long-acting form of filgrastim, intended for once-per-cycle fixed dose, subcutaneous injection for neutrophil support in patients receiving myelosuppressive chemotherapy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). [Teva]@@15046567@@@NO@@@NO REVIEW@@@@100%@@@@@@EMA, 8 August 2013@8/8/2013@@@@@@@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@LIPEGFILGRASTIM@@@@@LIPEGFILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@LONQUEX@@@@@LONQUEX||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@652.06@@@@@@@@@@@@108.68@@@@@@@@@@@@@@@@7/28/2017@652.06@652.06@2.41E+16@SOLUTION FOR INJECTION, PRE-FILLED SYRINGE, 0.6 ML@GB£@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14916664@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@GTI 2040 5 mg/kg daily by continuous iv infusion for 14 days plus docetaxel (75 mg/m2 iv every 21 days) and prednisone (orally 5 mg twice-daily). SOURCE: Lorus@@-@-@-@TORONTO, CANADA@@@@@14916664@-@@-@-@@NO REVIEW@@@@-@Global rights available for partnering@FIRST-LINE@NCT00087165@22@-@-@@@-@@1/1/2005@-@PMH-PHL-024@@-@-@@@II@II@@-@-@9 patients (41%) had a PSA response but final assessment of five patients is pending. One patients had PR, 8 had SD and 3 had progressive disease. It was well-tolerated with haematological toxicities confined to grade 3 adverse events. SOURCE: Lorus/AACR-NCI-EORTC; 18 November 2005@-@@@@COMBO@-@PREDNISONE@@@@-|PREDNISONE|||@LORUS THERAPEUTICS@@@@@LORUS THERAPEUTICS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@GTI-2501@@@@@GTI-2501||||@Antisense@@@@@Antisense||||@PSA@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
16791364@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791364@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NA@@@NO REVIEW@@@@@@@@16@@EMA, 16 December 2016@12/16/2016@@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NA@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@3498.207944@@@8@week@8 week@3498.21@3498.21@62.47@30@1.1511@1561.7@1682.31@1569.24@@@@@@@@@@0.52@1@@mg/m²@100@1@@@@@@@@@@@8/4/2017@52.06@52.06@688237@FILM-COATED TABLET@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14924266@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@ONTARIO, CANADA@@@Tesmilifene is a novel, small molecule that selectively targets multiple-drug resistant (MDR) tumor cells, sensitizing them to chemotherapy. Tesmilifene may offer clinical benefit in a number of tumor types and is being tested with a variety of chemotherapeutic regimens. In addition to the current pivotal trial, a Phase III trial of tesmilifene with doxorubicin in metastatic or recurrent breast cancer has been completed and a Phase II study to evaluate tesmilifene plus docetaxel (Taxotere) in patients with metastatic breast cancer is being conducted in collaboration with Sanofi-Aventis. In hormone-refractory prostate cancer (HRPC), two single-arm Phase II trials of tesmilifene in combination with chemotherapy (one with mitoxantrone plus prednisone; the other with cyclophosphamide) and a randomized Phase II trial comparing cyclophosphamide alone to cyclophosphamide plus tesmilifene have been conducted. Based on the clinical data generated from these three studies, the Company is currently evaluating additional clinical work in patients with HRPC. In addition, the Company and its partners are evaluating clinical studies in patients with gastric cancer as well as patients with hepatic cancer.@@14924266@with Antracycline and Taxane@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@-@-@@@@COMBO@TESMILIFENE@@@@@TESMILIFENE||||@YM BIOSCIENCES@@@@@YM BIOSCIENCES||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@DPPE@@@@@DPPE||||@Chemopotentiator@@@@@Chemopotentiator||||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922509@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@EPO906 IV, every three weeks, celecoxib by mouth twice a day every day @@-@-@-@BASEL, SWITZERLAND@1/1/2010@@Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel.@@14922509@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00159484@80@-@-@@@-@@10/1/2004@-@3c-03-19@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@PATUPILONE@CELECOXIB@@@@PATUPILONE|CELECOXIB|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@EPO-906@CELEBREX@@@@EPO-906|CELEBREX|||@Epothilone@@@@@Epothilone||||@MAXIMUM TOLERATED DOSE@DIARRHOEA@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924843@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@2 different treatment schedules of oral Xeloda with intravenous Eloxatin and IV Avastin @@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924843@Patients with locally advanced or metastatic colorectal cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00118755 @100-500 @-@-@@@-@@7/1/2005@-@-@@-@-@@@IV@IV@@-@-@Not yet available.@-@@@@COMBO@CAPECITABINE@OXALIPLATIN@BEVACIZUMAB@@@CAPECITABINE|OXALIPLATIN|BEVACIZUMAB||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@XELODA@ELOXATIN@@@@XELODA|ELOXATIN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921889@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Induction therapy (daunorubicin/cytarabin) and consolidation therapy (high-dose cytarabine) with midostaurin or placebo@@@@@BASEL, SWITZERLAND@3/1/2009@@@@14921889@Newly diagnosed FLT3-mutated AML in patients under 60 years@@@@@NO REVIEW@@@@@@@NCT00651261@514@@@@@@@4/1/2008@@CALGB-10603,@@@@@@EUDRACT-2006-006852-37;@III@@@@@@@@@COMBO@MIDOSTAURIN@CYTARABINE@@@@MIDOSTAURIN|CYTARABINE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@PKC-412@@@@@PKC-412||||@PKC Inhibitor@@@@@PKC Inhibitor||||@OVERALL SURVIVAL@@@@@@@@@@@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923399@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@EAGAN, MINNESOTA@@@Imprime PGG is a novel immunotherapy that can enhance the immune response against a number of disease indications. Imprime PGG works in concert with anti-tumor monoclonal antibodies to activate a large population of the body's immune cells (neutrophils) to kill cancer cells. Unlike other drugs that trigger a broad innate immune response, Imprime PGG selectively activates immune cells without inducing pro-inflammatory cytokines. This unique benefit reduces potential side effects of Imprime PGG. As a platform therapeutic in oncology, Imprime PGG has the potential to improve patient response rates for existing monoclonal antibody therapies in approved indications, create new indications for these drugs and enhance the efficacy of development-stage monoclonal antibody drugs.@@14923399@-@@-@-@@NO REVIEW@@@@-@-@-@-@90 patients@-@-@@@-@@3/1/2009@-@-@@-@-@@@II@II@@-@-@German regulatory authorities clear Phase II trial. [Biothera, 12 March 2009]@-@@@@COMBO@-@CETUXIMAB@CARBOPLATIN@PACLITAXEL@@-|CETUXIMAB|CARBOPLATIN|PACLITAXEL|@BIOTHERA PHARMA@@@@@BIOTHERA PHARMA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IMPRIME PGG@ERBITUX@@@@IMPRIME PGG|ERBITUX|||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@@@@@-@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924284@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive oxaliplatin and gemcitabine in week 1 and week 3 and no study medication in week 2 and 4@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14924284@Management of mixed Mullerian tumours of the uterus@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@NCT00476086@24@-@-@@@-@@8/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924196@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WOBURN, MASSACHUSSETTS@@@ARQ 501 is an intravenously administered drug that has completed Phase 2 clinical trials consisting of monotherapy trials in leiomyosarcoma and head and neck cancer, and a combination therapy trial in pancreatic cancer with gemcitabine. Further development of compounds working via the same mechanism as ARQ 501, activation of the E2F biological pathway, is currently under consideration. @@14924196@In combination with gemcitabine@@-@-@@NO REVIEW@@@@-@Further development of the compound is subject to a decision by Roche regarding its option to license rights to the E2F-1 programme.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@Survival data available as of late September, 2007 from the Phase 2 pancreatic cancer trial indicate an increase in survival times for patients treated with ARQ 501-gemcitabine combination therapy over historical data with gemcitabine alone.@-@@@@-@-@@@@@-||||@ARQULE@@@@@ARQULE||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ARQ-501@R-1668@@@@ARQ-501|R-1668|||@E2F1 Pathway Activator@@@@@E2F1 Pathway Activator||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922957@Onco@@@@@300f1014ntsdm@@@@@@Administration of oral erlotinib for four weeks (28 days) preoperatively in early stage (1A/B, 2A/B) NSCLC.@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14922957@-@@-@-@@NO REVIEW@@@@-@">> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]"@-@NCT00462995@36@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Not yet available@-@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@RESPONSE RATE@@@@@@@@@@EARLY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
16643799@Onco@@@@@@@@@@@"Rovalpituzumab tesirine, Experimental, Rovalpituzumab tesirine intravenous administration on Day 1 of a 42-Day cycle for 2 cycles.Topotecan, Active Comparator, Topotecan intravenous on Days 1 through 5 of each 21-Day cycle."@@@@@UNITED STATES@9/1/2019@@@@16643799@A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy@Both@@@@@Administered on Day 1 via intravenous infusion in a 42-day cycle for 2 cycles.@@@@@@NCT03061812@411@@@@@@@@@M16-289@@@Participant must have histologically or cytologically confirmed advanced or metastatic Small Cell Lung Cancer (SCLC) with documented first disease progression during or following front-line platinum-based systemic regimen  -  Tumor must have high Delta-like protein 3 (DLL3) expression as determined by the AbbVie designated central immunohistochemistry (IHC) laboratory.  -  Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per the Central Radiographic Assessment Committee (CRAC).  -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.  -  Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.@@ADULTS@Phase 3@III@@@@@@@@@MONO@ROVALPITUZUMAB TESIRINE@@@@@ROVALPITUZUMAB TESIRINE||||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@-@@@@@-||||@Other@@@@@Other||||@Objective response rate (ORR)@Overall Survival (OS)@@@@Progression Free Survival (PFS)@Duration of Objective Response (DOR)@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922135@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@4 doses of Alpharadin@@-@-@-@KJELSAS, NORWAY@@@Algeta's lead product based on the alpha emitter technology is Alpharadin, a product being developed as a new treatment for skeletal metastases in patients with late-stage, hormone refractory prostate cancer (HRPC). Alpharadin (radium-223 chloride) is a unique targeted therapeutic in phase III clinical trials for the treatment for HRPC that has metastasized to the skeleton.@@14922135@Patients with skeletal metastases from HRPC.@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@BCI-08@@-@-@@@I@I@@-@-@Trial started. SOURCE: 13 August 2008Trial to commence in Q2 08. SOURCE: Algeta, 21 February 2008@-@@@@MONO@-@@@@@-||||@ALGETA@@@@@ALGETA||||@@@@@@|||||||||@Prostate Cancer@HRPC@Bone Metastases@@@Prostate Cancer|HRPC|Bone Metastases|||||||@ALPHARADIN@@@@@ALPHARADIN||||@Other@@@@@Other||||@PHARMACOKINETICS@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@DOSIMETRY@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924801@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Soblidotin IV weekly times two every 3 weeks@@-@-@-@-@@@@@14924801@Progressive locally advanced or metastatic NSCLC@@-@-@@NO REVIEW@@@@-@Yakult Honsha joined developmend in March 2007 after dissolution of previous partnership between Teikoku Hormone and Daiichi Sankyo@-@NCT00061854@27@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@SOBLIDOTIN@@@@@SOBLIDOTIN||||@ASKA PHARMACEUTICAL@YAKULT HONSHA@@@@ASKA PHARMACEUTICAL|YAKULT HONSHA|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TZT-1027@@@@@TZT-1027||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16695982@Onco@@@@@300f1012ntsdm@@@@@@@@L01XE36@L01X@@BASEL, SWITZERLAND@@@Alectinib is a tyrosine kinase inhibitor that targets ALK and RET.@@16695982@Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.@@NA@@@@@@@0%@@SECOND-LINE@@@The recommended dose of Alecensa is 600 mg (four 150 mg capsules) taken twice daily with food (total daily dose of 1200 mg). Treatment with Alecensa should be continued until disease progression or unacceptable toxicity.@EMA, 16 February 2017@2/16/2017@@No@@@@@No@@@ALK POSITIVE@@II@APPROVED@@@@@@@@@MONO@ALECTINIB@@@@@ALECTINIB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALECENSA@@@@@ALECENSA||||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@@@@@@1@1@63040.30964@@@8.5@month@8.5 month@63040.31@63040.31@243.84@224@1.1511@6827.4@8425.66@6865.9@@@@@@@@@@0.2@1@@mg@1200@1@@@@@@@@@@@8/1/2017@30.48@30.48@11287648@HARD CAPSULE@EURO@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924651@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@20mg/m2 IV carfilzomib twice-weekly for 3 weeks every 28 days for 2 cycles@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14924651@-@@-@-@@NO REVIEW@@@@-@-@-@-@80@-@-@@@FDA orphan drug for multiple myeloma and Waldenstrom's macroglobulinaemia. SOURCE: Proteolix, 2 April 2008@@@-@-@@-@80 PATIENTS PREVIOUSLY TREATED WITH VELCADE BORTEZOMIB AND EITHER THALIDOMIDE OR LENALIDOMIDE@@@II@II@@-@-@Phase II data due Q1 2008@-@@@@MONO@CARFILZOMIB@@@@@CARFILZOMIB||||@ONYX@@@@@ONYX||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@PR-171@@@@@PR-171||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@RESPONSE RATE@SAFETY@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923723@Onco@@@@@@@@@@@After completed standard chemo-and radiation therapy; the safety and efficacy of vaccination therapy will be measured as time to progression after treatment with GV1001. [Gemvax]@@-@-@-@SOUTH KOREA@3/1/2009@@-@@14923723@Patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer.@@-@-@@NO REVIEW@@@@-@KAEL Co, through its subsidiary VaxOnco, will acquire GemVax from Pharmexa, including GV-1001. Financial details not disclosed. [KAEL, 31.10.2008]@-@NCT00509457@20@-@-@@@-@@11/1/2006@-@-@@-@Patients with NSCLC after having been treated with conventional therapy with radiotherapy and docetaxel as a radiosensitizer.@@@II@II@@-@-@Trial registered [Gemvax, 20.07.2007]@-@@@@-@-@@@@@-||||@KAEL CO.@PHARMEXA@@@@KAEL CO.|PHARMEXA|||@Norway@@@@@Norway|||||||||@NSCLC@@@@@NSCLC|||||||||@GV-1001@@@@@GV-1001||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@TIME TO PROGRESSION@@@@@T-CELL RESPONSE@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916628@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Ortataxel alone@@-@-@-@LEVERKUSEN, GERMANY@@@@@14916628@Taxane-resistant@@-@-@@NO REVIEW@@@@-@-@-@NCT00044538@84@-@-@@@-@@12/1/2001@-@Protocol No. 10653@@-@-@@@II@DISCONTINUED@@-@-@ASCO 2003; results from 25 evaluable patients showed that ortataxel resulted in a partial response in 3 patients (12%) and stable disease in 8 (32%). 8 patients had progressive disease. Treatment was well tolerated; adverse effects included fatigue, myalgia, nausea, vomiting, constipation, neuropathy, alopecia, diarrhea, stomatitis and arthralgia. Discontinued in December 2004.@-@@@@MONO@ORTATAXEL@@@@@ORTATAXEL||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BAY-598862@@@@@BAY-598862||||@Taxane@@@@@Taxane||||@RESPONSE RATE@SAFETY@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921636@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive polyvalent melanoma vaccine subcutaneously to the armpit and groin areas every 2 weeks for approximately 10 weeks (5 doses) and then every 4 weeks for up to approximately 1 year of total treatment (total of 15 doses). Patients with no evidence of response at week 24 receive no further treatment. Patients whose disease continues to respond after completion of study treatment are eligible for a new study in which they will continue treatment with polyvalent melanoma vaccine.@@-@-@-@DARMSTADT, GERMANY@@@@@14921636@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00128583@100@-@-@@@-@@@-@CV-MMAIT-5-001@@-@-@@@III@III@@-@-@The Stage IV melanoma phase of the trial was discontinued following recommendation from the IDSMB interim analysis, which concluded that there was unlikely to be a survival benefit for Canvaxin. The IDSMB recommended continuation of the trial in Stage III melanoma.@-@@@@MONO@MELANOMA CELLS@@@@@MELANOMA CELLS||||@MERCK SERONO@MICROMET@@@@MERCK SERONO|MICROMET|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@CANVAXIN@@@@@CANVAXIN||||@Vaccine@@@@@Vaccine||||@RESPONSE RATE@@@@@@@@@@MALIGNANT@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924222@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Gemcitabine and carboplatin chemotherapy with/without BSI-201@@-@-@-@BRISBANE, CALIFORNIA@@@@@14924222@Triple-negative breast cancer@@-@-@@NO REVIEW@@@@-@Sanofi-Aventis acquires Bi-Par [Sanofi-Aventis 15 April 2009 http://en.sanofi-aventis.com/binaries/20090415_bipar_acquisition_en_tcm28-24863.pdf ]@-@-@120@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@GEMCITABINE@CARBOPLATIN@@@-|GEMCITABINE|CARBOPLATIN||@BIPAR SCIENCES@SANOFI-AVENTIS@@@@BIPAR SCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@BSI-201@GEMZAR@@@@BSI-201|GEMZAR|||@PARP Inhibitor@@@@@PARP Inhibitor||||@-@@@@@@@@@@TRIPLE NEGATIVE@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921597@Onco@@@@@300f1008ntsdm@@@@@@FOLFOX + Recentin versus FOLFOX + placebo@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921597@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00494221@171@-@-@@@-@@6/1/2007@-@D8480C00039@@-@-@@@I/II@II@@-@@RESULTS PENDING (recruiting)@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14919165@Onco@@@@@@@@@@@N/A@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14919165@Treatment of transfusiondependent anaemia due to loworintermediate1risk MDS associated with deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities@@@@@NO REVIEW@@@N/A@@-@@@148@@MAA withdrawn after CHMP indicated that the currently available data, obtained from a single-arm Phase II study, do not allow it to conclude on a positive benefit-risk balance. SOURCE: Celgene, 2 June 2008EMEA CHMP negative opinion. SOURCE: Celgene, 24 January 2008@6/2/2008@@@@@@MDS003@@@@@@II@DISCONTINUED@@-@@@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@N/A@@@@@@@@@@@@@@@UNCONTROLLED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921862@Onco@@@@@300f1020ntsdm@@@@@@CT-2106 with infusional 5-FU.@@-@-@-@SEATTLE, WASHINGTON@4/1/2007@@@@14921862@Second-line in patients who failed an oxaliplatin plus 5-FU/FA regimen@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00291785@50@-@-@@@-@@3/1/2004@-@CAM201@@-@-@@@I/II@III@@-@-@RESULTS PENDING@-@@@@COMBO@-@FLUOROURACIL@@@@-|FLUOROURACIL|||@CELL THERAPEUTICS@@@@@CELL THERAPEUTICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CT-2106@5-FU@@@@CT-2106|5-FU|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14922936@Onco@@@@@300f1014ntsdm@@@@@@-@@-@-@-@VANCOUVER, CANADA@@@RNAi drugs have the potential to treat human diseases by “switching-off” disease causing genes.  The technology, representing one of the most promising and rapidly advancing frontiers in biology and drug discovery, was awarded the 2006 Nobel Prize for Physiology or Medicine.  RNAi drugs, such as siRNA, are unstable and require delivery technology to be effective.  In preclinical studies, Tekmira’s SNALP (stable nucleic acid-lipid particles) technology has been shown to be a safe and effective way to deliver RNAi drugs to disease sites.  Tekmira believes it has a leading intellectual property position in the field of siRNA delivery.   @@14922936@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Candidate selected; trial to start in H2 2009. SOURCE: Tekmira, 21 July 2008@-@@@@-@-@@@@@-||||@TEKMIRA PHARMACEUTICALS@@@@@TEKMIRA PHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@PLK1 SNALP@@@@@PLK1 SNALP||||@RNA@@@@@RNA||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14922436@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ARM1 - Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 176 mg/m2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg). ARM2: Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 176 mg/m2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg). SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@8/1/2008@@@@14922436@Combo with paclitaxel and carboplatin@@-@-@@NO REVIEW@@@@-@-@-@NCT00607048@40@-@-@@@-@@11/1/2007@-@A5021004@@-@-@@@I@I@@-@-@Dose-limiting toxicity was thromboembolism and grade 3 headache in 2 of 7 patients with 0.3MG/KG dose. MTD was 0.2MG/KG. 4 melanoma patients had PR at day 43. SOURCE: Pfizer/ASCO, 5 June 2006@-@@@@COMBO@-@PACLITAXEL@@@@-|PACLITAXEL|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CP-870893@@@@@CP-870893||||@mAb@Human@CD40@@@mAb|Human|CD40||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918816@Onco@@@@@@@@@@@Six 28-day cycles of cyclophosphamide, doxorubicin and 5-fluorouracil therapy, consisting of doxorubicin (25 mg/m2) and 5-fluorouracil (500 mg/m2) administered on days 1 and 8, and cyclophosphamide (100 mg) administered on days 1 to 14; patients received dofequidar (900 mg po) 30 min before doxorubicin.@@L1X9@L1X9@-@LEVERKUSEN, GERMANY@@@@@14918816@-@@-@-@@NO REVIEW@@@-@-@Licensed to TMRC in Japan@-@-@-@-@DEVELOPMENT DISCONTINUED IN FEBRUARY 2005 BY SCHERING AG BECAUSE OF A SHIFT IN PRIORITY.@@@-@@@-@N/A@@-@-@@@-@DISCONTINUED@@-@-@November 2004; results from 221 evaluable patients showed that the overall response rate for cyclophosphamide, doxorubicin and 5-fluorouracil alone was 42.6% versus 53.1% for this therapy combined with dofequidar (a 24.6% relative improvement and 10.5% absolute increase). Dofequidar significantly improved PFS in premenopausal patients who had no prior therapy or patients with advanced, stage IV primary tumour. Treatment with dofequidar combined with cyclophosphamide, doxorubicin and 5-fluorouracil was well tolerated. Discontinued in February 2005 due to shift in resources.@-@@@@-@DOFEQUIDAR FUMARATE@@@@@DOFEQUIDAR FUMARATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MS-209@@@@@MS-209||||@Other@@@@@Other||||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921831@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@5 mg/mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients - versus placebo@@-@-@-@-@8/1/2009@@@@14921831@Allogeneic HCT@@-@-@@NO REVIEW@@@@-@-@-@NCT00285259@240@-@-@@@-@@1/1/2006@-@CB01-202@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@VICAL@@@@@VICAL||||@@@@@@|||||||||@Supportive Care@Chronic Lymphocytic Leukaemia@Acute Lymphocytic Leukaemia@Chronic Myeloid Leukaemia@Hodgkin's Lymphoma@Supportive Care|Chronic Lymphocytic Leukaemia|Acute Lymphocytic Leukaemia|Chronic Myeloid Leukaemia|Hodgkin's Lymphoma|||||@VCL-CB01@CMV VACCINE@@@@VCL-CB01|CMV VACCINE|||@Vaccine@@@@@Vaccine||||@SAFETY@CMV VIREMIA@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924197@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WOBURN, MASSACHUSSETTS@@@ARQ 501 is an intravenously administered drug that has completed Phase 2 clinical trials consisting of monotherapy trials in leiomyosarcoma and head and neck cancer, and a combination therapy trial in pancreatic cancer with gemcitabine. Further development of compounds working via the same mechanism as ARQ 501, activation of the E2F biological pathway, is currently under consideration. @@14924197@-@@-@-@@NO REVIEW@@@@-@Further development of the compound is subject to a decision by Roche regarding its option to license rights to the E2F-1 programme.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ARQULE@@@@@ARQULE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ARQ-501@R-1668@@@@ARQ-501|R-1668|||@E2F1 Pathway Activator@@@@@E2F1 Pathway Activator||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922652@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BIIB-021 oral doses with or without Herceptin@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@9/1/2009@@@@14922652@Single-agent in HER2- advanced breast cancer or combo with Herceptin in HER2+ advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00412412@70@-@-@@@-@@11/1/2007@-@120BC101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@BOTH@-@@@@@-||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Breast Cancer@HER2-@@@@Breast Cancer|HER2-||||||||@BIIB-021@@@@@BIIB-021||||@HSP90 Inhibitor@HER2@@@@HSP90 Inhibitor|HER2|||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15413012@Onco@@@@@@@@@@@Abraxane® treatment in patients with metastatic breast cancer, , Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.@@@@@SUMMIT, NEW JERSEY@8/1/2016@@@@15413012@Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice@Female@@@@@@@@@@@NCT02655159@330@@@@@@@1/1/2016@@CEL-CMM-2015-01@@@Women ≥18 years of age.  -  Confirmed diagnosis of MBC (stage IV).  -  Breast adenocarcinoma confirmed histologically.  -  HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.  -  Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.  -  Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).@MONO@ADULTS@N/A@-@@@@@@@@@@-@@@@@-||||@CELGENE@@@@@CELGENE||||@Spain@@@@@Spain|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@-@@@@@-||||@Other@@@@@Other||||@OVERALL RESPONSE RATE @@@@@Overall Response Rate (ORR)@Disease control rate (DCR)@@@@@@@@@Case Control@RETROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922218@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ATN-224 with Velcade@@-@-@-@SAN DIEGO, CALIFORNIA@12/1/2007@@@@14922218@Combo with Velcade in patients relapsed from or refractory to Velcade@@-@-@@NO REVIEW@@@@-@-@-@NCT00352742@46@-@-@@@-@@6/1/2006@-@ATN-224-007@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@ATTENUON@@@@@ATTENUON||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ATN-224@@@@@ATN-224||||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@PDGF@@TK Inhibitor|Angiogenesis Inhibitor|VEGF|PDGF|@SAFETY@MAXIMUM TOLERATED DOSE@RESPONSE RATE@@@RESPONSE RATE@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919587@Onco@@@@@300f1015ntsdm@@@@@@@@N02AB03@N02A@@@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14919587@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@NO@@@NO REVIEW@@@@@Acquired via takeover of generics unit of Merck KGaA@@@@@Apr-98@@@@@@@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@PANPHARMA@@@@@PANPHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@GENERIC@@@@@GENERIC||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14921825@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CS-4047 with cisplatin and etoposide@@-@-@-@SUMMIT, NEW JERSEY@10/1/2010@@Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.@@14921825@Extensive disease SCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00537511@N/A@-@-@@@-@@10/1/2007@-@CC-4047-SCLC-002@@-@-@@@I/II@II@@-@-@Endpoint is assessed during 1 cycle.@-@@@@COMBO@POMALIDOMIDE@@@@@POMALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@ACTIMID@CC-4047@@@@ACTIMID|CC-4047|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917955@Onco@@@@@300f1015ntsdm@@@@@@@@V03AF03@V03A@@@@@Calcium folinate is the calcium salt of 5-formyl tetrahydrofolic acid. It is an active metabolite of folinic acid and an essential coenzyme for nucleic acid synthesis in cytotoxic therapy. Calcium folinate is frequently used to diminish the toxicity and counteract the action of folate antagonists, such as methotrexate. Calcium folinate and folate antagonists share the same membrane transport carrier and compete for transport into cells, stimulating folate antagonist efflux. It also protects cells from the effects of folate antagonist by repletion of the reduce folate pool. Calcium folinate serves as a pre-reduced source of H4 folate; it can therefore bypass folate antagonist blockage and provide a source for the various coenzyme forms of folic acid.@@14917955@Calcium folinate is indicated to diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”; also, in combination with 5-fluorouracil in cytotoxic therapy.@@NO@Mar-00@@NO REVIEW@@@@65%@@@@@@@@10/19/1989@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@LEUCOVORIN CALCIUM@@@@@LEUCOVORIN CALCIUM||||@THERABEL LUCIEN PHARMA@@@@@THERABEL LUCIEN PHARMA||||@@@@@@|||||||||@Sarcoma@Supportive Care@Colorectal Cancer@@@Sarcoma|Supportive Care|Colorectal Cancer|||||||@FOLINORAL@@@@@FOLINORAL||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@28@1.1511@6.79@8.95@7.24@@@@@@@@@@0.05@@@@@@@@@@@@@@@@8/1/2017@0.24@0.24@3.40E+12@CAPSULE@EURO@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924532@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@This is a first-in-class, first-in-clinic Hdm2 inhibitor which induces apoptosis (programmed cell death) in a number of cancer cell lines, and restores function of the p53 tumor suppressor protein through a novel mechanism of action; the compound is in phase I studies for non-small cell lung cancer and prostate cancer.@@14924532@HDM2 antagonist@@-@-@@NO REVIEW@@@@-@Ortho Biotech is part of the Johnson & Johnson group.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@JOHNSON & JOHNSON@ORTHO BIOTECH@@@@JOHNSON & JOHNSON|ORTHO BIOTECH|||@@@@@@|||||||||@NSCLC@Prostate Cancer@@@@NSCLC|Prostate Cancer||||||||@JNJ-26854165@@@@@JNJ-26854165||||@HDM2 antagonist@@@@@HDM2 antagonist||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922756@Onco@@@@@@@@@@@-@@-@-@-@MADISON, NEW JERSEY@6/1/2008@@Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In invitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.@@14922756@-@@-@-@@NO REVIEW@@@@-@Pfizer acquired Wyeth on 26 January 2009 in a deal worth U.S $68 billion [Pfizer 26.01.2009]@-@NCT00494091@80@-@-@@@-@@7/1/2007@-@-@@-@80 PATIENTS OF JAPANESE, CHINESE OR KOREAN ETHNICITY.@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TEMSIROLIMUS@@@@@TEMSIROLIMUS||||@WYETH@PFIZER@@@@WYETH|PFIZER|||@Asia-Pacific@@@@@Asia-Pacific|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@TORISEL@@@@@TORISEL||||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921808@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenous administration of homoharringtonine @@-@-@-@GEELONG, AUSTRALIA@@@@@14921808@-@@-@-@@NO REVIEW@@@@-@Available for partnering.@-@-@30@-@-@@@-@@@-@CGX-571-SOCA-101@@-@-@@@I/IIA@II@@-@-@RESULTS PENDING@-@@@@MONO@AMONAFIDE DIHYDROCHLORIDE@@@@@AMONAFIDE DIHYDROCHLORIDE||||@CHEMGENEX@@@@@CHEMGENEX||||@@@@@@|||||||||@Prostate Cancer@Ovarian Cancer@Breast Cancer@@@Prostate Cancer|Ovarian Cancer|Breast Cancer|||||||@QUINAMED@@@@@QUINAMED||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916759@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@OSI-930 daily with Tarceva at increasing doses until progression or toxicity@@-@-@-@MELVILLE, NEW YORK@5/1/2009@@@@14916759@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00603356@60@-@-@@@-@@11/1/2007@-@OSI-930-103@@-@-@@@I@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@ERLOTINIB@@@@-|ERLOTINIB|||@OSI PHARMACEUTICAL@@@@@OSI PHARMACEUTICAL||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OSI-930@TARCEVA@@@@OSI-930|TARCEVA|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924540@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Treatment with a dose of 275 mg/m2 LEP-ETU administered over 90 minute SOURCE: NeoPharm@@-@-@-@-@@@@@14924540@-@@NO@-@@NO REVIEW@@@@-@-@-@-@35@-@-@@@-@@3/1/2008@-@-@@-@-@@@OUTPATIENT STUDY@II@@-@-@RESULTS PENDING@-@@@@MONO@PACLITAXEL, LIPOSOMAL@@@@@PACLITAXEL, LIPOSOMAL||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@LEP-ETU@@@@@LEP-ETU||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923021@Onco@@@@@@@@@@@Once-daily WX-671 with weekly IV Gemzar. In Arm I, patients receive WX-671 once daily in weeks 1-8 and IV Gemzar over 30 minutes once weekly in weeks 1-7 of course 1. Administration in subsequent courses changes to weeks 1-4 and weeks 1-3 for WX-671 and Gemzar respectively.These repeat every 4 weeks subject to absence of disease progression or unacceptable toxicity. In Arm II, the only change is a lower dose of WX-671 than the previous Arm. In Arm III, patients only receive IV Gemzar under the same conditions as previously.@@-@-@-@-@@@@@14923021@-@@-@-@@NO REVIEW@@@STARTED IN JUNE  2007@-@-@-@NCT00499265@90@-@-@@@-@@@-@-@@-@90 PATIENTS WITH LOCALLY ADVANCED, INOPERABLE, NON-METASTATIC PANCREATIC CANCER.@@@II@II@@-@-@RESULTS PENDING; first results to be released in H1 2008.@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@WILEX@@@@@WILEX||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@WX-671@GEMZAR@@@@WX-671|GEMZAR|||@Protease Inhibitor@@@@@Protease Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924877@Onco@@@@@@@@@@@Patients will receive Avastin (15mg/kg IV on day 1 of each 3 week cycle) concomitantly with chemotherapy.@@L01XC07@L01X@-@BASEL, SWITZERLAND@@@Avastin (Bevacizumab) is a recombinant humanized monoclonalIgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in in vitro and in vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models ofangiogenesis. Administration of Bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.@@14924877@Avastin in combination with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00451906@>500@-@-@@@-@@8/1/2006@-@-@@-@-@@@IV@IV@@-@-@Not yet available@-@@@@-@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1@@@@@@@@@@@@@7.26@@@@@@@@@@@@@@@@@725.53@725.53@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916255@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops. [clinicaltrials.gov]@@-@-@-@-@12/1/2010@@@@14916255@Recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00737360@52@-@-@@@-@@8/1/2008@-@TAS106-9905@@-@>> Histologically confirmed head and neck carcinoma     >> Received prior platinum based regimen and developed disease progression or recurrence@@@II@II@@-@-@Trial registered. [Taiho, 18.08.2008]@-@@@@-@-@@@@@-||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@TAS-106@@@@@TAS-106||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@PHARMACOKINETICS@@@@REFRACTORY@METASTATIC@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924679@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924679@With interleukin 2@@-@-@@NO REVIEW@@@@-@Wilex obtained option to own full marketing rights to Rencarex from Centocor in October 2004. Wilex inked a marketing partnership with Spanish firm Esteve for Southern Europe in April 2004.  @-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@WILEX@CENTOCOR@JOHNSON & JOHNSON@@@WILEX|CENTOCOR|JOHNSON & JOHNSON||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@RENCAREX@WX-G250@@@@RENCAREX|WX-G250|||@mAb@Chimeric@@@@mAb|Chimeric|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921680@Onco@@@@@300f1008ntsdm@@@@@@Escalating dose of everolimus@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921680@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00622258@12@-@-@@@@@2/1/2003@-@CRAD001C1104@@-@-@@@I@I@@-@@@-@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@SAFETY@PHARMACOKINETICS@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14918958@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AUSTIN, TEXAS@@@@@14918958@-@@-@-@@NO REVIEW@@@@-@-@-@-@22@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@INGN 241 induced killing in all treated tumours, including in those patients who failed prior therapy with other anti-cancer agents. INGN 241 was well tolerated, and an MTD was not reached. Tumour growth control was observed in 44% of treated tumors. 2 of 5 patients treated at the highest dose showed objective responses (greater than 50% reduction in tumour size). Although INGN 241 was administered directly to tumors, evidence of distant biologic activity was observed, suggesting that it may have utility in treating primary tumours as well as metastatic disease.@-@@@@MONO@-@@@@@-||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@INGN-241@@@@@INGN-241||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918930@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CP 870893 was administered iv at doses ranging from 0.01-0.3 mg/kg to 29 patients with advanced solid tumours. The agent was given at day 1 and patients were followed for 43 days.@@-@-@-@NEW YORK, NEW YORK@@@@@14918930@-@@-@-@@NO REVIEW@@@@-@-@-@-@29@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Dose-limiting toxicity was thromboembolism and grade 3 headache in 2 of 7 patients with 0.3MG/KG dose. MTD was 0.2MG/KG. 4 melanoma patients had PR at day 43. SOURCE: Pfizer/ASCO, 5 June 2006@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CP-870893@@@@@CP-870893||||@mAb@Human@CD40@@@mAb|Human|CD40||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918907@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918907@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@40@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@FPI Q4 2006@-@@@@MONO@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@ANTI-CD40@@@@@ANTI-CD40||||@mAb@CD40@@@@mAb|CD40|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919293@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@7 days continuous infusion@@-@-@-@TOKYO, JAPAN@3/1/2007@@A small-molecule proapoptotic agent with potential antineoplastic activity. Survivin inhibitor YM155 selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is expressed during embryonal development and is absent in most normal, terminally differentiated tissues; upregulated in a variety of human cancers, its expression in tumors is associated with a more aggressive phenotype, shorter survival times, and a decreased response to chemotherapy. @@14919293@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00328588@37@-@-@@@-@@3/1/2006@-@LUCY@@-@-@@@155-CL-006; @II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTELLAS PHARMA@@@@@ASTELLAS PHARMA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@YM-155@@@@@YM-155||||@Survivin Suppressant@@@@@Survivin Suppressant||||@PARTIAL RESPONSE@COMPLETE RESPONSE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924684@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@9 cycles of Revlimid plus melphalan and prednisone@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14924684@Treatment of newly diagnosed MM@@@@@NO REVIEW@@@@@-@@@53@@@@@@@@@@@@53 ELDERLY PATIENTS@ELDERLY@@PHASE I/II@II@@@@EHA 2007; at two years, OS was 91% and EFS was 75%.@@@@@COMBO@LENALIDOMIDE@MELPHALAN@PREDNISONE@@@LENALIDOMIDE|MELPHALAN|PREDNISONE||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@OVERALL SURVIVAL@EVENT-FREE SURVIVAL@@@@@@@@@EARLY@@@@@OPEN-LABEL@MULTI-CENTRE@INTERNATIONAL@DOSE ESCALATION@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918932@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BETHESA, MARYLAND@@@DCVax products are being developed to activate all aspects of the immune response, both cellular and antibody, thus potentially providing a broader and longer lasting immune and clinical response. Northwest Biotherapeutics' products are deigned as pure, activated DC loaded with the immunogen as would naturally occur, and that are capable of migrating to lymph nodes. The intended result is a very robust, and full immune response consisting of both a specific cellular T cell response and a specific antibody response against the cancer associated antigen.@@14918932@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FDA cleared for this trial. SOURCE: Northwest@-@@@@-@-@@@@@-||||@NORTHWEST BIOTHERAPEUTICS@@@@@NORTHWEST BIOTHERAPEUTICS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@DCVAX@@@@@DCVAX||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920900@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920900@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@-@@NO REVIEW@@@@90%@-@-@-@-@Waldenstrom's Macroglobulinaemia: Leukeran is the treatment of choice in this indication. Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.@4/22/2004@@@-@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@-@-@@@-@DISCONTINUED@@NO REVIEW@SNS@NO LABELLED TRIAL@-@@@@-@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Waldenstrom's Macroglobinaemia@@@@Haematological Malignancy|Waldenstrom's Macroglobinaemia||||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@100@1.3598@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9/2/2015@@@779363@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
16076435@Onco@@@@@@@@@@@@@L01XE35@L01X@@LONDON, UNITED KINGDOM@9/1/2019@@Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.@@16076435@Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or After EGFR Tyrosine Kinase Receptor (TKI) Therapy@Both@@@@@@@@@@@NCT02777567@300@@@@@@@9/1/2016@@D5160R00009@@@Eligible for, or on active study drug treatment according to the approved label; patients with locally advanced or metastatic, EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase receptor (TKI) therapy  -  Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures@@@Phase 4@IV@@@@@@@@@MONO@OSIMERTINIB@@@@@OSIMERTINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAGRISSO@@@@@TAGRISSO||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@Proportion of patients with adverse events, serious adverse events and AEs of special interest (AESI)@Severity of (S)AEs@@@@OBJECTIVE RESPONSE RATE@PFS@@@@ADVANCED@METASTATIC@@@@Case-Only@PROSPECTIVE@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924190@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Archexin combined with Gemzar [Rexahn]@@-@-@-@-@@@Archexin is a first-in-class, potent Akt protein kinase inhibitor with potential utility to inhibit cancer cell survival and proliferation, angiogenesis and drug resistance. @@14924190@Adenocarcinoma of the lung@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@FDA orphan drug designation for renal cell carcinoma, pancreatic, glioblastoma, stomach and ovarian cancerss@@3/1/2009@-@-@@-@-@@@II@II@@-@-@FDA approval to commence trial [Rexahn, 24 March 2009]@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@REXAHN PHARMACEUTICALS@@@@@REXAHN PHARMACEUTICALS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ARCHEXIN@RX-0201@@@@ARCHEXIN|RX-0201|||@AKT inhibitor@@@@@AKT inhibitor||||@SAFETY@MAXIMUM TOLERATED DOSE@OVERALL SURVIVAL@@@-@@@@@-@@@@@SINGLE-ARM@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919153@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 21, 70, 210, 700 or 2100 mg/dose. @@-@-@-@PRINCETON, NEW JERSEY@9/1/2009@@@@14919153@-@@-@-@@NO REVIEW@@@@-@BMS acquires Medarex in July 2009@SECOND-LINE@NCT00593944@52@-@-@@@-@@2/1/2008@-@MDX1342-02@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MEDAREX@@@@@MEDAREX||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@MDX-1342@@@@@MDX-1342||||@mAb@@@@@mAb||||@ADVERSE EVENTS@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924663@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@-@@14924663@-@@-@-@@NO REVIEW@@@@-@>> Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]>> Ligand acquires Pharmacopeia in US$70 million deal. [Ligand, 24.09.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@-@-@@@@MONO@-@@@@@-||||@SCHERING-PLOUGH@PHARMACOPEIA@LIGAND PHARMACEUTICALS@MERCK & CO@@SCHERING-PLOUGH|PHARMACOPEIA|LIGAND PHARMACEUTICALS|MERCK & CO|@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PS-095760@@@@@PS-095760||||@Other@@@@@Other||||@-@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921516@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle@@-@-@-@TOKYO, JAPAN@@@@@14921516@Advanced solid tumours@@-@-@@NO REVIEW@@@@-@-@-@NCT00121732@40@-@-@@@-@@7/1/2005@-@E7974-A001-101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@E-7974@@@@@E-7974||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16078278@Onco@@@@@@@@@@@Nintedanib, Experimental, Nintedanib plus capecitabine, Experimental,@@L01XE31@L01X@@INGELHEIM, GERMANY@11/1/2017@@@@16078278@An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer@Both@@@@@@@@@@@NCT02780700@100@@@@@@@6/1/2016@@1199.251@@@Histologically or cytologically confirmed colorectal adenocarcinoma  -  Metastatic or locally advanced disease not amenable to curative surgery and/or radiotherapy  -  Eastern Cooperative Oncology Group (ECOG) performance status <= 1  -  At least one measurable lesion according to RECIST 1.1  -  Previously treated with all of the following: fluoropyrimidine, (e.g. 5-FU, capecitabine or TAS-102); oxaliplatin: Patients treated with oxaliplatin in adjuvant setting should have progressed within 6 months of completion of adjuvant therapy or they must have been treated with oxaliplatin for metastatic disease; Irinotecan; Vascular Endothelial Growth Factor (VEGF) directed treatment (e.g. bevacizumab, aflibercept, ramucirumab or regorafenib); cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumors  -  Minimal time interval of 3 weeks between the last administration of Colorectal Cancer (CRC) treatment (cytotoxics or targeted agents) and starting of trial therapy  -  Adequate liver and kidney function  -  Further inclusion criteria apply@BOTH@Adult@Phase 2@II@@@@@@@@@COMBO@NINTEDANIB@CAPECITABINE@@@@NINTEDANIB|CAPECITABINE|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@OFEV@GENERIC@@@@OFEV|GENERIC|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION FREE SURVIVAL@@@@@OVERALL SURVIVAL@OBJECTIVE RESPONSE RATE@@@@REFRACTORY@METASTATIC@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916801@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NOV-002 with paclitaxel and carboplatin versus paclitaxel and carboplatin alone@@-@-@-@-@3/1/2008@@@@14916801@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00347412@840@-@FDA SPA and Fast-track granted.Approved in Russia.@@@FDA SPA and Fast-track granted.Approved in Russia.@@11/1/2006@-@NOV002-C301@@-@-@@@III@III@@-@-@Target enrolment of 840 patients has been reached. The IDMC has recommended continuing trial as planned. Trial will conclude after reaching 725 events (expected in mid-2009). SOURCE: Novelos press release, 13 March 2008@-@@@@COMBO@-@@@@@-||||@NOVELOS THERAPEUTICS@@@@@NOVELOS THERAPEUTICS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@NOV-002@GLUTOXIM@@@@NOV-002|GLUTOXIM|||@Interleukin@Immunotherapy@@@@Interleukin|Immunotherapy|||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@FACTORIAL ASSIGNMENT@PIVOTAL@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919582@Onco@@@@@300f1015ntsdm@@@@@@@@L02BB03@L02B@NO@REKYAVIK, ICELAND@@@@@14919582@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@@@FIRST-LINE@@@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@10-Jul-08@7/10/2008@7/10/2008@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1.1511@42.89@54.2@45.76@@@@@@@@@@0.03@@@@@@@@@@@@@@@@8/1/2017@1.43@1.43@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@50@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14918933@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BETHESA, MARYLAND@@@DCVax products are being developed to activate all aspects of the immune response, both cellular and antibody, thus potentially providing a broader and longer lasting immune and clinical response. Northwest Biotherapeutics' products are deigned as pure, activated DC loaded with the immunogen as would naturally occur, and that are capable of migrating to lymph nodes. The intended result is a very robust, and full immune response consisting of both a specific cellular T cell response and a specific antibody response against the cancer associated antigen.@@14918933@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FDA cleared for this trial. SOURCE: Northwest@-@@@@-@-@@@@@-||||@NORTHWEST BIOTHERAPEUTICS@@@@@NORTHWEST BIOTHERAPEUTICS||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@DCVAX@@@@@DCVAX||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16161451@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE28@L01X@@BASEL, SWITZERLAND@@@Zykadia (ceritinib) is an oral, selective inhibitor of ALK.@@16161451@Indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.@Both@NA@@@@@@@REIMBURSEMENT RANGES BETWEEN 50% AND 80%@@SECOND-LINE@@163@The recommended dose of Zykadia is 750 mg taken orally once daily at the same time each day. The maximum recommended dose is 750 mg daily. Treatment should continue as long as clinical benefit is observed.@MHLW, 28 March 2016@3/28/2016@5/25/2016@No@@@@@No@@@(ALK)-positive@ADULTS@I@APPROVED@@@NHI@@@@@@MONO@CERITINIB@@@@@CERITINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZYKADIA@@@@@ZYKADIA||||@TK Inhibitor@@@@@TK Inhibitor||||@OVERALL RESPONSE RATE@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@5684601.362@@@7@month@7 month@5684601.36@5684601.36@26699.3@1@0.0091@5339.86@6297@@@@@@@@@@@35.6@1@@mg@750@1@@@@@@@@@@@8/30/2017@5339.86@5339.86@4291044M1021@CAPSULE@YEN@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14921674@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921674@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00124280@100@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@@-@CRAD001C2235@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922079@Onco@@@@@300f1020ntsdm@@@@@@Patients received Oncophage alone@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14922079@Colorectal cancer metastasised to the liver@@-@-@@NO REVIEW@@@@-@-@-@-@29@-@-@@@-@@@-@C-100-05@@-@-@@@II@II@@-@-@ASCO 2002; two years after surgery, overall survival and disease-free survival rates for the 29 patients who received Oncophage were 79% and 32%, respectively. Almost 60% of patients in the study demonstrated a significant, tumour-specific, T-cell immune response, which was subsequently found to be an independent factor for prognosis. There was no toxicity observed with Oncophage treatment. Antigenics' confirmation, data analysis and finalization of results reported by study investigators are ongoing.@-@@@@MONO@VITESPAN@@@@@VITESPAN||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Colorectal Cancer@Liver Cancer@@@@Colorectal Cancer|Liver Cancer||||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@OVERALL SURVIVAL@DISEASE-FREE SURVIVAL@IMMUNE RESPONSE@@@IMMUNE RESPONSE@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924924@Onco@@@@@@@@@@@N/A@@J07BM01@J07B@-@BRENTFORD, UNITED KINGDOM@7/1/2007@@Cervarix is a non-infectious recombinant vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral immune response. HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers across all regions worldwide.@@14924924@Young Males@@NO@-@@NO REVIEW@@@@-@-@-@NCT00120848@1113@-@"GSK received a ""complete response letter"" from the U.S. FDA; the FDA has completed its review of the application but has unanswered questions, which GSK need to address prior to being granted marketing approval. SOURCE: GSK December 2007BLA submitted with FDA in March 2007. SOURCE: GSK 30 March 2007"@3/30/2007@@-@@11/1/2003@-@580299007@@-@-@@@III@III@@-@-@Final results: vaccine efficacy was 91.6% against incident and infection and 100% against persistent infection with HPV-16/18. In the intention-to-treat analysis, the vaccine efficacy was 95.1% against persistent cervical infection with HPV-16/18 and 92.9% against cytological abnormalities associated with HPV-16/18 infection. SOURCE: GSK November 2004@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@GSK@@@@@GSK||||@Russia@@@@@Russia|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@CERVARIX@@@@@CERVARIX||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924579@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@DARMSTADT, GERMANY@@@Adecatumumab, also known as MT201, is a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors, and is Micromet's third candidate. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer.@@14924579@Combo with Taxotere@@-@-@@NO REVIEW@@@@-@Microment responsible for Phase Ib trial with docetaxel for metastatic breast cancer and monotherapy for solid tumours; Serono reimburses Micromet for its costs. SOURCE: Micromet, 5 December 2006@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@Overall response rate and time to progression was 20% and 127 days respectively in 19 patients. [MicroMet/ESMO 2008, 15.09.2008]@-@@@@COMBO@ADECATUMUMAB@DOCETAXEL@@@@ADECATUMUMAB|DOCETAXEL|||@MERCK SERONO@MICROMET@@@@MERCK SERONO|MICROMET|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MT-201@TAXOTERE@@@@MT-201|TAXOTERE|||@mAb@Human@EPCAM@@@mAb|Human|EPCAM||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923490@Onco@@@@@300f1012ntsdm@@@@@@Capecitabine:2 x 1250 mg/m2 day 1-14    followed by 1 week pause q day 21@@L01BC06 @L01B@-@BASEL, SWITZERLAND@12/1/2013@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14923490@Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT01249638@516@-@-@@@-@@12/1/2010@-@-@@-@-@@@III@III@@-@-@Trial registered. [Roche 29 November 2010]@-@@@@COMBO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@XELODA@AVASTIN@CAMPTO@@@XELODA|AVASTIN|CAMPTO||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@TIME OF FAILURE STRATEGY@@@@@RESPONSE RATE@QUALITY OF LIFE@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14922086@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@-@@@@@14922086@Breast cancer with progression of previously irradiated brain metastases@@-@-@@NO REVIEW@@@@-@-@-@NCT00538343@41@-@-@@@-@@10/1/2007@-@C-0703@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BERUBICIN HYDROCHLORIDE@@@@@BERUBICIN HYDROCHLORIDE||||@REATA PHARMACEUTICALS@@@@@REATA PHARMACEUTICALS||||@@@@@@|||||||||@Breast Cancer@Brain Cancer@@@@Breast Cancer|Brain Cancer||||||||@RTA-744@@@@@RTA-744||||@Anthracycline@@@@@Anthracycline||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924941@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BRISBANE, CALIFORNIA@1/1/2008@@@@14924941@Combo with chemotherapeutic regimens@@-@-@@NO REVIEW@@@@-@Sanofi-Aventis acquires Bi-Par [Sanofi-Aventis 15 April 2009 http://en.sanofi-aventis.com/binaries/20090415_bipar_acquisition_en_tcm28-24863.pdf ]@-@NCT00422682@72@-@-@@@-@@1/1/2007@-@20060102@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@BIPAR SCIENCES@SANOFI-AVENTIS@@@@BIPAR SCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BSI-201@@@@@BSI-201||||@PARP Inhibitor@@@@@PARP Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922441@Onco@@@@@@@@@@@Carboplatin will be given in combination with paclitaxel. In Arm A, patients also receive AG-013736 and in Arm B, patients receive bevacizumab. Paclitaxel will be given in combination with carboplatin. In Arm A, patients also receive AG-013736 and in Arm B, patients receive bevacizumab. In the comparator arm, bevacizumab will be given with carboplatin and paclitaxel, every 3 weeks. @@-@-@-@NEW YORK, NEW YORK@@@Axitinib is an oral, selective inhibitor of VEGFR 1, 2, 3 (vascular endothelial growth factor receptors 1, 2 and 3), which has been shown to induce tumor regression as a single-agent and in combination with chemotherapy. Inhibiting VEGF binding plays a key role in anti-angiogenesis - or blocking blood vessel formation which starves tumors of the blood and nutrients needed for growth. @@14922441@Axitinib with carboplatin and paclitaxel versus Avastin with carboplatin and paclitaxel@@-@-@@NO REVIEW@@@JANUARY 2008-MARCH 2010@-@Developed from Abgenix (now Amgen) mice, double-digit royalties to go to Medarex due to cross-licensing in this area@FIRST-LINE@NCT00600821@108@-@-@@@-@@@-@A4061030@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@AXITINIB@PACLITAXEL@@@@AXITINIB|PACLITAXEL|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AG-013736@@@@@AG-013736||||@TK Inhibitor@VEGF@PDGF@SCF@Angiogenesis Inhibitor@TK Inhibitor|VEGF|PDGF|SCF|Angiogenesis Inhibitor@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918955@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AUSTIN, TEXAS@@@@@14918955@-@@-@-@@NO REVIEW@@@@-@-@-@-@43 EVALUABLE @-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@ASCO June 2007 final data; survival was superior to historical controls and 5 patients remain progression free from 378 to 894 days following vaccination with INGN 225. Positive immune responses to INGN 225 were observed in 42% of evaluable patients. Of those with positive immune responses, 78.6% responded to chemotherapy compared with 33% of those without immune responses. The association of INGN 225 immune responses with increased responses to subsequent chemotherapy was statistically significant (p=0.01). The tumour response rate in patients with platinum-resistant disease who received chemotherapy following INGN 225 was 45%, which compares to a historical response rate of less than 15% in these patients.@-@@@@MONO@-@@@@@-||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@INGN-225@@@@@INGN-225||||@Vaccine@@@@@Vaccine||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924735@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm I: Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months. Arm II: Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.@@-@-@-@FREEPORT, NEW YORK@@@@@14924735@Prevention of skin cancer in renal transplant patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00089180@100@-@-@@@-@@3/1/2004@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@DIMERICINE@@@@@DIMERICINE||||@AGI DERMATICS@@@@@AGI DERMATICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@T4N5@@@@@T4N5||||@Enzyme@@@@@Enzyme||||@RESPONSE RATE@@@@@@@@@@-@@@@@PREVENTION@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922332@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@SGN-40 plus Velcade@@-@-@-@SEATTLE, WASHINGTON@@@@@14922332@-@@-@-@@NO REVIEW@@@@-@Genentech licensed the drug from Seattle Genetics in January 2007@-@NCT00664898@38@-@-@@@-@@4/1/2008@-@ACF4375g@@-@-@@@I@I@@-@-@Trial started. SOURCE: clinicaltrials.gov, 23 April 2008Trial to start in Q1 08. SOURCE: Genentech January 2008.@-@@@@COMBO@DACETUZUMAB@BORTEZOMIB@@@@DACETUZUMAB|BORTEZOMIB|||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@SGN-40@ANTI-CD40@VELCADE@@@SGN-40|ANTI-CD40|VELCADE||@mAb@Humanised@CD40@@@mAb|Humanised|CD40||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924157@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@TOKYO, JAPAN@@@@@14924157@Chemotherapy-induced thrombocytopaenia@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@"Phase II ""in planning"". SOURCE: Eisai, 3 March 2008"@-@@@@MONO@-@@@@@-||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Supportive Care@Thrombocytopaenia@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@@Supportive Care|Thrombocytopaenia|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma||||||@AKR-501@@@@@AKR-501||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922434@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@125 mg, oral, Days 1-21 of a 28-day cycle @@-@-@-@NEW YORK, NEW YORK@5/1/2009@@@@14922434@In patients who have received prior treatment@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00420056@16@-@-@@@-@@5/1/2007@-@A5481002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Mantle Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|||||||@PD-332991@@@@@PD-332991||||@Other@@@@@Other||||@SAFETY@PET@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922073@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The two treatment arms are either subcutaneous injection or intradermal injection, both with HSPPC-96.@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14922073@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00082459@40@-@-@@@-@@7/1/2002@-@C-100-23@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@VITESPAN@@@@@VITESPAN||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@ROUTE OF ADMINISTRATION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921616@Onco@@@@@@@@@@@AZD-6244 versus Xeloda@@-@-@-@BOULDER, COLORADO@@@This is a small molecule inhibitor that targets a key position in the Ras/Raf/MEK/ERK signaling pathway. This pathway is implicated in the development and progression of cancers. AZD6244 is a novel, orally active, potent, selective, non-ATP-competitive inhibitor of MEK 1 / 2 that has the potential to treat a range of malignant diseases. Oral administration of AZD6244 has demonstrated tumor suppressive or regressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung and breast cancer models. @@14921616@Patients who have failed one or two chemo therapies@@-@-@@NO REVIEW@@@@-@In December 2003, Array entered into an out-licensing and collaboration agreement with AstraZeneca to develop the MEK program in the field of oncology. Under the agreement AstraZeneca acquired exclusive worldwide rights to the clinical development candidate ARRY-886, along with ARRY-704 and an additional second-generation compound for oncology indications developed during the collaboration.@MULTIPLE@NCT00514761@64@-@-@@@-@@@-@D1532C00011@@-@-@@@II@II@@-@-@December 2007; study did not reach primary endpoint of delaying disease progression versus randomised comparator, and no apparent evidence of anti-tumour activity.@-@@@@MONO@-@@@@@-||||@ARRAY BIOPHARMA@ASTRAZENECA@@@@ARRAY BIOPHARMA|ASTRAZENECA|||@Brazil@@@@@Brazil|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ARRY-886@AZD-6244@@@@ARRY-886|AZD-6244|||@MEK Inhibitor@@@@@MEK Inhibitor||||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919002@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14919002@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PI3 KINASE INHIBITOR@@@@@PI3 KINASE INHIBITOR||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15046563@Onco@@@@@300f1012ntsdm@@@@@@@@L03AA14@L03A@@PETACH TIKVA, ISRAEL@@@Lonquex (lipegfilgrastim) is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) based on novel GlycoPEGylation technology. Lipegfilgrastim is a novel, pegylated and glycosylated long-acting form of filgrastim, intended for once-per-cycle fixed dose, subcutaneous injection for neutrophil support in patients receiving myelosuppressive chemotherapy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). [Teva]@@15046563@@@NA@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@@@@@EMA, 25 July 2013@7/25/2013@@@@@@@No@@@@@@APPROVED@@@GKV@NO LABELLED TRIAL@@@@@@LIPEGFILGRASTIM@@@@@LIPEGFILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@LONQUEX@@@@@LONQUEX||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@1302.21@1653.43@1340.71@@@@@@@@@@217.04@@@@@@@@@@@@@@@@8/1/2017@1302.21@1302.21@1546959@SOLUTION FOR INJECTION IN PREFILLED PEN (3 ML)@EURO@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
16406120@Onco@@@@@@@@@@@Atezolizumab, Experimental, Participants will receive atezolizumab every 3 weeks until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participants decision to withdraw from therapy, or death (whichever occurs first).@@@@@BASEL, SWITZERLAND@5/1/2022@@@@16406120@@Both@@@@@Participants will receive 1200 milligrams of atezolizumab by intravenous infusion every 3 weeks until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participants decision to withdraw from therapy, or death (whichever occurs first).@@@@@SECOND-LINE@NCT02928406@1000@@@@@@@12/1/2016@@MO29983@@@-  Participants with histologically documented locally advanced (tumor (T) 4b, any node (N); or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract  -  Participants with measurable and non-measurable dise@@ADULTS@Phase 3@III@@@@@@@@@MONO@ATEZOLIZUMAB@@@@@ATEZOLIZUMAB||||@ROCHE@@@@@ROCHE||||@Argentina@Australia@Austria@Canada@Netherlands@Argentina|Australia|Austria|Canada|Netherlands|||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@MPDL3280A@@@@@MPDL3280A||||@Other@@@@@Other||||@Percentage of Participants With Adverse event@@@@@Overall Survival (OS)@Progression Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)@@@@ADVANCED@METASTATIC@@@@Non-Randomized@Safety Study@Single Group Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922125@Onco@@@@@@@@@@@Forodesine oral alone@@-@-@-@BIRMINGHAM, ALABAMA@@@Forodesine HCl is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in clinical trials for indications including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). @@14922125@CTCL@@-@-@@NO REVIEW@@@FEBRUARY 2003-MAY 2004@-@In February 2006, BioCryst announced an exclusive licensing agreement with Mundipharma to develop and commercialise forodesine HCL for use in the treatment of oncology in markets across Europe, Asia, Australia and certain neighbouring countries.@-@NCT00061880@36@-@-@@@-@@@-@BIOCRYST-1777BC-103@@-@-@@@I/II@II@@-@-@ASH December 2007; the overall response rate for these subjects was 39%, including 2 subjects with complete response (6%) and 12 subjects with partial response (33%). For those patients with erythroderma at baseline, 65% of patients had significant improvement in erythroderma. @-@@@@MONO@FORODESINE@@@@@FORODESINE||||@BIOCRYST PHARMACEUTICALS@MUNDIPHARMA@@@@BIOCRYST PHARMACEUTICALS|MUNDIPHARMA|||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@CTCL@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|CTCL|||||||@FODOSINE@BCX-1777@@@@FODOSINE|BCX-1777|||@PNP Inhibitor@@@@@PNP Inhibitor||||@OBD@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@MULTI-CENTRE@DOSE ESCALATION@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922986@Onco@@@@@@@@@@@Patients will receive docetaxel every 21 days and tesmilifene will be admistered by a single infusion at start of docytaxel cycle.  @@-@-@-@ONTARIO, CANADA@@@Tesmilifene is a novel, small molecule that selectively targets multiple-drug resistant (MDR) tumor cells, sensitizing them to chemotherapy. Tesmilifene may offer clinical benefit in a number of tumor types and is being tested with a variety of chemotherapeutic regimens. In addition to the current pivotal trial, a Phase III trial of tesmilifene with doxorubicin in metastatic or recurrent breast cancer has been completed and a Phase II study to evaluate tesmilifene plus docetaxel (Taxotere) in patients with metastatic breast cancer is being conducted in collaboration with Sanofi-Aventis. In hormone-refractory prostate cancer (HRPC), two single-arm Phase II trials of tesmilifene in combination with chemotherapy (one with mitoxantrone plus prednisone; the other with cyclophosphamide) and a randomized Phase II trial comparing cyclophosphamide alone to cyclophosphamide plus tesmilifene have been conducted. Based on the clinical data generated from these three studies, the Company is currently evaluating additional clinical work in patients with HRPC. In addition, the Company and its partners are evaluating clinical studies in patients with gastric cancer as well as patients with hepatic cancer.@@14922986@with Docetaxel @@-@-@@NO REVIEW@@@-@-@YM inked a collaborative agreement with Sanofi for the tesmilifene docetaxel combination in Jan 2006@FIRST-LINE@NCT00364195@33@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@TESMILIFENE@DOCETAXEL@@@@TESMILIFENE|DOCETAXEL|||@YM BIOSCIENCES@SANOFI-AVENTIS@@@@YM BIOSCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@DPPE@TAXOTERE@@@@DPPE|TAXOTERE|||@Chemopotentiator@@@@@Chemopotentiator||||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924186@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Deforolimus is a novel small-molecule inhibitor of the protein mTOR, a “master switch” in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. @@14924186@Metastatic, HER2-positive breast cancer who have developed resistance to trastuzumab therapy@@-@-@@NO REVIEW@@@@-@Merck licensed the drug in July 2007 for US$75 mil. upfront, up to US$452 mil. in milestone payments and up to US$200 mil. in sales-related bonus. Merck will cover half development costs@-@-@33@-@-@@@-@@8/1/2008@-@-@@-@-@@@II@II@@-@-@Trial started. Enrollment due to be completed in H2 2009. SOURCE: Ariad, 30 July 2008@-@@@@MONO@RIDAFOROLIMUS@@@@@RIDAFOROLIMUS||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AP-23573@@@@@AP-23573||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412297@Onco@@@@@@@@@@@Iomab-B, Experimental, Iomab-B prior to HCTConventional Care, Active Comparator, Azacitidine (not allowed as a single agent), Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent), Doxorubicin, Etoposide, Fludarabine, Hydroxyurea (not allowed as a single agent), Idarubicin, L-Asparaginase, Mitoxantrone, Thioguanine@@@@@@4/1/2018@@@@15412297@A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia@Both@@@@@@@@@@@NCT02665065@150@@@@@@@6/1/2016@@Iomab-01@@@Be 55 years and older with active, relapsed or refractory Acute Myeloid Leukemia, Have 8/8 HCT donor match (related and unrelated), Karnofsky score ≥ 70@@ADULTS@Phase 3@III@@@@@@@@@@IOMAB-B@@@@@IOMAB-B||||@Actinium Pharmaceuticals@@@@@Actinium Pharmaceuticals||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@-@@@@@-||||@Other@@@@@Other||||@Durable Complete Remission (dCR)@@@@@OVERALL SURVIVAL (OS)@@@@@@@@@@RANDOMIZED@Efficacy Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918886@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@-@@@@@14918886@-@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Neutropenia and fatigue were the two most commonly reported side effects; however, no patients withdrew from the study as a result of any side effect. The researchers concluded that GFL has promising clinical activity as assessed by response rates compared to historical controls of 5-FU/LV with the same dose and schedule. Furthermore, the lack of additional toxicity allows other drugs to be added to the treatment. Additional correlative studies are in progress as a result of these findings. SOURCE: Acorn/AACR, 21 April 2008@-@@@@COMBO@INTEFERON GAMMA@FLUOROURACIL@LEUCOVORIN@@@INTEFERON GAMMA|FLUOROURACIL|LEUCOVORIN||@ACORN@@@@@ACORN||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@-@5-FU@@@@-|5-FU|||@Other@@@@@Other||||@RECIST@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923258@Onco@@@@@300f1012ntsdm@@@@@@Busulfan 4 x 0.8 mg/kg/d Intravenous Day -4 and -3 versus Treosulfan 14 g/m2/d Intravenous Day -6, -5, -4  [clinicaltrials.gov]@@-@-@-@-@9/1/2013@@-@@14923258@Treosulfan-Based Conditioning Versus Reduced-Intensity Conditioning (RIC)@@-@-@@NO REVIEW@@@@-@-@-@NCT00822393@545@-@FDA is currently reviewing GOG-191 and PREPARE to assess potential update of safety labels. SOURCE: FDA, January 2008@@@-@@11/1/2008@-@-@@-@Patients with acute myeloid leukaemia acc. to WHO, 2001 (AML in complete remission at transplant, i.e. blast counts < 5 % in bone marrow) or myelodysplastic syndrome acc. to WHO, 2001 (MDS with blast counts < 20 % in bone marrow during disease history) indicated for allogeneic haematopoietic progenitor cell transplantation but considered to be at increased risk for standard conditioning therapies @@@III@III@@-@-@Trial registered [Medac, 13 January 2009]@-@@@@MONO@TREOSULFAN@@@@@TREOSULFAN||||@MEDAC GMBH@@@@@MEDAC GMBH||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@Acute Myeloid Leukaemia@@@Haematological Malignancy|Myelodysplastic Syndrome|Acute Myeloid Leukaemia|||||||@-@@@@@-||||@Other@@@@@Other||||@EVENT-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
16423196@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE29@L01X@@TOKYO, JAPAN@@@@@16423196@Indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.@Both@NO@@@NO REVIEW@@@@100%@@SECOND-LINE@@153@The recommended daily dose of lenvatinib is 18 mg (one 10 mg capsule and two 4 mg capsules) once daily in combination with 5 mg of everolimus once daily. The daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/toxicity management plan.Treatment should continue as long as there is clinical benefit or until unacceptable toxicity occurs@EMA, 25 August 2016@8/25/2016@@@@@@@No@@@@ADULTS@@APPROVED@@@NHS@@@@@@COMBO@LENVATINIB@EVEROLIMUS@@@@LENVATINIB|EVEROLIMUS|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@KISPLYX@AFINITOR@@@@KISPLYX|AFINITOR|||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@ADVANCED@@@@@MULTICENTER@RANDOMIZED@Open Label@@@1@1@95720.06448@@@14.6@month@14.6 month@95720.06@95720.06@215.55@30@1.299@1437@@@@@@@@@@@@11.98@1@@mg@18@1@@@@@@@@@@@7/28/2017@47.9@47.9@3.36E+16@CAPSULE@GB£@@@@@@@@4@MG@4 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14923499@Onco@@@@@@@@@@@-@@-@-@-@TUSTIN, CALIFORNIA@@@@@14923499@GBM@@-@-@@NO REVIEW@@@@-@-@-@-@40@-@FDA HAS GRANTED ORPHAN DRUG AND FAST-TRACK DESIGNATIONS FOR GBM AND ANAPLASTIC ASTROCYTOMA@@@FDA HAS GRANTED ORPHAN DRUG AND FAST-TRACK DESIGNATIONS FOR GBM AND ANAPLASTIC ASTROCYTOMA@@8/1/2007@-@-@@-@40 PATIENTS WITH RELAPSED GBM@@@II@II@@-@-@From the dosimetry and Phase II trial, Cotara appears to be safe and well tolerated, with no dose-limiting adverse events. Patients who are continuing in the trials are being monitored for safety and overall survival, with several surpassing the median expected survival time for relapsed GBM patients. SOURCE: Peregrine, 11 March 2008@-@@@@MONO@-@@@@@-||||@PEREGRINE PHARMACEUTICALS@@@@@PEREGRINE PHARMACEUTICALS||||@India@@@@@India|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@COTARA@@@@@COTARA||||@mAb@Chimeric@Radiolabeled@@@mAb|Chimeric|Radiolabeled||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922601@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Drug: AMG-531- 1, 3, or 10 mcg/kg until Optimal Biologic Dose on Day -5 (pre dose) and on day after chemotherapy (post dose)beginning with Cycle 2. Drug: Carboplatin- AUC=11. Drug: Adriamycin  75-90 mg/m^2 IV. Drug: Ifosfamide 10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2. @@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 531 is being studied as a way to treat low platelet counts caused by chemotherapy. It binds to the thrombopoietin receptor and causes the bone marrow to make more platelets. @@14922601@Decrease risk and severity of low platelet counts in patients receiving carboplatin@@-@-@@NO REVIEW@@@@-@-@-@NCT00147225@24@-@-@@@-@@8/1/2005@-@2005-0099@@-@-@@@I/II@II@@-@-@Completion due in August 2008@-@@@@COMBO@ROMIPLOSTIM@ADRIAMYCIN@IFOSFAMIDE@@@ROMIPLOSTIM|ADRIAMYCIN|IFOSFAMIDE||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@AMG-531@@@@@AMG-531||||@Other@@@@@Other||||@PLATELET COUNT@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923257@Onco@@@@@300f1010ntsdm@@@@@@@@N02AB03@N02A@@BEERSE, BELGIUM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14923257@@@NO@@@NO REVIEW@@@@100%@@@@@@EMA, February 1980@@@@@@@@No@@@@@@APPROVED@@NO NICE REVIEW@NHS@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@SUBLIMAZE@@@@@SUBLIMAZE||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@5@1.299@6.53@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@1.31@1.31@4.52E+15@INJECTION 10 ML AMP@GB£@@@@@@@@500@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14924981@Onco@@@@@300f1014ntsdm@@@@@@Nexavar with cisplatin and radiation@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14924981@Epithelial carcinoma@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00510250@30@-@-@@@-@@@-@12138@@-@-@@@I/II; DDPDRO-002;@II@@-@-@Completion expected in June 2009.@-@@@@COMBO@SORAFENIB TOSYLATE@CISPLATIN@@@@SORAFENIB TOSYLATE|CISPLATIN|||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14920913@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are given karenitecin@@-@-@-@SAN ANTONIO, TEXAS@@@@@14920913@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00062491@-@-@-@@@-@@@-@KTN23106@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@KARENITECIN@@@@@KARENITECIN||||@BIONUMERIK@@@@@BIONUMERIK||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@BNP-1350@@@@@BNP-1350||||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@RESPONSE RATE@@@@@@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14925014@Onco@@@@@300f1012ntsdm@@@@@@BI-2536 administered as a single dose of 200MG IV versus 50MG IV on days 1,2 and 3@@-@-@-@INGELHEIM, GERMANY@12/1/2007@@This is a novel inhibitor of Polo-like kinase 1 (Plk-1), a cell cycle switch essential for cell proliferation. BI 2536 inhibits cell division (mitosis), resulting in cancer cell death by apoptosis. As the first Plk-1 inhibitor being tested in clinical trials, BI 2536 shows efficacy in a broad spectrum of cancers combined with better tolerability than conventional chemotherapeutic agents@@14925014@Advanced or metastatic NSCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00376623@96@-@-@@@-@@4/1/2006@-@1216.9@@-@-@@@II@II@@-@-@Trial registered [BI, 14.09.2006]@-@@@@MONO@-@@@@@-||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BI-2536@@@@@BI-2536||||@PLK-1 Inhibitor@@@@@PLK-1 Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@ADVANCED@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924890@Onco@@@@@@@@@@@Androgen deprivation with leuprolide, +/- docetaxel for clinically asymptomatic prostate cancer subjects with a rising PSA following definitive local therapy @@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14924890@Leuprolide, +/- Docetaxel for clinically asymptomatic prostate cancer subjects with a rising PSA@@-@-@@NO REVIEW@@@@-@-@-@NCT00514917@-@-@-@@@-@@7/1/2007@-@-@@-@Male patients@@@III@III@@-@-@RESULTS PENDING@-@@@@-@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924863@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Zybrestat with carboplatin and paclitaxel@@-@-@-@WALTHAM, MASSACHUSSETTS@@@@@14924863@Combo with carboplatin and paclitaxel@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@I@@-@-@In order to advance to the second stage of the trial, a minimum of 3 out of the first 18 patients treated with Zybrestat combination needed to achieve a partial response (PR) or better. Response was determined by the investigators based upon RECIST and/or ovarian cancer response biomarker (CA-125) criteria. This endpoint was met, and stable disease was observed in seven of the first 11 evaluable subjects in the clinical trial. The combination regimen of Zybrestat, carboplatin and paclitaxel appeared to be well-tolerated, with no observations of colon perforations that had been reported previously with anti-VEGF therapy in this patient population. SOURCE: Oxigene, 31 December 2007@-@@@@COMBO@COMBRETASTATIN A4 PRODRUG@PACLITAXEL@CARBOPLATIN@@@COMBRETASTATIN A4 PRODRUG|PACLITAXEL|CARBOPLATIN||@OXIGENE@@@@@OXIGENE||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ZYBRESTAT@@@@@ZYBRESTAT||||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@SIMON TWO-STAGE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16791368@Onco@@@@@300f1015ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791368@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NO@@@NO REVIEW@@@@NA@@@@16@@EMA, 16 December 2016@12/16/2016@3/15/2012@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NA@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@3135.999944@@@8@week@8 week@3136@3136@56@30@1.1511@1400@1553.45@1430@@@@@@@@@@0.47@1@@mg/m²@100@1@@@@@@@@@@@8/1/2017@46.67@46.67@3.40E+12@FILM-COATED TABLET@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922233@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Three weekly IV administration@@-@-@-@CAMBRIDGE, UNITED KINGDOM@10/1/2008@@AT-9283 is a small molecule inhibitor of several protein kinases associated with cancer, including aurora kinase.@@14922233@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00522990@60@-@-@@@-@@6/1/2006@-@AT92830002@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTEX THERAPEUTICS@@@@@ASTEX THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@Acute Lymphocytic Leukaemia@Chronic Myeloid Leukaemia@Myelodysplastic Syndrome@Haematological Malignancy|Acute Myeloid Leukaemia|Acute Lymphocytic Leukaemia|Chronic Myeloid Leukaemia|Myelodysplastic Syndrome|||||@AT-9283@@@@@AT-9283||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@SAFETY@TOLERABILITY@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921024@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@20 minute IV infusion, low dose (2mg) 4-5 times per years@@-@-@-@-@12/1/2007@@@@14921024@Stage III/IV; Shows high specificity against tumour-associated antigen CA-125 which is over-expressed in many late-stage ovarian cancer patients@@-@-@@NO REVIEW@@@@-@ViRexx partners the drug with United in the U.S. and Canada (via subsidiary United's subsidiary Unither Pharmaceuticals).@-@NCT00050375,@177@-@-@@@-@@12/1/2002@-@IMPACT II@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@OREGOVOMAB@@@@@OREGOVOMAB||||@UNITED THERAPEUTICS@VIREXX@@@@UNITED THERAPEUTICS|VIREXX|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@OVAREX@@@@@OVAREX||||@Immunotherapy@mAb@Murine@@@Immunotherapy|mAb|Murine||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@RELAPSED@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924615@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients received either three weekly vaccinations, starting four weeks after surgery, followed by a fourth booster vaccination, six months later or no additional treatment. @@-@-@-@FREDERICK, MARYLAND@@@@@14924615@Stage II colon cnacer@@-@-@@NO REVIEW@@@@-@Vaccinogen licensed exclusive rights from Intracel. SOURCE: Vaccinogen, 6 February 2008@-@-@254@-@-@@@-@@@-@-@@-@-@@@III@III@@-@-@The 5-year survival rate for patients who completed the course of treatment was 89.3%, and recurrence-free survival was significantly longer for patients who received the vaccine post-surgery, compared with those who received no additional treatment. A 41.4% reduction in the risk of recurrence was observed. SOURCE: Intracel, September 2004@-@@@@MONO@-@@@@@-||||@INTRACEL@@@@@INTRACEL||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ONCOVAX@@@@@ONCOVAX||||@Vaccine@@@@@Vaccine||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920898@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L01AA02@L01A@YES@BRENTFORD, UNITED KINGDOM@@@Leukeran is a bifunctional alkylating agent of the nitrogen mustard type that has been found active against selected human neoplastic diseases.@@14920898@Leukeran is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia@@NO@@@NO REVIEW@@@@90%@@@@@Waldenstrom's Macroglobulinaemia: Leukeran is the treatment of choice in this indication. Starting doses of 6-12 mg daily until leucopenia occurs are recommended followed by 2-8 mg daily indefinitely.@2-Jul-02@7/2/2002@2/27/2003@@@@Can severely suppress bone marrow function. Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@CHLORAMBUCIL@@@@@CHLORAMBUCIL||||@GSK@@@@@GSK||||@@@@@@|||||||||@Haematological Malignancy@Waldenstrom's Macroglobinaemia@@@@Haematological Malignancy|Waldenstrom's Macroglobinaemia||||||||@LEUKERAN@@@@@LEUKERAN||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@50@1.1511@2.16@3.37@2.32@@@@@@@@@@0.02@@@@@@@@@@@@@@@@8/4/2017@0.04@0.04@779470@FILM-COATED TABLET@EURO@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14916743@Onco@@@@@300f1018ntsdm@@@@@@Phenoxodiol 400MG three times daily in 28 day cycles that also includes carboplatin weekly; versus carboplatin in the same dose alone@@-@-@-@-@@@@@14916743@Platinum-resistant, recurrent epithelial overian cancer@@-@-@@NO REVIEW@@@@-@Marshall Edwards is a subsidiary of Novogen.@THIRD-LINE@NCT00382811@470@-@-@@@-@@10/1/2006@-@OVATURE@@-@-@@@III@III@@-@-@Independent data monitoring committee recommends continuation of trial. Study will now proceed to the intended full enrolment. SOURCE: Marshall Edwards, 9 June 2008First-patient in, November 2006. An analysis of interim results will be possible after 95 patients have disease progression. SOURCE: Novogen, 24 November 2006@-@@@@COMBO@PHENOXODIOL@CARBOPLATIN@@@@PHENOXODIOL|CARBOPLATIN|||@NOVOGEN@MARSHALL EDWARDS@@@@NOVOGEN|MARSHALL EDWARDS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@-@@@@@-||||@MSTR@@@@@MSTR||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@PARALLEL ASSIGNMENT@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14919292@Onco@@@@@300f1018ntsdm@@@@@@Initial Cohort: Experimental: NY-ESO-1 Iscomatrix vaccine intramuscular injection every 4 weeks for 3 doses (1 cycle). NY-ESO-1 Iscomatrix vaccine (100 microgram of NY-ESO-1 protein formulated with 120 microgram of Iscomatrix adjuvant). Treatment may continue for further cycles unless other systemic melanoma treatment is required. (This cohort was completed in 2005). Additional Cohort: Experimental: Cyclophosphamide (300mg/sq.m dose) intravenous injection 1 day prior to each vaccination with NY-ESO-1 Iscomatrix vaccine (100 microgram of NY-ESO-1 protein formulated with 120 microgram of Iscomatrix adjuvant) which is administered by intramuscular injection every 4 weeks for 3 doses (1 cycle). Treatment may continue for further cycles unless other systemic melanoma treatment is required. @@-@-@-@VICTORIA, AUSTRALIA@3/1/2009@@@@14919292@Stage III or IV melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00518206@16@-@-@@@-@@12/1/2003@-@LUD2002-013@@-@-@@@II; CTN Trial No.: 2007/123, CTN-Protocol# LUD2002-013AMEND; @II@@-@-@RESULTS PENDING@-@@@@BOTH@-@@@@@-||||@CSL@@@@@CSL||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ISCOMATRIX ADJUVANT@@@@@ISCOMATRIX ADJUVANT||||@Immunotherapy@@@@@Immunotherapy||||@RECIST@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
16408062@Onco@@@@@@@@@@@"Part 1 Arm 1, Experimental, Oprozomib formulation 1 plus dexamethasonePart 1 Arm 2, Experimental, Oprozomib formulation 2 plus dexamethasonePart 2 Arm 1, Experimental, Oprozomib formulation 1 plus pomalidomide and dexamethasonePart 2 Arm 2, Experimental, Oprozomib formulation 2 plus pomalidomide and dexamethasone"@@@@@THOUSAND OAKS, CALIFORNIA@4/1/2020@@@@16408062@A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma@Both@@@@@Oprozomib formulation 1 plus dexamethasone@@@@@FIRST-LINE@NCT02939183@38@@@@@@@11/1/2016@@20160104@@@-  Subject must have a pathologically documented, definitively diagnosed, multiple myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include a proteasom@@ADULTS@Phase 1@I@@@@@@@@@COMBO@OPROZOMIB@POMALIDOMIDE@DEXAMETHASONE@@@OPROZOMIB|POMALIDOMIDE|DEXAMETHASONE||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Myeloma@@@@@Myeloma|||||||||@-@IMNOVID@GENERIC@@@-|IMNOVID|GENERIC||@Other@@@@@Other||||@Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone@@@@@@@@@@RELAPSED@REFRACTORY@@@@Non-Randomized@Safety/Efficacy Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924240@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14924240@The detection and characterisation of metastatic lymph nodes in patients with pelvic cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@APPROVABLE LETTER RECEIVED FROM FDA IN MARCH 2005, ADVANCED THERAPEUTICS AND GUERBET ARE RESPONDING WITH CLINICAL DATA FROM PELVIC CANCERS.@@@-@@@-@-@@-@PATIENTS WITH PELVIC CANCERS@@@-@FILED@@-@-@Demonstrated that it only accumulates in normal lymph node tissue and can therefore facilitate differentiation between cancerous nodes and normal nodes. @-@@@@-@FERUMSTRAN-10@@@@@FERUMSTRAN-10||||@AMAG PHARMACEUTICALS@GUERBET@@@@AMAG PHARMACEUTICALS|GUERBET|||@@@@@@|||||||||@Other@@@@@Other|||||||||@COMBIDEX@@@@@COMBIDEX||||@Imaging@@@@@Imaging||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919107@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Odanacatib; 5mg oral, once daily for approximately 36 months versus placebo@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@1/1/2010@@Odanacatib is a highly selective, potent inhibitor of the cathepsin K enzyme.  Cathepsin K enzyme plays a key role in breaking down the protein in bone.  In cancer that has spread to the bones, tumor cells speed up the normal process of bone breakdown and formation, which in turn results in further tumor growth and bone destruction.  By inhibiting cathepsin K activity, odanacatib represents a potential novel therapeutic approach for metastatic bone disease that works differently from other commonly used medicines.@@14919107@Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00691899@1550@-@-@@@-@@8/1/2008@-@MK0822-030@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@ODANACATIB@@@@@ODANACATIB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Bone Metastases@Prostate Cancer@@@@Bone Metastases|Prostate Cancer||||||||@MK-822@@@@@MK-822||||@Other@@@@@Other||||@METASTASIS-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921470@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@EM-1421 applied topically to cervix of patients with CIN 1, 2 or 3.@@-@-@-@-@@@@@14921470@Cervical intraepithelial neoplasia induced by HPV@@-@-@@NO REVIEW@@@@-@-@-@NCT00154089@N/A@-@-@@@-@@@-@EM-1421 #201@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@TERAMEPROCOL@@@@@TERAMEPROCOL||||@ERIMOS PHARMACEUTICAL@@@@@ERIMOS PHARMACEUTICAL||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@EM-1421@@@@@EM-1421||||@Survivin Suppressant@@@@@Survivin Suppressant||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918911@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AQ4N 200MG/M2 single dose before elective surgery@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@@@14918911@-@@-@-@@NO REVIEW@@@@-@Novacea licensed from KuDOS, which was acquired by AstraZeneca, and BTG.@-@-@32@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@AQ4N was actively converted to AQ4 in all 95 tumour samples with the highest levels in glioblastoma multiforme (1.2g/g mean) and head and neck cancer (0.65g/g mean). SOURCE: Clinical Cancer Research, February 2008@-@@@@MONO@BANOXANTRONE@@@@@BANOXANTRONE||||@NOVACEA@@@@@NOVACEA||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Solid Tumours@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Solid Tumours|||||||@AQ4N@@@@@AQ4N||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@RESPONSE RATE@SAFETY@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924245@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MELBOURNE, AUSTRALIA@@@Afamelanotide (CUV1647) acts by increasing the levels of melanin in the skin; it appears to shield against subsequent prolonged UV irradiation (UVR). Afamelanotide is delivered from a subcutaneous dissolving implant approximately the size of a grain of rice.  Increased pigmentation of the skin appears after 2 days and lasts up to 2 months. @@14924245@Photoxicity prevention in photodynamic therapy.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@II@@-@-@Trial commenced. [Clinuvel, 6.10.2008]@-@@@@MONO@AFAMELANOTIDE@@@@@AFAMELANOTIDE||||@CLINUVEL PHARMACEUTICALS@@@@@CLINUVEL PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@CUV-1647@@@@@CUV-1647||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921749@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive hu14.18-interleukin-2 fusion protein IV over 4 hours on days 1-3. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.@@-@-@-@DARMSTADT, GERMANY@@@@@14921749@Neuroblastoma; paediatric@@-@-@@NO REVIEW@@@@-@-@-@NCT00082758@60@-@-@@@-@@8/1/2005@-@COG-ANBL0322@@-@-@PAEDIATRIC@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TOCOTUZUMAB CELMOLEUKIN@@@@@TOCOTUZUMAB CELMOLEUKIN||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@EMD-273063@KS IL2@@@@EMD-273063|KS IL2|||@EPCAM@@@@@EPCAM||||@RESPONSE RATE@ADVERSE EVENTS@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920919@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intratumoural/intersititial TransMid compared with best standard of care@@-@-@-@HAMILTON, BERMUDA@6/1/2007@@@@14920919@Non-resectable glioblastoma multiforme@@-@-@@NO REVIEW@@@@-@-@-@NCT00083447@323@-@-@@@-@@5/1/2004@-@KSB311RCIII001@@-@-@@@III@DISCONTINUED@@-@-@Discontinued in February 2007 after analysis of the probability of patients receiving the drug achieving the target survival rate was unlikely.@-@@@@-@TRANSFERRIN, MODIFIED DIPHTHERIA TOXIN@@@@@TRANSFERRIN, MODIFIED DIPHTHERIA TOXIN||||@CELTIC PHARMA@@@@@CELTIC PHARMA||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@TRANSMID@XR-311@@@@TRANSMID|XR-311|||@Other@@@@@Other||||@-@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924787@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@12/1/2008@@@@14924787@-@@-@-@@NO REVIEW@@@@-@Extra-APL rights for Japan, and all overseas rights, licensed from Nippon Shinyaku. South Korean APL rights licensed to Choongwae Pharma. North American APL rights licensed to Innovive for royalties and payments in December 2006. Innovive also holds optio@SECOND-LINE@NCT00520208@50@-@-@@@-@@9/1/2007@-@-@@-@50 PATIENTS WITH ADUTE PROMYELOCYTIC LEUKEMIA PATIENTS WHO HAVE RECEIVED PRIOR THERAPY WITH ALL-TRANS-RETINOIC ACID (ATRA) AND ARSENIC TRIOXIDE (ATO).  @@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TAMIBAROTENE@@@@@TAMIBAROTENE||||@TMRC CO.@NIPPON SHINYAKU@INNOVIVE PHARMACEUTICAL@@@TMRC CO.|NIPPON SHINYAKU|INNOVIVE PHARMACEUTICAL||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@TM-411@AMNOLAKE@@@@TM-411|AMNOLAKE|||@Retinoid@@@@@Retinoid||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921377@Onco@@@@@@@@@@@Arimidex and Faslodex versus Arimidex@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921377@Adjuvant for postmenopausal patients with breast cancer@@-@-@@NO REVIEW@@@STARTED IN APRIL 2006@-@-@-@NCT00357110@176@-@-@@@-@@@-@FAME@@-@-@@@D6990C00001; ABCSG2; EUDRACT NO 2005-005715-22 / @II@@-@-@RESULTS PENDING (recruiting)@-@@@@ADJUVANT@FULVESTRANT@ANASTROZOLE@@@@FULVESTRANT|ANASTROZOLE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@ARIMIDEX@@@@FASLODEX|ARIMIDEX|||@Hormone Antagonist@@@@@Hormone Antagonist||||@DISSEMINATED TUMOUR CELLS@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923400@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@EAGAN, MINNESOTA@@@Imprime PGG is a novel immunotherapy that can enhance the immune response against a number of disease indications. Imprime PGG works in concert with anti-tumor monoclonal antibodies to activate a large population of the body's immune cells (neutrophils) to kill cancer cells. Unlike other drugs that trigger a broad innate immune response, Imprime PGG selectively activates immune cells without inducing pro-inflammatory cytokines. This unique benefit reduces potential side effects of Imprime PGG. As a platform therapeutic in oncology, Imprime PGG has the potential to improve patient response rates for existing monoclonal antibody therapies in approved indications, create new indications for these drugs and enhance the efficacy of development-stage monoclonal antibody drugs.@@14923400@-@@-@-@@NO REVIEW@@@@-@-@-@-@90 patients@-@-@@@-@@3/1/2009@-@-@@-@-@@@II@II@@-@-@German regulatory authorities clear Phase II trial. [Biothera, 12 March 2009]@-@@@@COMBO@-@BEVACIZUMAB@CARBOPLATIN@PACLITAXEL@@-|BEVACIZUMAB|CARBOPLATIN|PACLITAXEL|@BIOTHERA PHARMA@@@@@BIOTHERA PHARMA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IMPRIME PGG@ERBITUX@@@@IMPRIME PGG|ERBITUX|||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@@@@@-@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14916168@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Single-agent TKI-258@@-@-@-@BASEL, SWITZERLAND@@@TKI258 is an oral TKI that has been demonstrated preclinically to target multiple growth-factor receptors: Fibroblast growth-factor receptor (FGFR), which plays a role in cell development, angiogenesis, and tumorigenesis1 VEGFR, which mediates angiogenesis and lymphangiogenesis2 PDGFR, which is associated with tumor progression and metastasis3 KIT, a receptor that induces cell proliferation and inhibits apoptosis4 Fms-like tyrosine kinase 3 (FLT-3), which mediates cell growth and survival and inhibits tumor-cell differentiation and apoptosis5 Due to its target profile, TKI258 exhibits both antitumor and antiangiogenic activity, and induces apoptosis in preclinical models of various cancers (acute myelogenous leukemia [AML], multiple myeloma, prostate, breast, colon, lung, renal, melanoma, bladder, and ovarian).@@14916168@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00303251@60@-@-@@@-@@@-@TKI258A2105@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TKI-258@@@@@TKI-258||||@TK Inhibitor@FGF@VEGF@@@TK Inhibitor|FGF|VEGF||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921139@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area. @@L01DC01@L01D@-@-@2/1/2009@@@@14921139@Anterior and posterior head and neck squamous cell carcinoma; suspended in Phase III trials in June 2007@@-@-@@NO REVIEW@@@@-@-@-@NCT00198315@212@-@-@@@-@@6/1/2004@-@HNBE-03-01@@-@-@@@III@CLINICAL HOLD@@-@-@In June 2007, a DMC concluded that risk-benefit profile compared to surgery was unfavourable; trial enrolment suspended.@-@@@@MONO@BLEOMYCIN @@@@@BLEOMYCIN ||||@INOVIO BIOMEDICAL@@@@@INOVIO BIOMEDICAL||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@MEDPULSER@@@@@MEDPULSER||||@Cytotoxic Antibiotic@@@@@Cytotoxic Antibiotic||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ELECTRICAL PULSE DELIVERY@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916311@Onco@@@@@@@@@@@Patients will be assessed for their rate of muscle wasting during an initial blinded study run-in period of up to 6 weeks, and thereafter randomised to active or control treatment for a further 12 week period.@@-@-@-@LONDON, UNITED KINGDOM@@@@@14916311@Patients with NSCLC who are already showing signs of cachexia@@-@-@@NO REVIEW@@@OCTOBER 2007-JULY 2009@-@-@-@-@64@-@FAST-TRACK DESIGNATION BY FDA. SPA with FDA in October 2007; it was agreed that some modifications to the protocol and endpoints need to be made, amending the design used in the trial already conducted. The trial will commence immediately and is expected to take approximately nine months, but is expected to result in a faster review process on completion of clinical development.@@@-@@@-@STUDY 208@@-@Patients with NSCLC who are already showing signs of cachexia@@@III@III@@-@-@UK and Hungarian authorities have apporved commencement of trial. SOURCE: Ark, 30 May 2008Trial set up in aftermath of SPA meeting with FDA in October 2007 to garner new endpoints.@-@@@@-@IMIDAPRIL@@@@@IMIDAPRIL||||@ARK THERAPEUTICS@@@@@ARK THERAPEUTICS||||@@@@@@|||||||||@Supportive Care@Cachexia@@@@Supportive Care|Cachexia||||||||@VITOR@EG-006@@@@VITOR|EG-006|||@Other@@@@@Other||||@CACHEXIA@@@@@@@@@@-@@@@@MULTI-CENTRE@PILOT@RANDOMISED@PLACEBO-CONTROLLED@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922706@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@L02BG04@L02B@-@BASEL, SWITZERLAND@10/1/2009@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14922706@Postmenopausal women@@-@-@@NO REVIEW@@@@-@-@-@NCT00549822@18@-@-@@@-@@10/1/2007@-@07-109@@-@-@@@II@II@@-@-@Trial registered. [Novartis, 24.10.2007]@-@@@@MONO@LETROZOLE@@@@@LETROZOLE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@@@@@FEMARA||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@SERUM CA15-3@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922712@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Electroporation mediated intramuscular delivery of mouse tyrosinase plasmid DNA vaccine over one year@@-@-@-@-@@@@@14922712@Melanoma patients at risk for progression or recurrence@@-@-@@NO REVIEW@@@@-@-@-@NCT00471133@25@-@-@@@-@@4/1/2007@-@07-003@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ICHOR MEDICAL SYSTEMS@@@@@ICHOR MEDICAL SYSTEMS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@DNA VACCINE@@@@@DNA VACCINE||||@Vaccine@@@@@Vaccine||||@SAFETY@IMMUNE RESPONSE@@@@@@@@@-@@@@@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924224@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients with suspected renal cancer will be examined before surgery with the CA9-SCAN imaging procedure. @@-@-@-@-@@@@@14924224@Imaging PET@@-@-@@NO REVIEW@@@@-@Wilex inked a marketing and distribution agreement with IBA Molecular in December 2006.@-@-@-@-@FILING EXPECTED AT THE EARLIEST IN 2008.@@@-@@@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@WX-G250, RADIOACTIVELY LABELLED@@@@@WX-G250, RADIOACTIVELY LABELLED||||@WILEX@IBA MOLECULAR@@@@WILEX|IBA MOLECULAR|||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@CA9-SCAN@@@@@CA9-SCAN||||@Imaging@@@@@Imaging||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924508@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14924508@Anaplastic astrocytoma@@-@-@@NO REVIEW@@@@-@Hana receives notice from Nasdaq that it has regained compliance with minimum US$1 bid price. SOURCE: Hana, 28 April 2008@-@-@-@-@Orphan drug (FDA; for malignant glioma). SOURCE: Hana, June 2006@@@Orphan drug (FDA; for malignant glioma). SOURCE: Hana, June 2006@@@-@-@@-@-@@@-@DISCONTINUED@@-@-@Discontinued in January 2007 due to resource allocation.@-@@@@-@ROPIDOXURIDINE@@@@@ROPIDOXURIDINE||||@HANA BIOSCIENCES@@@@@HANA BIOSCIENCES||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@IPDR@@@@@IPDR||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922753@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@A prime-boost treatment strategy will be employed wherein the plasmid component will be administered on Days 1, 4, 15 and 18 of each treatment cycle followed by administration of peptides on Days 29 and 32 of the treatment cycle. All components will be administered separately into superficial inguinal lymph nodes under ultrasound guidance . Subjects will undergo immunologic evaluation on Day 39 of each treatment cycle, and will undergo an evaluation for extent of disease following every other treatment cycle. Subjects who do not have evidence of progressive neoplasia may remain in the clinical trial and receive up to 6 cycles of clinical trial treatment. SOURCE: clinicaltrials.gov@@-@-@-@-@@@@@14922753@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00423254@24@-@-@@@-@@2/1/2007@-@1@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GLOBEIMMUNE@@@@@GLOBEIMMUNE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MKC-1160-PP@@@@@MKC-1160-PP||||@Vaccine@Immunotherapy@@@@Vaccine|Immunotherapy|||@IMMUNE RESPONSE@SAFETY@ADVERSE EVENTS@@@ADVERSE EVENTS@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916699@Onco@@@@@300f1018ntsdm@@@@@@PEP005 Topical (at a concentration of 0.05%) when applied once a day on two consecutive days in the treatment of SCCIS. SOURCE: Peplin@@-@-@-@EMERYVILLE, CALIFORNIA@12/1/2006@@@@14916699@Squamous cell carcinoma in situ (SCCIS)@@-@-@@NO REVIEW@@@@-@-@-@NCT00329121@24@-@-@@@-@@5/1/2006@-@PEP005-008@@-@-@@@II@II@@-@-@PEP005 Topical demonstrated a favourable safety profile and was well tolerated. There were no drug related serious adverse events. The majority of local skin responses were graded mild and resolved spontaneously, typically within one month of treatment. Application of PEP005 Topical on two consecutive days resulted in an overall histological clearance of 36% of SCCIS tumours and clinical clearance of 64% of SCCIS tumours. In light of the observed favourable safety profile of two days treatment at 0.05%, the concentration used in this study and the highest concentration used in earlier studies, Peplin will seek higher concentration in the treatment of non-melanoma skin cancer. Peplin has recently initiated a dose escalation trial PEP005-009 to assess higher clearance rates. SOURCE: Peplin, 9 March 2007@-@@@@MONO@-@@@@@-||||@PEPLIN@@@@@PEPLIN||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PEP-005@@@@@PEP-005||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TOPICAL GEL@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14922277@Onco@@@@@300f1010ntsdm@@@@@@-@@-@-@-@COPENHAGEN, DENMARK@9/1/2007@@@@14922277@B-CLL not amendable to allogeneic HSCT@@-@-@@NO REVIEW@@@@-@Topotarget completes takeover of Apoxis. SOURCE: Apoxis, 27 June 2007@-@-@10@-@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@12/1/2006@-@AP3005, @@-@-@@@I/II EudraCT number 2006-002850-31@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TOPOTARGET@APOXIS SA@@@@TOPOTARGET|APOXIS SA|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|||||||@APO-866@@@@@APO-866||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@TOLERABILITY@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14921515@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@E7974 administered on days 1 and 15 of a 28-day cycle@@-@-@-@TOKYO, JAPAN@@@@@14921515@Solid malignancies, including metastatic refractory prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00130169@40@-@-@@@-@@1/1/2006@-@E7974-A001-102@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Solid Tumours@Prostate Cancer@@@@Solid Tumours|Prostate Cancer||||||||@E-7974@@@@@E-7974||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@METASTATIC@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922431@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@A6 received through multiple injections@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14922431@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00083928@60@-@-@@@-@@5/1/2004@-@Å6-003@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ÅNGSTROM PHARMACEUTICALS@@@@@ÅNGSTROM PHARMACEUTICALS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@Å6@@@@@Å6||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@CA125 RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916141@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Tariquidar or placebo with vinorelbine@@-@-@-@-@@@@@14916141@Combo with vinorelbine@@-@-@@NO REVIEW@@@@-@QLT in-licensed the drug from Xenova in North America in August 2001.@FIRST-LINE@NCT00042315@490@-@FDA fast-track status@@@-@@6/1/2002@-@TQD LUNG 002@@-@-@@@III@DISCONTINUED@@-@-@Trial discontinued. SOURCE: QLT, 12 May 2003Trial placed on hold by IDSMC amid safety concerns. SOURCE: QLT, 26 February 2003@-@@@@ADJUVANT@TARIQUIDAR@@@@@TARIQUIDAR||||@QLT@XENOVA@@@@QLT|XENOVA|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XR-9576@@@@@XR-9576||||@Anthracycline@@@@@Anthracycline||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@DOUBLE-BLIND@RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923907@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Thyrogen alone@@H01AB01@H01A@NO@CAMBRIDGE, MASSACHUSSETTS@@@@@14923907@Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer; in December 2007, approved in combination with radioiodine to ablate, or destroy, the remaining thyroid tissue in patients who have had their cancerous thyroids removed.@@NO@@@NO REVIEW@@@@@@@@358@Thyrogen 0.9 mg intramuscularly may be administered every 24 hours for two doses or every 72 hours for three doses.@FDA, 30 November 1998@11/30/1998@@@@@NONE@LABEL@No@15-Nov@358 [WELL-DIFFERENTIATED THYROID CANCER]@@@III 2 STUDIES@APPROVED@@@MEDICARE@Total positive withdrawal scans: 79% and 85% detected in first and second trials respectively, 13% and 15% not detected respectively.@@@@@ADJUVANT@THYROTROPIN ALFA@@@@@THYROTROPIN ALFA||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@THYROGEN@@@@@THYROGEN||||@Other@@@@@Other||||@DIAGNOSTIC@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@2021.28@2021.28@@2@1@3065@@@@@@@@@@@@1393.18@@@@@@@@@@@@@@@@8/2/2017@1532.5@1532.5@58468-0030-02@LYOPHILISATE FOR SOLUTION FOR INJECTION (VIAL)@US$@@@@@@@@1.1@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923720@Onco@@@@@@@@@@@Oxaliplatin and vinorelbine with or without Herceptin @@L01XA03@L01X@-@PARIS, FRANCE@4/1/2007@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14923720@Advanced breast carcinoma @@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@NCT00403988@40@-@-@@@-@@6/1/2004@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@TRASTUZUMAB@VINORELBINE@@@OXALIPLATIN|TRASTUZUMAB|VINORELBINE||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@Lebanon@@@@@Lebanon|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ELOXATIN@HERCEPTIN@@@@ELOXATIN|HERCEPTIN|||@Platinum@@@@@Platinum||||@RESPONSE RATE@TIME TO PROGRESSION@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923260@Onco@@@@@300f1012ntsdm@@@@@@AP-12009 10MG versus standard chemotherapy@@-@-@-@-@@@TGF-beta 2 inhibitor@@14923260@Anaplastic astrocytoma@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@AP-12009 median survival of 37.2 months versus 21.7 months in control arm. SOURCE: Antisense/ASCO, 3 June 2008@Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies. @@@@MONO@TRABEDERSEN@@@@@TRABEDERSEN||||@ANTISENSE PHARMA@@@@@ANTISENSE PHARMA||||@@@@@@|||||||||@Astrocytoma@@@@@Astrocytoma|||||||||@AP-12009@@@@@AP-12009||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14921357@Onco@@@@@300f1008ntsdm@@@@@@Faslodex 250mg, 250mg with 250mg loading regimen and 500mg@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921357@ER-positive advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00305448@135@-@-@@@-@@11/1/2005@-@FINDER I@@-@135 PATIENTS WHO ARE RELAPSED OR PROGRESSING AFTER PREVIOUS ENDOCRINE THERAPY@@@II@II@@-@@RESULTS PENDING (recruiting)@-@@@@MONO@FULVESTRANT@@@@@FULVESTRANT||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@@@@@FASLODEX||||@Hormone Antagonist@@@@@Hormone Antagonist||||@RESPONSE RATE@@@@@@@@@@ADVANCED@RELAPSED@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14924121@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@10 and 25mg tablets of asoprisnil was given daily for 18 months to women with abnormal uterine bleeding associated with uterine fibroids after an initial 6 months. @@-@-@-@-@1/1/2007@@@@14924121@Benign uterine tumours; myoma@@-@-@@NO REVIEW@@@@-@Abbott/Takeda joint venture TAP Pharmaceuticals dissolved. Abbott received rights to Lupron franchise; Takeda received the remaining organisation and pipeline - though Abbott receives payments based on TAP's current and future products. SOURCE: Takeda, 19@-@NCT00156208@166@-@-@@@-@@4/1/2004@-@-@@-@-@@@III@III@@-@-@As a result of some subjects receiving asoprisnil developing endometrial changes, dosing was prematurely discontinued for all participants.In most subjects, endometrial changes reversed after asoprisnil discontinuation. @-@@@@-@ASOPRISNIL@@@@@ASOPRISNIL||||@BAYER HEALTHCARE@TAKEDA PHARMACEUTICAL@TAP PHARMACEUTICALS@@@BAYER HEALTHCARE|TAKEDA PHARMACEUTICAL|TAP PHARMACEUTICALS||@@@@@@|||||||||@Myoma@@@@@Myoma|||||||||@-@@@@@-||||@Hormone Antagonist@@@@@Hormone Antagonist||||@-@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924550@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Talampanel with radiation therapy@@-@-@-@PETACH TIKVA, ISRAEL@@@@@14924550@In combination with radiation therapy with recurrent and adjuvant temozolomide.@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Ivax, which licensed it from Lilly@SECOND-LINE@NCT00267592@72@-@-@@@-@@4/1/2004@-@-@@-@72 PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME. @@@II@II@@-@-@RESULTS PENDING Previous epilepsy studies have shown an MTD of 100mg and plasma elimination half-life of 6.8 hours. @-@@@@ADJUVANT@TALAMPANEL@@@@@TALAMPANEL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@LY-300164@@@@@LY-300164||||@Other@@@@@Other||||@RESPONSE RATE@SAFETY@@@@@@@@@RELAPSED@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924170@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-745 versus placebo as an injection@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 745 targets inhibition of myostatin and is being investigated for its potential to inhibit muscle loss associated with a variety of diseases/conditions. @@14924170@Prostate cancer in men receiving androgen-deprivation therapy@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@-@@-@-@@@UNIVERSITY OF WASHINGTON@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@AMG-745@@@@@AMG-745||||@Other@@@@@Other||||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920971@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21; Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14; Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7; single intravenous infusion of 1 x 10^9 AlloStim cells@@-@-@-@-@12/1/2008@@@@14920971@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00558675@25@-@-@@@-@@2/1/2008@-@ITL-001-HMC@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@IMMUNOVATIVE THERAPIES@@@@@IMMUNOVATIVE THERAPIES||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ALLOSTIM@@@@@ALLOSTIM||||@Immunotherapy@@@@@Immunotherapy||||@TOXICITY@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921494@Onco@@@@@@@@@@@After all 14 patients have received 3 courses of Alimta (9 weeks of NovoTTF-100L treatment), these patients will be analyzed for toxicity. If the incidence of device related serious adverse events is < 20%, the trial will continue to the second stage where 42 patients will be assessed for safety and efficacy as part of a phase II study (including the first 14 patients in the phase I study). [clinicaltrials.gov]@@-@-@-@-@11/1/2009@@-@@14921494@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00749346@42@-@-@@@-@@5/1/2008@-@EF-15@@-@>>  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)     >> Stage IV or IIIB with malignant pleural effusion, also locally advanced NSCLC not otherwise amenable to local treatment (surgery or radiotherapy)    >> One line of prior chemotherapy@@@I/II@II@@-@-@Trial registered. [NovoCure, 09.09.2008]@-@@@@-@-@PEMETREXED@@@@-|PEMETREXED|||@NOVOCURE@@@@@NOVOCURE||||@Switzerland@@@@@Switzerland|||||||||@NSCLC@@@@@NSCLC|||||||||@NOVOTTF-100L@ALIMTA@@@@NOVOTTF-100L|ALIMTA|||@Other@@@@@Other||||@TOXICITY@@@@@TIME TO PROGRESSION@@@@@ADVANCED@@@@@OPEN-LABEL@NON-RANDOMISED@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916663@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@LONDON, UNITED KINGDOM@2/1/2009@@AZD0530 is an orally available, dual-specific, Src/Abl kinase inhibitor that is being evaluated to determine its effects as an anti-invasive agent. AZD0530 is being studied in a variety of clinical settings in solid tumors and leukemias.@@14916663@Soft tissue sarcomas@@-@-@@NO REVIEW@@@@-@-@-@NCT00659360@37@-@-@@@-@@2/1/2008@-@PMH-PHL-054@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@AZD-0530@@@@@AZD-0530||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
16791362@Onco@@@@@300f1020ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791362@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NA@@@NO REVIEW@@@@@@@@16@@EMA, 16 December 2016@12/16/2016@@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NA@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@4106.681544@@@8@week@8 week@4106.68@4106.68@73.33@30@1.1229@1833.34@3025.75@1915.86@@@@@@@@@@0.61@1@@mg/m²@100@1@@@@@@@@@@@6/7/2017@61.11@61.11@41873011@COATED TABLET@EURO@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924200@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arry-543 in combination with capecitabine@@-@-@-@BOULDER, COLORADO@@@@@14924200@Maintenance therapy for metastatic breast cancer patients (with Herceptin trastuzumab); metastatic breast cancer (with capecitabine).@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@1/1/2008@-@-@@-@-@@@I/II@II@@-@-@-@-@@@@COMBO@-@CAPECITABINE@@@@-|CAPECITABINE|||@ARRAY BIOPHARMA@@@@@ARRAY BIOPHARMA||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@ARRY-543@XELODA@@@@ARRY-543|XELODA|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@-@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916191@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@AVE-9633 on day 1,4 and 7 of a 4-week cycle by IV infusion@@-@-@-@PARIS, FRANCE@@@@@14916191@CD33-positive AML@@-@-@@NO REVIEW@@@@-@-@-@NCT00543972@25@-@-@@@-@@9/1/2007@-@TED10219, AVE9633@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AVE-9633@@@@@AVE-9633||||@Other@@@@@Other||||@DOSE-LIMITING TOXICITY@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921979@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Alimta in combination with the oral taxane@@-@-@-@NEW YORK, NEW YORK@@@@@14921979@Combination with Alima@@-@-@@NO REVIEW@@@@-@-@-@NCT00103831@N/A@-@-@@@-@@@-@CA165-021@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@TAXANE@@@@@TAXANE||||@BMS@@@@@BMS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BMS-275183 @@@@@BMS-275183 ||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@DOSE RANGE@SAFETY@RESPONSE RATE@@@RESPONSE RATE@@@@@RELAPSED@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921668@Onco@@@@@@@@@@@-@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921668@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00390195@134@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@10/1/2006@-@CRAD001C2453@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@Taiwan@@@@@Taiwan|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919056@Onco@@@@@@@@@@@OncoGel in combination with pre-operative chemoradiotherapy versus pre-operative chemoradiotherapy alone@@-@-@-@RUNCORN, UNITED KINGDOM@@@Paclitaxel is a widely used anticancer agent that prevents cell replication, by stabilizing microtubules, and increases the sensitivity of cells to damage caused by radiation.OncoGel is a thermosensitive, biodegradable gel that solidifies when injected into the site of a tumour. It is designed to release paclitaxel into the tumour continuously over four to six weeks and to achieve a far greater concentration of paclitaxel in the tumour than when paclitaxel is administered intravenously at the maximum tolerated dose (MTD).@@14919056@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of MacroMed in December 2006. Diatos licensed exclusive rights to develop and commercialise OncoGel worldwide except for North America and Korea. Diatos also received rights to sublicense OncoGel and to develop and commercialise @-@-@124@-@-@@@-@@1/1/2008@-@N/A@@-@-@@@IIB@II@@-@-@First-patient-in (FPI) in January 2008. Preliminary date due in H1 2010. SOURCE: Protherics, 24 January 2008@-@@@@COMBO@PACLITAXEL POLYMER GEL REGEL@@@@@PACLITAXEL POLYMER GEL REGEL||||@PROTHERICS@DIATOS@@@@PROTHERICS|DIATOS|||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@ONCOGEL@@@@@ONCOGEL||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@OVERALL SURVIVAL@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921916@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Cetuximab 400 mg/m2 X 1, followed by 250mg/m2 + Irinotecan 350 mg/m2 + Brivanib 200 mg; versus placebo@@-@-@-@NEW YORK, NEW YORK@1/1/2011@@@@14921916@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00594984@114@-@-@@@-@@2/1/2008@-@CA182-025@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@BRIVANIB ALANINATE@CETUXIMAB@IRINOTECAN@@@BRIVANIB ALANINATE|CETUXIMAB|IRINOTECAN||@BMS@@@@@BMS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@BMS-582664@ERBITUX@CAMPTOSAR@@@BMS-582664|ERBITUX|CAMPTOSAR||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PHARMACOKINETICS@SAFETY@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921904@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly administration of ABI-009@@-@-@-@UNITED STATES@11/1/2008@@ABI-009 is a nab particle version of rapamycin@@14921904@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00635284@42@-@-@@@-@@1/1/2008@-@CA401@@-@-@@@I@I@@-@-@Phase II studies expected to commence H2 2007@-@@@@MONO@RAPAMYCIN NANOPARTICLE ALBUMIN-BOUND@@@@@RAPAMYCIN NANOPARTICLE ALBUMIN-BOUND||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ABI-009@@@@@ABI-009||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15051141@Onco@@@@@300f1015ntsdm@@@@@@-@@-@-@-@INGELHEIM, GERMANY@3/1/2011@@This is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. @@15051141@Phase I Open Label Trial to Assess Safety of BIBW 2992 With Vinorelbine in Solid Tumors Known to Overexpress HER2 and/or EGFR.@@-@-@@NO REVIEW@@@@-@-@-@NCT00906698@48@-@-@@@-@@5/1/2009@-@1200.69@@-@"Histologically or cytologically confirmed diagnosis of malignancy that is now advanced, non resectable and/or metastatic. Tumours historically known to overexpress EGFR and/or HER2. "@@@I@I@@-@-@Trial registered. [BI, 14 May 2009 ]@-@@@@COMBO@AFATINIB@VINORELBINE@@@@AFATINIB|VINORELBINE|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BIBW-2992@NAVELBINE@@@@BIBW-2992|NAVELBINE|||@TK Inhibitor@EGFR@HER2@@@TK Inhibitor|EGFR|HER2||@MAXIMUM TOLERATED DOSE@@@@@OVERALL RESPONSE@@@@@@@@@@SAFETY@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
15412804@Onco@@@@@@@@@@@KPT-8602, Experimental, 5 mg starting dose@@@@@@12/1/2016@@@@15412804@Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma@Both@@@@@@@@@@@NCT02649790@116@@@@@@@1/1/2016@@KCP-8602-801@@@Evidence of disease progression:  -  Symptomatic relapsed or refractory requiring current treatment.  -  Previously treated with ≥ 3 prior regimens (lines of therapy) that included at least one of each of the following: alkylating agent, immunomodulatory drug, proteasome inhibitor, and a steroid.  -  Must be refractory to most recent anti-cancer regimen.  -  Must have measurable disease defined by one of the following:  -  Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or for IgA myeloma, by quantitative IgA; or  -  Urinary M-protein excretion at least 200 mg/24 hours; or  -  Serum Free Light Chain (Serum FLC) whereby the involved light chain measures ≥ 10 mg/dL and with an abnormal ratio.  -  Eastern Cooperative Oncology Group performance status of ≤ 1.@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@@-@@@@@-||||@KARYOPHARM THERAPEUTICS@@@@@KARYOPHARM THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@KPT-8602@@@@@KPT-8602||||@Other@@@@@Other||||@Evaluate dose limiting toxicities of KPT-8602@@@@@@@@@@MULTIPLE@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922307@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients randomised 2:1; 250 with Allovectrin-7 and 125 with either dacarbazine or temozolomide.@@-@-@-@-@@@@@14922307@Stage III/IV metastatic melanoma@@-@-@@NO REVIEW@@@@-@>> Teva licenses Israeli rights. [Teva, 4 August 2009]>> Asia rights licensed to AnGes; co-development programme.@FIRST-LINE@NCT00395070@375@-@-@@@Orphan drug@@10/1/2006@-@AIMMVICAL@@-@375 PATIENTS WITH RECURRENT METASTATIC MELANOMA WHO CAN HAVE UNDERGONE SURGERY, ADJUVANT THERAPY AND/OR BIOTHERAPY BUT NOT TREATED WITH CHEMO@@@III@III@@-@-@IDMC gives Vical go-ahead to complete the trial. [Vical, 25 March 2009]@-@@@@MONO@-@@@@@-||||@VICAL@ANGES MG@TEVA PHARMACEUTICAL@@@VICAL|ANGES MG|TEVA PHARMACEUTICAL||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ALLOVECTIN-7@@@@@ALLOVECTIN-7||||@Gene Therapy@Immunotherapy@@@@Gene Therapy|Immunotherapy|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@SINGLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922207@Onco@@@@@@@@@@@Aflibercept once every 2 weeks versus placebo@@-@-@-@PARIS, FRANCE@@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. @@14922207@Combo with Gemzar@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@-@NCT00574275@630@-@-@@@-@@12/1/2007@-@AVE0005, @@-@-@@@EudraCT 2007-003476-19; @III@@-@-@RESULTS PENDING@-@@@@COMBO@AFLIBERCEPT@@@@@AFLIBERCEPT||||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@VEGF-TRAP@@@@@VEGF-TRAP||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916602@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Rituxan given intravenously once weekly for four weeks and 1018 ISS given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.@@-@-@-@-@12/1/2008@@@@14916602@B-cell follicular lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00251394@30@-@-@@@-@@7/1/2004@-@R21 @@-@-@@@II; 03-411, @II@@-@-@Endpoint after 2 years@-@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@DYNAVAX TECHNOLOGIES@@@@@DYNAVAX TECHNOLOGIES||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@Follicular lymphoma@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|Follicular lymphoma||||||@1018 ISS@RITUXAN@@@@1018 ISS|RITUXAN|||@TLR-targeted@@@@@TLR-targeted||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924844@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC06 @L01B@-@BASEL, SWITZERLAND@2/1/2008@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924844@Patients with locally advanced, non-metastatic rectosigmoid carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00216424@40@-@-@@@-@@2/1/2005@-@-@@-@-@@@II@IV@@-@-@RESULTS PENDING@-@@@@MONO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924143@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924143@Phase II to begin by end-2007@@-@-@@NO REVIEW@@@@-@Acceleron and Celgene formed a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The companies also signed an option agreement for certain discovery stage programs.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@A Phase IIa study in multiple myeloma will be started later this year. SOURCE: Acceleron, 20 February 2008@-@@@@-@-@@@@@-||||@ACCELERON PHARMA@CELGENE@@@@ACCELERON PHARMA|CELGENE|||@@@@@@|||||||||@Supportive Care@Bone Loss@@@@Supportive Care|Bone Loss||||||||@ACE-011@@@@@ACE-011||||@Hormone Antagonist@@@@@Hormone Antagonist||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16064785@Onco@@@@@300f1008ntsdm@@@@@@@@V10XX03@V10X@@LEVERKUSEN, GERMANY@@@Radium 223 dichloride (radium 223) is an alpha particle-emitting radioactive therapeutic agent with an anti-tumor effect on bone metastases.@@16064785@Indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@The dose regimen of Xofigo is an activity of 50 kBq per kg body weight, given at 4 week intervals for 6 injections.@MHLW, 1 March 2016@3/1/2016@@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@RADIUM RA 223 DICHLORIDE@@@@@RADIUM RA 223 DICHLORIDE||||@BAYER HEALTHCARE@ALGETA@@@@BAYER HEALTHCARE|ALGETA|||@@@@@@|||||||||@Prostate Cancer@HRPC@Bone Metastases@@@Prostate Cancer|HRPC|Bone Metastases|||||||@XOFIGO@@@@@XOFIGO||||@Other@@@@@Other||||@@@@@@@@@@@METASTATIC@REFRACTORY@@@@@@@@@76.5@kg@2221638.948@@@24@week@24 week@2221638.95@2221638.95@13224.04@1@0.0091@580820.64@684930@@@@@@@@@@@@28@@KBQ/KG@50@1@@@@@@@@@@@8/30/2017@580820.64@580820.64@4291432A1025@SOLUTION FOR INJECTION - 6 ML@YEN@@@@@@@@6000@KBQ@1000 KBQ/ML@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14921734@Onco@@@@@@@@@@@Faslodex 500mg versus Faslodex 250mg@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921734@ER-positive advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00099437@720@-@-@@@-@@8/1/2005@-@CONFIRM  @@-@-@@@III@III@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@FULVESTRANT@@@@@FULVESTRANT||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@@@@@FASLODEX||||@Hormone Antagonist@@@@@Hormone Antagonist||||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921586@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive DX-8951f IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for survival.@@-@-@-@TOKYO, JAPAN@@@@@14921586@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00004108@37@-@-@@@-@@9/1/1999@-@DAIICHI-8951A-PRT016@@-@-@@@MDA-ID-99145, MSKCC-99058, UCHSC-00891; @II@@-@-@RESULTS PENDING@-@@@@MONO@EXATECAN MESYLATE@@@@@EXATECAN MESYLATE||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@DX-8951F@@@@@DX-8951F||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TUMOUR RESPONSE@@@@@@@@@@-@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917976@Onco@@@@@300f1010ntsdm@@@@@@Foscan alone@@L01XD05@L01X@NO@EAST LONGMEADOW, MASSACHUSSETTS@@@@@14917976@Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy. @@NO@-@@NO REVIEW@@@@100%@Licensed from QLT@-@-@147@The dose is 0.15mg/kg body weight.@EMEA approval [EMEA, 24 October 2001]@10/24/2001@@-@@@Special care must be taken to prevent extravasation at the injection site. If extravasation occurs, protect the area from light for at least 3 months. There is no known benefit from injecting the extravasation site with another substance.@LABEL@@-@-@@@III@DISCONTINUED@@The SMC advised in May 2004 that temoporfin is not recommended for the palliative treatment of advanced head and neck cancer.@NHS@Median duration of tumour response was 57 days for overall responseand 84 days for complete response.@-@@@@MONO@TEMOPORFIN@@@@@TEMOPORFIN||||@BIOLITEC@@@@@BIOLITEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@FOSCAN@@@@@FOSCAN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@@@@1@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3/6/2013@@@7.82E+15@SOLUTION FOR INJECTION, 5 ML@GB£@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14918984@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14918984@-@@-@-@@NO REVIEW@@@@-@Worldwide rights licensed from Angiogene.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II/III@III@@-@-@Phase II/III trials to commence. SOURCE: Medicinova, June 2007Phase I results presented at ASCO June 2006; open-label, dose escalation, safety and PK study as an infusion once every 3 weeks with a 20-day recovery period between doses (1 cycle). An MTD of 180 mg/m2 was established in this study; the most common side effects of MN-029 were characteristic of other vascular disrupting agents and included nausea, vomiting, fatigue and diarrhoea. 9 patients (of 34) had stable disease after 3 cycles of treatment, including 2 patients with carcinoid tumours for 27 cycles or more. Tumour blood flow reduction assessed by DCE-MRI was recorded at doses greater than or equal to 120 mg/m2.@-@@@@-@-@@@@@-||||@MEDICINOVA@@@@@MEDICINOVA||||@@@@@@|||||||||@Ovarian Cancer@NSCLC@@@@Ovarian Cancer|NSCLC||||||||@MN-029@@@@@MN-029||||@Angiogenesis Inhibitor@Vascular Disrupting Agent@@@@Angiogenesis Inhibitor|Vascular Disrupting Agent|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15413485@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@@@@@@15413485@An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation@Both@@@@@@@@@@SECOND-LINE@NCT02547675@@@@@@@@@@CO-1686-031@@@Unresectable locally advanced or metastatic NSCLC with EGFR activating mutation (excluding exon 20 insertion) and presence of the T790M mutationPrior treatment with an approved or experimental EGFR-directed therapyEastern Cooperative Oncology Group (ECOG) performance status 0-1Adequate hematological and biological functionWritten informed consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study-specific evaluation@EGFR MUTATION@ADULTS@@-@@@@@@@@@MONO@ROCILETINIB@@@@@ROCILETINIB||||@CLOVIS ONCOLOGY@@@@@CLOVIS ONCOLOGY||||@United States@@@@@United States|||||||||@NSCLC@@@@@NSCLC|||||||||@CO-1686@@@@@CO-1686||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@OPEN LABEL@MULTICENTER@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922554@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily; versus placebo@@-@-@-@BRENTFORD, UNITED KINGDOM@11/1/2013@@@@14922554@Post Transplant Thrombocytopenia@@-@-@@NO REVIEW@@@@-@The GSK-Ligand collaboration began in 1997 to utilize Ligand's expertise and technology to discover small-molecule drugs to control hematopoieses and treat patients with cancer, anemia or platelet deficiencies. The research phase of the collaboration ende@-@NCT01000051@60@-@-@@@-@@11/1/2009@-@2009-0106@@-@Patients >/= 35 days post HCT with Platelet count </= 20 x 10^9/l sustained for 7 days or patients are platelet transfusion dependent, and Neutrophil count >/= 1.5 x 10^9/l (Patients can be on myeloid or erythroid growth factors for example filgrastim),@@@II@II@@-@-@Trial registered [GSK, 20 October 2009]@-@@@@MONO@ELTROMBOPAG@@@@@ELTROMBOPAG||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@Thrombocytopaenia@@@@Supportive Care|Thrombocytopaenia||||||||@PROMACTA@@@@@PROMACTA||||@Thrombopoietin Agonist@@@@@Thrombopoietin Agonist||||@PLATELET COUNT@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923999@Onco@@@@@300f1015ntsdm@@@@@@@@V03AF01@V03A@NO@DEERFIELD, ILLINOIS@@@@@14923999@@@YES@@@NO REVIEW@@@@@@@@@@Oct-84@@@@@@Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions. The majority of these patients received mesna orally. Mesnex has been developed as an agent to reduce the risk of ifosfamide induced haemorrhagic cystitis. It will not prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide therapy. Mesnex does not prevent haemorrhagic cystitis in all patients. Up to 6% of patients treated with mesna have developed haematuria (>50 RBC/hpf or WHO grade 2 and above). As a result, a morning specimen of urine should be examined for the presence of haematuria (microscopic evidence of red blood cells) each day prior to ifosfamide therapy. If haematuria develops when Mesnex is given with ifosfamide according to the recommended dosage schedule, depending on the severity of the hematuria, dosage reductions or discontinuation of ifosfamide therapy may be initiated. In order to reduce the risk of hematuria, Mesnex must be administered with each dose of ifosfamide as outlined in@@No@@@@@@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@MESNA@@@@@MESNA||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@UROMITEXAN@@@@@UROMITEXAN||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9173104R@SOLUTION FOR PERFUSION  (VIAL 10 ML)@EURO@@@@@@@@1@G@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14923428@Onco@@@@@300f1012ntsdm@@@@@@N/A@@-@-@-@BERLIN, GERMANY@@@MGN1703 is based on the DNA immunomodulator dSLIM developed by Mologen In dSLIM (“double Stem Loop Immunomodulator”), it has developed an innovative TLR9 agonist. Use of dSLIM activates the immune system to protect against tumor-associated antigens by targeting the TLR9 receptor on certain immune cells. As a result of chemotherapy and radiotherapy, tumor-associated antigens are released by cancer cells. The immune system activated by dSLIM is in a position to overcome its fatal tolerance towards cancer cells and advance against them strategically.@@14923428@Treatment in various cancers@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@"Trial to start ""in a few weeks time"". SOURCE: Mologen, 29 May 2008"@-@@@@MONO@-@@@@@-||||@MOLOGEN@@@@@MOLOGEN||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@MGN-1703@@@@@MGN-1703||||@Immunotherapy@TLR-targeted@@@@Immunotherapy|TLR-targeted|||@SAFETY@IMMUNE RESPONSE@@@@@@@@@-@@@@@MULTI-CENTRE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14919004@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14919004@-@@-@-@@NO REVIEW@@@@-@ProNAi has partnered with Novosom AG and Polymun AG to develop liposome-based technologies to deliver the company's unique DNAi oligonucleotides.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@IND to commence clinical trials cleared. SOURCE: ProNAi Therapeutics, 20 March 2008@-@@@@-@-@@@@@-||||@PRONAI THERAPEUTICS@@@@@PRONAI THERAPEUTICS||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@PNT-2258@@@@@PNT-2258||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921582@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive exatecan mesylate IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR receive 6 additional courses beyond CR.@@-@-@-@TOKYO, JAPAN@@@@@14921582@Rhabdomyosarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00055939@27@-@-@@@-@@1/1/2003@-@DAIICHI-8951A-PRT033,@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@EXATECAN MESYLATE@@@@@EXATECAN MESYLATE||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Sarcoma@@@@@Sarcoma|||||||||@DX-8951F@@@@@DX-8951F||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@OVERALL SURVIVAL@@PARTIAL RESPONSE@OVERALL SURVIVAL@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924710@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@@@14924710@The detection and characterisation of metastatic lymph nodes in patients with pelvic cancer@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@MAA submitted in November 2006 but withdrawn in December 2007 after the CHMP indicated that the Phase III date does not provide sufficient statistical demonstration of efficacy.@@@-@@@-@-@@-@PATIENTS WITH PELVIC CANCERS@@@GUERBET-RUN TRIAL@DISCONTINUED@@-@-@Demonstrated that it only accumulates in normal lymph node tissue and can therefore facilitate differentiation between cancerous nodes and normal nodes. @-@@@@-@FERUMSTRAN-10@@@@@FERUMSTRAN-10||||@GUERBET@@@@@GUERBET||||@@@@@@|||||||||@Other@@@@@Other|||||||||@SINEREM@@@@@SINEREM||||@Imaging@@@@@Imaging||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922457@Onco@@@@@@@@@@@20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops. [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@10/1/2010@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922457@CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00560560@160@-@-@@@-@@12/1/2007@-@A4021006@@-@>> Patients who have stage IV colorectal cancer >> Patients whose disease has worsened despite prior anti-cancer therapy >> Patients who have satisfactory bonemarrow, kidney and liver function@@@II@II@@-@-@Trial registered. [Pfizer, 15.11.2007]@-@@@@MONO@FIGITUMUMAB@@@@@FIGITUMUMAB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CP-751,871@@@@@CP-751,871||||@mAb@Human@@@@mAb|Human|||@6-MONTH SURVIVAL@@@@@OVERALL SURVIVAL@SAFETY@PROGRESSION-FREE SURVIVAL@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916793@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Combo with docetaxel@@-@-@-@SAN DIEGO, CALIFORNIA@6/1/2009@@@@14916793@Combo with standard chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00630110@174@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@2/1/2008@-@NPI-2358-101@@-@-@@@I@I@@-@-@Trial initiated. SOURCE: Nereus, 20 March 2008@-@@@@COMBO@-@DOCETAXEL@@@@-|DOCETAXEL|||@NEREUS PHARMACEUTICALS@@@@@NEREUS PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@NPI-2358@TAXOTERE@@@@NPI-2358|TAXOTERE|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924167@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-162 versus Zometa@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (“RANKL”), a key mediator of the cells responsible for bone breakdown. Denosumab is being studied across a range of conditions, including osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, and multiple myeloma. @@14924167@Bone metastases in patients with multiple myeloma or advanced cancer (except breast and/or prostate cancer).@@-@-@@NO REVIEW@@@@-@Japanese rights licensed to Daiichi Sankyo for US$20 mil upfront and royalties in July 2007, and Daiichi Sankyo will pay US$150 mil of expected worldwide development costs through 2009.@-@NCT00330759@N/A@-@-@@@-@@@-@-@@-@-@@@III@III@@-@-@Trial registered. Preliminary results expected early 2009. [Amgen, 25.05.2006]@-@@@@MONO@DENOSUMAB@@@@@DENOSUMAB||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@AMG-162@@@@@AMG-162||||@mAb@Human@RANK Ligand@@@mAb|Human|RANK Ligand||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921562@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive carmustine in ethanol intratumorally over 5 minutes during stereotactic biopsy or open craniotomy. Cohorts of 3-6 patients receive escalating doses of DTI-015 until the MTD is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity. (Phase I of this study closed to accrual as of 01/15/2002.) Additional patients then receive treatment with DTI-015 at the recommended phase II dose. Patients are followed at 4, 8, and 12 weeks and then every 1-3 months until disease progression.@@-@-@-@REDWOOD CITY, CALIFORNIA@@@@@14921562@Recurrent, inoperable brain cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00006656@18@-@-@@@-@@6/1/2000@-@DTI-9901, @@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@CARMUSTINE@@@@@CARMUSTINE||||@DIRECT THERAPEUTICS@@@@@DIRECT THERAPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@DTI-015@@@@@DTI-015||||@Alkylating Agent@@@@@Alkylating Agent||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ETHANOL SOLVENT@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924483@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@UNITED STATES@@@HPDSCs are immature and versatile stem cells with potentially broad therapeutic applications in, for example, leukemia and other hematological malignancies, solid tumor cancers, and autoimmune diseases. CCT is also conducting research on other types of stem cells derived from the placenta that are obtained via additional proprietary methodologies.@@14924483@Clinical application of a human placenta-derived stem cells (HPDSCs) for hematopoietic reconstitution. @@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@@-@-@@-@-@PAEDIATRIC@@I@I@@-@-@Trial commenced. SOURCE: Celgene, 2 May 2008@-@@@@MONO@-@@@@@-||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@HPDSC@@@@@HPDSC||||@Gene Therapy@@@@@Gene Therapy||||@SAFETY@OVERALL SURVIVAL@@@@@@@@@-@@@@@MULTI-CENTRE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916762@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Administered once or twice daily until disease progression or toxicity@@-@-@-@MELVILLE, NEW YORK@6/1/2009@@@@14916762@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00514007@60@-@-@@@-@@12/1/2006@-@OSI-906-101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@OSI PHARMACEUTICAL@@@@@OSI PHARMACEUTICAL||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OSI-906@@@@@OSI-906||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922074@Onco@@@@@300f1020ntsdm@@@@@@Patients received Oncophage with GM-CSF and IFN-alpha@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14922074@Metastatic melanoma; combination trial@@-@-@@NO REVIEW@@@@-@-@-@-@18@-@-@@@-@@@-@C-100-22@@-@-@@@II@II@@-@-@ASCO 2004 results from 18 of the evaluable patients with stage IV melanoma, all of whom underwent surgery, then received Oncophage in combination with GM-CSF and IFN-alpha; 1 of 2 patients rendered disease-free by surgery remained free of disease for 419 days. Of 16 patients with residual melanoma post-surgery, 10 experienced disease stabilisation, lasting from 97 to 372 days. Of 16 patients evaluated for immunological response, 6 of them — all exhibiting stabilised disease — had a demonstrable increase in antimelanoma immune response.@-@@@@COMBO@VITESPAN@GM-CSF@@@@VITESPAN|GM-CSF|||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@DISEASE-FREE SURVIVAL@STABLE DISEASE@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14919031@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Bexarotene 400mg/m2 daily plus prophylactic levothyroxine and a lipid-lowering agent.@@L01XX25@L01X@-@TOKYO, JAPAN@@@@@14919031@NSCLC@@-@-@@NO REVIEW@@@@-@Global rights licensed by Eisai from Ligand in September 2006. Cephalon acquired European rights through takeover of Zeneus in December 2005.@THIRD-LINE@-@146@-@-@@@-@@@-@N/A@@2016@-@@@II@II@@-@-@ASCO June 2006 final results;  median and 1-year survival were 6 months and 25%, respectively. Baseline albumin < 3 g/dL and PS = 2 were significantly associated with shorter survival. For 26 patients who developed hypertriglyceridemia plus skin rash by Day 21, median and 1-year survival were 12 months and 44%, respectively, vs. 2 months and 12% in 36 patients with neither (p = 0.0003). PR was reported in 1 patient. When assessed by FACT-G, quality of life was improved or stabilized in 65% of patients. Randomised trial is warranted.@-@@@@COMBO@BEXAROTENE@@@@@BEXAROTENE||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARGRETIN@@@@@TARGRETIN||||@Retinoid@@@@@Retinoid||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@RELAPSED@@@@OPEN-LABEL@NON-RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922606@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Thalidomide combined with lomustine and Temodal@@L04AX02@L04A@-@SUMMIT, NEW JERSEY@8/1/2009@@The mechanism of action is not fully understood. It possesses immunomodulatory, anti-inflammatory and anti-angiogenic properties; the immunologic effects vary substantially under different conditions, but may be related to the suppression of excessive TNF-alpha production and down-modulation of selcted cell surface adhesion molecules involved in leukocyte migration.@@14922606@Thalidomide with Temodal and lomustine@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00527657@48@-@-@@@EMEA'S COMP issues positive opinion to grant ORPHAN DRUG status for CLL treatment@@2/1/2006@-@2004-0595@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@THALIDOMIDE@@@@@THALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Melanoma / Skin Cancer@Brain Cancer@@@@Melanoma / Skin Cancer|Brain Cancer||||||||@THALOMID@@@@@THALOMID||||@Immunotherapy@@@@@Immunotherapy||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916252@Onco@@@@@300f1015ntsdm@@@@@@N/A@@N02AA01@N02A@NO@NEW YORK, NEW YORK@@@@@14916252@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@Feb-00@@NO REVIEW@@@@65%@@@@N/A@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals. Elderly: As with all narcotics, a reduction in dosage may be advisable in the elderly, as appropriate. Children: Not recommended.@@@3/31/2000@@@@Caution should be exercised:- in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose should be reduced, or its use should be avoided in cases of hepatic or renal failure; and - in patients suffering from the following conditions: hypotension, convulsive disorders, dependence (severe withdrawal symptoms if withdrawn abruptly) and prostatic hypertrophy.@N/A@No@@@@@N/A@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@No clinical data on label.@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTISKENAN@@@@@ACTISKENAN||||@Opioid Analgesic@@@@@Opioid Analgesic||||@N/A@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@14@1.1807@1.37@1.85@1.67@@@@@@@@@@0.02@@@@@@@@@@@@@@@@9/1/2017@0.1@0.1@3.40E+12@CAPSULE@EURO@@@@@@@@5@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
16670255@Onco@@@@@300f1018ntsdm@@@@@@@@L02BA01@L02B@@LONDON, UNITED KINGDOM@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@16670255@Primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).@@@@@NO REVIEW@@@@@@@@@The recommended maximum dose is 20 mg daily for 5 years.@TGA, 8 April 2016@4/8/2016@@@@@@@No@@@@@@APPROVED@@@@@@@@@MONO@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NOLVADEX-D@@@@@NOLVADEX-D||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@1@1@538.375@@@5@year@5 year@538.38@538.38@0.3@30@0.779@8.85@20.08@9.52@@@@@@@@@@@1@@mg@20@1@@@@@@@@@@@8/1/2017@0.3@0.3@2385-2413-GE-AP@FILM COATED TABLET@A$@@@@@@@@20@MG@20 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14921009@Onco@@@@@@@@@@@Iressa 250mg tablet per day. [AstraZeneca]@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@6/1/2010@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14921009@Maintenance therapy in locally advanced or metastatic Stage IIIB/IV NSCLC@@-@-@@NO REVIEW@@@@-@-@MAINTENANCE@NCT00770588@296@-@-@@@-@@9/1/2008@-@INFORM@@-@>> Histologically or cytologically confirmed locally advanced or metastatic (stage=IIIB/IV) non-small cell lung cancer (NSCLC) before the front line chemotherapy. Note: sputum cytology alone is not acceptable      >> Patients have completed 4 cycles of first line platinum contained doublet chemotherapy without progression or intolerable toxicity.     >> Patients with PR or SD on study entry need to have one or more measurable lesions according to RECIST criteria.@@@IV@IV@@-@-@Trial registered. [AstraZeneca, 9.10.2008]@-@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@IRESSA@@@@@IRESSA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@OVERALL SURVIVAL@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922874@Onco@@@@@300f1014ntsdm@@@@@@Followed a dose-to-effect self-titration protocol.@@-@-@-@ONTARIO, CANADA@@@@@14922874@Treatment of patients with of opioid-naïve patients with poste operative acute pain@@-@-@@NO REVIEW@@@@-@Acquired through US$3.7 mil takeover of Delex in 2005.@-@-@-@-@-@@@-@@@-@-@@-@-@@@IIA@II@@-@-@95% of post-surgical patients achieved clinically meaningful analgesia after self-administration of AeroLEF to treat their moderate-to-severe pain. Patients reported rapid onset of analgesia followed by an long period of pain relief. @-@@@@-@FENTANYL, LIPOSOME ENCAPSULATED @@@@@FENTANYL, LIPOSOME ENCAPSULATED ||||@YM BIOSCIENCES@@@@@YM BIOSCIENCES||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@AEROLEF@@@@@AEROLEF||||@Opioid Analgesic@@@@@Opioid Analgesic||||@PAIN RELIEF@@@@@@@@@@-@@@@@SINGLE-DOSE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14924687@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@25MG OF ONCE-DAILY ORAL REVLIMID@@L04AX04@L04A@@SUMMIT, NEW JERSEY@@@The lenalidomide mechanism of action includes anti-neoplastic, anti-angiogenic, pro-erythropoietic, and immunomodulatory properties. Specifically, lenalidomide inhibits proliferation of certain haematopoietic tumour cells (including MM plasma tumour cells and those with deletions of chromosome 5), enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells, inhibits angiogenesis by blocking the migration and adhesion of endothelial cells and the formation of microvessels, augments foetal haemoglobin production by CD34+ haematopoietic stem cells, and inhibits production of pro-inflammatory cytokines (e.g., TNF-a and IL-6) by monocytes.@@14924687@Treatment of relapsed or refractory chronic lymphocytic leukemia@@@@@NO REVIEW@@@@@-@@@45@@@@@@@@@@@@45 CLL PATIENTS WHO RECIVED LESS THAN TWO PRIOR THERAPIES@@@II@II@@@@Revlimid produced complete remission in 18% of patients and partial remission in 40% of patients. Median progression-free survival was 19.4 months. Clinical responses were seen in 44% of patients with 17p or 11q cytogenetic abnormalities and in 30% of patients with fludarabine-refractory disease.@@@@@MONO@LENALIDOMIDE@@@@@LENALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@REVLIMID@@@@@REVLIMID||||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919037@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Sequential ascending single intraveous dose of TG-0054@@-@-@-@-@@@@@14919037@Healthy subjects@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@NDA filing expected within 2 years. SOURCE: CMS, 17 January 2008@1/17/2008@@-@@5/1/2008@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TAIGEN BIOTECHNOLOGY@@@@@TAIGEN BIOTECHNOLOGY||||@@@@@@|||||||||@Other@@@@@Other|||||||||@TG-0054@@@@@TG-0054||||@CXCR4 Antagonist@@@@@CXCR4 Antagonist||||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922693@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Treatment with eltrombopag tablets once per day for 90 days. @@-@-@-@BRENTFORD, UNITED KINGDOM@12/1/2010@@@@14922693@A Pilot Study of a Thrombapoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)@@-@-@@NO REVIEW@@@@-@The GSK-Ligand collaboration began in 1997 to utilize Ligand's expertise and technology to discover small-molecule drugs to control hematopoieses and treat patients with cancer, anemia or platelet deficiencies. The research phase of the collaboration ende@-@NCT00961064@30@-@-@@@-@@7/1/2009@-@09-H-0199@@-@Diagnosis of MDS, with WHO classification of RA, RARS, RCMD-RS, or RCMD with refractory thrombocytopenia.@@@II@II@@-@-@Trial registered [GSK, 15 August 2009]@-@@@@MONO@ELTROMBOPAG@@@@@ELTROMBOPAG||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@Thrombocytopaenia@Myelodysplastic Syndrome@@@Supportive Care|Thrombocytopaenia|Myelodysplastic Syndrome|||||||@PROMACTA@@@@@PROMACTA||||@Thrombopoietin Agonist@@@@@Thrombopoietin Agonist||||@PLATELET COUNT@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919178@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Group A - Observation, standard of care. All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. Group B - Leukopheresis, vaccines x 3, rescan if stable repeat leukopheresis + three more vaccines. All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. Group C - Leukopheresis, ATRA pills with vaccine x 3, re-scan, stable-repeat leukopheresis plus ATRA pills with vaccine x 3-Rescan. All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. @@-@-@-@AUSTIN, TEXAS@10/1/2012@@@@14919178@Extensive stage SCLC@@-@-@@NO REVIEW@@@@-@-@-@NCT00617409@80@-@-@@@-@@2/1/2008@-@MCC-15206,@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@INTROGEN THERAPEUTICS@@@@@INTROGEN THERAPEUTICS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@INGN-225@@@@@INGN-225||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924274@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WESTMINSTER, COLORADO@@@@@14924274@Discontinued in Phase II trials in June 2007 after ENRICH trial failed statistical significance.@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@DISCONTINUED IN JUNE 2007 AFTER ENRICH TRIAL FAILED STATISTICAL SIGNIFICANCE.@@@-@@@-@-@@-@-@@@II@DISCONTINUED@@-@-@Discontinued in June 2007 after ENRICH trial failed to demonstrate a statistically significant improvement in overall survival in patients receiving efaproxyn plus WBRT, compared to patients receiving WBRT alone. SOURCE: Allos, 19 June 2007@-@@@@-@EFAPROXIRAL@@@@@EFAPROXIRAL||||@ALLOS THERAPEUTICS@@@@@ALLOS THERAPEUTICS||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@EFAPROXYN@@@@@EFAPROXYN||||@Radiolabeled@@@@@Radiolabeled||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919354@Onco@@@@@300f1012ntsdm@@@@@@@@L02BB03@L02B@NO@REKYAVIK, ICELAND@@@@@14919354@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@90% (MINIMUM CO-PAYMENT: EUR5, MAXIMUM CO-PAYMENT: EUR10)@@FIRST-LINE@@@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@@@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@@No@@@@@@APPROVED@@@GKV@@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@30@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3668023@FILM-COATED TABLET@EURO@@@@@@@@150@MG@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
15413016@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@"Ublituximab + TGR-1202, Experimental, Ublituximab IV treatment + TGR-1202 oral daily dose"@@@@@@9/1/2019@@@@15413016@A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304@Both@@@@@ublituximab IV infusion@@@@@@NCT02656303@300@@@@@@@1/1/2016@@UTX-TGR-204@@@Prior treatment in clinical trial UTX-TGR-304  -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2@COMBO@ADULTS@Phase 2@-@@@@@@@@@@UBLITUXIMAB@@@@@UBLITUXIMAB||||@TG THERAPEUTICS@@@@@TG THERAPEUTICS||||@United States@@@@@United States|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@TG-1101@TGR-1202@@@@TG-1101|TGR-1202|||@Other@@@@@Other||||@OVERALL RESPONSE RATE @@@@@@@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921605@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Zactima with weekly cisplatin@@-@-@-@LONDON, UNITED KINGDOM@5/1/2009@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14921605@Previously untreated, unresected Stage III/IV squamous cell carcinoma of the head and neck@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00450138@48@-@-@@@-@@12/1/2006@-@D4200C00062@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@VANDETANIB@CISPLATIN@@@@VANDETANIB|CISPLATIN|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918896@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@DUBLIN, IRELAND@@@@@14918896@Chemotherapy-induced diarrhoea@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@2/1/2008@-@N/A@@-@-@@@II@II@@-@-@First-patient-in February 2008. SOURCE: AGI Therapeutics, 5 February 2008@-@@@@MONO@MECAMYLAMINE@@@@@MECAMYLAMINE||||@AGI THERAPEUTICS@@@@@AGI THERAPEUTICS||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@AGI-004@@@@@AGI-004||||@Other@@@@@Other||||@STOOL CONSISTENCY@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@PATCH, TRANSDERMAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922674@Onco@@@@@@@@@@@Enzastaurin/fulvestrant versus fulvestrant alone@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922674@In combination with fulvestrant@@-@-@@NO REVIEW@@@3.5 YEARS@-@-@SECOND-LINE@NCT00451555@132@-@-@@@-@@@-@10736H6Q-MC-S023  @@-@-@@@II@II@@-@-@Completion expected August 2009.@-@@@@COMBO@ENZASTAURIN@FULVESTRANT@@@@ENZASTAURIN|FULVESTRANT|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@LY-317615@@@@@LY-317615||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@COMPLETE RESPONSE@PARTIAL RESPONSE@STABLE DISEASE@@@STABLE DISEASE@@@@@METASTATIC@REFRACTORY@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922850@Onco@@@@@300f1018ntsdm@@@@@@-@@-@-@-@SEATTLE, WASHINGTON@@@GPx is the dominant catalytic antioxidant enzyme within the inner ear, and a loss of its activity results in irreparable damage to hair cells, neurons and non-sensory tissues that are critical for hearing and balance. SPI-3005 is designed to attenuate these side effects without inhibiting the therapeutic efficacy of platinum or taxane based chemotherapies,@@14922850@Advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy@@-@-@@NO REVIEW@@@-@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@IND filed with FDA. SOURCE: Sound, 23 July 2008@-@@@@MONO@EBSELEN@@@@@EBSELEN||||@SOUND PHARMACEUTICALS@@@@@SOUND PHARMACEUTICALS||||@@@@@@|||||||||@Supportive Care@Hearing Loss@Head & Neck Cancer@@@Supportive Care|Hearing Loss|Head & Neck Cancer|||||||@SPI-3005@@@@@SPI-3005||||@Other@@@@@Other||||@HEARING LOSS@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14924223@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BRISBANE, CALIFORNIA@@@@@14924223@BRCA-negative ovarian cancer@@-@-@@NO REVIEW@@@@-@Sanofi-Aventis acquires Bi-Par [Sanofi-Aventis 15 April 2009 http://en.sanofi-aventis.com/binaries/20090415_bipar_acquisition_en_tcm28-24863.pdf ]@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial started. SOURCE: BiPar, 8 May 2008@-@@@@-@-@@@@@-||||@BIPAR SCIENCES@SANOFI-AVENTIS@@@@BIPAR SCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@BSI-201@@@@@BSI-201||||@PARP Inhibitor@@@@@PARP Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924628@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@OvaRex with carboplatin and paclitaxel@@-@-@-@-@@@@@14924628@Newly diagnosed advanced ovarian cancer@@-@-@@NO REVIEW@@@@-@ViRexx partners the drug with United in the U.S. and Canada (via subsidiary United's subsidiary Unither Pharmaceuticals).@FIRST-LINE@NCT00086632@40@-@-@@@-@@@-@-@@-@40 PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER@@@II@II@@-@-@ASCO 2007; adding OvaRex to front-line chemotherapy improved clinical, cellular and humoral responses compared to patients receiving the drug as second-line treatment.@-@@@@COMBO@OREGOVOMAB@CARBOPLATIN@PACLITAXEL@@@OREGOVOMAB|CARBOPLATIN|PACLITAXEL||@UNITED THERAPEUTICS@VIREXX@@@@UNITED THERAPEUTICS|VIREXX|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@OVAREX@@@@@OVAREX||||@Immunotherapy@mAb@Murine@@@Immunotherapy|mAb|Murine||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@2@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921029@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Given as intravenous infusion weekly for two consecutive weeks every three weeks@@-@-@-@-@@@@@14921029@Immunoconjugate of cytotoxic maytansinoid drug DM1 with humanised monoclonal antibody huN901@@-@-@@NO REVIEW@@@@-@-@-@NCT00625508@35@-@-@@@-@@3/1/2005@-@IMMUNO-003@@-@-@@@, DFCI-05031; @I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@IMMUNOGEN@@@@@IMMUNOGEN||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@BB-10901@IMGN-901@@@@BB-10901|IMGN-901|||@mAb@Humanised@@@@mAb|Humanised|||@DOSE-LIMITING TOXICITY@@@@@@@@@@REFRACTORY@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16423928@Onco@@@@@@@@@@@Arm 1, Experimental, ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).Arm 2, Experimental, ABBV-428 plus nivolumab.Arm A, B, and C, Experimental, Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.Arm D, Experimental, Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.@@@@@UNITED STATES@4/1/2019@@@@16423928@A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors@Both@@@@@ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.@@@@@@NCT02955251@142@@@@@@@11/1/2016@@M15-819@@@Participants must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.  -  Participants have adequate bone marrow, renal, hepatic and coagulation function.  -  For all dose expansion arms, participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1  -  Participants in combination therapy cohorts must have an advanced solid tumor where the use of nivolumab is standard therapy.@@ADULTS@Phase 1@I@@@@@@@@@COMBO@-@NIVOLUMAB@@@@-|NIVOLUMAB|||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ABBV-428@OPDIVO@@@@ABBV-428|OPDIVO|||@Other@@@@@Other||||@Number of participants with adverse events@Maximum tolerated dose (MTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab@Maximum observed serum concentration (Cmax) of ABBV-428@@@Objective Response Rate (ORR)@Duration of Objective Response (DOR)@@@@ADVANCED@@@@@Non-Randomized@Safety Study@Single Group Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924884@Onco@@@@@@@@@@@S-1 versus Xeloda@@-@-@-@-@@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14924884@Gastric cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Phase II study shows overall response rate of 27% and 29% for S-1 and Xeloda (capecitabine) respectively; median TTP/overall survival was 4.2/8.2 months versus 4.7/9.5 months respectively (British Journal of Cancer, 2008, (99, 584-590). SOURCE: Taiho, 12 August 2008@-@@@@-@TEGAFUR GIMERACIL OTERACIL POTASSIUM @@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM ||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@S-1@@@@@S-1||||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916609@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@PX-478 given orally on days 1 to 5 in a 21-day cycle@@-@-@-@BELLEVUE, WASHINGTON@@@@@14916609@-@@-@-@@NO REVIEW@@@@-@Oncothyreon will restructure to focus on development of PX-478 and PX-866 following the transfer of manufacturing responsibilities of Stimuvax to Merck KGaA. [Oncothyreon, 20.12.2008]@-@NCT00522652@36@-@-@@@-@@8/1/2007@-@PX-478-001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ONCOTHYREON@@@@@ONCOTHYREON||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@PX-478@@@@@PX-478||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@PHARMACOKINETICS@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924498@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@WILMINGTON, DELAWARE@@@INCB18424 is Incyte's lead internally developed JAK inhibitor. The compound is a potent JAK inhibitor that is greater than 100 fold selective against a broad panel of kinases and is being developed as an oral treatment for MF, PV and ET, multiple myeloma, hormone refractory prostate cancer, and rheumatoid arthritis and as an oral and topical treatment for psoriasis.@@14924498@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@Trial to start in Q1 08@-@@@@-@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@INCB-18424@@@@@INCB-18424||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922754@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Experimental arm: Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses. Control group: Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly. @@@@@@6/1/2012@@AS101 is a tellurium based small compound with immunomodulating characteristics which attributed to the direct inhibition of the anti-inflammatory cytokine IL-10@@14922754@Phase II Open Study to Evaluate Safety and Efficacy of AS101 for the Treatment of Thrombocytopenia in Solid Tumor@@@@@NO REVIEW@@@@@@@NCT00926354@40@@@@@@@6/1/2009@@#71 REV 00@@@Appropriate histology of solid tumors. Platelet counts < 70,000/µl.@@@II@II@@@@Trial registered [Biomas 17 June 2009 ]@@@@@COMBO@AS101@@@@@AS101||||@BioMas@@@@@BioMas||||@@@@@@|||||||||@Solid Tumours@Thrombocytopaenia@Supportive Care@@@Solid Tumours|Thrombocytopaenia|Supportive Care|||||||@AS101@@@@@AS101||||@Other@@@@@Other||||@Incidence of thrombocytopenia events@@@@@SAFETY@@@@@@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@@@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920584@Onco@@@@@300f1014ntsdm@@@@@@NO LABELLED TRIAL@@L01XX05@L01X@NO@NEW YORK, NEW YORK@@@@@14920584@@@@@@NO REVIEW@@@@@@@@@Continuous therapy: Hydrea 20-30mg/kg should be given daily in single doses. Dosage should be based on the patient's actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts. Intermittent therapy: Hydrea 80mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Hydrea should be omitted.@1-Dec-67@12/1/1967@@@@@The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide therapy. If WBC falls below 2.5x109/L or platelet count to <100x109/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal. Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@RAMQ@NO LABELLED TRIAL@@@@@@HYDROXYUREA@@@@@HYDROXYUREA||||@BMS@@@@@BMS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@HYDREA@@@@@HYDREA||||@Anti-metabolite@@@@@Anti-metabolite||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@0.7881@102.03@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/19/2017@1.02@1.02@465283100@CAPSULE@C$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14919025@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@@@14919025@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@@@-@N/A@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@SP-1049C@@@@@SP-1049C||||@Other@@@@@Other||||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924736@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@N02AB03@N02A@-@-@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14924736@Cancer pain@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@RESULTS PENDING@-@@@@-@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@TANABE MITSUBISHI@@@@@TANABE MITSUBISHI||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@TA-8317@@@@@TA-8317||||@Opioid Analgesic@@@@@Opioid Analgesic||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL TRANSMUCOSAL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921767@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@SNX-1012 with multiple doses against placebo@@-@-@-@NEW YORK, NEW YORK@@@@@14921767@Oral mucositis in cancer@@-@-@@NO REVIEW@@@@-@Pfizer acquired Serenex for an undisclosed sum. SOURCE: Serenex, 3 March 2008 In September 2005, Serenex in-licensed worldwide rights to develop and commercialise SNX-1012 from Mucosal Therapeutics.@-@NCT00385515@960@-@-@@@-@@7/1/2006@-@CLN2-006@@-@-@@@II@II@@-@-@Due to complete trials in early 2008, delayed from initial expectation of early-2007.@-@@@@-@-@@@@@-||||@PFIZER@SERENEX@@@@PFIZER|SERENEX|||@@@@@@|||||||||@Supportive Care@Mucositis@@@@Supportive Care|Mucositis||||||||@SNX-1012@@@@@SNX-1012||||@Other@@@@@Other||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@PLACEBO-CONTROLLED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918782@Onco@@@@@300f1018ntsdm@@@@@@N/A@@-@-@-@-@@@@@14918782@Biliary cancer@@-@-@@NO REVIEW@@@@-@Marshall Edwards is a subsidiary of Novogen.@-@-@N/A@-@FDA orphan drug for Stage IIB-IV malignant melanoma. SOURCE: Novogen, 18 February 2008FDA orphan drug for pancreatic cancer and cholangiocarcinoma. SOURCE: 22 January 2008@2/18/2008@@FDA orphan drug for Stage IIB-IV malignant melanoma. SOURCE: Novogen, 18 February 2008FDA orphan drug for pancreatic cancer and cholangiocarcinoma. SOURCE: 22 January 2008@@@-@N/A@@-@-@@@I@I@@-@-@IND planned for mid-2008 and Phase Ib expected thereafter. SOURCE: Novogen@-@@@@-@TRIPHENIOL@@@@@TRIPHENIOL||||@NOVOGEN@MARSHALL EDWARDS@@@@NOVOGEN|MARSHALL EDWARDS|||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@NV-196@@@@@NV-196||||@MSTR@@@@@MSTR||||@PHARMACOKINETICS@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14924837@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Capecitabine and CPT-11 combination in a preoperative setting followed by chemoradiation with capecitabine@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924837@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00216086 @29@-@-@@@-@@1/1/2005@-@-@@-@-@@@II@II@@-@-@Not yet available.@-@@@@COMBO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@PFIZER@@@@ROCHE|PFIZER|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922680@Onco@@@@@@@@@@@Xeloda/enzastaurin versus Xeloda alone@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14922680@In combination with capecitabine@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00437294@120@-@-@@@-@@@-@10536H6Q-MC-S035  @@-@-@@@II@II@@-@-@Completion expected August 2009.@-@@@@COMBO@ENZASTAURIN@CAPECITABINE@@@@ENZASTAURIN|CAPECITABINE|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@LY-317615@XELODA@@@@LY-317615|XELODA|||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@CANCER TISSUE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923001@Onco@@@@@@@@@@@IMC-11F8 in combo with mFOLFOX6@@-@-@-@NEW YORK, NEW YORK@@@IMC-11F8 is a fully human IgG1 monoclonal antibody that blocks the ligand binding site of EGFR. The EGFR signaling network is involved in triggering and regulating the malignant growth of many EGFR-expressing epithelial tumors. Inhibition of the EGFR pathway in cells can result in disruption of cell cycle progression, mitosis, and potentiation of apoptosis. Decreased production of angiogenesis factors may occur as a result of EGFR inhibition. @@14923001@Treatment-naïve patients@@-@-@@NO REVIEW@@@STARTED IN AUGUST 2007@-@>> Acquisition completed. [Lilly, 24.11.2008]         >> Lilly acquires ImClone for US$6.5 billion. [Lilly, 7.10.2008]       >> BMS Offers US$4.3Billion for ImClone or US$60.0 per share in cash. [BMS, 1 August 2008]@FIRST-LINE@-@40@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Trial registered [ImClone, 9.08.2007]@-@@@@COMBO@-@@@@@-||||@IMCLONE@LILLY@@@@IMCLONE|LILLY|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@IMC-11F8@FOLFOX6@@@@IMC-11F8|FOLFOX6|||@TK Inhibitor@EGFR@mAb@Human@@TK Inhibitor|EGFR|mAb|Human|@SAFETY@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922029@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CEP-701 administered in sequence with standard chemotherapy@@-@-@-@FRAZER, PENNSYLVANIA@@@@@14922029@-@@-@-@@NO REVIEW@@@@-@Licensed from Kyowa Hakko; supplied by Abbott/TAP. Original licensing agreement with Schwarz Pharma terminated.@SECOND-LINE@NCT00079482@220@-@-@@@-@@10/1/2003@-@C701A204ONUS  @@-@-@@@II@II@@-@-@Completion expected in October 2008@-@@@@COMBO@LESTAURTINIB@@@@@LESTAURTINIB||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CEP-701@@@@@CEP-701||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16791365@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791365@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NA@@@NO REVIEW@@@@@@@@16@@EMA, 16 December 2016@12/16/2016@@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NA@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@3498.208@@@8@week@8 week@3498.21@3498.21@62.47@30@1.1511@4685.1@4930.65@4692.64@@@@@@@@@@0.52@1@@mg/m²@100@1@@@@@@@@@@@8/4/2017@156.17@156.17@688241@FILM-COATED TABLET@EURO@@@@@@@@300@MG@300 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14921569@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@SUMMIT, NEW JERSEY@3/1/2004@@@@14921569@Cancer fatigue in adult patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00047476@160@-@-@@@-@@6/1/2002@-@d-MPH-COG-002@@-@-@@@II@II@@-@-@Celgene continues to weigh its options on this indication, which is supplemental to a core ADHD setting, and maintains its licensing rights for it.@-@@@@MONO@DEXMETHYLPHENIDATE HYDROCHLORIDE@@@@@DEXMETHYLPHENIDATE HYDROCHLORIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Supportive Care@Cancer Fatigue@@@@Supportive Care|Cancer Fatigue||||||||@FOCALIN@@@@@FOCALIN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924892@Onco@@@@@@@@@@@MK-457 as a 5-day IV infusion every 2-3 weeks@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@@@14924892@Treatment-resistant CML and Ph+ ALL@@-@-@@NO REVIEW@@@@-@Merck & Co licensed rights to develop and commercialised MK-457 and other follow-on Aurora kinase inhibitors in June 2004.@MULTIPLE@-@270@-@The trial was designed to support registration of MK-0457 (VX-680) in one or more cancer indications for which there is currently little or no effective treatment.@@@-@@12/1/2006@-@-@@-@-@@@II@CLINICAL HOLD@@-@-@Trial suspended by Merck in November 2007 pending full analysis of all efficacy and safety data. Preliminary data saw one case of QTc prolongation.@-@@@@MONO@-@@@@@-||||@MERCK & CO@VERTEX@@@@MERCK & CO|VERTEX|||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@Acute Lymphocytic Leukaemia@@@Haematological Malignancy|Chronic Myeloid Leukaemia|Acute Lymphocytic Leukaemia|||||||@VX-680@MK-457@@@@VX-680|MK-457|||@Aurora Kinase Inhibitor@bcr-abl@@@@Aurora Kinase Inhibitor|bcr-abl|||@SAFETY@@@@@@@@@@ADVANCED@@@@@PIVOTAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16406122@Onco@@@@@@@@@@@Nivolumab and Ipilimumab Combination, Active Comparator, Nivolumab and Ipilimumab CombinationNivolumab and BMS-986016 Combination, Experimental, Nivolumab and BMS-986016 Combination@@L01XC17@L01X@@NEW YORK, NEW YORK@11/1/2021@@@@16406122@A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)@Both@@@@@@@@@@-@NCT02935634@910@@@@@@@11/1/2016@@CA018-003@@@Advanced Gastric Cancer  -  Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work  -  Must have at least 1 lesion with measurable disease@@ADULTS@Phase 2@II@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@-@@@NIVOLUMAB|IPILIMUMAB|-||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@GIST@@@@@GIST|||||||||@OPDIVO@YERVOY@BMS-986016@@@OPDIVO|YERVOY|BMS-986016||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Objective Response Rate (ORR)@Duration of Response (DOR)@Progression-free Survival Rate (PFSR)@@@Incidence of Adverse Events (AEs)@Incidence of Serious Adverse Events (SAEs)@@@@ADVANCED@@@@@Randomized@Safety/Efficacy Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922641@Onco@@@@@@@@@@@Patients received Iressa with 5-FU, leucovorin and radiotherapy@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@2/1/2004@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14922641@Resectable gastric cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00237900@34@-@-@@@-@@7/1/2003@-@1839IL0539  @@-@-@@@I/II@DISCONTINUED@@-@-@19 adverse events recorded, 12 of which considered related. 7 serious events (2 nausea). Study was terminated early due to the toxicity.@-@@@@COMBO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Finland@@@@@Finland|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918999@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@NEW YORK, NEW YORK@@@@@14918999@Advanced cancer@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@7/1/2007@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-337210@@@@@PF-337210||||@VEGF@TK Inhibitor@Angiogenesis Inhibitor@@@VEGF|TK Inhibitor|Angiogenesis Inhibitor||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922613@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-510 in patients with incurable head and neck cancer@@-@-@-@UNITED STATES@@@A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). @@14922613@ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer @@-@-@@NO REVIEW@@@@-@-@-@NCT00113334@37@-@-@@@-@@4/1/2005@-@2003-1027@@-@-@@@IB/II@II@@-@-@Trial registered [Abbott, 7.06.2005]@-@@@@MONO@THROMBOSPONDIN@@@@@THROMBOSPONDIN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ABT-510@@@@@ABT-510||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15255112@Onco@@@@@300f1008ntsdm@@@@@@@@L01XC17@L01X@@OSAKA, JAPAN@@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-expressed ligands, programmed death-ligand 1 (PD-L1/B7-H1) and PD-L2 (B7-DC). Blocking of the interaction of the PD-1 receptor with its ligands may allow T-cells to elicit an anti-tumor immune response.@@15255112@Indicated for the treatment of patients with unresectable melanoma@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@35@@MHLW, 1 September 2014@9/1/2014@9/1/2014@Yes@@@@@No@@@@@III@APPROVED@@@NHI@@@@@@@NIVOLUMAB@@@@@NIVOLUMAB||||@ONO PHARMACEUTICALS@@@@@ONO PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@@@@@@@@@@@UNRESECTABLE@@@@@@@@@@76.5@kg@7761983.485@@@11@month@11 month@7761983.48@7761983.48@23199.46@1@0.0091@63684.8@75100@@@@@@@@@@@3184.24@21@@mg/kg@2@1@@@@@@@@@@@8/30/2017@63684.8@63684.8@4291427A1024@INTRAVENOUS INFUSION 2 ML@YEN@@@@@@@@20@MG@10 MG/ML@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
16624510@Onco@@@@@@@@@@@Investigational immunotherapy, Experimental, Specified Dose of nivolumab and ipilimumab on Specified DaysStandard of care chemotherapy, Active Comparator, Specified Dose of Gemcitabine / cisplatin or Gemcitabine / carboplatin on Specified Days@@L01XC17@L01X@@NEW YORK, NEW YORK@8/26/2020@@@@16624510@A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer@Both@@@@@Specified Dose on Specified Days@@@@@FIRST-LINE@NCT03036098@690@@@@@@@@@CA209-901@@@For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  -  Metastatic or inoperable urothelial cancer  -  Must have at least 1 lesion with measurable disease  -  Must have full activity or, if limited, must be able to walk and carry out activities such as light house work or office work  -  No prior systemic chemotherapy treatment in the metastatic setting@@ADULTS@Phase 3@III@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Progression free survival (PFS) in cisplatin-ineligible participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)@Overall survival (OS) of cisplatin-ineligible participants@@@@Progression free survival (PFS) in all participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)@Overall survival (OS) in all participants@@@@METASTATIC@UNRESECTABLE@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918905@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918905@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008"@-@-@30-40@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FPI Q4 08@-@@@@COMBO@-@LENALIDOMIDE@DEXAMETHASONE@@@-|LENALIDOMIDE|DEXAMETHASONE||@GENENTECH@@@@@GENENTECH||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ANTI-CD40@REVLIMID@@@@ANTI-CD40|REVLIMID|||@mAb@CD40@@@@mAb|CD40|||@-@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920914@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are given karenitecin@@-@-@-@SAN ANTONIO, TEXAS@@@@@14920914@Patients with relapsed or refractory NSCLC or solid tumours@@-@-@@NO REVIEW@@@@-@-@-@NCT00097903@-@-@-@@@-@@@-@KTN22208@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@KARENITECIN@@@@@KARENITECIN||||@BIONUMERIK@@@@@BIONUMERIK||||@@@@@@|||||||||@NSCLC@Solid Tumours@@@@NSCLC|Solid Tumours||||||||@BNP-1350@@@@@BNP-1350||||@Camptothecin@Topoisomerase I Inhibitor@@@@Camptothecin|Topoisomerase I Inhibitor|||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924150@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@TORONTO, CANADA@@@AE37 is designed to stimulate an immune response against the tumor-causing gene HER-2/neu, which occurs in a significant percentage of patients with breast cancer as well as other cancers. A robust immune response against HER-2/neu has the potential to destroy tumor cells even at sites in the body distant from the primary tumor.@@14924150@Safety and immunological response of breast and ovarian cancer patients to a combination of AE37 plus a peptide vaccine designed to stimulate cytotoxic T lymphocytes (CTL)@@-@-@@NO REVIEW@@@@-@Antigen Express is a subsidiary of Generex.@-@-@-@-@-@@@-@@8/1/2008@-@-@@-@-@@@I@I@@-@-@>>First patient dosed. [Generex 3 March 2009]>>Trial started. SOURCE: Generex, 8 August 2008>>Investigational NDA filed. SOURCE: Generex, 9 July 2008@-@@@@COMBO@-@@@@@-||||@GENEREX@ANTIGEN EXPRESS@@@@GENEREX|ANTIGEN EXPRESS|||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@@@@Breast Cancer|Ovarian Cancer||||||||@AE-37@PEPTIDE VACCINE@@@@AE-37|PEPTIDE VACCINE|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924613@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oncophage once weekly for four weeks followed by biweekly injections until vaccine depletion.@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14924613@Recurrent glioma@@-@-@@NO REVIEW@@@@-@-@-@-@30@-@-@@@-@@@-@-@@-@-@@@ABTA/NCI-sponsored trial@III@@-@-@Preliminary Phase 1 results were presented at the 75th annual meeting of the American Association of Neurological Surgeons in April 2007 and showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline (P < .001).@-@@@@-@VITESPAN@@@@@VITESPAN||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@OVERALL SURVIVAL@@@@@@@@@@RELAPSED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916019@Onco@@@@@@@@@@@Arm A: Irinotecan (65mg/m2 day 1 and 8) with cisplatin Arm B: Etoposide 100mg/m2 days 1,2 and 3 with cisplatin@@L01XX19@L01X@-@NEW YORK, NEW YORK@12/1/2010@@Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.@@14916019@Irinotecan Hydrochloride And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer@@-@-@@NO REVIEW@@@@-@Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan@FIRST-LINE@NCT00143455@406@-@-@@@-@@6/1/2002@-@XRP4174D-3001@@-@Histologically or cytologically proven Small Cell Lung Cancer (SCLC)  WHO performance status : 0, 1@@@III@III@@-@BNF@RESULTS PENDING@-@@@@COMBO@IRINOTECAN@CISPLATIN@@@@IRINOTECAN|CISPLATIN|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@CAMPTOSAR@CAMPTO@@@@CAMPTOSAR|CAMPTO|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@OVERALL SURVIVAL@-@@@@TOLERABILITY@RESPONSE RATE@QUALITY OF LIFE@@@EXTENSIVE@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15413050@Onco@@@@@@@@@@@tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD).@@@@@LONDON, UNITED KINGDOM@5/1/2018@@@@15413050@UBC (Urothelial Bladder Cancer)/ TNBC (Triple-negative Breast Cancer)/ PDAC (Pancreatic Ductal Adenocarcinoma)@Both@@@@@@@912@@@@NCT02527434@77@@@@@@@11/1/2015@@D4884C00001, 2015-002934-32@@@Histologically or cytologically documented solid tumor malignancies, including but not limited to 1 of the following: UBC, Metastatic PDAC, TNBC; 2. Are intolerant, are ineligible for, or have refused treatment with standard first-line therapy; 3. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with computed tomography (CT) (preferred) or magnetic resonance imaging (MRI) scans and that is suitable for accurate repeated measurements.@MONO@ADULTS@Phase 2@II@@@@Overall Survival@@@@@@TREMELIMUMAB@@@@@TREMELIMUMAB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@United States@Belgium@South Korea@Netherlands@Poland@United States|Belgium|South Korea|Netherlands|Poland|||||@Bladder Cancer@Breast Cancer@Pancreatic Cancer@@@Bladder Cancer|Breast Cancer|Pancreatic Cancer|||||||@MEDI-4736@@@@@MEDI-4736||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Objective response rate@@@@@DURATION OF RESPONSE@DISEASE CONTROL RATE@PROGRESSION-FREE SURVIVAL@@@ADVANCED@@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922144@Onco@@@@@@@@@@@Ertumaxomab will be administered as a 3-hour constant rate infusion with a dosing interval of 7 days. Each patient will participate in this study for up to 7 months (includes the up to 21 days screening period, 14 days treatment period, and up to 180 days/6 months follow-up), with 3-monthly post-study follow-up until the patient becomes progressive. [clinicaltrials.gov]@@-@-@-@-@@@Ertumaxomab is a trifunctional bispecific antibody targeting Her-2/neu on tumor cells and CD3 on T cells. Trifunctional antibodies represent a new concept for targeted anticancer therapy. This new antibody class has the capability to redirect T cells and accessory immune effector cells (e.g. macrophages, dendritic cells [DCs] and natural killer [NK] cells) to the tumor site. According to preclinical data, trifunctional antibodies activate these immune cells, which can trigger a complex anti-tumor immune response.@@14922144@Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer@@-@-@@NO REVIEW@@@JULY 2006-@-@-@SECOND-LINE@NCT00351858@40@-@-@@@-@@@-@BC-02@@-@Metastatic (stage IV) and not curable adenocarcinoma of the breast HER-2 overexpression 3+ or 2+ FISH positive @@@II@II@@-@-@Trial registered [Fresenius, 12.06.2006]@-@@@@-@ERTUMAXOMAB@@@@@ERTUMAXOMAB||||@FRESENIUS BIOTECH@@@@@FRESENIUS BIOTECH||||@@@@@@|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@-@@@@@-||||@mAb@HER2@@@@mAb|HER2|||@RESPONSE RATE@@@@@TIME TO PROGRESSION@DURATION OF RESPONSE@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917749@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N02AB03@N02A@@CORONA, CALIFORNIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14917749@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@Authorised generic of Actiq@@@@@FDA, 6 September 2006@9/6/2006@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@WATSON PHARMACEUTICALS@CEPHALON@@@@WATSON PHARMACEUTICALS|CEPHALON|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@4105@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@136.83@136.83@63459-0512-30@LOZENGE@US$@@@@@@@@1200@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924485@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Hu3S193 alone@@-@-@-@-@@@@@14924485@Ovarian epithelial, primary peritoneal or fallopian tube cancer in platinum refractory or resistant patients@@-@-@@NO REVIEW@@@@-@-@MULTIPLE@NCT00617773@56@-@-@@@-@@3/1/2008@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@RECEPTA BIOPHARMA@@@@@RECEPTA BIOPHARMA||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@HU3S193@@@@@HU3S193||||@mAb@Humanised@@@@mAb|Humanised|||@RECIST@CA125 RESPONSE@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16511652@Onco@@@@@@@@@@@"Isatuximab, Experimental, Isatuximab administration every week for 4 or 8 weeks (Induction), followed by administration every 2 weeks (Maintenance). Dexamethasone, acetaminophen, ranitidine, and diphenhydramine will be administered as premedications. - Type: Experimental"@@@@@PARIS, FRANCE@7/1/2020@@@@16511652@Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)@Both@@@@@Pharmaceutical form:solution Route of administration: intravenous@@@@@SECOND/THIRD LINE@NCT02999633@39@@@@@@@1/1/2017@@ACT14596@@@-  Patients must have a known diagnosis of ALL of T cell origin, including T-LBL and T-ALL with extramedullary involvement at relapse confirmed by biopsy.  -  Patients must be previously treated for T-ALL or T-LBL and have relapsed or are refractory to mo@@16 Years - N/A@Phase 2@II@@@@@@@@@MONO@ISATUXIMAB@@@@@ISATUXIMAB||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Acute Lymphocytic Leukaemia@@@@@Acute Lymphocytic Leukaemia|||||||||@SAR650984@@@@@SAR650984||||@Other@@@@@Other||||@Objective response rate@@@@@Duration of response - time@Progression free survival - time@@@@@@@@@Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16446193@Onco@@@@@@@@@@@"SAR566658 (Part 1), Experimental, SAR566658 will be given as Dose 1 (cohort 1) and Dose 2 (cohort 2) at Day 1 and Day 8 every 3 weeks intravenouslySAR566658 (Part 2), Experimental, SAR566658 (Part 2) - SAR566658 will be given as Dose 1 or Dose 2 (depending on dose level selected from part 1) at Day 1 and Day 8 every 3 weeks intravenously"@@@@@PARIS, FRANCE@1/1/2019@@@@16446193@Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer@Both@@@@@Pharmaceutical form:Solution Route of administration: Intravenous@@@@@SECOND-LINE@NCT02984683@62@@@@@@@1/1/2017@@ACT14884@@@-  Measurable Metastatic triple negative breast cancer (TNBC).  -  Patients with CA6-positive disease.  -  Patients received at least 1 prior chemotherapy regimen but no more than 3 for advanced/metastatic disease.  -  Prior anticancer therapy must have c@CA6-positive@ADULTS@Phase 2@II@@@@@@@@@MONO@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SAR566658 (ACT14884)@@@@@SAR566658 (ACT14884)||||@Other@@@@@Other||||@Objective response rate (ORR)@@@@@Disease control rate@Duration of response - time@@@@METASTATIC@@@@@Randomized@Safety/Efficacy Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924883@Onco@@@@@@@@@@@ONTAK monotherapy@@L01XX29@L01X@-@TOKYO, JAPAN@@@Ontak is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. ONTAK is a genetically-engineered cytotoxic fusion protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, resulting in a molecule that is cytotoxic for cells bearing the target IL-2 receptor. Ontak was granted approval in February 1999 under Subpart E, an FDA regulation that allows the accelerated approval of a biologic agent based on a surrogate endpoint or an effect on a clinical endpoint other than survival. The process by which Ontak received accelerated approval requires a confirmatory, placebo-controlled Phase III trial. Accelerated approval is most commonly granted in serious diseases or for medications that fill an unmet medical need. @@14924883@Previously treated CLL@@-@-@@NO REVIEW@@@@-@Global rights licensed from Ligand in September 2006@SECOND-LINE@NCT00055146@41@-@-@@@-@@3/1/2003@-@-@@2014@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@DENILEUKIN DIFTITOX@@@@@DENILEUKIN DIFTITOX||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ONTAK@@@@@ONTAK||||@Interleukin@@@@@Interleukin||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924241@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Coramsine infusion over 12-week cycle@@-@-@-@-@@@@@14924241@-@@-@-@@NO REVIEW@@@@-@-@-@-@80-90@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING; trial suspended in November 2006 but  new development plan approved with TGA in May 2007@-@@@@-@SOLASONINE AND SOLAMARGINE@@@@@SOLASONINE AND SOLAMARGINE||||@SOLBEC PHARMACEUTICALS@@@@@SOLBEC PHARMACEUTICALS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@Melanoma / Skin Cancer@@@Kidney Cancer|Renal Cell Carcinoma|Melanoma / Skin Cancer|||||||@CORAMSINE@@@@@CORAMSINE||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921189@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@TNFerade combo with Xeloda and radiation therapy followed by surgical resection; versus Xeloda and radiation therapy followed by surgical resection@@-@-@-@-@@@@@14921189@Preoperative chemoradiotherapy; combo with Xeloda@@-@-@@NO REVIEW@@@@-@-@-@NCT00137878@-@-@-@@@-@@@-@GV-001.007@@-@-@@@II@II@@-@-@The treatment was both feasible and appeared to be well tolerated. Prior to treatment, four of the seven patients were classified as highly likely to need sphincter removing surgerywith colostomy. Subsequent to TNFerade plus chemoradiation, all seven patients who underwent surgical resection had successful sphincter sparing procedures. Five of the seven patients achieved pathological complete response. Based on these preliminary data, the NCI study is continuing to enroll more patients. SOURCE: GenVec/American Society for Therapeutic Radiology and Oncology, 31 October 2007@-@@@@COMBO@-@CAPECITABINE@@@@-|CAPECITABINE|||@GENVEC@@@@@GENVEC||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@TNFERADE@XELODA@@@@TNFERADE|XELODA|||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918237@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14918237@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@EBEWE PHARMA@@@@@EBEWE PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9301393T@POWDER FOR SOLUTION FOR PERFUSION, 20 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14923990@Onco@@@@@300f1020ntsdm@@@@@@Uftoral/calcium folinate versus Mayo regimen/calcium folinate@@L01BC53@L01B@-@DARMSTADT, GERMANY@@@@@14923990@First-line treatment of metastatic colorectal cancer with calcium folinate.@@NO@-@@NO REVIEW@@@@100%@-@-@-@1196@The dose of Uftoral is 300 mg/m2/day tegafur and 672 mg/m2/day uracil combined with 90 mg/day oral calcium folinate, given in three divided doses (preferably every 8 hours). Calcium folinate should be taken at the same time as Uftoral. Doses should be taken at least one hour before or one hour after meals for 28 consecutive days.@N/A@@@-@@@-@LABEL@No@-@1196 [METASTATIC COLORECTAL CANCER]@@@III STUDY-011 AND STUDY-012@DISCONTINUED@@@SSN@The median survival time was 12.4 months (95% CI: 11.2-13.6 months) and 13.4 months in the Uftoral/calcium folinate and the 5FU/calcium folinate treatment groups, respectively (Study-011). The median TTP was 3.4 months and 3.3 months respectively.@-@@@@COMBO@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFT@MAYO REGIMEN@@@@UFT|MAYO REGIMEN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@36@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@4/30/2013@@@34864052@HARD CAPSULE@EURO@@@@@@@@@@100 MG|224 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924551@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Talampanel alone@@-@-@-@PETACH TIKVA, ISRAEL@@@@@14924551@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Ivax, which licensed it from Lilly@SECOND-LINE@NCT00062504@91@-@-@@@-@@@-@-@@-@91 PATIENTS WITH HIGH GRADE GLIOMAS @@@II@II@@-@-@RESULTS PENDING Previous epilepsy studies have shown an MTD of 100mg and plasma elimination half-life of 6.8 hours. @-@@@@MONO@TALAMPANEL@@@@@TALAMPANEL||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@LY-300164@@@@@LY-300164||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918991@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@OncoVEX combined with chemo and radiation@@-@-@-@WOBURN, MASSACHUSSETTS@@@@@14918991@Combo with first-line chemotherapy and radiation@@-@-@@NO REVIEW@@@@-@-@-@-@50@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@Among 43 of 50 patients, OncoVex patients responded; there were 6 complete responses, 5 of which are still ongoing at 4-27 months. SOURCE: BioVex, 3 June 2008@-@@@@COMBO@-@@@@@-||||@BIOVEX@@@@@BIOVEX||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@ONCOVEX@GM-CSF@@@@ONCOVEX|GM-CSF|||@Gene Therapy@Immunotherapy@@@@Gene Therapy|Immunotherapy|||@TOLERABILITY@@@@@@@@@@LOCALLY ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924590@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral AE-941 twice daily every 4 weeks@@-@-@-@QUEBEC, QUEBEC@@@@@14924590@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00022282@-@-@-@@@-@@4/1/2001@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@AE-941@@@@@AE-941||||@AETERNA ZENTARIS@@@@@AETERNA ZENTARIS||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@NEOVASTAT@@@@@NEOVASTAT||||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@RESPONSE RATE@SAFETY@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922646@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Lumiliximab in combination with fludarabine, cyclophosphamide and Rituxan@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@12/1/2008@@@@14922646@-@@-@-@@NO REVIEW@@@@-@Biogen Idec and Seikagaku terminated their development partnership for lumiliximab for a variety of indications in January 2004.@-@NCT00103558@37@-@-@@@-@@3/1/2004@-@152-30@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@LUMILIXIMAB@RITUXIMAB@FLUDARABINE@CYCLOPHOSPHAMIDE@@LUMILIXIMAB|RITUXIMAB|FLUDARABINE|CYCLOPHOSPHAMIDE|@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@ANTI-CD23 MAB@RITUXAN@FCR@@@ANTI-CD23 MAB|RITUXAN|FCR||@mAb@Chimeric@CD23@@@mAb|Chimeric|CD23||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919276@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@OMP-21M18  0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression [OncoMed]@@-@-@-@-@11/1/2009@@-@@14919276@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00744562@30@-@FDA orphan drug. SOURCE: ActivBiotics press release, 6 March 2008EMEA COMP orphan drug. SOURCE: ActivBiotics, 5 February 2008@3/6/2008@@-@@8/1/2008@-@M18-001@@-@>> Subjects must have a histologically confirmed malignancy that is metastatic or unresectable for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit. In addition, subjects must have a tumor that is at least 2 x 2 cm and is radiographically apparent on CT or MRI. >> Subjects must have received their last chemotherapy, biologic, or investigational therapy at least 4 weeks prior to enrollment, 6 weeks if the last regimen included BCNU or mitomycin C.@@@I@I@@-@-@Trial registered. [OncoMed, 29.08.2008]@-@@@@-@-@@@@@-||||@ONCOMED PHARMACEUTICALS@@@@@ONCOMED PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OMP-21M18@@@@@OMP-21M18||||@Other@@@@@Other||||@SAFETY@@@@@PHARMACOKINETICS@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924838@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administration of Xeloda and Oxaliplatin @@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924838@Patients with metastatic or unresectable gastric or gastroesophageal junction cancer@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00183898@53@-@-@@@-@@12/1/2004@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@CAPECITABINE@OXALIPLATIN@@@@CAPECITABINE|OXALIPLATIN|||@ROCHE@SANOFI-AVENTIS@@@@ROCHE|SANOFI-AVENTIS|||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@XELODA@ELOXATIN@@@@XELODA|ELOXATIN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917747@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N02AB03@N02A@@CORONA, CALIFORNIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14917747@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@Authorised generic of Actiq@@@@@FDA, 6 September 2006@9/6/2006@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@WATSON PHARMACEUTICALS@CEPHALON@@@@WATSON PHARMACEUTICALS|CEPHALON|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@2668@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@88.93@88.93@63459-0506-30@LOZENGE@US$@@@@@@@@600@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923023@Onco@@@@@@@@@@@-@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14923023@-@@-@-@@NO REVIEW@@@-@-@-@-@-@-@initial 175 mg doses to the efficacy outcome is currently not known.@>> Merck withdraws EU application following provisional review. [Merck & Co, 18 February 2009]>> MAA filed in November 2007. [Merck & Co, 26 November 2007]@2/18/2009@@-@@@-@-@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@VORINOSTAT@@@@@VORINOSTAT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@ZOLINZA@@@@@ZOLINZA||||@HDAC@@@@@HDAC||||@-@@@@@@@@@@ADVANCED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921099@Onco@@@@@300f1012ntsdm@@@@@@As the preference of elderly patients for IV or oral administration is not known, the mode of application of ibandronate will be according to their choice.@@-@-@-@BASEL, SWITZERLAND@10/1/2010@@@@14921099@Ibandronate with or without capecitabine in elderly patients with early breast cancer @@-@-@@NO REVIEW@@@@-@Licensed from SmithKline Beecham in January 2001 in exchange for North American rights to Coreg@-@NCT00196859,@1500@-@-@@@-@@6/1/2004@-@ICE@@-@1500 female patients aged 65 years or over@ELDERLY@@III@III@@-@-@Not yet available@-@@@@COMBO@IBANDRONATE@@@@@IBANDRONATE||||@ROCHE@ASTRAZENECA@@@@ROCHE|ASTRAZENECA|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@BONDRONAT@@@@@BONDRONAT||||@Bisphosphonate@@@@@Bisphosphonate||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@EARLY@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14916446@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients with hepatoblastoma being treated with cisplatin given STS@@-@-@-@DURHAM, NORTH CAROLINA@@@@@14916446@Platinum-based chemotherapy-induced hearing loss@@-@-@@NO REVIEW@@@@-@Licensed from OHSU@-@-@100@-@RECEIVED FDA ORPHAN DRUG DESIGNATION IN THE PREVENTION OF PLATINUM-INDUCED OTOTOXICITY IN PAEDIATRIC PATIENTS.@@@RECEIVED FDA ORPHAN DRUG DESIGNATION IN THE PREVENTION OF PLATINUM-INDUCED OTOTOXICITY IN PAEDIATRIC PATIENTS.@@10/1/2007@-@SIOPEL@@-@-@@@III@III@@-@-@Trial activated. SOURCE: Adherex, 26 March 2008@-@@@@MONO@SODIUM THIOSULFATE@@@@@SODIUM THIOSULFATE||||@ADHEREX TECHNOLOGIES@@@@@ADHEREX TECHNOLOGIES||||@@@@@@|||||||||@Supportive Care@Hearing Loss@@@@Supportive Care|Hearing Loss||||||||@STS@@@@@STS||||@Other@@@@@Other||||@OTOXICITY@@@@@@@@@@-@@@@@MULTI-CENTRE@PROSPECTIVE@RANDOMISED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919026@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@SP1049C plus BSC versus BSC alone@@-@-@-@MONTREAL, CANADA@@@@@14919026@Advanced adenocarcinoma of the oesophagus, gastroesophageal junction and stomach in patients who have failed adjuvant or 1st or 2nd line therapy@@-@-@@NO REVIEW@@@@-@-@-@-@300@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@@@-@N/A@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Stomach Cancer@Oesophageal Cancer@@@@Stomach Cancer|Oesophageal Cancer||||||||@SP-1049C@@@@@SP-1049C||||@Other@@@@@Other||||@N/A@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921912@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BMS-663513 0.1MG/KG 0.3, 1.3, 6 or 10MG/KG q 3 weeks, 12 weeks@@-@-@-@WILMINGTON, DELAWARE@1/1/2012@@@@14921912@Combo with either radiotherapy or radiotherapy plus paclitaxel and carboplatin@@-@-@@NO REVIEW@@@@-@-@-@NCT00461110@68@-@-@@@-@@12/1/2007@-@CA186-005@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@INCYTE CORP.@@@@@INCYTE CORP.||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@INCB-7839@@@@@INCB-7839||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@SAFETY@TOLERABILITY@@@TOLERABILITY@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921908@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit @@-@-@-@NEW YORK, NEW YORK@12/1/2009@@@@14921908@Hedgehog pathway inhibitor@@-@-@@NO REVIEW@@@@-@-@-@NCT00670189@60@-@-@@@-@@6/1/2008@-@CA194-002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BMS@@@@@BMS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BMS-833923@XL-139@@@@BMS-833923|XL-139|||@Other@@@@@Other||||@SAFETY@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916477@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Every 21 days. Dose Escalating. 2 hour infusion@@L01XC12@L01X@-@SEATTLE, WASHINGTON@9/1/2008@@@@14916477@CD30-positive haematological malignancies@@@@@NO REVIEW@@@@@@@NCT00430846@51@-@A special protocol assessment has been agreed on for the design of the study [Seattle Genetics, 22.01.2009]@@@@@11/1/2006@-@SG035-0001@@@-@@@I@I@@@@RESULTS PENDING@Trial initiated [Seattle Genetics 19 February 2009]@@@@MONO@BRENTUXIMAB@@@@@BRENTUXIMAB||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@Non-Hodgkin's Lymphoma@@@Haematological Malignancy|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|||||||@ADCETRIS@@@@@ADCETRIS||||@Other@CD30@@@@Other|CD30|||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INTRAVENOUS@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921828@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BUFFALO, NEW YORK@1/1/2008@@@@14921828@Androgen-Independent Prostate Cancer@@-@February 1998 (FDA)@@NO REVIEW@@@@-@-@-@NCT00417274@30@-@On 5 September 2007 AGI Dermatics announced that T4N5 (DIMERICINE) has been granted Fast Track status by the US FDA for the treatment of solar and ultraviolet photosensitivity in patients with xeroderma pigmentosum (XP).@9/5/2007@@-@@12/1/2006@-@CBL-DD-05-C-H-2003@@-@-@@@II@II@@-@-@Enrolment completed. SOURCE: Cleveland, 7 May 2008@-@@@@MONO@QUINACRINE@@@@@QUINACRINE||||@CLEVELAND BIOLABS@@@@@CLEVELAND BIOLABS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@CURAXIN@@@@@CURAXIN||||@Other@@@@@Other||||@PSA@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916795@Onco@@@@@300f1018ntsdm@@@@@@NPI-0052 IV weekly vorinostat oral daily @@-@-@-@SAN DIEGO, CALIFORNIA@9/1/2009@@@@14916795@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00667082@40@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@3/1/2008@-@NPI-0052-103@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@VORINOSTAT@@@@-|VORINOSTAT|||@NEREUS PHARMACEUTICALS@@@@@NEREUS PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@Pancreatic Cancer@Melanoma / Skin Cancer@@@NSCLC|Pancreatic Cancer|Melanoma / Skin Cancer|||||||@NPI-0052@ZOLINZA@@@@NPI-0052|ZOLINZA|||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@MAXIMUM TOLERATED DOSE@RPD2@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14923777@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@NEW YORK, NEW YORK@@@@@14923777@Recommended as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women when hormonal therapy is indicated. It may also be used in women who were diagnosed as having had disseminated breast carcinoma when premenopausal, in whom ovarian function has been subsequently terminated. It was found to be effective in approximately 15% of patients with advanced or disseminated mammary cancer evaluated according to the following criteria: 1) those with a measurable decrease in size of all demonstrable tumour masses; 2) those in whom more than 50% of non-osseous lesions decreased in size although all bone lesions remained static; and 3) those in whom more than 50% of total lesions improved while the remainder were static.@@@temporary authorization in France@@NO REVIEW@@@@@@@@@The recommended oral dose is 250 mg qid. In order to evaluate the response, therapy with testolactone should be continued for a minimum of three months unless there is active progression of the disease.@@@@@@@NONE@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@TESTOLACTONE@@@@@TESTOLACTONE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@TESLAC@@@@@TESLAC||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922303@Onco@@@@@@@@@@@Patients will be randomized 2-to-1 in favor of Alpharadin, which will be given as six injections of 50 kBq/kg body weight, four weeks apart. SOURCE: Algeta@@-@-@-@KJELSAS, NORWAY@@@Algeta's lead product based on the alpha emitter technology is Alpharadin, a product being developed as a new treatment for skeletal metastases in patients with late-stage, hormone refractory prostate cancer (HRPC). Alpharadin (radium-223 chloride) is a unique targeted therapeutic in phase III clinical trials for the treatment for HRPC that has metastasized to the skeleton.@@14922303@Patients with skeletal metastases from HRPC.@@-@-@@NO REVIEW@@@6 MONTHS@-@-@-@-@750@-@-@@@-@@@-@ALSYMPCA@@-@-@@@III@III@@-@-@>>Patient from the US will now be included in the trial. [Algeta 3 February 2009]>>Patient recruitment for 750 patients started. [Algeta, 18 June 2008]>>Trial design approved for 450 patients. [Algeta, 20 December 2007]@-@@@@COMBO@-@@@@@-||||@ALGETA@@@@@ALGETA||||@@@@@@|||||||||@Prostate Cancer@HRPC@Bone Metastases@@@Prostate Cancer|HRPC|Bone Metastases|||||||@ALPHARADIN@@@@@ALPHARADIN||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@PSA@@@@@REFRACTORY@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@PIVOTAL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921070@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ILX651 IV daily for 5 consecutive days once every 3 weeks@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14921070@Hormone refractory prostate cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Ilex in 2004@-@NCT00082134@40@-@-@@@-@@@-@ILX651-241@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TASIDOTIN@@@@@TASIDOTIN||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ILX-651@@@@@ILX-651||||@Depsipeptide@@@@@Depsipeptide||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922250@Onco@@@@@300f1012ntsdm@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@12/1/2006@@Bendamustine is an alkylating that is a bifunctional mechlorethamine derivative. Mechlorethamine and its derivatives dissociate into electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties. The bifunctional covalent linkage can lead to cell death via several pathways. The exact mechanism of action of bendamustine remains unknown. Bendamustine is active against both quiescent and dividing cells.@@14922250@Bendamustine in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy@@-@-@@NO REVIEW@@@@-@Cephalon acquired U.S. rights through takeover of Salmedix, which licensed it from Fujisawa (Astellas. It is marketed by MundiPharma as Ribomustin in Germany as a single or combination agent for indolent NHL, MM and CLL under the name Ribomustin. SymBio h@-@NCT00168922@50@-@-@@@-@@2/1/2001@-@AS 02@@-@-@@@II@II@@-@-@Trial registered. [Ribosepharm, 9.09.2005]@-@@@@MONO@BENDAMUSTINE@@@@@BENDAMUSTINE||||@MUNDIPHARMA@RIBOSEPHARM@@@@MUNDIPHARMA|RIBOSEPHARM|||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@TREANDA@RIBOMUSTIN@@@@TREANDA|RIBOMUSTIN|||@Alkylating Agent@Nitrogen Mustard Analogue@@@@Alkylating Agent|Nitrogen Mustard Analogue|||@TIME TO PROGRESSION@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14921860@Onco@@@@@300f1015ntsdm@@@@@@CT-2106 as a single agent@@-@-@-@SEATTLE, WASHINGTON@7/1/2006@@@@14921860@Advanced ovarian cancer in patients who have failed one prior platinum and taxane-based regimen@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00291837@40@-@-@@@-@@11/1/2004@-@CAM203@@-@-@@@II@III@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CELL THERAPEUTICS@@@@@CELL THERAPEUTICS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@CT-2106@@@@@CT-2106||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924809@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LEXINGTON, MASSACHUSSETTS@@@@@14924809@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA non-approvable letter related to CMC supplement. SOURCE: Indevus, 19 December 2007FDA approvable letter for SNDA to reintroduce Valstar valrubicin to treat refractory bladder cancer in patients not candidates for bladder removal. SOURCE: Indevus, August 2007@12/19/2007@@-@@@-@-@@-@-@@@-@FILED@@-@-@-@-@@@@-@VALRUBICIN@@@@@VALRUBICIN||||@INDEVUS PHARMACEUTICALS@@@@@INDEVUS PHARMACEUTICALS||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@VALSTAR@@@@@VALSTAR||||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@-@@@@@@@@@@-@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16380448@Onco@@@@@@@@@@@"LY3039478, Experimental, LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met."@@@@@INDIANAPOLIS, INDIANA@5/1/2017@@@@16380448@A Phase 1 Study of LY3039478 in Japanese Patients With Advanced Solid Tumors@Both@@@@@Administered orally@@@@@FIRST-LINE@NCT02836600@12@@@@@@@8/1/2016@@16191@@@#NAME?@@ADULTS@Phase 1@I@@@@@@@@@MONO@OTHER@@@@@OTHER||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LY3039478@@@@@LY3039478||||@Other@@@@@Other||||@Number of Participants with LY3039478 Dose-Limiting Toxicities (DLTs)@@@@@Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3039478@PK: Area Under the Curve (AUC) of LY3039478@@@@@@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925007@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@N02AA01@N02A@NO@READING, UNITED KINGDOM@@@@@14925007@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Link Holdings in November 2006@@@@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals.@EMA, August 1995@@@@@@Caution should be exercised in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose of Zomorph should be reduced, or its use should be avoided in cases of hepatic or renal failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@ARCHIMEDES PHARMA@@@@@ARCHIMEDES PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ZOMORPH@@@@@ZOMORPH||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@60@1.299@43.6@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@0.73@0.73@4.04E+15@CAPSULE MODIFIED RELEASE@GB£@@@@@@@@200@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
16160507@Onco@@@@@@@@@@@Dose 1, Experimental, Dose 2, Experimental, Dose 3, Experimental, Dose 4, Experimental,@@@@@MARYLAND, UNITED STATES@1/1/2018@@@@16160507@A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma@Both@@@@@@@@@@ADJUVANT@NCT02811822@24@@@@@@@6/1/2016@@GMI-1271-230@@@- Males and females ≥ 18 years of age  2. Confirmed diagnosis of Multiple Myeloma  3. Subjects with progressive MM who have received at least 1 prior therapy and who have already undergone or are not expected to undergo hematopoietic stem cell transplanta@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@GLYCOMIMETICS@@@@@GLYCOMIMETICS||||@Ireland@@@@@Ireland|||||||||@Myeloma@@@@@Myeloma|||||||||@GMI-1271@@@@@GMI-1271||||@Other@@@@@Other||||@Safety assessed by frequency, severity and relatedness of AEs@OVERALL RESPONSE RATE @@@@Clinical benefit rate = Stringent Complete Response + Complete Response + Very Good Partial Response + Partial Response + Minimal Response + Stable Disease@TIME TO RESPONSE@@@@@@@@@NON-RANDOMIZED@Safety Study@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916535@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@-@@@@@14916535@Adenocarcinomas bearing the RAAG12 antigen@@-@-@@NO REVIEW@@@@-@MacroGenics acquires Raven. SOURCE: MacroGenics, 17 July 2008Licensed from Spirogen in May 2003@-@NCT00101972@53@-@-@@@-@@@-@RV-2004-002@@-@-@@@I/II; SCMP-REFMAL-63, SCMP-TSN-04-094; @II@@-@-@Results to be presented at ASCO 30 May 2008. SOURCE: Raven press release, 11 March 2008@-@@@@MONO@-@@@@@-||||@RAVEN BIOTECHNOLOGIES@MACROGENICS@@@@RAVEN BIOTECHNOLOGIES|MACROGENICS|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@RAV-12@@@@@RAV-12||||@mAb@Chimeric@@@@mAb|Chimeric|||@CTCAE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921027@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single IV infusion once every 3 weeks@@-@-@-@-@@@@@14921027@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00625716@40@-@-@@@-@@2/1/2005@-@IMMUNO-101, @@-@-@@@IMMUNO-045-5011-228, UTHSC-IDD-0504; @I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@IMMUNOGEN@@@@@IMMUNOGEN||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@HUC242-DM4@@@@@HUC242-DM4||||@mAb@Humanised@@@@mAb|Humanised|||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@OPEN-LABEL@NON-RANDOMISED@DOSE ESCALATION@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922354@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@PF-299804 45mg continuous oral dosing@@-@-@-@NEW YORK, NEW YORK@11/1/2010@@This is an irreversible pan-ERBB inhibitor. PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo. Additionally, PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers. @@14922354@Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00768664@56@-@-@@@-@@11/1/2008@-@A7471027@@-@-@@@II@II@@-@-@Trial registered. [Pfizer, 07.10.2008]@-@@@@MONO@DACOMITINIB@@@@@DACOMITINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@PF-299804@@@@@PF-299804||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@RESPONSE RATE@@@@@PROGRESSION-FREE SURVIVAL@BIOMARKER@HER2@@@RELAPSED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921676@Onco@@@@@@@@@@@Combo with carboplatin, paclitaxel and Avastin@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921676@Combo with Avastin, carboplatin and paclitaxel@@-@-@@NO REVIEW@@@FEBRUARY 2007-@-@-@FIRST-LINE@NCT00457119@120@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@@-@CRAD001C2114@@-@-@@@I@II@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@BEVACIZUMAB@@@@EVEROLIMUS|BEVACIZUMAB|||@NOVARTIS@GENENTECH@@@@NOVARTIS|GENENTECH|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AFINITOR@RAD-001@AVASTIN@@@AFINITOR|RAD-001|AVASTIN||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@DOSE-LIMITING TOXICITY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925053@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@YOKOHAMA, JAPAN@3/1/2013@@PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and metastasize.@@14925053@A Phase Ia/Ib Clinical Trial of PRI-724 in Subjects With Advanced Solid Tumors@@@@@@@@@@@@NCT01302405@64@@@@@@@2/1/2011@@@@@In the dose-escalation part of the study (Phase Ia), patients must have histological or cytological evidence of solid tumor malignancy; in the MTD-expansion (Phase Ib) cohort, patients must have histological or cytological evidence of colorectal or pancreatic cancer. Patients must have neoplastic disease that is metastatic or unresectable, that has recurred or progressed following standard therapy, not be candidates for standard therapy, or have a malignancy for which no standard therapy exists. In the Phase Ib, patients must have tumors accessible for biopsy, and they must have measurable disease according to the response evaluation criteria in solid tumors (RECIST 1.1) criteria.@@@I@I@@@@@@@@@@-@@@@@-||||@PRISM BIOLAB@@@@@PRISM BIOLAB||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PRI-724@@@@@PRI-724||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@SINGLE GROUP ASSIGNMENT@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922319@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AEG-35156 administered by daily 2-hour infusions for 3 days prior to chemotherapy with ara-C and idarubicin followed by once-weekly 2-hour infusions of AEG35156.@@-@-@-@MONTREAL, QUEBEC@@@@@14922319@Combo with idarubicin@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@-@-@-@-@@@-@@@-@AEG35156@@-@-@@@I/II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@-@IDARUBICIN@@@@-|IDARUBICIN|||@AEGERA THERAPEUTICS@@@@@AEGERA THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AEG-35156@@@@@AEG-35156||||@XIAP Inhibitor@@@@@XIAP Inhibitor||||@SAFETY@RESPONSE RATE@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924827@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW HAVEN, CONNECTICUT@@@Cloretazine (VNP40101M) is a small molecule that works by damaging DNA. Cloretazine releases the DNA chloroethylating agent 90CE after entering the blood stream. 90CE chloroethylates the O6 position of guanine residues, ultimately resulting in an interstrand DNA cross-link. Interstrand DNA cross-links are difficult to repair and are toxic to cells. Cloretazine demonstrated a broad spectrum of anticancer activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan. In preclinical studies, Cloretazine has been combined with other anticancer agents such as cytarabine (Ara-C). In addition, Cloretazine or its metabolite, has been shown to be capable of crossing the blood brain barrier in preclinical models.@@14924827@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@6/1/2004@-@-@@-@-@@@-@II@@-@-@RESULTS PENDING@-@@@@MONO@CLORETAZINE@@@@@CLORETAZINE||||@VION PHARMACEUTICALS@@@@@VION PHARMACEUTICALS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@VNP-40101M@@@@@VNP-40101M||||@Alkylating Agent@@@@@Alkylating Agent||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923014@Onco@@@@@@@@@@@Inducted chemotherapy with docetaxel-cisplatine and 5-fluoruracil (TPF) combination vs cisplatin-5 fluoruracil (PF) followed by concomitant treatment with cisplatine and conventional radiotherapy vs concomitant treatment with cisplatine and conventional radiotherapy.@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14923014@-@@-@-@@NO REVIEW@@@Started in December 2002@-@-@-@NCT00261703@442@-@-@@@-@@@-@-@@-@-@@@III@II@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@CISPLATIN@@@@DOCETAXEL|CISPLATIN|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922975@Onco@@@@@@@@@@@Docetaxel plus prednisone with mitoxantrone plus prednisone @@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14922975@Patients with hormone-refractory metastatic prostate cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00436839@240@-@-@@@-@@1/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@PREDNISONE@@@@DOCETAXEL|PREDNISONE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@China@@@@@China|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924786@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924786@Various Phase I/II trials already completed; new Coley-led Phase I/II trials to be conducted in 2008.@@-@-@@NO REVIEW@@@@-@Programme acquired by Coley Pharmaceutical from 3M in June 2007 for US$20 million in addition to royalties; Pfizer bought Coley in November 2007.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TLR@@@@@TLR||||@TLR-targeted@@@@@TLR-targeted||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924244@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@CUDC-305 is an orally available, small molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a member of a class of proteins called molecular chaperones that play a fundamental role in the folding, stabilization and degradation of their client proteins under normal or stressful conditions. Hsp90, in particular, has become an attractive therapeutic target for the treatment of cancer because a majority of its client proteins are involved in cellular signaling transduction and have been identified as potential contributors to various aspects of cancer cell growth and survival. Inhibitors of Hsp90 activity may be of therapeutic value if they can prevent Hsp90 chaperones from protecting proteins involved in cancer and allow them to be degraded.@@14924244@-@@-@-@@NO REVIEW@@@@-@Debiopharm will assume all future development responsibility for Curis' HSP90 technology, including CUDC-305. [Curis, 6 August 2009]@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@>> IND to be filed in the Autumn of 2009 [Curis, 6 August 2009]>> IND to be filed in mid-2009. [Curis, 21.07.2008]@-@@@@MONO@-@@@@@-||||@CURIS@DEBIOPHARM@@@@CURIS|DEBIOPHARM|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CUDC-305@@@@@CUDC-305||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922631@Onco@@@@@300f1037ntsdm@@@@@@NO LABELLED TRIAL@@L02AE02@L02A@NO@OSAKA, JAPAN@@@This is a synthetic nonapeptide analogue of naturally occurring gonadotrophin releasing hormone (GnRH) which possesses greater potency than the natural hormone. It is a peptide and therefore unrelated to the steroids. Chronic administration results in an inhibition of gonadotrophin production and subsequent suppression of ovarian and testicular steroid secretion. This effect is reversible on discontinuation of therapy. Administration of leuprorelin acetate results in an initial increase in circulating levels of gonadotrophins which leads to a transient increase in gonadal steroid levels in both men and women. Continued administration of leuprorelin acetate results in a decrease of gonadotrophin and sex steroid levels. In men serum testosterone levels, initially raised in response to early luteinising hormone (LH) release, fall to castrate levels in about 2-4 weeks. Oestradiol levels will decrease to postmenopausal levels in premenopausal women within one month of initiating treatment.@@14922631@Treatment of metastatic prostate cancer; metastatic breast cancer; uterine fibroids; precocious puberty; and endometriosis@@NO@@@NO REVIEW@@@@100%@@@@@One injection every four weeks.@@@@No@@@@NO LABELLED TRIAL@No@@@@@@APPROVED@@NO REVIEW@SNS@NO LABELLED TRIAL@@@@@@LEUPROLIDE ACETATE@@@@@LEUPROLIDE ACETATE||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Prostate Cancer@Breast Cancer@@@@Prostate Cancer|Breast Cancer||||||||@PROCRIN@@@@@PROCRIN||||@LH-RH Analog@@@@@LH-RH Analog||||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTABLE SUSPENSION@EURO@@@@@@@@7.5@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14922569@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV every 3 weeks@@-@-@-@PARIS, FRANCE@@@@@14922569@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00539682@40@-@-@@@-@@10/1/2007@-@2006-1092@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@SAR-3419@@@@@SAR-3419||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917748@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N02AB03@N02A@@CORONA, CALIFORNIA@@@Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.@@14917748@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@Authorised generic of Actiq@@@@@FDA, 6 September 2006@9/6/2006@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@WATSON PHARMACEUTICALS@CEPHALON@@@@WATSON PHARMACEUTICALS|CEPHALON|||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTIQ@@@@@ACTIQ||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@3158@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@105.27@105.27@63459-0508-30@LOZENGE@US$@@@@@@@@800@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924669@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@72-hour continuous infusion of PX-12 given on the first three days of a 21-day cycle@@-@-@-@BELLEVUE, WASHINGTON@@@PX-12 is a small molecule designed to inhibit thioredoxin-1. Increased levels of thioredoxin-1 have been noted in many types of cancer cells, including hepatoma, lung cancers, squamous cervical carcinoma, primary gastric cancers and colorectal carcinomas. Increased levels of thioredoxin-1 are associated with decreased sensitivity to a variety of common chemotherapy agents and may cause or contribute to drug resistance. @@14924669@Advanced metastatic tumours@@-@-@@NO REVIEW@@@@-@Oncothyreon will restructure to focus on development of PX-478 and PX-866 following the transfer of manufacturing responsibilities of Stimuvax to Merck KGaA. [Oncothyreon, 20.12.2008]@-@-@28@-@FDA SPA AND FAST-TRACK GRANTED.@@@-@@6/1/2008@-@-@@-@-@@@IB@I@@-@-@Trial started. SOURCE: Oncothyreon, 11 June 2008@-@@@@MONO@-@@@@@-||||@ONCOTHYREON@@@@@ONCOTHYREON||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PX-12@@@@@PX-12||||@Other@@@@@Other||||@SAFETY@@@@@PHARMACOKINETICS@PHARMACODYNAMICS@@@@METASTATIC@-@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922352@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Drug taken orally@@-@-@-@NEW YORK, NEW YORK@12/1/2009@@@@14922352@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00585195@60@-@-@@@-@@5/1/2006@-@A8081001@@-@-@@@I@I@@-@-@>>57% of anaplastic lymphoma kinase (ALK)-positive patients had either a complete or partial response to treatment [Pfizer, 27.10.10 http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp]>>Endpoint over 2.5 years@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-2341066@@@@@PF-2341066||||@TK Inhibitor@@@@@TK Inhibitor||||@DOSE RANGE@SAFETY@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921915@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Brivanib oral 800MG once daily until progression versus placebo@@-@-@-@NEW YORK, NEW YORK@6/1/2010@@@@14921915@Advanced NSCLC, transitional cell carcinoma, soft tissue sarcoma, gastric/oesophageal adenocarcinoma or pancreatic cancer including ampulla of vater@@-@-@@NO REVIEW@@@@-@-@-@NCT00633789@300@-@-@@@-@@5/1/2008@-@CA182-026@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BRIVANIB ALANINATE@@@@@BRIVANIB ALANINATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@NSCLC@Sarcoma@Pancreatic Cancer@Oesophageal Cancer@Bladder Cancer@NSCLC|Sarcoma|Pancreatic Cancer|Oesophageal Cancer|Bladder Cancer|||||@BMS-582664@@@@@BMS-582664||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921358@Onco@@@@@@@@@@@Zarnestra versus best supportive care that includes hydroxyurea@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.@@14921358@Newly diagnosed AML in elderly patients (70 years or older)@@-@-@@NO REVIEW@@@@-@-@-@NCT00093990@450@-@Johnson & Johnson will not file for the AML indication. SOURCE: Johnson & Johnson, 17 July 2007@7/17/2007@@-@@@-@FIGHT@@-@-@ELDERLY@@R115777-AML-301; @III@@-@-@8% complete remission but failed to show statistically significant efficacy versus best supportive care.@-@@@@MONO@TIPIFARNIB@@@@@TIPIFARNIB||||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@ZARNESTRA@@@@@ZARNESTRA||||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924942@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BRISBANE, CALIFORNIA@4/1/2008@@@@14924942@-@@-@-@@NO REVIEW@@@@-@Sanofi-Aventis acquires Bi-Par [Sanofi-Aventis 15 April 2009 http://en.sanofi-aventis.com/binaries/20090415_bipar_acquisition_en_tcm28-24863.pdf ]@-@NCT00298675@36@-@-@@@-@@3/1/2006@-@20060101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIPAR SCIENCES@SANOFI-AVENTIS@@@@BIPAR SCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BSI-201@@@@@BSI-201||||@PARP Inhibitor@@@@@PARP Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918902@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ascending dose, administered every other day though additional schedules are anticipated. SOURCE: Anadys@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14918902@-@@-@-@@NO REVIEW@@@@-@-@-@-@60@-@-@@@-@@2/1/2008@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ANADYS@@@@@ANADYS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ANA-773@@@@@ANA-773||||@TLR-targeted@@@@@TLR-targeted||||@SAFETY@TOLERABILITY@PHARMACODYNAMICS@@@PHARMACODYNAMICS@@@@@ADVANCED@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922082@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Rexin-G Dose 1; Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity. Rexin-G Dose 2; Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity@@-@-@-@-@12/1/2008@@@@14922082@Osteosarcoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00572130@30@-@The drug has been approved in the Philippines for use as a first-line and adjuvant therapy for pancreatic and breast cancer and a second-line therapy for all other solid tumors that are refractory to standard chemotherapy.@@@-@@12/1/2007@-@C07-110@@-@-@@@II@II@@-@-@Endpoint assessed after 12-18 months.@-@@@@MONO@-@@@@@-||||@EPEIUS BIOTECHNOLOGIES@@@@@EPEIUS BIOTECHNOLOGIES||||@@@@@@|||||||||@Bone Metastases@Sarcoma@@@@Bone Metastases|Sarcoma||||||||@REXIN-G@@@@@REXIN-G||||@Gene Therapy@@@@@Gene Therapy||||@RESPONSE RATE@PET@@@@@@@@@REFRACTORY@METASTATIC@@@@OPEN-LABEL@UNCONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922072@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@150 mg/day armodafinil concurrent with one cycle of taxane chemotherapy (21 or 28 days) versus placebo [Cephalon]@@-@-@-@FRAZER, PENNSYLVANIA@1/1/2010@@@@14922072@Armodafinil Treatment for Patients With Fatigue Associated With Taxane Chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00825227@160@-@-@@@-@@12/1/2008@-@C10953@@-@The patient has locally advanced or metastatic breast cancer, androgen-independent advanced prostate cancer, or progressive non-small cell lung cancer who is receiving, or is scheduled to receive, single-agent taxane chemotherapy (paclitaxel, docetaxel, or albumin-bound paclitaxel) administered on a conventional 21-day or 28-day cycle for that taxane.@@@II@II@@-@-@Trial registered. [Cephalon, 15.01.2009]@-@@@@-@ARMODAFINIL@@@@@ARMODAFINIL||||@CEPHALON@@@@@CEPHALON||||@@@@@@|||||||||@Supportive Care@Cancer Fatigue@@@@Supportive Care|Cancer Fatigue||||||||@NUVIGIL@@@@@NUVIGIL||||@Other@@@@@Other||||@BRIEF FATIGUE INVENTORY@SEVERE FATIGUE@@@@@@@@@-@@@@@DOUBLE-BLIND@RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916567@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@RH-1 administered via IV infusion over 3 hours once every 21 days. Patients will receive starting doses of RH1 at 1.5 mg/m2, with dose escalation in subsequent cohorts based on toxicity.  SOURCE: Allos@@-@-@-@WESTMINSTER, COLORADO@3/1/2010@@@@14916567@Advanced solid tumours or NHL@@-@-@@NO REVIEW@@@@-@-@-@NCT00558727@60@-@-@@@-@@11/1/2007@-@RH-1-002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ALLOS THERAPEUTICS@@@@@ALLOS THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Solid Tumours@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Solid Tumours|||||||@RH1@@@@@RH1||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919049@Onco@@@@@@@@@@@N/A@@L02AE03@L02A@-@VERDUN, QUEBEC@@@Ambrilia has developed a novel formulation of the 3-month release version of Zoladex (goserelin) 10.8mg, a Luteinizing Hormone-Releasing Hormone (LHRH) analogue indicated for hormone-sensitive prostate cancer and several gynecological indications such as fibro-myomas and endometriosis. Ambrilia's goserelin is an injectable depot formulation. The original product worldwide sales(1) reached $US1.1B in 2007 (+10% year-over-year growth), with the 3-month depot formulation capturing approximately 70% of this market.@@14919049@N/A@@-@-@@NO REVIEW@@@@-@Ambrilia aiming to divest this by end-2008. SOURCE: Ambrilia, 24 March 2008@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@N/A@II@@-@-@>> Trial initiated. [Ambrilia, 21.08.2008]      >> Clinical testing of generic Zoladex 3-month implant to begin in H1 2008 (potentially first-to-market). [Ambrilia, 24.03.2008]@-@@@@-@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@AMBRILIA BIOPHARMA@@@@@AMBRILIA BIOPHARMA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@-@@@@@-||||@LH-RH Analog@@@@@LH-RH Analog||||@N/A@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@1@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@IMPLANT@-@@@@@@@@10.8@MG@10.8 MG@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14925006@Onco@@@@@300f1010ntsdm@@@@@@NO LABELLED TRIAL@@N02AA01@N02A@NO@READING, UNITED KINGDOM@@@@@14925006@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@@@NO REVIEW@@@@100%@Acquired through takeover of Link Holdings in November 2006@@@@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals.@EMA, May 1995@@@@@@Caution should be exercised in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose of Zomorph should be reduced, or its use should be avoided in cases of hepatic or renal failure.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@NHS@NO LABELLED TRIAL@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@ARCHIMEDES PHARMA@@@@@ARCHIMEDES PHARMA||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ZOMORPH@@@@@ZOMORPH||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@60@1.299@16.2@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/28/2017@0.27@0.27@3.78E+15@CAPSULE MODIFIED RELEASE@GB£@@@@@@@@60@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14918732@Onco@@@@@300f1020ntsdm@@@@@@Arenegry as a single-agent every 3 weeks@@-@-@-@MILAN, ITALY@10/1/2008@@NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumourvasculature. It consists of a tumour homing peptide (NGR) selectively binding tumour blood vessels, fused to the powerful human anticancer cytokine TNF. The resulting molecule has unique biological properties, including induction of tumour vascular permeability and normalisation, and a direct biological antitumour activity. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents: currently, in addition to mesothelioma and colorectal cancer, single agent Phase II trials are ongoing in hepatocellular carcinoma and small-cell lung cancer; for colorectal cancer, it is also being tested in a Phase II trial in combination with Xelox. Also ongoing is a Phase I trial in combination with cisplatin, while a Phase I trial in combination with doxorubicin was successfully completed.@@14918732@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00483509@27@-@-@@@-@@12/1/2006@-@NGR007@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@ARENEGYR@@@@@ARENEGYR||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924637@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14924637@In combination with GM-CSF@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00088660@255@-@-@@@-@@6/1/2004@-@-@@-@ABOUT 255 PATIENTS WITH METASTATIC (STAGE IV) PANCREATIC CANCER WHO HAVE FAILED A GEMCITABINE-CONTAINING CHEMOTHERAPY REGIMEN. @@@III@DISCONTINUED@@-@-@In July 2006, Therion announced PANVAC-VF did not meet its primary efficacy endpoint of improving overall survival compared to palliative chemotherapy or best supportive care.@-@@@@COMBO@-@@@@@-||||@THERION BIOLOGICS@@@@@THERION BIOLOGICS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@PANVAC-VF@@@@@PANVAC-VF||||@Vaccine@@@@@Vaccine||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16626375@Onco@@@@@@@@@@@Flat-Dose, Experimental, Nivolumab flat dose + IpilimumabWeight-Based Dose, Experimental, Nivolumab weight-based dose + Ipilimumab@@L01XC17@L01X@@NEW YORK, NEW YORK@7/1/2018@@@@16626375@A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)@Both@@@@@Experimental: Flat-Dose: Nivolumab flat dose + IpilimumabExperimental: Weight-Based Dose: Nivolumab weight-based dose + Ipilimumab@@@@@@NCT03048136@224@@@@@@@@@CA209-955@@@Stage IV or recurrent non-Small cell lung cancer  -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1  -  Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events@Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events@@@@Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)@Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)@@@@@@@@@RANDOMISED@PARALLEL ASSIGNMENT@NO MASKING@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921826@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CC-4047 alone for metastatic HRPC@@-@-@-@SUMMIT, NEW JERSEY@4/1/2005@@Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.@@14921826@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00072722@36@-@-@@@-@@9/1/2003@-@CC-4047-PC-002@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@POMALIDOMIDE@@@@@POMALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@ACTIMID@CC-4047@@@@ACTIMID|CC-4047|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@RESPONSE RATE@SAFETY@@@@@@@@@REFRACTORY@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16379396@Onco@@@@@@@@@@@@@@@@-@12/1/2017@@@@16379396@A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation@Both@@@@@@@creatine clearance rate: ≥ 50 mL/min; LVEF: ≥ 50%; QTcF: < 470 ms for female and < 450 ms for male.  - Signed informed consent@@@SECOND-LINE@NCT02834936@55@@@@@@@7/1/2016@@HR-BLTN-Ⅱ-NSCLC@@@- ECOG performance status of 0 to 1.   - Life expectancy of more than 3 months.  - At least one measurable lesion exists.(RECIST 1.1).  - Histologically or cytologic confirmed Non-small cell lung cancer, Phase IIIB or IV according to IASLC 2009.  - Failed@HER2-POSITIVE@ADULTS@Phase 2@II@@@@@@@@@MONO@PYROTINIB@@@@@PYROTINIB||||@JIANGSU HENGRUI MEDICINE@@@@@JIANGSU HENGRUI MEDICINE||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@BLTN@@@@@BLTN||||@Other@@@@@Other||||@pyrotinib treatment, Experimental,@Objective Response Rate (ORR)@@@@Progression free survival (PFS)@Incidence and Intensity of Adverse Events@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16727180@Onco@@@@@300f1018ntsdm@@@@@@@@L03AX03@L03A@@WHITEHOUSE STATION, NEW JERSEY@@@@@16727180@OncoTICE is used as a treatmentof primary of recurrent carcinoma in situ (CID) of the urinary bladder. OncoTICE is also used after transurethral resection for the prevention of recurrenceof high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage Ta (grade 2 or 3) or T1(grade 1, 2, or 3). OncoTICE is only reccommended for stage Ta grade 1 tumours, when there is judged to be a high risk of tumour recurrence.@@No@@@NO REVIEW@@@@@@@@@@TGA, 27 May 1997@5/27/1997@@No@@@@@No@@@@@@APPROVED@@@PBS@@@@@@MONO@BACILLUS CALMETTE-GUERIN@@@@@BACILLUS CALMETTE-GUERIN||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@ONCOTICE@@@@@ONCOTICE||||@Immunotherapy@@@@@Immunotherapy||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@3@0.779@467.24@524.22@502.38@@@@@@@@@@12.46@@@@@@@@@@@@@@@@8/1/2017@155.75@155.75@2487-0264-GE-MK@POWDER FOR INTRAVESICAL INSTILLATION (VIAL) - 2 ML@A$@@@@@@@@12.5@MG@12.5 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
15971755@Onco@@@@@@@@@@@@@@@@CAMBRIDGE, MASSACHUSSETTS@6/1/2020@@@@15971755@A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)@Both@@@@@Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg. Subjects will take duvelisib until disease progression or unacceptable toxicity.@@@@@@NCT02711852@500@@@@@@@4/1/2016@@IPI-145-23@@@Have participated in a previous study of duvelisib, and:  -  Be actively receiving duvelisib monotherapy on the previous study (within 14 days of study entry) and demonstrating clinical benefit (complete response [CR]/ partial response [PR]/ stable disease [SD]) of continued use, or  -  Be in the survival follow-up phase of a previous duvelisib study  -  Have completed the required components of the previous study and be appropriate for enrollment into this long-term continued treatment and follow-up study, as determined by the Sponsor@MONO@ADULTS@Phase 2@II@@@@@@@@@@DUVELISIB@@@@@DUVELISIB||||@INFINITY PHARMACEUTICALS@@@@@INFINITY PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@-@@@@@-||||@PI3 KINASE INHIBITOR@@@@@PI3 KINASE INHIBITOR||||@ADVERSE EVENTS@@@@@@@@@@@@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922844@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Study gel applied to right side of face and crossed over to both sides after 1 week.@@N01BB02@N01B@NO@@@@@@14922844@Indicated for the reduction of pain caused by radiation and side-effects of EGFR such as rash and itching.@@NA@@@NO REVIEW@@@@@@FIRST-LINE@@15-Oct@@@@@@@@NONE@LABEL@No@N/A@10-15 [TAKING ERBITUX, VECTIBIX OR TARCEVA]@@@II@APPROVED@@N/A@@Treatment versus no treatment showed significant improvement in self-reported itch and pain.@@@@@MONO@LIDOCAINE@@@@@LIDOCAINE||||@MPM MEDICAL@@@@@MPM MEDICAL||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@REGENECARE@@@@@REGENECARE||||@Other@@@@@Other||||@EGFR RASH@@@@@@@@@@@@@@@PILOT@CROSSOVER@@@@@@Invalid Factory Price@@@@@@@@@@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@GEL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16401506@Onco@@@@@@@@@@@MV-NIS and nivolumab, Experimental, MV-NIS will be administered intratumorally as a single dose on day 1. Nivolumab will be given at day 15 and then every 2 weeks.@@@@@ROCHESTER MN@1/1/2019@@@@16401506@Phase 1 Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus (Edmonston Strain) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)@Both@@@@@@@@@@FIRST-LINE@NCT02919449@42@@@@@@@1/1/2017@@VYR-MV1-101@@@Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS.  -  Patient meets the FDA-approved indication for nivolumab treatment in NSCLC (Opdivo® USPI 2016).  -  ECOG Performance Status (PS) 0 or 1.  -  Ability to provide informed consent.  -  Adequate hematological, liver and kidney function.  -  Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration.  Key@@ADULTS@Phase 1@I@@@@@@@@@COMBO@-@NIVOLUMAB@@@@-|NIVOLUMAB|||@VYRIAD@@@@@VYRIAD||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@MV-NIS@OPDIVO@@@@MV-NIS|OPDIVO|||@Other@@@@@Other||||@Maximum Tolerated Dose (MTD) of MV-NIS in combination with nivolumab@@@@@@@@@@RECURRENT@METASTATIC@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16668400@Onco@@@@@300f1018ntsdm@@@@@@Ibrutinib: 420 mg daily or 840 mg daily@@L01XE27@L01X@@BEERSE, BELGIUM@6/1/2013@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.@@16668400@Adult patients with CLL/SLL who have received at least one prior therapy@@NA@@@NO REVIEW@@@@0%@@SECOND-LINE@NCT01105247@133@420 mg taken orally once daily (three 140 mg capsules once daily)@TGA, 15 December 2016@12/15/2016@@No@@4/1/2010@@PCYC-1102-CA@No@@@@@II@APPROVED@@@@@@@@@MONO@IBRUTINIB@@@@@IBRUTINIB||||@JANSSEN PHARMACEUTICAL@@@@@JANSSEN PHARMACEUTICAL||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@@@@@IMBRUVICA||||@TK Inhibitor@@@@@TK Inhibitor||||@SAFETY@@@@@PROGRESSION-FREE SURVIVAL@RESPONSE RATE@@@@@@@@@OPEN-LABEL@NON-RANDOMISED@SINGLE GROUP ASSIGNMENT@@@1@1@Invalid Factory Price@@@@@@@@@@0.779@@@@@@@@@@@@@@1@@mg@420@1@@@@@@@@@@@@@@@@A$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14921098@Onco@@@@@300f1018ntsdm@@@@@@AZD-2281 given orally twice daily. BRCA identified by using Myriad Genetics BRACAnalysis test@@-@-@-@LONDON, UNITED KINGDOM@@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14921098@BRCA1 or 2-positive breast cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00494234@40@-@-@@@-@@6/1/2007@-@ICEBERG-1@@-@40 PATIENTS WITH ADVANCED BRCA1 OR BRCA2-POSITIVE BREAST CANCER@@@KU36-44; D0180C00009 / @II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AZD-2281@@@@@AZD-2281||||@PARP Inhibitor@@@@@PARP Inhibitor||||@SAFETY@RESPONSE RATE@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@ADVANCED@@@@@OPEN-LABEL@NON-COMPARATIVE@INTERNATIONAL@MULTI-CENTRE@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14916596@Onco@@@@@@@@@@@IV infusion at a dose level of 0.20mg/kg per day versus allopurinol 100MG tablet@@-@-@-@PARIS, FRANCE@3/1/2008@@In humans, uric acid is the final step in the catabolic pathway of purines. The acute increase in plasma levels of uric acid subsequent to the lysis of large numbers of malignant cells and during cytoreductive chemotherapy may lead to impairment of renal function and renal failure resulting from the precipitation of crystals of uric acid in renal tubules. Rasburicase is a highly potent uricolytic agent that catalyses enzymatic oxidation of uric acid into allantoin, a water soluble product, easily excreted by the kidneys in the urine. The enzymatic oxidation of uric acid leads to stoichiometric formation of hydrogen peroxide. The increased of hydrogen peroxide over ambient levels can be eliminated by endogenous antioxidants and the only increased risk is for haemolysis in G6PD deficient and inherited anaemia patients.@@14916596@Registrational trial for hyperuricaemia in Chinese patients with leukaemia or lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00607152@72@-@-@@@-@@10/1/2007@-@RASBU_00351@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@RASBURICASE@@@@@RASBURICASE||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@China@@@@@China|||||||||@Supportive Care@Haematological Malignancy@@@@Supportive Care|Haematological Malignancy||||||||@FASTURTEC@ELITEK@@@@FASTURTEC|ELITEK|||@Detoxifying Agent@Urate Oxidase Enzyme@@@@Detoxifying Agent|Urate Oxidase Enzyme|||@URIC ACID CONCENTRATION@DURATION OF RESPONSE@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916150@Onco@@@@@300f1008ntsdm@@@@@@CPT-11, 5-FU and 1-LV (FOLFIRI) versus CPT-11 with S-1 (IRIS)@@-@-@-@-@@@S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.@@14916150@Unresectable colorectal cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis returns its territory rights to Taiho Pharmaceutical for the development and commercialization of the oral anti-cancer agent S-1. Taiho will pursue further development of S-1 outside of Japan with gastric cancer included. SOURCE: Taiho, 18 July 2008@SECOND-LINE@NCT00284258@400@-@-@@@-@@@-@TOP-003  @@-@-@@@II/III; 01023010 / @III@@-@@RESULTS PENDING@-@@@@COMBO@TEGAFUR GIMERACIL OTERACIL POTASSIUM @@@@@TEGAFUR GIMERACIL OTERACIL POTASSIUM ||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@S-1@FOLFIRI@@@@S-1|FOLFIRI|||@Fluoropyrimidine@@@@@Fluoropyrimidine||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14924938@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients have received at least one prior regimen@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@@@14924938@Ewing's family tumour and desmoplastic small round cell tumours@@-@-@@NO REVIEW@@@@-@Takeda and Amgen signed a deal in February 2008 through which, in its first part, Takeda acquired Japanese rights for up to 13 molecules in Amgen's pipeline, including Vectibix (panitumumab), AMG-108, AMG-317, AMG-386, AMG-479 and AMG-655, for US$200 mil.@-@NCT00563680@45@-@-@@@-@@10/1/2007@-@20060283@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@AMGEN@TAKEDA PHARMACEUTICAL@@@@AMGEN|TAKEDA PHARMACEUTICAL|||@@@@@@|||||||||@Bone Metastases@@@@@Bone Metastases|||||||||@AMG-479@@@@@AMG-479||||@mAb@Human@@@@mAb|Human|||@RECIST@RESPONSE RATE@COMPLETE RESPONSE@@@COMPLETE RESPONSE@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16161672@Onco@@@@@300f1008ntsdm@@@@@@@@L01XX25@L01X@@@@@@@16161672@@@NA@@@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@13@300 mg/m²/day as an initial dose with subsequent dosing depending on body surface area (please refer to label). Treatment should be continued as long as the patient is deriving benefit.@@@1/4/2016@@@@@@No@@@@@I/II@APPROVED@@@NHI@@@@@@MONO@BEXAROTENE@@@@@BEXAROTENE||||@MINOPHAGEN PHARMACEUTICAL@@@@@MINOPHAGEN PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@CTCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|CTCL||||||@TARGRETIN@@@@@TARGRETIN||||@Retinoid@@@@@Retinoid||||@@@@@@@@@@@@@@@@@@@@@1.75@m²@2790201.12@@@24@week@24 week@2790201.12@2790201.12@16608.34@1@0.0091@2372.62@2797.9@@@@@@@@@@@31.63@1@@mg/m²@300@1@@@@@@@@@@@8/30/2017@2372.62@2372.62@4291042M1022@CAPSULE@YEN@@@@@@@@75@MG@75 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14922681@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@LY-2181308 alone@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922681@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00415155@60@-@-@@@-@@@-@10460H8Z-MC-JACS@@-@-@@@I/II@II@@-@-@Completion expected July 2008.@-@@@@MONO@-@@@@@-||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@LY-2181308@@@@@LY-2181308||||@Survivin Suppressant@@@@@Survivin Suppressant||||@MAXIMUM TOLERATED DOSE@TIME TO PROGRESSION@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922649@Onco@@@@@300f1012ntsdm@@@@@@BI-811283 two doses combo with cytarabine@@-@-@-@INGELHEIM, GERMANY@12/1/2009@@@@14922649@Previous untreated AML ineligible for intensive treatment@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00632749@160@-@-@@@-@@3/1/2008@-@1247.3, @@-@-@@@EudraCT No.: 2007-005684-10; @I@@-@-@RESULTS PENDING@-@@@@COMBO@-@CYTARABINE@@@@-|CYTARABINE|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@BI-811283@@@@@BI-811283||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@PHARMACOKINETICS@@@PHARMACOKINETICS@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14919131@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive siplizumab IV over 4 hours on days 1 and 2 every 2 weeks for 16 weeks OR on days 1-3 every 2 weeks for 16 weeks OR on days 1 and 14, then weekly for 16 weeks in the absence of disease progression or unacceptable toxicity. Patients with a positive treatment response (e.g., stable disease, minor response, partial response, or complete response) after 16 weeks of treatment may continue to receive MEDI-507 as above in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of MEDI-507 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. SOURCE: clinicaltrials.gov@@-@-@-@-@@@@@14919131@Lymphoproliferative disorders@@-@-@@NO REVIEW@@@@-@AstraZeneca acquires MedImmune in US$15 billion deal. [AstraZeneca, 23.04.2007]@-@NCT00075361@88@-@-@@@-@@11/1/2003@-@MEDIMMUNE-MI-CP094@@-@-@@@NCI-04-C-0031, @DISCONTINUED@@-@-@RESULTS PENDING@-@@@@MONO@SIPLIZUMAB@@@@@SIPLIZUMAB||||@MEDIMMUNE@ASTRAZENECA@@@@MEDIMMUNE|ASTRAZENECA|||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@MEDI-507@@@@@MEDI-507||||@mAb@Humanised@CD2@@@mAb|Humanised|CD2||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922677@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administered i.v. on days 1 and 15 of each 28 day cycle; until progression or unacceptable toxicity develops. @@-@-@-@SAN DIEGO, CALIFORNIA@12/1/2008@@@@14922677@-@@-@-@@NO REVIEW@@@@-@Licensed exclusive rights from Roswell Park Cancer Institute@-@NCT00582985@22@-@-@@@-@@12/1/2007@-@105ST101@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@TRACON PHARMACEUTICALS@@@@@TRACON PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@TRC-105@@@@@TRC-105||||@mAb@Human@Chimeric@Angiogenesis Inhibitor@@mAb|Human|Chimeric|Angiogenesis Inhibitor|@SAFETY@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921472@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ara-C chemotherapy in combination with EL-625 and idarubicin@@-@-@-@OMAHA, NEBRASKA@5/1/2007@@@@14921472@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00074737@45@-@-@@@-@@4/1/2004@-@ELP1001@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@CENERSEN SODIUM@IDARUBICIN@@@@CENERSEN SODIUM|IDARUBICIN|||@ELEOS INC.@@@@@ELEOS INC.||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@EL-625@@@@@EL-625||||@Other@@@@@Other||||@DOSE RANGE@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918721@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The 7 planned dose levels are 0.0003 mg/kg, 0.003 mg/kg, 0.015 mg/kg, 0.075 mg/kg, 0.3 mg/kg, 1.0 mg/kg and 3.0 mg/kg. The subjects will receive up to a total of 4 administrations of Anti-KIR (1-7F9) with a dosing interval between each administration of 4 weeks. SOURCE: clinicaltrials.gov@@-@-@-@-@5/1/2009@@@@14918721@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00552396@33@-@-@@@-@@5/1/2007@-@NN1975-1837@@-@-@@@I@DISCONTINUED@@-@-@Novo Nordisk exited all oncology interests in February 2008 and thus suspended all activities in this area. SOURCE: Novo Nordisk Earnings Conference Call, 31 January 2008@-@@@@MONO@-@@@@@-||||@NOVO NORDISK@@@@@NOVO NORDISK||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ANTI-KIR@1-7F9@@@@ANTI-KIR|1-7F9|||@mAb@Human@@@@mAb|Human|||@SAFETY@TOLERABILITY@@@@@@@@@-@@@@@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922310@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ADH-1 in combination with normthermic isolated limb infusion of melphalan@@-@-@-@DURHAM, NORTH CAROLINA@8/1/2008@@@@14922310@Combo with melphalan@@-@-@@NO REVIEW@@@@-@-@-@NCT00421811@31@-@FDA orphan drug in combination with melphalan for Stage IIB/C, III and IV malignant melanoma. SOURCE: Adherex, 22 February 2008@2/22/2008@@FDA orphan drug in combination with melphalan for Stage IIB/C, III and IV malignant melanoma. SOURCE: Adherex, 22 February 2008@@4/1/2007@-@AHX-01-007@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@ADHEREX TECHNOLOGIES@@@@@ADHEREX TECHNOLOGIES||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@EXHERIN@ADH-1@@@@EXHERIN|ADH-1|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@SAFETY@TOLERABILITY@@@@@@@@@LOCALLY ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16642997@Onco@@@@@300f1037ntsdm@@@@@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@16642997@XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).@@YES@@@NO REVIEW@@@@@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@53@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) takencontinuously.@EMA, 25 August 2016@8/25/2016@12/1/2013@No@@@@Study 1001@No@@@ROS1-positive@@@APPROVED@@@SNS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@ADVANCED@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@127928.2512@@@19.3@month@19.3 month@127928.25@127928.25@217.92@60@1.1511@5230.2@5497.55@5237.74@@@@@@@@@@0.44@1@@mg@500@1@@@@@@@@@@@8/4/2017@87.17@87.17@694400@CAPSULE@EURO@@@@@@@@200@MG@200 MG@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14923726@Onco@@@@@@@@@@@In Arm 1, docetaxel 35 mg/m2 will be administered on days 1 and 8, whereas cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks. In Arm 2, docetaxel 35 mg/m2 will be administered on days 1 and 8, whereas oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.@@L01XA03@L01X@-@PARIS, FRANCE@7/1/2009@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14923726@Combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer.@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@NCT00510107@90@-@-@@@-@@7/1/2007@-@-@@-@90 patients with advanced gastric cancer @@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@DOCETAXEL@CISPLATIN@@@OXALIPLATIN|DOCETAXEL|CISPLATIN||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@South Korea@@@@@South Korea|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@ELOXATIN@TAXOTERE@@@@ELOXATIN|TAXOTERE|||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916678@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.@@-@-@-@-@@@@@14916678@-@@-@-@@NO REVIEW@@@@-@Merger between Kyowa Hakko and Kirin Pharma announced in October 2007.@-@NCT00072189@17-33@-@-@@@-@@11/1/2003@-@PHII-33@@-@-@@@UCD-200311478-01, CHNMC-PHII-33, NCI-5536; @II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@KYOWA HAKKO KOGYO@KIRIN PHARMA@@@@KYOWA HAKKO KOGYO|KIRIN PHARMA|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@UCN-01@KW-2401@@@@UCN-01|KW-2401|||@PKC Inhibitor@@@@@PKC Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921187@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@TNFerade combo with radiotherapy and Erbitux@@-@-@-@-@@@@@14921187@Elderly or frail patients@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00496236@N/A@-@-@@@-@@@-@GV-001.010 (TNF-ELF)@@-@-@ELDERLY@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@CETUXIMAB@@@@-|CETUXIMAB|||@GENVEC@@@@@GENVEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@TNFERADE@ERBITUX@@@@TNFERADE|ERBITUX|||@Gene Therapy@@@@@Gene Therapy||||@MAXIMUM TOLERATED DOSE@RESPONSE RATE@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916468@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@BOSTON, MASSACHUSSETTS@@@@@14916468@Advanced blood and bone marrow cancers@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00421213@40@-@-@@@-@@@-@SGL20003@@-@-@@@II@II@@-@-@40 patients evaluable for safety and 21 evaluable for efficacy. In 3 of 7 lymphoma patients evaluable for efficacy, 1 patient (peripheral T-cell lymphoma) achieved a complete response, one patient (nodular sclerosis) is ongoing in cycle 3 with a PET scan interval response, and one patient (B-cell lymphoma) is ongoing with stable disease after 5 cycles of therapy. Of 14 leukemia patients evaluable for efficacy, 6 patients achieved stable disease (3 MDS and 3 CML) and 1 patient withdrew consent prior to efficacy evaluation. The study is ongoing and patient accrual continues. In these patients, therapy with darinaparsin was well tolerated with the most common serious adverse events being constitutional (pyrexia), pulmonary (dyspnea), cardiovascular (hypotension), and infection (sepsis) related. SOURCE: Ziopharm/AACR, 16 April 2008@-@@@@MONO@DARINAPARSIN@@@@@DARINAPARSIN||||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@ZIO-101@@@@@ZIO-101||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924466@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@TOKYO, JAPAN@@@@@14924466@Radiotherapy sensitizer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of MGI Pharma@-@-@-@-@Filing delayed as company had planned to submit accelerated Subpart H approval based on Phase II data but FDA approved another drug for the specific indication in October 2007 which precludes Eisai from doing this. Eisai now anticipates a filing in 2009/2010 with results from Study 301 (second-line breast cancer) and Study 305 (third-line breast cancer) in Phase III development.FILING FOR SUBPART H ACCELERATED APPROVAL DUE IN DECEMBER 2007 AS A THIRD-LINE BREAST CANCER TREATMENT@@@-@@@-@-@@-@-@@@I@I@@-@-@IND in preparation. SOURCE: Eisai, 1 February 2008@-@@@@-@-@@@@@-||||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Other@@@@@Other|||||||||@GPI-21016@@@@@GPI-21016||||@Radiation Sensitiser@@@@@Radiation Sensitiser||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918859@Onco@@@@@300f1008ntsdm@@@@@@NK-105 at a dose of 10MG/M2 once every 3 weeks@@-@-@-@-@@@@@14918859@-@@-@-@@NO REVIEW@@@@-@Licensed from NanoCarrier.@-@-@N/A@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@@The recommended dose for Phase II was found to be 150MG/M2 every 3 weeks with the MTD at 180MG/M2; dose-limiting toxicity was grade IV neutropaenia. Antitumour response was seen in one pancreatic cancer patient. Trials are expected to begin in ovarian, gastric and pancreatic cancer in 2006. SOURCE: Nippon Kayaku/ASCO, 6 June 2006@-@@@@MONO@PACLITAXEL, MICELLE@@@@@PACLITAXEL, MICELLE||||@NIPPON KAYAKU@@@@@NIPPON KAYAKU||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@NK-105@@@@@NK-105||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14925011@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Once a week injection of 160 IU/m2 of ADI-PEG 20 @@-@-@-@-@10/1/2003@@@@14925011@Hepatocellular carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00056992@34@-@-@@@-@@9/1/2002@-@2206@@-@-@@@II@II@@-@-@Final results: tumour regression in 47% of patients.@-@@@@MONO@-@@@@@-||||@PHOENIX PHARMACOLOGICS@@@@@PHOENIX PHARMACOLOGICS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@ADI-PEG20@@@@@ADI-PEG20||||@Enzyme@@@@@Enzyme||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922650@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dosing of BIIB-021 with frequency and duration@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14922650@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00618735@68@-@-@@@-@@2/1/2008@-@120ST103@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Solid Tumours@HER2+@@@@Solid Tumours|HER2+||||||||@BIIB-021@@@@@BIIB-021||||@HSP90 Inhibitor@HER2@@@@HSP90 Inhibitor|HER2|||@SAFETY@TOLERABILITY@PHARMACOKINETICS@@@PHARMACOKINETICS@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918783@Onco@@@@@300f1018ntsdm@@@@@@-@@-@-@-@-@@@"Provecta is an injectable small-molecule agent with a basic compound called Rose Bengal which is a synthetic dye that has been used by eye doctors in order to detect unhealthy blood vessels. This compound has been in use for many decades. When Rose Bengal is injected into a cancerous tumor and the tumor has been destroyed, the immune system experiences an awareness of cancerous cells. The immune system then seeks out similar cells throughout the entire body in order to attack and destroy the unhealthy cells. Provecta, when it is within the cancerous cell's membrane, causes the lysosomes (a part of the cell that contains digestive enzymes which cause the destruction of the cell) to rupture or leak. Provecta causes the cancerous cell to be destroyed from within the cell itself. Provecta also causes what is known as the ""bystander effect"" which is a response from the immune system that coerces the body to fight any tumors that are spread from the site of the injection. "@@14918783@Non-resectable liver cancer@@-@-@@NO REVIEW@@@-@-@-@-@-@10@-@-@@@-@@@-@N/A@@-@-@@@I/II@II@@-@-@Trial to start in H1 08. SOURCE: Provectus, January 2008@-@@@@MONO@-@@@@@-||||@PROVECTUS PHARMACEUTICALS@@@@@PROVECTUS PHARMACEUTICALS||||@@@@@@|||||||||@Liver Cancer@@@@@Liver Cancer|||||||||@PROVECTA@PV-10@@@@PROVECTA|PV-10|||@Other@@@@@Other||||@RECIST@@@@@@@@@@METASTATIC@@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14921102@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months (28-day cycles). SOURCE: Ziopharm@@-@-@-@BOSTON, MASSACHUSSETTS@3/1/2009@@@@14921102@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00591136@40@-@-@@@-@@4/1/2003@-@IBL1001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@INDIBULIN@@@@@INDIBULIN||||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Solid Tumours@Sarcoma@Ovarian Cancer@@@Solid Tumours|Sarcoma|Ovarian Cancer|||||||@ZIO-301@@@@@ZIO-301||||@Other@@@@@Other||||@PET SCAN ANTI-TUMOUR EFFECT@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916761@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@OSI-906 days 1-3, 1-5 or 1-7 every 14 days@@-@-@-@MELVILLE, NEW YORK@6/1/2009@@@@14916761@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00514306@75@-@-@@@-@@12/1/2006@-@OSI-906-102@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@OSI PHARMACEUTICAL@@@@@OSI PHARMACEUTICAL||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OSI-906@@@@@OSI-906||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921574@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The fused dendritic/tumor cells will be returned to the patient in a series of vaccines, six weeks apart. SOURCE: Genzyme@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14921574@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00050323@30@-@-@@@-@@11/1/2002@-@DCREN-005-01@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@DENDRITIC VACCINE@@@@@DENDRITIC VACCINE||||@Vaccine@@@@@Vaccine||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918913@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Azixa with oxaliplatin versus oxaliplatin or Azixa alone@@-@-@-@SALT LAKE CITY, UTAH@@@@@14918913@Primary brain cancer@@-@-@@NO REVIEW@@@@-@Myriad licensed the MX-90745 series of apoptosis inducing compounds in December 2003 from Maxim Pharmaceuticals (now EpiCept)@-@-@-@-@-@@@-@@3/1/2007@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@BOTH@-@@@@@-||||@MYRIAD GENETICS@@@@@MYRIAD GENETICS||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@AZIXA@MPC-6827@@@@AZIXA|MPC-6827|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@RANDOMISED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16425170@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE24@L01X@@@@@Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases.@@16425170@Relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukaemia@@NA@18-Nov-16@11/18/2016@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@@MHLW, 18 November 2016@11/18/2016@@@@@@@No@@@@@@APPROVED@@@NHI@@@@@@MONO@PONATINIB@@@@@PONATINIB||||@OTSUKA PHARMACEUTICAL@@@@@OTSUKA PHARMACEUTICAL||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@ICLUSIG@@@@@ICLUSIG||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@@@@@@@@@@@RELAPSED@REFRACTORY@@@@@@@@@1@1@1301974.56@@@81@day@81 day@1301974.56@1301974.56@16073.76@1@0.0091@5357.92@6318.3@@@@@@@@@@@357.19@1@@mg@45@1@@@@@@@@@@@8/30/2017@5357.92@5357.92@4291048F1020@TABLET@YEN@@@@@@@@15@MG@15 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14922497@Onco@@@@@@@@@@@Docetaxel/Gemzar versus docetaxel alone@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922497@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00191243@240@-@-@@@-@@3/1/2002@-@5758B9E-MC-S241  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@DOCETAXEL@@@@GEMCITABINE HYDROCHLORIDE|DOCETAXEL|||@LILLY@@@@@LILLY||||@Finland@@@@@Finland|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GEMZAR@TAXOTERE@@@@GEMZAR|TAXOTERE|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@TIME TO TREATMENT FAILURE@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15409676@Onco@@@@@@@@@@@AFM13 + Pembrolizumab, Experimental, Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.@@@@@@9/1/2017@@@@15409676@A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)@Both@@@@@@@@@@@NCT02665650@33@@@@@@@3/1/2016@@AFM13-103@@@1. Diagnosis of CD30+ classical Hodgkin lymphoma reconfirmed by histopathology. Note: where reconfirmation is not possible, patients will still be eligible where they have confirmation clearly documented in their medical records.  2. Relapsed or refractory disease after standard therapy including brentuximab vedotin (Adcetris®).  3. Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug which could interact with this trial not less than 4 weeks (or 5 half-lives of the drug, whichever occurs later) prior to first dose of study drug. Cessation of small molecule tyrosine kinase inhibitors must be at least 7 days prior to first dose of study drug.  4. Completion of, if applicable, an autologous stem cell transplantation (ASCT) at least 3 months prior to first dose of study drug.  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) <2.  Main@@ADULTS@Phase 1@I@@@@@@@@@@AFM13@@@@@AFM13||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@-@@@@@-||||@Other@@@@@Other||||@Number of participants experiencing dose limiting toxicity (DLT) during combination treatment@@@@@Number and frequency of adverse events@@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@TREATMENT@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921840@Onco@@@@@@@@@@@N/A@@-@-@-@BASEL, SWITZERLAND@@@Nilotinib is an inhibitor of the Bcr-Abl kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. In vitro, nilotinib inhibited Bcr-Abl mediated proliferation of murine leukemic cell lines and human cell lines derived from Ph+ CML patients. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine Bcr-Abl xenograft model. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: Bcr-Abl (20-60 nM), PDGFR (69 nM) and c-Kit (210 nM).@@14921840@Nilotinib in adults in blast crisis who are imatinib-resistant or intolerant@@-@-@@NO REVIEW@@@@-@-@-@NCT00264160@20@-@-@@@-@@12/1/2006@-@CAMN107AIL01@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@MONO@NILOTINIB@@@@@NILOTINIB||||@NOVARTIS@@@@@NOVARTIS||||@Israel@@@@@Israel|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@TASIGNA@@@@@TASIGNA||||@TK Inhibitor@bcr-abl@PDGF@SCF@@TK Inhibitor|bcr-abl|PDGF|SCF|@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922775@Onco@@@@@300f1018ntsdm@@@@@@2-hour and 4-hour infusion groups@@-@-@-@-@@@@@14922775@-@@-@-@@NO REVIEW@@@@-@-@-@-@19@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@Eight of the nineteen patients enrolled in the 2-hour and 4-hour infusion groups of the Phase I clinical trial completed six or more cycles of treatment and as a result were able to be evaluated for the Phase IIA component of the trial.  Of the eight, three displayed significant partial responses.  One of the three patients had metastatic renal cell carcinoma, and showed a long term durable response (>15 months).  Of the other two significant partial responders, one patient passed away due to the long term effects of cancer (even though he had >50% tumour reduction) the other reported stable disease and experienced good quality of life. The Phase I cancer trial was also designed to provide QoL data using the industry standard EORTC questionnaire.  Results from the 2 hour infusion patients confirm that a significant portion of patients treated with Coramsine showed improvement in QoL parameters usually negatively affected by cancer chemotherapy. SOURCE: Solbec@-@@@@MONO@SOLASONINE AND SOLAMARGINE@@@@@SOLASONINE AND SOLAMARGINE||||@SOLBEC PHARMACEUTICALS@@@@@SOLBEC PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@CORAMSINE@@@@@CORAMSINE||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14924832@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924832@GBM@@-@-@@NO REVIEW@@@@-@Macrochem acquired Virium. SOURCE: Virium, 28 April 2008@-@-@23@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Overall RR of 32%, including stable disease with media survival of 5.4 months.@-@@@@-@-@@@@@-||||@MACROCHEM CORP@VIRIUM PHARMACEUTICAL@@@@MACROCHEM CORP|VIRIUM PHARMACEUTICAL|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@VP-101@EL-532@@@@VP-101|EL-532|||@HDAC@@@@@HDAC||||@RESPONSE RATE@@@@@@@@@@MALIGNANT@RELAPSED@@@@DOSE ESCALATION@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922536@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@One injection every four months@@L02AE04@L02A@-@PARIS, FRANCE@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins. @@14922536@-@@-@-@@NO REVIEW@@@@-@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@FIRST-LINE@NCT00415246@100@-@DISCONTINUED IN PHASE III TRIALS IN JUNE 2007@@@-@@@-@2-55-52014-145  @@2010@100 PATIENTS WITH PROSTATE CANCER@@@III@III@@-@-@Sustainable blood levels of triptorelin were not achieved; no safety issues; trial discontinued but Ipsen plans to develop a new 4-month formulation@-@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@IPSEN@DEBIOPHARM@@@@IPSEN|DEBIOPHARM|||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@DECAPEPTYL@@@@@DECAPEPTYL||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916470@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@BOSTON, MASSACHUSSETTS@@@@@14916470@-@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00303199@48@-@-@@@-@@@-@SGL 2001@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@DARINAPARSIN@@@@@DARINAPARSIN||||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ZIO-101@@@@@ZIO-101||||@Other@@@@@Other||||@CTCAE@EMBT@SAFETY@@@SAFETY@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921679@Onco@@@@@300f1008ntsdm@@@@@@10MG daily@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921679@Advanced gastric cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00519324@52@-@-@@@@@8/1/2007@-@CRAD001C1201@@-@-@@@II@II@@-@@@-@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RECIST@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14916469@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@BOSTON, MASSACHUSSETTS@@@@@14916469@-@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00423644@40@-@-@@@-@@@-@SGL 2001b@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@DARINAPARSIN@@@@@DARINAPARSIN||||@ZIOPHARM ONCOLOGY@@@@@ZIOPHARM ONCOLOGY||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@ZIO-101@@@@@ZIO-101||||@Other@@@@@Other||||@CTCAE@EMBT@SAFETY@@@SAFETY@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16423932@Onco@@@@@@@@@@@"PDR001, Experimental, 90 patients will be administered PDR001 infusion."@@@@@BASEL, SWITZERLAND@12/1/2019@@@@16423932@An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment EUDRACT 2016-002522-36@Both@@@@@PDR001 is a high-affinity, ligand-blocking, humanized IgG4 antibody directed against Programmed Death-1 (PD-1) receptor that blocks the binding of PD-L1 and PD-L2. PDR001 dose is 400 mg infusion every 4 weeks.@@@@@@NCT02955069@90@@@@@@@2/1/2017@@CPDR001E2201@@@- Pathologically confirmed, well-differentiated advanced, non-functional neuroendocrine tumor of GI, pancreatic or thoracic origin.  -  No history of, and no active symptoms related to carcinoid syndrome.  -  Patients must have been pretreated for advance@@ADULTS@Phase 2@II@@@@@@@@@@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@PDR001@@@@@PDR001||||@Other@@@@@Other||||@Overall response rate@@@@@Duration of response@Disease Control@@@@METASTATIC@ADVANCED@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918920@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@LONDON, UNITED KINGDOM@@@@@14918920@Also being developed in Phase I trials for CLL and paediatric ALL@@-@-@@NO REVIEW@@@@-@CAT licensed it in July 2006 from Enzon, which had acquired it from the NCI@-@-@-@-@-@@@-@@@-@N/A@@-@-@PAEDIATRIC@@II@II@@-@-@ASCO 2007; the activity of CAT 3888 in CdA-resistant hairy cell leukemia was confirmed with high complete response and overall response rates. CAT 3888 response was higher in patients without splenectomy and with mild-moderate splenomegaly. The only serious toxicity was completely reversible grade 3 hemolytic uremic syndrome.@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Hairy Cell Leukaemia@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Hairy Cell Leukaemia|||||||@CAT-3888@@@@@CAT-3888||||@mAb@Murine@Immunotoxin@CD22@@mAb|Murine|Immunotoxin|CD22|@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922500@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Gemzar/LY-293111 versus Gemzar/placebo@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922500@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00055250@130@-@-@@@-@@@-@4840H6H-MC-JEAL  @@-@-@@@II@II@@-@-@Trial completed but results RESULTS PENDING@-@@@@COMBO@-@GEMCITABINE@@@@-|GEMCITABINE|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@LY-293111@GEMZAR@@@@LY-293111|GEMZAR|||@LTB4 Receptor Antagonist@@@@@LTB4 Receptor Antagonist||||@OVERALL SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916453@Onco@@@@@@@@@@@Oral administration for both 4SC-201 and Nexavar@@@@@Planegg-Martinsried, Germany@@@@@14916453@A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment@@@@@@@@JULY 2009 - MARCH 2012@@@@NCT00943449@48@@@@@@@@@SHELTER@@@Patients exhibiting progressive disease under Sorafenib treatmentChild-Pugh class A and B. Only patients with Child-Pugh index class B of not more than 7 will be includedECOG performance status 0, 1 or 2@@@II@II@@@@>>Primary endpoint met. Resminostat in combination with sorafenib was able to prevent further progression of the disease for at least 12 weeks in two-thirds of the currently 15 evaluable patients and considerably longer - well over a year - in individual cases. Accordingly, the progression-free survival rate (PFSR) after 12 weeks is currently 66.6% for the combination therapy group and 33.3% for the monotherapy group of currently 9 evaluable patients. Furthermore, median progression-free survival (PFS), which is defined as the period of time for which the progression of the disease can be halted, is presently 4.6 months (140 days) for the combination therapy group and 1.4 months (42 days) for the monotherapy group.[4SC 19 January, 2012 http://www.4sc.de/news-media/corporate-news/2012 ]>>Trial registered. [21 July 2009, 4SC AG]@@@@@COMBO@RESMINOSTAT@@@@@RESMINOSTAT||||@4SC@@@@@4SC||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@4SC-201@@@@@4SC-201||||@Other@@@@@Other||||@PROGRESSION-FREE SURVIVAL@@@@@SAFETY@BIOMARKERS@@@@ADVANCED@@@@@OPEN-LABEL@NON-RANDOMISED@PARALLEL-ARM@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921612@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AZD-4877 alone@@-@-@-@LONDON, UNITED KINGDOM@@@@@14921612@Cell cycle inhibitor@@-@-@@NO REVIEW@@@@-@-@-@NCT00486265@N/A@-@-@@@-@@6/1/2007@-@D2782C00007  @@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@AZD-4877@@@@@AZD-4877||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921757@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@MCS-100 is an M-CSF antibody.@@14921757@MCS110 in Patients With Prostate Cancer and Bone Metastases@@-@-@@NO REVIEW@@@@-@-@-@NCT00757757@100@-@-@@@-@@9/1/2008@-@CMCS110A2101@@-@Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment @@@I/II@I@@-@-@Trial registered. [Novartis, 21.09.2008]@-@@@@-@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Prostate Cancer@Bone Metastases@@@@Prostate Cancer|Bone Metastases||||||||@MCS-100@@@@@MCS-100||||@mAb@@@@@mAb||||@DOSE-LIMITING TOXICITY@ADVERSE EVENTS@@@@BONE RESORPTION MARKERS@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920136@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01AA01@L01A@@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14920136@@@@@@NO REVIEW@@@@@@@@@@FDA, 21 May 2008@5/21/2008@@@@@@@No@@@@@@APPROVED@@@MEDICARE@@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Breast Cancer@Ovarian Cancer@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Breast Cancer|Ovarian Cancer||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@366.25@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@366.25@366.25@10019-0955-01@LYOPHILISATE FOR SOLUTION FOR INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924797@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L02AE04@L02A@-@CORONA, CALIFORNIA@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins. @@14924797@Line extension@@-@-@@NO REVIEW@@@@-@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@RESULTS PENDING@-@@@@-@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@WATSON PHARMACEUTICALS@DEBIOPHARM@@@@WATSON PHARMACEUTICALS|DEBIOPHARM|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TRELSTAR@@@@@TRELSTAR||||@LH-RH Analog@@@@@LH-RH Analog||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTABLE SUSPENSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922168@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NO LABELLED TRIAL@@A14AA08@A14A@YES@-@@@@@14922168@Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections or severe trauma, and in some patients who withough definite pathophysiologic reasons fail to gain or to maintain normal weight.@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@-@-@-@The daily adult dosage is 2.5MG to 20MG given in 2 to 4 divided doses.@-@@@-@@@Peliosis hepatitis has been reported in patients receiving androgenic anabolic steroid therapy. These cysts are sometimes present with minimal hepatic dysfunction, but at other times they have been associated with liver failure.@NO LABELLED TRIAL@@-@-@@@-@DISCONTINUED@@-@MEDICARE@NO LABELLED TRIAL@-@@@@ADJUVANT@OXANDROLONE@@@@@OXANDROLONE||||@UPSHER SMITH@@@@@UPSHER SMITH||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@OXANDRIN@@@@@OXANDRIN||||@Anabolic Steroid@@@@@Anabolic Steroid||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@60@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@1/8/2015@@@54396-0110-60@TABLET@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920982@Onco@@@@@@@@@@@Patients receive Iressa or carboplatin / paclitaxel DC@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14920982@First-line NSCLC@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00322452@1212@-@-@@@-@@3/1/2006@-@IPASS@@-@-@@@III / D791AL00001 (V-15-32) / @III@@-@-@Iressa was better tolerated and more effective than conventional chemotherapy. [AstraZeneca/ESMO, 16.09.2008]@-@@@@MONO@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@Asia-Pacific@@@@@Asia-Pacific|||||||||@NSCLC@@@@@NSCLC|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@RANDOMISED@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922280@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly AP-23573@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Deforolimus is a novel small-molecule inhibitor of the protein mTOR, a “master switch” in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. @@14922280@Androgen-independent prostate cancer; taxane resistant@@-@-@@NO REVIEW@@@@-@Merck licensed the drug in July 2007 for US$75 mil. upfront, up to US$452 mil. in milestone payments and up to US$200 mil. in sales-related bonus. Merck will cover half development costs@-@NCT00110188@38@-@-@@@-@@5/1/2005@-@AP23573-04-204@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@RIDAFOROLIMUS@@@@@RIDAFOROLIMUS||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@AP-23573@@@@@AP-23573||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14925029@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intratumoral injection of 10(6) pfu/mL, followed three weeks later by 10(8) pfu/mL every two weeks to a maximum of 24 injections.@@-@-@-@WOBURN, MASSACHUSSETTS@@@@@14925029@Stage IIIc and IV malignant melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00289016@60@-@-@@@-@@10/1/2005@-@203@@-@-@@@II@II@@-@-@ASGT June 2007; 7 patients have been enrolled into the trial so far, receiving between 2-15 injections of OncoVEX GM-CSF. 1 patient achieved a complete target lesion response and resolution of tumours at reporter sites in the lung, liver and subcutaneous axillary fold; the patient is off therapy and disease-free 12.5 months after start of therapy. 3 patients achieved stable disease in the target lesion. No serious adverse events were reported.@-@@@@MONO@-@@@@@-||||@BIOVEX@@@@@BIOVEX||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ONCOVEX@@@@@ONCOVEX||||@Gene Therapy@Immunotherapy@@@@Gene Therapy|Immunotherapy|||@RESPONSE RATE@OVERALL SURVIVAL@TIME TO PROGRESSION@@@TIME TO PROGRESSION@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922571@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Gimatecan on Days 1-5 during each 28-day cycle@@-@-@-@BASEL, SWITZERLAND@@@@@14922571@-@@-@-@@NO REVIEW@@@@-@Worldwide rights licensed to Novartis in 2003@-@NCT00493571@30@-@-@@@-@@8/1/2007@-@2006-0943@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@GIMATECAN@@@@@GIMATECAN||||@NOVARTIS@SIGMA TAU@@@@NOVARTIS|SIGMA TAU|||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@LBQ-707@@@@@LBQ-707||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16511655@Onco@@@@@@@@@@@Nivolumab/Ipilimumab Combination, Experimental, Specified dose on specified days@@L01XC17@L01X@@NEW YORK, NEW YORK@1/1/2019@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16511655@An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)@Both@@@@@@@@@@FIRST-LINE@NCT03001882@100@@@@@@@1/1/2017@@CA209-592@@@Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease  -  Measurable disease by CT or MRI  -  Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work@@ADULTS@Phase 2@II@@@@@@@@@@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Objective Response Rate (ORR)@@@@@Objective Response Rate (ORR) of patient subgroups defined by baseline biomarkers@Disease Control Rate (DCR) of patient subgroups defined by baseline biomarkers@@@@EARLY@@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@Treatment@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919075@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Intramuscular injection of 40, 80 or 160 IU/M2 once weekly for 9 weeks@@-@-@-@-@8/1/2008@@@@14919075@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00520299@38@-@-@@@-@@7/1/2007@-@MSKCC IRB #06-165, @@-@-@@@I/II@II@@-@-@Final results: tumour regression in 47% of patients.@-@@@@MONO@-@@@@@-||||@PHOENIX PHARMACOLOGICS@@@@@PHOENIX PHARMACOLOGICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ADI-PEG20@@@@@ADI-PEG20||||@Enzyme@@@@@Enzyme||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916001@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@TOKYO, JAPAN@12/1/2008@@@@14916001@HPV/cervical dysplasia@@-@-@@NO REVIEW@@@@-@Eisai acquired through takeover of MGI Pharma.@-@NCT00264732@288@-@-@@@-@@7/1/2005@-@ZYC1-004@@-@-@@@II/III@III@@-@-@RESULTS PENDING@-@@@@MONO@AMOLIMOGENE@@@@@AMOLIMOGENE||||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@ZYC-101A@@@@@ZYC-101A||||@Other@@@@@Other||||@CIN 2/3 RESOLUTION@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16406117@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE16@L01X@@NEW YORK, NEW YORK@@@@@16406117@XALKORI is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).@@YES@@@NO REVIEW@@@@100%@Acquired through takeover of Pharmacia Corp., which acquired it from Sugen@@@53@The recommended dose schedule of XALKORI is 250 mg twice daily (500 mg daily) takencontinuously.@EMA, 25 August 2016@8/25/2016@@No@@@@Study 1001@No@@@ROS1-positive@@@APPROVED@@@NHS@@@@@@MONO@CRIZOTINIB@@@@@CRIZOTINIB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XALKORI@@@@@XALKORI||||@PDGF@@@@@PDGF||||@OBJECTIVE RESPONSE RATE@DURATION OF RESPONSE@@@@@@@@@ADVANCED@@@@@MULTICENTER@SINGLE-ARM@@@@1@1@80283.62371@@@19.3@month@19.3 month@80283.62@80283.62@136.76@60@1.299@4102.88@@4689@@@@@@@@@@0.27@1@@mg@500@1@@@@@@@@@@@7/28/2017@68.38@68.38@2.16E+16@HARD CAPSULE@GB£@@@@@@@@250@MG@250 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14921716@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@160mg/m2 per week dosing@@-@-@-@MENLO PARK, CALIFORNIA@3/1/2008@@@@14921716@Treating advanced CLL@@-@-@@NO REVIEW@@@@-@-@-@NCT00124189@48@-@-@@@-@@7/1/2005@-@CP04-151@@-@-@@@I/II@II@@-@-@June 2007; one-third of patients had stable disease. Well-tolerated and maximum tolerated dose has not yet been reached (peak plasma concentrations of the compound stand at 10µg/mL).@-@@@@MONO@-@@@@@-||||@GERON@@@@@GERON||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@GRN-163L@@@@@GRN-163L||||@Telomerase Inhibitor@@@@@Telomerase Inhibitor||||@SAFETY@@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919298@Onco@@@@@@@@@@@Either twenty-four or twelve hours prior to surgery, the patient will receive an intravenous dose of 1 mg/kg of LS11, given IV by slow push over 3-5 minutes.@@-@-@-@BELLEVUE, WASHINGTON@@@Litx is a targeted treatment. Destruction of tumor tissue with Litx occurs only where light is delivered in sufficient quantity, thereby sparing the patient the debilitating side effects common to therapies such as radiation and chemotherapy. Litx requires a specific amount of light at a specific wavelength to energize the LS11 drug molecules before tissue destruction occurs, and tissue destruction then occurs only in the immediate vicinity of the LED array. Because the Litx system can control the location and amount of light exposure, it can maintain clean boundaries between destroyed and spared tissue. In addition, LS11 has been shown to accumulate preferentially in tumor tissue, which could be important in the treatment of some solid tumors. @@14919298@Primary or recurrent glioma@@-@Development terminated, looking for licensing partners@@NO REVIEW@@@@-@-@MULTIPLE@NCT00409214@18@-@-@@@-@@11/1/2006@-@LSO-OL007@@-@-@@@II@II@@-@-@Trial registered [LSO, 7.12.2006]@-@@@@MONO@TALAPORFIN SODIUM@@@@@TALAPORFIN SODIUM||||@LIGHT SCIENCES ONCOLOGY@@@@@LIGHT SCIENCES ONCOLOGY||||@Serbia@@@@@Serbia|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@LS-11@LITX@@@@LS-11|LITX|||@Other@@@@@Other||||@SAFETY@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921658@Onco@@@@@300f1010ntsdm@@@@@@Continuous maintenance treatment@@-@-@-@INGELHEIM, GERMANY@@@@@14921658@Relapsed ovarian cancer, fallopian tube cancer or primary peritoneal cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00370175@90@-@-@@@-@@3/1/2006@-@CRUK-1199.9@@-@-@@@II@II@@-@-@Endpoint is PFS at 9 months of treatment.@-@@@@MONO@-@@@@@-||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@VARGATEF@BIBF-1120@@@@VARGATEF|BIBF-1120|||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14916413@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@12/1/2009@@@@14916413@Untreated AML in patients older than 60@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00607997@55@-@-@@@-@@2/1/2008@-@SPO-0014@@-@-@ELDERLY@@II@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SUNESIS PHARMACEUTICALS@@@@@SUNESIS PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@SNS-032@@@@@SNS-032||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918819@Onco@@@@@@@@@@@One IM injection of 11.25 MG in two groups of 10 patients@@L02AE04@L02A@-@LAUSANNE, SWITZERLAND@@@Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotrophins. @@14918819@-@@-@-@@NO REVIEW@@@-@-@Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialisation rights of Decapeptyl in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan). [Ipsen, 31 October 2007]@-@-@20@-@To be filed in 2008@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Botte formulations were able to induce castration levels (<1.735 nmol/1) of testosterone within 3 to 4 weeks post-injection, and to maintain levels below 1.735 nmol/I tilt the end of 3rd month. The bioavailability of one formulation (DLGSD-395-21) tended to be greater. SOURCE: Debiopharm, 2001@-@@@@MONO@TRIPTORELIN PAMOATE@@@@@TRIPTORELIN PAMOATE||||@DEBIOPHARM@@@@@DEBIOPHARM||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TRELSTAR@DECAPEPTYL@@@@TRELSTAR|DECAPEPTYL|||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@@@@@@@@@@ADVANCED@@@@@MULTI-CENTRE@OPEN-LABEL@NON-COMPARATIVE@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921321@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1, 0.3, 1.0, 3.0, 10.0 or 15.0 mg/kg IV (one dose every 14 days) SOURCE: Genzyme@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@3/1/2008@@@@14921321@RCC or malignant melanoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00356460@36@-@-@@@-@@7/1/2006@-@GC100800305@@-@-@@@I@I@@-@-@Maximum tolerated dose was 15mg/kg; 1 patient experiences a partial repsonse; time to progression was 22.4-52.4 weeks. No dose-limiting toxicities seen. SOURCE: Genzyme/ASCO, 2 June 2008@-@@@@MONO@-@@@@@-||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Melanoma / Skin Cancer@Kidney Cancer@Renal Cell Carcinoma@@@Melanoma / Skin Cancer|Kidney Cancer|Renal Cell Carcinoma|||||||@GC-1008@@@@@GC-1008||||@mAb@Human@@@@mAb|Human|||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916698@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Administered either as a single application or as two applications (day 1 and 8)@@-@-@-@EMERYVILLE, CALIFORNIA@@@@@14916698@Superficial basal cell carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00432185@58@-@-@@@-@@2/1/2007@-@PEP005-009@@-@-@@@II@II@@-@-@This trial has the goal of optimising the dose of PEP005 Topical for the treatment of superficial basal cell carcinoma (sBCC). The 009 trial is expected to define the MTD of PEP005 Topical gel when applied to a sBCC either with one application or two applications of drug, one week apart. It is being conducted under Peplin's open IND application with FDA. SOURCE: Peplin@-@@@@MONO@-@@@@@-||||@PEPLIN@@@@@PEPLIN||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PEP-005@@@@@PEP-005||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TOPICAL GEL@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921664@Onco@@@@@@@@@@@Weekly everolimus with trastuzumab and vinorelbine@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921664@HER2-overexpressing; combo with Herceptin and vinorelbine@@-@-@@NO REVIEW@@@FEBRUARY 2007-@-@-@-@NCT00426530@60@-@-@@@EMEA issued positive opinion to grant Orphan Drug status for everolimus to treat neuroendocrine gastroenteropancreatic tumours@@@-@CRAD001J2102@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@TRASTUZUMAB@@@@EVEROLIMUS|TRASTUZUMAB|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AFINITOR@RAD-001@HERCEPTIN@@@AFINITOR|RAD-001|HERCEPTIN||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@DOSE-LIMITING TOXICITY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921830@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@PI3K inhibitor@@14921830@Advanced Solid Malignancies Including Patients With Advanced Breast Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00600275`@130@-@-@@@-@@12/1/2007@-@CBGT226A2101@@-@>> Histologically-confirmed, advanced solid tumors      >> Progressive, recurrent unresectable disease@@@I/II@II@@-@-@Trial registered. [Novartis, 11.01.2008]@-@@@@-@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Solid Tumours@Breast Cancer@@@@Solid Tumours|Breast Cancer||||||||@BGT-226@@@@@BGT-226||||@TK Inhibitor@@@@@TK Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@PHARMACOKINETICS@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916701@Onco@@@@@300f1014ntsdm@300f1813ntsdm@@@@@-@@L01XE03@L01X@-@BASEL, SWITZERLAND@@@The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.@@14916701@Erlotinib and concurrent palliative thoracic radiation therapy @@-@-@@NO REVIEW@@@@-@">> Roche announces US$43.7 billion proposal to assume full control of Genentech. [Roche, 21 July 2008]      >> To meet FTC requirements for its merger with Warner Lambert, Pfizer was was forced to divest its stake in erlotinib in June 2000 back to OSI. In January 2001, Genentech and Roche licensed global co-development and commercialisation. [OSI, January 2001]       >> Pfizer acquired major stake in Oncogene (now OSI) to form a collaborative research programme. [Oncogene, 8.07.1986]"@-@NCT00391248@45@-@-@@@-@@@-@PEARL @@-@-@@@II@II@@-@-@Not yet available@-@@@@MONO@ERLOTINIB HYDROCHLORIDE@@@@@ERLOTINIB HYDROCHLORIDE||||@ROCHE@@@@@ROCHE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARCEVA@@@@@TARCEVA||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@LUNG CANCER SYMPTOM SCALE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@C$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@49@Canada@@@@@@@@
14924531@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@This is a novel, second-generation pan-Histone Deacetylase (HDAC) inhibitor with anti-tumor activity against solid and hematological malignancies, which interferes with expression of genes that control cancer cell proliferation, angiogenesis and metastasis; phase I trials are ongoing.@@14924531@-@@-@-@@NO REVIEW@@@@-@Ortho Biotech is part of the Johnson & Johnson group.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@JOHNSON & JOHNSON@ORTHO BIOTECH@@@@JOHNSON & JOHNSON|ORTHO BIOTECH|||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@JNJ-26481585@@@@@JNJ-26481585||||@HDAC@@@@@HDAC||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16400067@Onco@@@@@@@@@@@Pre-Randomization, Experimental, Subjects will receive single-agent ibrutinib for 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cyclesMRD- negative subjects, Placebo Comparator, ibrutinib or placeboMRD-positive subjects, Active Comparator, ibrutinib plus venetoclax or ibrutinib only@@L01XE27@L01X@@BEERSE, BELGIUM@2/1/2021@@Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion,@@16400067@Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma@Both@@@@@@@@@@FIRST-LINE@NCT02910583@150@@@@@@@12/1/2016@@PCYC-1142-CA@@@Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria (Hallek 2008), with active disease meeting at least 1 IWCLL criteria for requiring treatment.  -  Measurable nodal disease by computed tomography (CT)  -  Adequate hepatic, and renal function  -  Adequate hematologic function  -  absolute neutrophil count >750/µL  -  platelet count >30,000 /μL  -  hemoglobin >8.0 g/dL@@ADULTS@Phase 2@II@@@@@@@@@BOTH@IBRUTINIB@VENETOCLAX@@@@IBRUTINIB|VENETOCLAX|||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Chronic Lymphocytic Leukaemia@@@@@Chronic Lymphocytic Leukaemia|||||||||@IMBRUVICA@VENCLEXTA@@@@IMBRUVICA|VENCLEXTA|||@TK Inhibitor@@@@@TK Inhibitor||||@MRD-negative clinical response rate@Disease free survival@@@@@@@@@-@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@Double Blind (Subject,  Investigator,  Outcomes Assessor)@TREATMENT@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919058@Onco@@@@@@@@@@@Patients were randomly assigned to one of two dose regimens of Teverelix LA.  20 patients received the higher dose and 18 patients received the lower dose. SOURCE: Ardana@@-@-@-@EDINBURGH, UNITED KINGDOM@@@@@14919058@-@@-@-@@NO REVIEW@@@@-@Development costs are assumed by Ardana Biosciences from 'terna Zentaris. As part of the agreement, Zentaris will provide certain development services and supply clinical samples to Ardana. On April 2, 2004, Ardana extended its agreement and acquired full@-@-@38@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Preliminary results: Mean testosterone levels in the higher and lower dose groups at baseline were 3.71 ng/ml and 4.3 ng/ml respectively. Suppression of testosterone was attained in both dose groups by Day 3 in 18/20 and 14/18 patients, respectively. Preliminary data from the higher dose group shows that reduction of testosterone levels to castration level was attained in 19/20 patients.  For these 19 patients, the duration of castration was between 54 and 147 days with 17 patients being castrated for 8 weeks (56 days) or more. Also noted in the higher dose group was a rapid effect on PSA levels. At Week 4, 14/19 (74%) of patients had normalised PSA (< 4.0 ng/ml).  Mean PSA levels for the group were normalised at 8 weeks. SOURCE: Ardana, 4 September 2007@-@@@@MONO@TEVERELIX@@@@@TEVERELIX||||@ARDANA BIOSCIENCE@@@@@ARDANA BIOSCIENCE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TEVERELIX LA@@@@@TEVERELIX LA||||@LH-RH Analog@@@@@LH-RH Analog||||@SERUM TESTOSTERONE@MEDICAL CASTRATION@PSA@@@PSA@@@@@-@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921911@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@BMS-663513 0.1MG/KG 0.3, 1.3, 6 or 10MG/KG q 3 weeks, 12 weeks@@-@-@-@NEW YORK, NEW YORK@1/1/2012@@@@14921911@Combo with either radiotherapy or radiotherapy plus paclitaxel and carboplatin@@-@-@@NO REVIEW@@@@-@Medarex receives part-royalties and milestones.@-@NCT00461110@68@-@-@@@-@@12/1/2007@-@CA186-005@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BMS@@@@@BMS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@BMS-663513@@@@@BMS-663513||||@mAb@@@@@mAb||||@MAXIMUM TOLERATED DOSE@SAFETY@TOLERABILITY@@@TOLERABILITY@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920927@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@GVAX alone@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@1/1/2006@@@@14920927@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00116467@55@-@-@@@-@@3/1/2001@-@K-0009@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@CELL GENESYS@@@@@CELL GENESYS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GVAX LEUKAEMIA@@@@@GVAX LEUKAEMIA||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16671596@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE36@L01X@@@@@Alectinib is a tyrosine kinase inhibitor that targets ALK and RET.@@16671596@Treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer.@@NA@@@@@@@@@@@46@@MHLW, 20 June 2014@6/20/2014@11/28/2015@Yes@@@@@No@@@ALK POSITIVE@@II@APPROVED@@@NHI@@@@@@MONO@ALECTINIB@@@@@ALECTINIB||||@CHUGAI PHARMACEUTICAL@@@@@CHUGAI PHARMACEUTICAL||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ALECENSA@@@@@ALECENSA||||@TK Inhibitor@@@@@TK Inhibitor||||@@@@@@@@@@@UNRESECTABLE@ADVANCED@@@@@@@@@1@1@7643275.086@@@11.2@month@11.2 month@7643275.09@7643275.09@22436.72@1@0.0091@5609.18@6614.6@@@@@@@@@@@37.39@1@@mg@600@1@@@@@@@@@@@8/30/2017@5609.18@5609.18@4291032M3021@CAPSULE@YEN@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
16423930@Onco@@@@@@@@@@@"Dose Escalation Dose 1, Experimental, BMS-986012 Dose Escalation Dose 1Dose Escalation Dose 2, Experimental, BMS-986012 Dose Escalation Dose 2Chemotherapy Combination, Active Comparator, BMS-986012 + Cisplatin + Etoposide"@@@@@NEW YORK, NEW YORK@10/1/2018@@@@16423930@A Phase 1 Study of the Safety and Tolerability of BMS-986012 in Subjects With Small Cell Lung Cancer@Both@@@@@@@@@@FIRST-LINE@NCT02949895@18@@@@@@@1/1/2017@@CA001-045@@@-For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  -  Histological or cytological confirmed small cell lung cancer (SCLC)  -  Eastern Cooperative Oncology Group Performance Status 0-1  @@ADULTS@Phase 1@I@@@@@@@@@COMBO@-@Cisplatin@Etoposide@@@-|Cisplatin|Etoposide||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@BMS-986012@GENERIC@GENERIC@@@BMS-986012|GENERIC|GENERIC||@Other@@@@@Other||||@Number of participants with adverse events (AEs)@Number of participants with serious adverse events (SAEs )@Number of Discontinuations due to AEs@@@Maximum observed serum concentration (Cmax)@Time of maximum observed serum concentration(Tmax)@@@@@@@@@Non-Randomized@Safety Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921511@Onco@@@@@300f1008ntsdm@@@@@@Zoladex 10.8mg Depot given 3 monthly versus Zoladex 3.6mg Depot monthly@@L02AE03@L02A@-@LONDON, UNITED KINGDOM@@@Zoladex (D-Ser(But)6 Azgly10 LHRH) is a synthetic analogue of naturally occurring LHRH. On chronic administration Zoladex results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. This effect is reversible on discontinuation of therapy. Initially, Zoladex, like other LHRH agonists, may transiently increase serum testosterone concentration in men and serum estradiol concentration in women.@@14921511@Pre-menopausal women with ER-positive early breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00303524@168@-@-@@@-@@10/1/2005@-@EBC STUDY  @@-@-@@@II@II@@-@@Trial is finished, but results not available.@-@@@@MONO@GOSERELIN ACETATE@@@@@GOSERELIN ACETATE||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZOLADEX@@@@@ZOLADEX||||@LH-RH Analog@@@@@LH-RH Analog||||@OESTROGEN@@@@@@@@@@EARLY@@@@@RANDOMISED@PARALLEL ASSIGNMENT@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14921194@Onco@@@@@@@@@@@-@@-@-@-@BRENTFORD, UNITED KINGDOM@@@GSK-249553 is a MAGE3 protein specific vaccine.@@14921194@GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection@@-@-@@NO REVIEW@@@May 2002-June 2009@-@-@-@NCT00290355@180@-@-@@@-@@@-@GSK-249553/004@@-@>> At least 18 years of age at the time of resection.     >> Pathologically proven, surgically staged squamous or non-squamous IB, IIA or IIB NSCLC, and complete surgical resection.     >> Tumour shows expression of MAGE-3 antigen.     >> Recovered from surgery for at least 4 weeks and not more than 6 weeks.     >>ECOG performance status of = 1 at the time of randomisation.@@@II@II@@-@-@>> Trial registered. [GSK, 10.02.2006]       @-@@@@ADJUVANT@MAGE-3 RECOMBINANT PHARMACCINE@@@@@MAGE-3 RECOMBINANT PHARMACCINE||||@GSK@@@@@GSK||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@GSK-249533@SB-249533@@@@GSK-249533|SB-249533|||@Vaccine@@@@@Vaccine||||@TIME TO PROGRESSION@@@@@DISEASE-FREE SURVIVAL@MAGE-3 EXPRESSION@GENE EXPRESSION@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922598@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG 531 administered following chemotherapy (R-HyperCVAD alternating with R-Ara-C/MTX)@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 531 is being studied as a way to treat low platelet counts caused by chemotherapy. It binds to the thrombopoietin receptor and causes the bone marrow to make more platelets. @@14922598@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00299182@36@-@FDA orphan designation@@@FDA orphan designation@@3/1/2006@-@2005-0146@@-@-@@@I/II@II@@-@-@Completion due in March 2008@-@@@@COMBO@ROMIPLOSTIM@@@@@ROMIPLOSTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@AMG-531@R-HYPERCVAD@@@@AMG-531|R-HYPERCVAD|||@Other@@@@@Other||||@SAFETY@OPTIMAL BIOLOGIC DOSE@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922993@Onco@@@@@@@@@@@Once-a-day ondansetron versus 8MG Zofran twice daily.@@-@-@-@-@@@Ondansetron is a potent, highly selective 5HTs receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomoting reflex by activating vagal afferents via 5HTs receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.@@14922993@-@@-@-@@-@@@-@-@-@-@-@-@-@-@@@-@@@-@-@@-@Healthy volunteers@@@N/A@-@@-@-@Endpoint met of ensuring similar pharmacokinetic profile as twice-daily Zofran in healthy volunteers. No serious adverse events. SOURCE: Eurand, 26 February 2008@-@@@@MONO@ONDANSETRON HYDROCHLORIDE@@@@@ONDANSETRON HYDROCHLORIDE||||@EURAND@@@@@EURAND||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@EUR-1025@@@@@EUR-1025||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@PHARMACOKINETICS@@@@@@@@@@-@@@@@PILOT@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916392@Onco@@@@@@@@@@@Myocet, Herceptin and paclitaxel versus Herceptin and paclitaxel alone@@L01DB01@L01D@-@-@@@The active substance in Myocet is doxorubicin HCl. Doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase II, intercalation with DNA and RNA polymerases, free radical formation and membrane binding. Liposomal-encapsulated compared with conventional doxorubicin was not found more active in doxorubicin resistant cell lines in vitro. In animals, liposome-encapsulated doxorubicin reduced the distribution to heart and gastrointestinal mucosa compared with conventional doxorubicin, while antitumoural efficacy in experimental tumours was maintained. @@14916392@-@@-@-@@NO REVIEW@@@@-@Licensed future commercialisation in North America from Zeneus Pharma in October 2004@FIRST-LINE@NCT00294996@600@-@Fast track designation from US FDA. [7 January 2010 Sopherion http://www.sopherion.com/news/releases/Press%20Release%205%20FDA%20Fast%20Track%20Designation%2001%2006%2010%20FINAL.pdf ]@1/7/2010@@-@@1/1/2006@-@STM01-102  @@-@-@@@III@III@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@DOXORUBICIN, PEGYLATED LIPOSOMAL @TRASTUZUMAB@@@@DOXORUBICIN, PEGYLATED LIPOSOMAL |TRASTUZUMAB|||@SOPHERION THERAPEUTICS@@@@@SOPHERION THERAPEUTICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@MYOCET@HERCEPTIN@@@@MYOCET|HERCEPTIN|||@Cytotoxic Antibiotic@Anthracycline@@@@Cytotoxic Antibiotic|Anthracycline|||@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922281@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AP-23573 once daily for 5 days every two weeks at 12.5mg/day.@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Deforolimus is a novel small-molecule inhibitor of the protein mTOR, a “master switch” in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. @@14922281@Recurrent or relapsed endometrial cancer@@-@-@@NO REVIEW@@@@-@Merck licensed the drug in July 2007 for US$75 mil. upfront, up to US$452 mil. in milestone payments and up to US$200 mil. in sales-related bonus. Merck will cover half development costs@-@NCT00122343@44@-@-@@@-@@7/1/2005@-@AP23573-04-203@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@RIDAFOROLIMUS@@@@@RIDAFOROLIMUS||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@AP-23573@@@@@AP-23573||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924889@Onco@@@@@@@@@@@Immediate adjuvant hormonal therapy (Eligard) in combination with taxotere administered every three weeks versus hormonal therapy alone versus deferred therapy followed by the same therapeutic options in patients with prostate cancer at high risk of relapse after radical prostatectomy.@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14924889@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00283062@1696@-@-@@@-@@1/1/2006@-@-@@-@1696 male patients@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@LEUPROLIDE@@@@DOCETAXEL|LEUPROLIDE|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@FACTORIAL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919003@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Seven escalating doses of IL-12 delivered intratumourally through elecroporation system@@L01DC01@L01D@-@-@@@@@14919003@-@@-@-@@NO REVIEW@@@@-@-@-@-@24@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@No dose-limiting toxicity was noted. The experimental regimen was safe and well tolerated. There was a dose-dependent increase in IL-12 protein expression in the treated lesions. Electroporated tumors demonstrated marked lymphocytic infiltrates. Of 19 patients with both treated and untreated distal lesions, two (10%) showed complete regression of all lesions (including distal untreated lesions), suggesting a systemic effect of the therapy.  8 additional patients (42%) showed a systemic response resulting in stable disease or objective regression of untreated lesions. SOURCE: Inovio/DNA Vaccines Forum, 11 March 2008@-@@@@MONO@-@@@@@-||||@INOVIO BIOMEDICAL@@@@@INOVIO BIOMEDICAL||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PLASMID IL-12@@@@@PLASMID IL-12||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15000092@Onco@@@@@@@@@@@All patients received Cerepro plus standard care (surgical removal of the tumour followed by radiotherapy of primary tumours only or chemotherapy. @@-@-@-@LONDON, UNITED KINGDOM@@@@@15000092@Malignant glioma; filed in Europe in October 2005.@@-@-@@NO REVIEW@@@-@-@-@-@-@250@-@ARK Therapeutics withdraws MAA [EMEA, 18 March 2010, http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/001103/WC500076157.pdf ]>> MAA filed with EMEA. [Ark, 01.12.2008]                  >> MAA withdrawn; planning to resubmit in 2008 with data from ongoing Phase III trial. [Ark, 2007]            >> CHMP negative opinion asking for more clinical data; technical chemistry and manufacturing controls were acceptable. [CHMP, 2007]                  >> Filed MAA with EMEA under exceptional circumstances on Phase II data. [Ark, September 2005]@3/18/2010@@ORPHAN DRUG IN EMEA AND FDA@@@-@STUDY 904@@-@-@@@III@WITHDRAWN@@-@-@Cerepro demonstrated an 81% increase in mean survival (from 39 weeks to 71 weeks) compared to standard care in 70 patients. The difference between the groups was statistically significant even when study results were adjusted for the main disease prognostic factors of age, gender, tumour type, histology and Karnofski score. DSMB recommended continuation of Phase III trial in July 2007.@-@@@@COMBO@SITIMAGENE CERADENOVEC@@@@@SITIMAGENE CERADENOVEC||||@ARK THERAPEUTICS@@@@@ARK THERAPEUTICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@CEREPRO@@@@@CEREPRO||||@Gene Therapy@@@@@Gene Therapy||||@OVERALL SURVIVAL@KARNOFSKY SCALE@@@@@@@@@MALIGNANT@@@@@RANDOMISED@CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924848@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@XL888 is a fully synthetic, orally available, small molecule that was derived from a novel chemical scaffold. XL888 is a potent and selective ATP-competitive inhibitor of HSP90, and binds to its target in a manner that is structurally distinct from other HSP90 inhibitors currently in the clinic. In preclinical studies, XL888 inhibits the proliferation of a broad panel of human tumor cell lines and induces marked degradation of HSP90 client proteins. In addition, XL888 is highly active in multiple human tumor xenograft models in mice. Pharmacokinetic studies in rodent and non-rodent species demonstrate that XL888 is preferentially retained in tumors relative to plasma and liver. The activity profile of XL888 is highly supportive of its clinical development for the treatment of cancers driven by HSP90 client proteins.@@14924848@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@IND filed. [Exelixis, 2.10.2008]@-@@@@MONO@-@@@@@-||||@EXELIXIS@@@@@EXELIXIS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@XL-888@@@@@XL-888||||@HSP90 Inhibitor@@@@@HSP90 Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920206@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BA01@L02B@YES@PETACH TIKVA, ISRAEL@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920206@@@NO@@@NO REVIEW@@@@@Via takeover of Ivax@@@@@@@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@30@1@94.81@@@@@@@@@@@@0.16@@@@@@@@@@@@@@@@8/2/2017@3.16@3.16@00054-4834-13@FILM-COATED TABLET@US$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922234@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ARM1: AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops. ARM2: placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops @@-@-@-@MALVERN, PENNSYLVANIA@3/1/2009@@@@14922234@Combo with doxetaxel@@-@-@@NO REVIEW@@@@-@Partnering opportunity@-@NCT00544960@102@-@-@@@-@@9/1/2007@-@AT-101-CS-204@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DOCETAXEL@@@@-|DOCETAXEL|||@ASCENTA THERAPEUTICS@@@@@ASCENTA THERAPEUTICS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@AT-101@TAXOTERE@@@@AT-101|TAXOTERE|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924888@Onco@@@@@@@@@@@Docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14924888@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00382720@270@-@-@@@-@@9/1/2006@-@-@@-@270 patients aged 18 and above@@@-@II@@-@-@RESULTS PENDING@-@@@@COMBO@DOCETAXEL@OXALIPLATIN@@@@DOCETAXEL|OXALIPLATIN|||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TAXOTERE@ELOXATIN@@@@TAXOTERE|ELOXATIN|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923256@Onco@@@@@300f1010ntsdm@@@@@@-@@N02AB03@N02A@-@BEERSE, BELGIUM@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals. @@14923256@-@@-@-@@NO REVIEW@@@@100%@-@-@-@-@-@Feb-80@@@-@@@-@-@@-@-@@@-@DISCONTINUED@@100%; no NICE review@NHS@RESULTS PENDING@-@@@@-@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@JANSSEN CILAG@@@@@JANSSEN CILAG||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@T-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|T-Cell Lymphoma|||||||@SUBLIMAZE@@@@@SUBLIMAZE||||@Opioid Analgesic@@@@@Opioid Analgesic||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@@@@10@1.5665@@@@@@@@@@@@@@@@@@@@@@@@@@@@@7/19/2015@@@3.98E+15@INJECTION 2 ML AMP@GB£@@@@@@@@100@MCG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14919043@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@The phase 1 dose escalation study is designed to evaluate the safety, tolerability and pharmacokinetics of TRU-016; and a Phase 2 expansion cohort designed to further evaluate safety and to estimate clinical activity of TRU- 016 in patients with previously treated CLL or small lymphocytic leukemia. SOURCE: Trubion, 27 March 2008@@-@-@-@SEATTLE, WASHINGTON@@@@@14919043@-@@-@-@@NO REVIEW@@@@-@-@-@-@N/A@-@-@@@-@@3/1/2008@-@N/A@@-@-@@@I/II@II@@-@-@Trial started. SOURCE: Trubion, 27 March 2008@-@@@@MONO@-@@@@@-||||@TRUBION PHARMACEUTICALS@@@@@TRUBION PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@TRU-016@@@@@TRU-016||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@MAXIMUM TOLERATED DOSE@RESPONSE RATE@@@RESPONSE RATE@@@@@-@@@@@DOSE ESCALATION@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16161452@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE35@L01X@@LONDON, UNITED KINGDOM@@@Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type.@@16161452@Indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)@Both@NA@17-Jun-16@6/17/2016@NO REVIEW@@@@REIMBURSEMENT RANGES BETWEEN 50% AND 80%@@@@411@The recommended dose of TAGRISSO is 80 mg tablet once a day until disease progression or unacceptable toxicity.@MHLW, 25 May 2016@5/25/2016@5/25/2016@@@@@@No@@@EGFR T790M mutation-positive@ADULTS@@APPROVED@@@NHI@@@@@@MONO@OSIMERTINIB@@@@@OSIMERTINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TAGRISSO@@@@@TAGRISSO||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@@@@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@6245989.595@@@9.7@month@9.7 month@6245989.6@6245989.6@21170.32@1@0.0091@10585.16@12482.5@@@@@@@@@@@264.63@1@@mg@80@1@@@@@@@@@@@8/30/2017@10585.16@10585.16@4291045F1027@TABLET@YEN@@@@@@@@40@MG@40 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14921606@Onco@@@@@@@@@@@Zactima versus placebo@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14921606@Medullary thyroid cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00410761@232@-@-@@@-@@12/1/2006@-@D4200C00058  @@-@-@@@II@II@@-@-@ASCO June 2007 follow-up on results in hereditary medullary thyroid cancer; 20% (6/30) of patients experienced a partial response (duration of response 59-260 days) and another 30% (9/30) of patients experienced stable disease of 24 weeks, yielding a disease control rate of 50% (15/30).@-@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921320@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Single 15-minute IV infusion three times weekly. SOURCE: Genzyme@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@1/1/2008@@@@14921320@Unresectable HCC who are not eligible for surgical care@@-@-@@NO REVIEW@@@@-@-@-@NCT00081900@45@-@-@@@-@@3/1/2004@-@GD3-165-101@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@GENZYME@@@@@GENZYME||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@DENSPM@@@@@DENSPM||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@DOSE-LIMITING TOXICITY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921599@Onco@@@@@@@@@@@Recentin 45mg versus placebo@@-@-@-@LONDON, UNITED KINGDOM@@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921599@mRCC who have had no previous VEGF therapy@@-@-@@NO REVIEW@@@Started in January 2007@-@-@FIRST-LINE@NCT00423332@65@-@-@@@-@@@-@D8480C00030@@-@-@@@EUDRACT NO. 2006-002455-33 / @II@@-@-@RESULTS PENDING (recruiting)@-@@@@MONO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@RECENTIN@AZD-2171@@@@RECENTIN|AZD-2171|||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@TUMOUR SIZE@@@@@@@@@@METASTATIC@RELAPSED@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921793@Onco@@@@@@@@@@@Surgery and capecitabine/oxaliplatin as adjuvant therapy versus surgery alone.@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14921793@Oxaliplatin in combination with capecitabine as adjuvant therapy for chemotherapy-naïve patients who underwent potentially curative resection for gastric cancer. @@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@NCT00411229@1024@-@-@@@-@@6/1/2006@-@CLASSIC@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@Asia-Pacific@@@@@Asia-Pacific|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CONCENTRATE FOR INFUSION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922587@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Emend alone@@A04AD12@A04A@-@WHITEHOUSE STATION, NEW JERSEY@@@@@14922587@Prevention of CINV associated with moderately emetogenic chemotherapy (MEC).@@-@-@@NO REVIEW@@@@-@Japanese rights with Ono.@-@NCT00337727@850@-@3-Mar@@@-@@@-@2006_016  @@JANUARY 2011; JUNE 2012 (EMESIS)@-@@@III@III@@-@-@Completion expected in May 2008.@-@@@@MONO@APREPITANT@@@@@APREPITANT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@EMEND@@@@@EMEND||||@NK1 Antagonist@@@@@NK1 Antagonist||||@COMPLETE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924282@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Combination of two chemotherapy agents, oxaliplatin and gemcitabine with radiation therapy@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14924282@Neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@-@NCT00456599@60@-@-@@@-@@4/1/2007@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@NEOADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924980@Onco@@@@@@@@@@@Nexavar alone@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14924980@-@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@-@NCT00478114@15@-@-@@@-@@@-@12750@@-@-@@@III@III@@-@-@Completion expected August 2009@-@@@@MONO@SORAFENIB TOSYLATE@@@@@SORAFENIB TOSYLATE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@Thailand@@@@@Thailand|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@NEXAVAR@@@@@NEXAVAR||||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@TIME TO PROGRESSION@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924107@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV administration @@-@-@-@-@@@@@14924107@Second-line or third-line therapy @@-@-@@NO REVIEW@@@@-@Under a July 2001 collaboration, Wyeth acquired exclusive rights to develop, manufacture and commercialise MAC 321.@SECOND-LINE@NCT00063427@-@-@-@@@-@@@-@-@@-@PATIENTS WHO HAVE FAILED PRIOR CHEMOTHERAPY CONTAINING IRINOTECAN (CPT-11), 5 FLUOROURACIL (5-FU), AND/OR OXALIPLATIN FOR ADVANCED (RELAPSED) METASTATIC COLON CANCER @@@II@II@@-@-@RESULTS PENDING@-@@@@-@MILATAXEL ORAL@@@@@MILATAXEL ORAL||||@TAXOLOG@WYETH@@@@TAXOLOG|WYETH|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@-@@@@@-||||@Taxane@@@@@Taxane||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919288@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-751 by mouth daily for 21 days, then off treatment for 7 days before next cycle begins.@@-@-@-@UNITED STATES@@@An orally bioavailable antimitotic sulfonamide. ABT-751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of microtubules, thereby preventing tumor cell replication. This agent also disrupts tumor neovascularization, reducing tumor blood flow and so inducing a cytotoxic effect@@14919288@Renal cell cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00073112@-@-@-@@@-@@9/1/2003@-@M02-416  @@-@-@@@II@II@@-@-@RESULTS PENDING (completed).@-@@@@MONO@-@@@@@-||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@ABT-751@@@@@ABT-751||||@Plant Alkaloid@Vascular Disrupting Agent@@@@Plant Alkaloid|Vascular Disrupting Agent|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918810@Onco@@@@@@@@@@@-@@-@-@-@AUSTIN, TEXAS@@@Advexin therapy combines the p53 tumor suppressor with a non-replicating, non-integrating adenoviral delivery system we have developed and extensively tested. The p53 gene is one of the most potent members of a group of naturally-occurring tumor suppressors, which act to kill cancer cells, arrest cancer cell growth and protect cells from becoming cancerous. Introgen's clinical trial strategy for Advexin is to test it in a variety of life-threatening cancers for which there are no effective treatments. Introgen is seeking to register Advexin for the treatment of head and neck cancer and Li-Fraumeni Syndrome. Additional late stage clinical trials in breast and lung cancers will enable Introgen to add follow-on indications. @@14918810@Li-Fraumeni Syndrome@@-@-@@NO REVIEW@@@-@-@Introgen forms Gendux as a gene therapy subsidiary in the UK. [Introgen, 28.09.1998]@-@-@-@-@>Accepted for review by EMEA in November 2007 under the Exceptional Circumstances Approval rules. If approved, Advexin would be the world's first treatment specific for an inherited cancer syndrome. [Introgen, 27.11.2007]>Orphan drug [EMEA; September 2006]@@@-@@@-@N/A@@-@-@@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@CONTUSUGENE LADENOVEC@@@@@CONTUSUGENE LADENOVEC||||@INTROGEN THERAPEUTICS@GENDUX@@@@INTROGEN THERAPEUTICS|GENDUX|||@@@@@@|||||||||@Other@@@@@Other|||||||||@ADVEXIN@@@@@ADVEXIN||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@-@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923728@Onco@@@@@@@@@@@Patients received Genexol-PM 230MG/M2 and cisplatin 60MG/M2 on day 1 of a 3-week cycle. Dose escalation up to 300MG/M2 was carried out in the second cycle of Genexol if prespecified toxic effects were not observed previously.@@-@-@-@-@@@@@14923728@Advanced NSCLC@@-@-@@NO REVIEW@@@@-@CJ Corp licensed rights to Genexol-PM, though details of the agreement have not been disclosed. SOURCE: Samyang, May 2007/19 December 2000Samyang and MacroMed terminated their collaboration agreement for Genexol using MacroMed's Regel drug delivery syst@FIRST-LINE@-@69@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-haematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively).  SOURCE: Samyang/Annals of Oncology, 2007; 18(12) 2009-2014@-@@@@COMBO@PACLITAXEL, LOADED POLYMERIC MICELLE@CISPLATIN@@@@PACLITAXEL, LOADED POLYMERIC MICELLE|CISPLATIN|||@SAMYANG@CJ CORP@@@@SAMYANG|CJ CORP|||@South Korea@@@@@South Korea|||||||||@NSCLC@@@@@NSCLC|||||||||@GENEXOL-PM@@@@@GENEXOL-PM||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@1@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS@-@@@@@@@@30@MG@30 MG/5 ML@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922682@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@LY-573636 alone@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14922682@Platinum-resistant ovarian cancer@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00428610@50@-@-@@@-@@@-@10410H8K-MC-JZAG  @@-@-@@@II@II@@-@-@Completion expected in March 2010.@-@@@@MONO@-@@@@@-||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@LY-573636@@@@@LY-573636||||@Sulfonamide@@@@@Sulfonamide||||@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@@@PARTIAL RESPONSE@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922639@Onco@@@@@300f1012ntsdm@@@@@@Study of extending treatment in patients who received Iressa in other trials.@@L01XE02@L01X@-@LONDON, UNITED KINGDOM@@@The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinasesassociated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR isexpressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFRreceptor expression and response to gefitinib@@14922639@Long-term follow-up trial@@-@-@@NO REVIEW@@@@-@-@-@NCT00357734@100@-@-@@@-@@5/1/2004@-@1839IL0555  @@-@-@@@D7913L00008@III@@-@-@RESULTS PENDING (recruiting)@-@@@@BOTH@GEFITINIB@@@@@GEFITINIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Other@@@@@Other|||||||||@IRESSA@ZD-1839@@@@IRESSA|ZD-1839|||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@SAFETY@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14921242@Onco@@@@@300f1015ntsdm@@@@@@@@V03AF01@V03A@NO@BRUSSELS, BELGIUM@@@@@14921242@@@@@@NO REVIEW@@@@@@@@@@1-Aug-76@8/1/1976@@@@@Allergic reactions to mesna ranging from mild hypersensitivity to systemic anaphylactic reactions have been reported. Patients with autoimmune disorders who were treated with cyclophosphamide and mesna appeared to have a higher incidence of allergic reactions. The majority of these patients received mesna orally. Mesnex has been developed as an agent to reduce the risk of ifosfamide induced haemorrhagic cystitis. It will not prevent or alleviate any of the other adverse reactions or toxicities associated with ifosfamide therapy. Mesnex does not prevent haemorrhagic cystitis in all patients. Up to 6% of patients treated with mesna have developed haematuria (>50 RBC/hpf or WHO grade 2 and above). As a result, a morning specimen of urine should be examined for the presence of haematuria (microscopic evidence of red blood cells) each day prior to ifosfamide therapy. If haematuria develops when Mesnex is given with ifosfamide according to the recommended dosage schedule, depending on the severity of the hematuria, dosage reductions or discontinuation of ifosfamide therapy may be initiated. In order to reduce the risk of hematuria, Mesnex must be administered with each dose of ifosfamide as outlined in@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@MESNA@@@@@MESNA||||@UCB PHARMA@@@@@UCB PHARMA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@MUCOFLUID@@@@@MUCOFLUID||||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+24@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14921617@Onco@@@@@@@@@@@AZD-6244 versus Xeloda@@-@-@-@BOULDER, COLORADO@@@This is a small molecule inhibitor that targets a key position in the Ras/Raf/MEK/ERK signaling pathway. This pathway is implicated in the development and progression of cancers. AZD6244 is a novel, orally active, potent, selective, non-ATP-competitive inhibitor of MEK 1 / 2 that has the potential to treat a range of malignant diseases. Oral administration of AZD6244 has demonstrated tumor suppressive or regressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung and breast cancer models. @@14921617@-@@-@-@@NO REVIEW@@@@-@In December 2003, Array entered into an out-licensing and collaboration agreement with AstraZeneca to develop the MEK program in the field of oncology. Under the agreement AstraZeneca acquired exclusive worldwide rights to the clinical development candidate ARRY-886, along with ARRY-704 and an additional second-generation compound for oncology indications developed during the collaboration.@SECOND-LINE@NCT00372944@64@-@-@@@-@@9/1/2006@-@D1532C00008  @@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@-@@@@@-||||@ARRAY BIOPHARMA@ASTRAZENECA@@@@ARRAY BIOPHARMA|ASTRAZENECA|||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ARRY-886@AZD-6244@@@@ARRY-886|AZD-6244|||@MEK Inhibitor@@@@@MEK Inhibitor||||@N/A@@@@@@@@@@ADVANCED@METASTATIC@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922610@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@@@14922610@Paediatric and adult patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00100152@N/A@-@-@@@-@@7/1/2005@-@2004_097@@-@-@ALL@@I@I@@-@-@Endpoint is not available.@-@@@@MONO@-@@@@@-||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@T-Cell Lymphoma@@@Haematological Malignancy|Acute Lymphocytic Leukaemia|T-Cell Lymphoma|||||||@MK-752@@@@@MK-752||||@Other@@@@@Other||||@N/A@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412300@Onco@@@@@@@@@@@Level 0, Other, Nintedanib low dose with docetaxelLevel 1, Other, Nintedanib medium dose with docetaxelLevel 2, Other, Nintedanib high dose with docetaxelLevel 3, Other, Nintedanib continuous high dose with docetaxel@@L01CD02@L01C@@INGELHEIM, GERMANY@1/1/2018@@@@15412300@An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy@Both@@@@@Low Dose@@@@@@NCT02668393@30@@@@@@@2/1/2016@@1199.224@@@Patients with histologically/ cytologically confirmed locally advanced or metastatic lung adeno carcinoma after failure of first line platinum - based chemotherapy (patients with non-target lesion only are eligible). Prior immunotherapy is allowed.  Further inclusion criteria apply@@ADULTS@Phase 1@I@@@@@@@@@@NINTEDANIB@DOCETAXEL@@@@NINTEDANIB|DOCETAXEL|||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VARGATEF@TAXOTERE@@@@VARGATEF|TAXOTERE|||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@Number of patients with Dose Limiting Toxicity (DLT) for nintedanib with weekly docetaxel during the first treatment cycle@Maximum Tolerated Dose (MTD) of nintedanib in association with weekly docetaxel.@@@@@@@@@@@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924557@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC01@L01B@-@-@@@@@14924557@Liver prodrug formulation of cytarabine (araC) to treat HCC@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Both FDA and EMEA have given MB07133 Orphan Drug status.@@@Both FDA and EMEA have given MB07133 Orphan Drug status.@@@-@-@@-@-@@@II@II@@-@-@Phase I/II trial completed.@-@@@@-@CYTARABINE MONOPHOSPHATE@@@@@CYTARABINE MONOPHOSPHATE||||@METABASIS THERAPEUTICS@@@@@METABASIS THERAPEUTICS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@MB-07133@@@@@MB-07133||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16379389@Onco@@@@@@@@@@@Arm 1, Experimental, Quizartinib and Cytarabine to be used in both the Induction period and the Consolidation period.And either Idarubicin or Daunorubicin to be used in the Induction period.@@@@@TOKYO, JAPAN@11/1/2017@@@@16379389@Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)@Both@@@@@[Induction period] Once-daily repeated oral administration day 8 to day 21. [Consolidation period] Once-daily repeated oral administration day 6 to day 19.@@@@@FIRST-LINE@NCT02834390@18@@@@@@@7/1/2016@@AC220-A-J102@@@-  No prior treatment for AML (including quizartinib)  -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 to 2@@ADULTS@Phase 1@I@@@@@@@@@COMBO@QUIZARTINIB@CYTARABINE@IDARUBICIN@DAUNORUBICIN@@QUIZARTINIB|CYTARABINE|IDARUBICIN|DAUNORUBICIN|@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@World@@@@@World|||||||||@Acute Myeloid Leukaemia@@@@@Acute Myeloid Leukaemia|||||||||@AC-220@GENERIC@ZAVEDOS@KAN-979@@AC-220|GENERIC|ZAVEDOS|KAN-979|@FLT3 inhibitor@@@@@FLT3 inhibitor||||@Number of subjects experiencing adverse events@Cmax profile of quizartinib and its active metabolite@Tmax profile of quizartinib and its active metabolite@@@@@@@@@@@@@Safety Study@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922344@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@PF-3512676 in combination with docetaxel.@@-@-@-@NEW YORK, NEW YORK@@@@@14922344@HER-2 negative disease with documented disease progression after (neo)adjuvant treatment with an anthracycline.@@-@-@@NO REVIEW@@@@-@In May 2005, Pfizer licensed global rights for NSCLC and breast cancer from Coley; Pfizer subsequently bought Coley in November 2007. @FIRST-LINE@NCT00471159@100@-@-@@@-@@8/1/2007@-@A8501007@@-@-@@@-@DISCONTINUED@@-@-@June 2007; interim analysis of Phase III data by DSMC showed no evdience of clinical efficacy over standard cytotoxic chemo alone; risk-benefit profile did not justify continuation.@-@@@@ADJUVANT@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@PF-3512676@CPG-7909@@@@PF-3512676|CPG-7909|||@TLR-targeted@Immunotherapy@Vaccine@@@TLR-targeted|Immunotherapy|Vaccine||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919197@Onco@@@@@@@@@@@Matuzumab with ECX versus ECX alone@@-@-@-@DARMSTADT, GERMANY@@@A monoclonal antibody that is being studied in the treatment of some types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Matuzumab binds to the epithelial growth factor receptor (EGFR) on tumor cells and blocks growth signals.@@14919197@Gastric cancer@@-@-@@NO REVIEW@@@1.5 YEARS@-@Takeda licensed co-development rights from Merck KGaA in September 2005. Merck and ImClone amended their Erbitux and EGFR antibody licensing agreement in May 2007 to accommodate this deal.@FIRST-LINE@-@70@N/A@-@@@-@@@-@MATRIX@@-@-@@@EMD 72000-032@DISCONTINUED@@-@-@"Merck Serono and Takeda discontinued development of the drug in all indications ""based on clinical findings to date"". SOURCE: Merck Serono/Takeda, 18 February 2008Takeda-led trial here is still proceeding despite failure in mCRC. SOURCE: Takeda, August 2007"@-@@@@COMBO@MATUZUMAB@@@@@MATUZUMAB||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@EMD-72000@@@@@EMD-72000||||@mAb@Humanised@EGFR@@@mAb|Humanised|EGFR||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16379395@Onco@@@@@@@@@@@BLZ945 single agent, Experimental, BLZ945 + PDR001, Experimental,@@@@@BASEL, SWITZERLAND@6/1/2019@@@@16379395@A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors@Both@@@@@@@@@@FIRST-LINE@NCT02829723@151@@@@@@@10/1/2016@@CBLZ945X2101@@@Phase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1    Phase I: Patients with a site of disease amenable to biopsy, and willing to undergo a new tumor biopsy at screening, and during treatment.   Phase II: Patients with advanced/metastatic tumors in the below selected indications, with at least one measurable lesion as determined by RECIST v1.1 or RANO  -  advanced pancreatic cancer  -  advanced triple negative breast cancer,  -  recurrent glioblastoma  Other protocol defined inclusion criteria may apply@BOTH@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@World@@@@@World|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BLZ945@PDR001@@@@BLZ945|PDR001|||@Other@@@@@Other||||@Number of participants with Dose Limiting Toxicities (DLTs)@Progression Free Survival (PFS) per RECIST v.1.1 or RANO criteria@@@@Pharmacodynamics tumor changes from baseline of immunological markers@Progression free survival (PFS)@@@@ADVANCED@METASTATIC@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919111@Onco@@@@@@@@@@@Vorinostat 300 mg b.i.d. capsules twice daily300 mg b.i.d. capsules twice daily up to 24 weeks of treatment; 14 consecutive day treatment followed by 7-day rest in 21-day cycles until disease progression or unacceptable toxicity.@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@@@Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (ClassI) and HDAC6 (Class II) at nanomolar concentrations (IC50<86 nM). These enzymes catalyze the removalof acetyl groups from the lysine residues of proteins, including histones and transcription factors. In somecancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenictranscription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones isassociated with a condensed chromatin structure and repression of gene transcription. Inhibition ofHDAC activity allows for the accumulation of acetyl groups on the histone lysine residues resulting in anopen chromatin structure and transcriptional activation. In vitro, vorinostat causes the accumulation ofacetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. Themechanism of the antineoplastic effect of vorinostat has not been fully characterized.@@14919111@Patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy@@-@-@@NO REVIEW@@@JULY 2005-MARCH 2010@-@-@-@NCT00128102@660@-@-@@@-@@@-@MK0683-014@@-@-@@@II/III 2005_010, @III@@-@-@RESULTS PENDING@-@@@@MONO@VORINOSTAT@@@@@VORINOSTAT||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Mesothelioma@@@@@Mesothelioma|||||||||@ZOLINZA@@@@@ZOLINZA||||@HDAC@@@@@HDAC||||@OVERALL SURVIVAL@SAFETY@TOXOCITY@@@TOXOCITY@@@@@MALIGNANT@ADVANCED@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916478@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Low-dose cytarabine chemotherapy plus either SGN-33 or placebo@@-@-@-@SEATTLE, WASHINGTON@@@@@14916478@Elder patients aged 60 and older with previously untreated AML@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00528333@210@-@-@@@-@@9/1/2007@-@SG033-0003@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@LINTUZUMAB@CYTARABINE@@@@LINTUZUMAB|CYTARABINE|||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@SGN-33@@@@@SGN-33||||@mAb@Humanised@CD33@@@mAb|Humanised|CD33||@OVERALL SURVIVAL@SAFETY@QUALITY OF LIFE@@@QUALITY OF LIFE@@@@@-@@@@@DOUBLE-BLIND@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916794@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Days 1, 8 and 15 in a 28 day cycle @@-@-@-@SAN DIEGO, CALIFORNIA@12/1/2008@@@@14916794@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00322608@35@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@4/1/2006@-@NPI-2358-100@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NEREUS PHARMACEUTICALS@@@@@NEREUS PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@Solid Tumours@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Solid Tumours||||||@NPI-2358@@@@@NPI-2358||||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919126@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MER-101 20MG tablets with zoledronic acid 20MG weekly for 8 weeks or zoledronic acid 20MG once a day for 4 consecutive days during week 1, weekly for weeks 5,6,7,8; versus zoledronic acid injection 4MG every 4 weeks for 8 weeks@@-@-@-@-@11/1/2008@@@@14919126@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00636740@30@-@-@@@-@@2/1/2008@-@MER-101-03@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@ZOLEDRONIC ACID@@@@-|ZOLEDRONIC ACID|||@MERRION PHARMACEUTICALS@@@@@MERRION PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@MER-101@ZOMETA@@@@MER-101|ZOMETA|||@Bisphosphonate@@@@@Bisphosphonate||||@BONE METABOLISM@@@@@@@@@@REFRACTORY@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918992@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Onzar (9mcg/kg or 12mcg/kg) every 3 weeks for 4 cycles.@@-@-@-@TOKYO, JAPAN@@@@@14918992@Phase IV melanoma@@-@-@@NO REVIEW@@@@-@Acquired through deal with Ligand@-@-@7@-@-@@@-@@@-@N/A@@2014@-@@@II@II@@-@-@November 2006 results from part 1; all patients alive at 12 months, 2 patients on 8mcg/kg developed new detectable tumours. 5 patients saw significant tumour regression after 4 cycles of 12mcg/kg.@-@@@@MONO@DENILEUKIN DIFTITOX@@@@@DENILEUKIN DIFTITOX||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ONZAR@@@@@ONZAR||||@Interleukin@@@@@Interleukin||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16408068@Onco@@@@@@@@@@@"LY3200882 Schedule 1 Escalation, Experimental, LY3200882 Schedule 2 Escalation, Experimental, LY3200882 Schedule 1 Expansion, Experimental, LY3200882 Schedule 2 Expansion, Experimental, "@@@@@INDIANAPOLIS, INDIANA@3/1/2020@@@@16408068@A Phase 1 Study of LY3200882 in Patients With Solid Tumors@Both@@@@@Administered orally@@@@@-@NCT02937272@146@@@@@@@10/1/2016@@16185@@@-  The participant must have histological or cytological evidence of cancer.  -  Have adequate organ function.  -  Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.  -  Are able to swallow capsules and tablets.@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LY3200882@@@@@LY3200882||||@Other@@@@@Other||||@Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)@Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)@@@@Pharmacokinetics (PK): Area Under the Curve (AUC) (AUC[0-24]) at Steady State of LY3200882@PK: AUC Zero to Infinity (AUC[0-∞]) at Steady State of LY3200882@@@@@@@@@Non-Randomized@Safety Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918728@Onco@@@@@300f1020ntsdm@@@@@@Arenegry every 3 weeks with doxorubicin@@-@-@-@MILAN, ITALY@10/1/2009@@NGR-hTNF is a vascular targeting agent with unique mode of action, and a first-in-class compound in the class of peptide/cytokine complexes able to selectively target the tumourvasculature. It consists of a tumour homing peptide (NGR) selectively binding tumour blood vessels, fused to the powerful human anticancer cytokine TNF. The resulting molecule has unique biological properties, including induction of tumour vascular permeability and normalisation, and a direct biological antitumour activity. NGR-hTNF is undergoing clinical development both as single agent and in combination with several different chemotherapeutic agents: currently, in addition to mesothelioma and colorectal cancer, single agent Phase II trials are ongoing in hepatocellular carcinoma and small-cell lung cancer; for colorectal cancer, it is also being tested in a Phase II trial in combination with Xelox. Also ongoing is a Phase I trial in combination with cisplatin, while a Phase I trial in combination with doxorubicin was successfully completed.@@14918728@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00484432@37@-@-@@@-@@10/1/2007@-@NGR012@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DOXORUBICIN@@@@-|DOXORUBICIN|||@MOLMED@@@@@MOLMED||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ARENEGYR@@@@@ARENEGYR||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@RECIST@@@@@@@@@@METASTATIC@ADVANCED@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14916798@Onco@@@@@300f1018ntsdm@@@@@@IV injection of NPI-0052 on Days 1, 8, 15 of 28 day cycle in patients with advanced malignancies other than multiple myeloma versus IV injection of NPI-0052 on Days 1, 8, 15 of 28 day cycle in patients with multiple myeloma @@-@-@-@SAN DIEGO, CALIFORNIA@9/1/2009@@@@14916798@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00629473@50@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@7/1/2007@-@NPI 0052-102@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NEREUS PHARMACEUTICALS@@@@@NEREUS PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@Haematological Malignancy@@@@Solid Tumours|Haematological Malignancy||||||||@NPI-0052@@@@@NPI-0052||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@MAXIMUM TOLERATED DOSE@RPD2@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14922486@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ARM1; patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer. ARM2; Patients will receive 22mg/m2 as intravenous infusion. 6 CYCLES.@@-@-@-@LEVERKUSEN, GERMANY@1/1/2009@@@@14922486@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00313248@75@-@First Phase III trials planned for 2008.@@@-@@3/1/2006@-@91466, 307975@@-@-@@@II@II@@-@-@Completion due in January 2009. First Phase III trials planned for 2008.@-@@@@MONO@SAGOPILONE@@@@@SAGOPILONE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZK-EPO@ZK-219477@@@@ZK-EPO|ZK-219477|||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924718@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Somatuline Autogel administered every 4 weeks by injection@@-@-@-@PARIS, FRANCE@6/1/2009@@@@14924718@-@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00326469@30@-@-@@@-@@5/1/2006@-@-@@-@30 PATIENTS NOT ELIGIBLE FOR SURGERY OR CHEMO.@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@LANREOTIDE@@@@@LANREOTIDE||||@IPSEN@@@@@IPSEN||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@SOMATULINE AUTOGEL@@@@@SOMATULINE AUTOGEL||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@60, 90, 120MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916568@Onco@@@@@300f1015ntsdm@@@@@@Gemzar/oxaliplatin plus Rituxan (R-GEMOX) for 4 cycles@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14916568@CD20-positive large B-cell lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00169195@50@-@-@@@-@@@-@R-GEMOX  @@-@-@@@II@II@@-@-@Completion expected in January 2008.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@OXALIPLATIN@@@@GEMCITABINE HYDROCHLORIDE|OXALIPLATIN|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|||||||@GEMZAR@ELOXATIN@@@@GEMZAR|ELOXATIN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@RESPONSE RATE@COMPLETE RESPONSE@PARTIAL RESPONSE@@@PARTIAL RESPONSE@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14923495@Onco@@@@@@@@@@@Six subcutaneous injections at 3-week intervals.@@-@-@-@-@@@@@14923495@Stage III/IV NSCLC@@-@-@@NO REVIEW@@@@-@-@-@-@22@-@EMEA GRANTED ORPHAN DRUG DESIGNATION FOR VX-001 TO TREAT TERT-POSITIVE NSCLC IN HLA-A2-POSITIVE PATIENTS IN Q4 2007.@@@EMEA GRANTED ORPHAN DRUG DESIGNATION FOR VX-001 TO TREAT TERT-POSITIVE NSCLC IN HLA-A2-POSITIVE PATIENTS IN Q4 2007.@@@-@-@@-@-@@@I/II@II@@-@-@July 2007 JCO; 16 patients showed immune response after 2nd vaccination; overall survival was 30 months compared to 4.1 months on those who did not respond to vaccine. 8 patients showed SD lasting a median of 11.2 months.@-@@@@MONO@-@@@@@-||||@VAXON BIOTECH@@@@@VAXON BIOTECH||||@Greece@@@@@Greece|||||||||@NSCLC@@@@@NSCLC|||||||||@VX-001@@@@@VX-001||||@Telomerase Inhibitor@Vaccine@@@@Telomerase Inhibitor|Vaccine|||@OVERALL SURVIVAL@STABLE DISEASE@@@@@@@@@-@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924220@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Oral clodronic acid or placebo combined with adjuvant therapy@@-@-@-@LEVERKUSEN, GERMANY@@@@@14924220@Primary breast cancer@@-@-@@NO REVIEW@@@@-@-@-@-@1069@-@MAY 2005 APPROVABLE LETTER REQUIRING FURTHER TRIAL DATA.@@@-@@@-@-@@-@-@@@-@III@@-@-@March 2006; data for 555 patients. Patients in the clodronic acid group achieved a reduction in bone turnover, with a 26% decrease in PINP serum levels, compared with an increase in PINP levels of 5% from baseline in the placebo group (p is less than. Baseline PINP values were identical in the 49 patients who developed bone metastases and the 499 patients who remained metastasis-free at one year. Of the women who developed metastases, PINP values were significantly higher at one year. In the Bonefos group, 55% achieved a response (more than 20% decrease in PINP levels) compared with 31% in the placebo group. Disease progression as defined by more than 20% increase in PINP levels was observed in 23% and 41% of the patients respectively.@-@@@@COMBO@CLODRONIC ACID@@@@@CLODRONIC ACID||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Breast Cancer@Bone Metastases@@@@Breast Cancer|Bone Metastases||||||||@BONEFOS@@@@@BONEFOS||||@Bisphosphonate@@@@@Bisphosphonate||||@RESPONSE RATE@PINP@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924947@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AMG-531 alone at different doses@@-@-@-@THOUSAND OAKS, CALIFORNIA@@@AMG 531 is being studied as a way to treat low platelet counts caused by chemotherapy. It binds to the thrombopoietin receptor and causes the bone marrow to make more platelets. @@14924947@Thrombocytopaeniac subjects with MDS@@-@-@@NO REVIEW@@@@-@-@-@NCT00303472@84@-@FDA orphan designation@@@FDA orphan designation@@1/1/2006@-@20050159@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@ROMIPLOSTIM@@@@@ROMIPLOSTIM||||@AMGEN@@@@@AMGEN||||@@@@@@|||||||||@Haematological Malignancy@Myelodysplastic Syndrome@@@@Haematological Malignancy|Myelodysplastic Syndrome||||||||@AMG-531@@@@@AMG-531||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16624585@Onco@@@@@300f1018ntsdm@@@@@@@@L01XE28@L01X@@BASEL, SWITZERLAND@@@Zykadia (ceritinib) is an oral, selective inhibitor of ALK.@@16624585@Indicated as monotherapy for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or who are intolerant of crizotinib.@Both@NO@@@@@@@@@SECOND-LINE@@163@The recommended dose of ZYKADIA is 750 mg taken orally once daily at the same time each day. Continue treatment as long as the patient is deriving clinical benefit from therapy.@TGA, 31 March 2016@3/31/2016@2/1/2017@Yes@@@@@No@@@(ALK)-positive@ADULTS@I@APPROVED@@@PBS@@@@@@MONO@CERITINIB@@@@@CERITINIB||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ZYKADIA@@@@@ZYKADIA||||@TK Inhibitor@@@@@TK Inhibitor||||@OVERALL RESPONSE RATE@DURATION OF RESPONSE@PROGRESSION-FREE SURVIVAL@@@@@@@@METASTATIC@@@@@MULTICENTER@SINGLE-ARM@OPEN-LABEL@@@1@1@50590.02032@@@7@month@7 month@50590.02@50590.02@237.61@150@0.779@7128.3@7276.18@7198.24@@@@@@@@@@0.32@1@@mg@750@1@@@@@@@@@@@8/1/2017@47.52@47.52@3714-0482-GE-NV@HARD CAPSULE@A$@@@@@@@@150@MG@150 MG@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
16408064@Onco@@@@@@@@@@@Nivolumab and Ipilimumab Combination, Active Comparator, Nivolumab and Ipilimumab CombinationNivolumab and BMS-986016 Combination, Experimental, Nivolumab and BMS-986016 Combination@@L01XC17@L01X@@NEW YORK, NEW YORK@11/1/2021@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16408064@A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)@Both@@@@@@@@@@FIRST-LINE@NCT02935634@910@@@@@@@11/1/2016@@CA018-003@@@For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com    -  Advanced Gastric Cancer  -  Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work  -  Must have at least 1 lesion with measurable disease@@ADULTS@Phase 2@II@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@GIST@@@@@GIST|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Objective Response Rate (ORR)@Duration of Response (DOR)@Progression-free Survival Rate (PFSR)@@@Incidence of Adverse Events (AEs)@Incidence of Serious Adverse Events (SAEs)@@@@ADVANCED@@@@@Randomized@Safety/Efficacy Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924522@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ixabepilone administered at 6mg/m2 for 5 consecutive days every 2 weeks.@@L01C@L01C@-@NEW YORK, NEW YORK@@@Ixabepilone is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone. Ixabepilone is a semi-synthetic analog of epothilone B. Ixabepilone binds directly to ß-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of  ß-II and  ß-III microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including efflux transporters, such as MRP-1 and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.@@14924522@Metastatic renal cell carcinoma@@-@-@@NO REVIEW@@@@-@-@-@-@54@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@ASCO May 2004; 8 patients (15%) achieved partial responses and 7 had minor or mixed responses.@-@@@@MONO@IXABEPILONE@@@@@IXABEPILONE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Kidney Cancer@@@@@Kidney Cancer|||||||||@IXEMPRA@BMS-247550@@@@IXEMPRA|BMS-247550|||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921518@Onco@@@@@300f1008ntsdm@@@@@@N/A@@-@-@-@TOKYO, JAPAN@@@@@14921518@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of MGI Pharma@-@NCT00280397@30@-@"Filing delayed as company had planned to submit accelerated Subpart H approval based on Phase II data but FDA approved another drug for the specific indication in October 2007 which precludes Eisai from doing this. Eisai now anticipates a filing in 2009/2010 with results from Study 301 (second-line breast cancer) and Study 305 (third-line breast cancer) in Phase III development.FILING FOR SUBPART H ACCELERATED APPROVAL DUE IN DECEMBER 2007 AS A THIRD-LINE BREAST CANCER TREATMENT"@@@-@@1/1/2006@-@E7080-J081-103@@-@-@@@I@I@@-@@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@MGI PHARMA@@@@EISAI|MGI PHARMA|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@E-7080@@@@@E-7080||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14923751@Onco@@@@@300f1037ntsdm@@@@@@Neadjuvant chemotherapeutic treatment (XELOX) followed by chemoradiotherapy (XELOX/RT) and surgery versus chemoradiotherapy followed by surgery and chemotherapy@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14923751@Rectal neoplasms@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@NCT00421824@108@-@-@@@-@@5/1/2006@-@-@@-@108 patients with high risk rectal cancer@@@II@II@@-@-@-@-@@@@COMBO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ELOXATIN@XELOX@@@@ELOXATIN|XELOX|||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
16667511@Onco@@@@@@@@@@@"Venetoclax + Low Dose Cytarabine (LDAC), Experimental, Venetoclax 600 mg orally every day (QD) QD on Days 1 - 28 plus LDAC 20 mg/m^2 subcutaneously QD on Days 1 - 10 (28 day cycle)Placebo + LDAC, Placebo Comparator, Matching Placebo for Venetoclax 600 mg orally QD on Days 1 - 28 plus LDAC 20 mg/m^2 subcutaneous QD on Days 1 - 10 (28 day cycle)"@@L01XX52@L01X@@@1/1/2022@@@@16667511@A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy@Both@@@@@tablet@@@@@FIRST-LINE@NCT03069352@175@@@@@@@@@M16-043@@@Participants must have histological confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, is ineligible for intensive induction chemotherapy.  -  Participants must have adequate renal and liver function.@@ADULTS@Phase 3@III@@@@@@@@@COMBO@VENETOCLAX@CYTARABINE@@@@VENETOCLAX|CYTARABINE|||@ABBVIE@@@@@ABBVIE||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@VENCLEXTA@GENERIC@@@@VENCLEXTA|GENERIC|||@Other@@@@@Other||||@Overall survival (OS)@@@@@Percentage of participants with complete remission (CR) or complete remission with incomplete marrow recovery (CRi)@Event-free survival (EFS)@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16398906@Onco@@@@@@@@@@@"Drug: BAL101553, Experimental, "@@@@@SWITZERLAND@12/1/2018@@@@16398906@An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors@Both@@@@@48-hour intravenous infusion at MTD. Oral capsule daily for one week during Cycle 2, dose calculated based on PK modeling@@@@@FIRST-LINE@NCT02895360@82@@@@@@@8/1/2016@@CDI-CS-003@@@- Age ≥ 18 years  -Patients with either histologically or cytologically confirmed advanced or recurrent solid tumor, who failed standard therapy or for whom no effective standard therapy is available.  - Measurable tumor disease (according to Response Eva@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@MONO@BAL101553@@@@@BAL101553||||@BASILEA PHARMACEUTICA@@@@@BASILEA PHARMACEUTICA||||@Switzerland@@@@@Switzerland|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@-@@@@@-||||@Other@@@@@Other||||@To determine the maximum tolerated dose and characterize dose limiting toxicities of BAL101553 based on the number of participants with adverse effects as measure of tolerability at various dose levels@@@@@To evaluate safety and tolerability of BAL101553 treatment based on the number of participants with adverse events at various dose levels@To evaluate safety and tolerability of BAL101553 treatment based on the number of participants with safety laboratory changes versus baseline@@@@ADVANCED@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@TREATMENT@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919286@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABT-510 in combination with carboplatin / Taxol.@@-@-@-@UNITED STATES@@@A synthetic peptide that mimics the anti-angiogenic activity of the endogenous protein thrombospondin-1 (TSP-1). ABT-510 inhibits the actions of several pro-angiogenic growth factors important to tumor neovascularization; these pro-angiogenic growth factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). @@14919286@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00061646@25@-@-@@@-@@3/1/2003@-@M02-429@@-@-@@@II@CLINICAL HOLD@@-@-@>> Trial terminated. [Abbot, 10.08.2007]        >> Trial registered. [Abbott, 02.06.2003]@-@@@@COMBO@THROMBOSPONDIN@CARBOPLATIN@PACLITAXEL@@@THROMBOSPONDIN|CARBOPLATIN|PACLITAXEL||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ABT-510@@@@@ABT-510||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920207@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BA01@L02B@YES@PETACH TIKVA, ISRAEL@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920207@@@NO@@@NO REVIEW@@@@@Via takeover of Ivax@@@@@@@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@500@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00093-0782-05@FILM-COATED TABLET@US$@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16511653@Onco@@@@@@@@@@@Nivolumab plus Ipilimumab, Experimental, Specified dose on specified daysPlatinum doublet chemotherapy, Active Comparator, Specified dose on specified days@@L01XC17@L01X@@NEW YORK, NEW YORK@7/1/2019@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16511653@Randomized, OpenLabel, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum Doublet Chemotherapy in Early Stage NSCLC@Both@@@@@@@@@@FIRST-LINE@NCT02998528@326@@@@@@@1/1/2017@@CA209-816@@@Early stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissue  -  Lung function capacity capable of tolerating the proposed lung surgery  -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1  -  Available tissue of primary lung tumor@@ADULTS@Phase 3@III@@@@@@@@@COMBO@NIVOLUMAB@IPILIMUMAB@@@@NIVOLUMAB|IPILIMUMAB|||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@OPDIVO@YERVOY@@@@OPDIVO|YERVOY|||@mAb@Human@PD-1 Inhibitor@@@mAb|Human|PD-1 Inhibitor||@Major Pathological Response (MPR) rate@@@@@Event free survival (EFS)@Overall survival (OS)@@@@EARLY@@@@@Randomized@Safety/Efficacy Study@Parallel Assignment@Open Label@Treatment@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923174@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Talc vs. concurrent control@@@@NO@WOBURN, MASSACHUSSETTS@@@@@14923174@Sclerosol Intrapleural Aerosol, administered by aerosol during thoracoscopy or open thoracotomy, is indicated to prevent recurrence of malignant pleural effusions in symptomatic patients.@@NO@@@NO REVIEW@@@@@@@@N/A@Sclerosol Intrapleural Aerosol (sterile talc powder) is administered after adequate drainage of the effusion. It has been suggested that success of the pleurodesis is related to the completeness of the drainage of the pleural fluid, as well as full reexpansion of the lung, both of which will promote symphysis of the pleural surfaces. The usual dosage is a single 4-8 g dose delivered intrapleurally from the spray canister (1-2 cans), which delivers talc at a rate of 0.4 g per second.@@@@@@@NONE@LABEL@No@N/A@@@@III 4 STUDIES@APPROVED@@@@Talc and control: 64% and 41%, 61% and 43%, 78% and 39% respectively.@@@@@MONO@STERILE TALC POWDER@@@@@STERILE TALC POWDER||||@BRYAN CORP@@@@@BRYAN CORP||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@SCLEROSOL@@@@@SCLEROSOL||||@Other@@@@@Other||||@DURATION OF RESPONSE@RESPONSE RATE@@@@@@@@@@@@@@PROSPECTIVE@RANDOMISED@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@4@MG@4 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916229@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@NO LABELLED TRIAL@@M04AA01@M04A@NO@BEDFORD, OHIO@@@@@14916229@Allopurinol Sodium for Injection is indicated for the management of patients with leukaemia, lymphoma, and solid tumour malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.@@NO@@@NO REVIEW@@@@@@@@@Adult: 200-400MG/M2/day. Child: 200MG/M2/day.@@@@@@@Should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic rection. Dose should be adjusted if co-administered with Purinethol or Imuran.@NO LABELLED TRIAL@No@@@@@@APPROVED@@N/A@MEDICARE@NO LABELLED TRIAL@@@@@@ALLOPURINOL@@@@@ALLOPURINOL||||@BEDFORD LABORATORIES@@@@@BEDFORD LABORATORIES||||@@@@@@|||||||||@Supportive Care@Haematological Malignancy@Acute Lymphocytic Leukaemia@Acute Myeloid Leukaemia@Non-Hodgkin's Lymphoma@Supportive Care|Haematological Malignancy|Acute Lymphocytic Leukaemia|Acute Myeloid Leukaemia|Non-Hodgkin's Lymphoma|||||@GENERIC@@@@@GENERIC||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@55390-0106-01@INJECTION@US$@@@@@@@@500@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922235@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AT-101 in combination with Rituxan@@-@-@-@MALVERN, PENNSYLVANIA@8/1/2008@@@@14922235@Previously untreated Grade I-II follicular NHL combo with Rituxan@@-@-@@NO REVIEW@@@@-@Partnering opportunity@FIRST-LINE@NCT00440388@52@-@-@@@-@@10/1/2006@-@AT-101-CS-203@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@ASCENTA THERAPEUTICS@@@@@ASCENTA THERAPEUTICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@AT-101@RITUXAN@@@@AT-101|RITUXAN|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16418069@Onco@@@@@@@@@@@"IBI301, Experimental, Rituximab, Active Comparator, "@@@@@CHINA@4/1/2018@@@@16418069@A Multicenter, Randomized, Double-blinded, Parallel Controlled Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients@Both@@@@@IBI301 375mg/㎡@@@@@FIRST-LINE@NCT02945215@140@@@@@@@11/1/2016@@CIBI301A201@@@- CD20-positive B-cell lymphoma. - 18 years to 65 years.  - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. -Signed an informed consent.  - Obtained CR (complete remission) or CRu (uncertain complete remission) after the prior ther@@ADULTS@Phase 1@I@@@@@@@@@COMBO@-@RITUXIMAB@@@@-|RITUXIMAB|||@INNOVENT BIOLOGICS@@@@@INNOVENT BIOLOGICS||||@@@@@@|||||||||@B-Cell Lymphoma@@@@@B-Cell Lymphoma|||||||||@IBI301@MABTHERA@@@@IBI301|MABTHERA|||@Other@@@@@Other||||@AUC0-inf of IBI301 and rituximab@@@@@Peak Plasma Concentration (Cmax)@Percentage and absolute value of CD19+@@@@@@@@@Randomized@Bio-equivalence Study@Parallel Assignment@Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922219@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Two dose levels of ATN-224@@-@-@-@SAN DIEGO, CALIFORNIA@5/1/2008@@@@14922219@Relapsed, early stage prostate cancer not on hormone therapy@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00405574@50@-@-@@@-@@11/1/2006@-@ATN-224-005@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ATTENUON@@@@@ATTENUON||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ATN-224@@@@@ATN-224||||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@PDGF@@TK Inhibitor|Angiogenesis Inhibitor|VEGF|PDGF|@PSA@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16676451@Onco@@@@@@@@@@@@@@@@BASEL, SWITZERLAND@@@@@16676451@An Open-labeled, Multi-Center, Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy@Both@@@@@Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21@@@@@@NCT03114228@@@@@@@@@@CPKC412A2001X@@@Written informed consent must be obtained prior to any screening procedures.  2. Patients must have a documented unequivocal diagnosis of AML according to WHO 2008 classification (≥20% blasts in the bone marrow and/or peripheral blood), excluding M3 (acute promyelocytic leukemia). Patients with secondary AML are eligible, e.g. patients with antecedent history of treatment for prior malignancy. AML patients with a history of antecedent treatment for myelodysplasia (MDS), e.g. azacitidine or decitabine, remain eligible for treatment on this study. These agents must have been discontinued for a period of at least 30 days or 5 half-lives of the drug (whichever is greater) before midostaurin can be administered.  3. Patients must have a documented FLT3 mutation (ITD or TKD)  4. Patients must be 18 years of age or older; elderly patients must be fit to receive intensive induction and consolidation chemotherapy  5. Patients must enroll prior to completion of cycle 2 of the consolidation chemotherapy.  6. Patients must have an ECOG Performance Status of ≤ 2  7. Patients requiring intrathecal chemotherapy must have a minimum washout of 48 hours prior to the first dose of midostaurin  8. Patients must have the following laboratory values:  1. Total Bilirubin ≤ 2.5 x ULN  2. Serum Creatinine ≤ 2.5 x ULN@@@@-@@@@@@@@@MONO@MIDOSTAURIN@@@@@MIDOSTAURIN||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@PKC412@@@@@PKC412||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
16379392@Onco@@@@@@@@@@@Nivolumab, Experimental,@@L01XC17@L01X@@NEW YORK, NEW YORK@10/1/2018@@Nivolumab is an investigational, fully-human IgG4 anti-PD-1 receptor blocking monoclonal antibody that binds to the checkpoint receptor PD-1 (programmed death-1) expressed on activated T cells. Nivolumab inhibits the binding of PD-1 with its tumor-express@@16379392@An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies@Both@@@@@Flat Dose@@@@@FIRST-LINE@NCT02832167@150@@@@@@@7/1/2016@@CA209-627@@@Diagnosed with advanced or metastatic malignancy  -  Received standard of care treatment for primary malignancy and standard of care treatment for relapsed cancer  -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1@@ADULTS@Phase 2@II@@@@@@@@@MONO@NIVOLUMAB@@@@@NIVOLUMAB||||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@World@@@@@World|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@OPDIVO@@@@@OPDIVO||||@PD-1 Inhibitor@@@@@PD-1 Inhibitor||||@Clinical Benefit Rate measured by radiologic tumor assessments@@@@@Overall Survival rate (OS)@Duration of clinical response@@@@ADVANCED@METASTATIC@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14918887@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Acolbifene after tamoxifen failure@@-@-@-@-@@@@@14918887@Breast cancer progressed after tamoxifene@@-@-@@NO REVIEW@@@@-@Previously acolbifene was discontinued in Phase III trials at Schering-Plough.@SECOND-LINE@-@-@-@-@@@-@@@-@N/A@@-@PATIENTS WHO HAVE FAILED HORMONE THERAPY.@@@III@III@@-@-@"August 2007 Nature; acolbifene induced a ""positive response"" in a significant proportion of patients. Previously acolbifene was discontinued in Phase III trials at Schering-Plough."@-@@@@MONO@ACOLBIFENE@@@@@ACOLBIFENE||||@ENDOCEUTICS@@@@@ENDOCEUTICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@-@@@@@-||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@-@@@@@@@@@@ADVANCED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924891@Onco@@@@@@@@@@@MTD of IV Cloretazine given every 7 days in conjunction with daily temozolomide@@-@-@-@NEW HAVEN, CONNECTICUT@@@Cloretazine (VNP40101M) is a small molecule that works by damaging DNA. Cloretazine releases the DNA chloroethylating agent 90CE after entering the blood stream. 90CE chloroethylates the O6 position of guanine residues, ultimately resulting in an interstrand DNA cross-link. Interstrand DNA cross-links are difficult to repair and are toxic to cells. Cloretazine demonstrated a broad spectrum of anticancer activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan. In preclinical studies, Cloretazine has been combined with other anticancer agents such as cytarabine (Ara-C). In addition, Cloretazine or its metabolite, has been shown to be capable of crossing the blood brain barrier in preclinical models.@@14924891@Relapsed or progressive adult malignant glioma@@-@-@@NO REVIEW@@@@-@-@-@-@29@-@-@@@-@@@-@-@@-@29 PATIENTS; intitially groups of 3-6 patients will be enrolled in the Phase I portion to establish MTD; to be followed by expanded Phase II trial.@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@CLORETAZINE@TEMOZOLOMIDE@@@@CLORETAZINE|TEMOZOLOMIDE|||@VION PHARMACEUTICALS@@@@@VION PHARMACEUTICALS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@VNP-40101M@TEMODAL@@@@VNP-40101M|TEMODAL|||@Alkylating Agent@@@@@Alkylating Agent||||@SAFETY@MAXIMUM TOLERATED DOSE@@@@@@@@@RELAPSED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916734@Onco@@@@@@@@@@@Temodar with radiotherapy followed by sequential Temodar versus radiotherapy alone.@@-@-@-@KENILWORTH, NEW JERSEY@@@Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound MTIC. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.@@14916734@NSCLC with CNS metastasis@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00266812@82@-@-@@@-@@6/1/2005@-@P04071@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@TEMOZOLOMIDE@@@@@TEMOZOLOMIDE||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@Austria@@@@@Austria|||||||||@NSCLC@@@@@NSCLC|||||||||@TEMODAR@@@@@TEMODAR||||@Alkylating Agent@@@@@Alkylating Agent||||@SAFETY@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921671@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@10MG/d plus octreotide depot@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14921671@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00412061@390@-@-@@@@@12/1/2006@-@CRAD001C2325@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@COMBO@EVEROLIMUS@OCTREOTIDE@@@@EVEROLIMUS|OCTREOTIDE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@AFINITOR@RAD-001@SANDOSTATIN@@@AFINITOR|RAD-001|SANDOSTATIN||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@PROGRESSION-FREE SURVIVAL@RECIST@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918977@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arzoxifene 20 or 50mg/d@@-@-@-@INDIANAPOLIS, INDIANA@@@@@14918977@-@@-@-@@NO REVIEW@@@@-@-@-@-@1122@-@-@@@-@@@-@N/A@@-@-@@@II@III@@-@-@ASCO May 2001; greatest response was seen in tamoxifen-sensitive group on 20mg/d, but no significant dose-response was observed. Phase III trials showed no improvement over tamoxifen.@-@@@@MONO@ARZOXIFENE@@@@@ARZOXIFENE||||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@LY-353381@@@@@LY-353381||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@RESPONSE RATE@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924927@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@NEW YORK, NEW YORK@@@@@14924927@-@@-@-@@NO REVIEW@@@@-@In May 2005, Pfizer licensed global rights for NSCLC and breast cancer from Coley; Pfizer subsequently bought Coley in November 2007. @SECOND-LINE@NCT00233506@48@-@-@@@-@@7/1/2004@-@200402002@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@PF-3512676@CPG-7909@@@@PF-3512676|CPG-7909|||@TLR-targeted@Immunotherapy@Vaccine@@@TLR-targeted|Immunotherapy|Vaccine||@DOSE RANGE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916198@Onco@@@@@300f1015ntsdm@@@@@@N/A@@N02AA01@N02A@NO@NEW YORK, NEW YORK@@@@@14916198@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@Feb-00@@NO REVIEW@@@@65%@@@@N/A@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals. Elderly: As with all narcotics, a reduction in dosage may be advisable in the elderly, as appropriate. Children: Not recommended.@@@1/3/2000@@@@Caution should be exercised:- in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose should be reduced, or its use should be avoided in cases of hepatic or renal failure; and - in patients suffering from the following conditions: hypotension, convulsive disorders, dependence (severe withdrawal symptoms if withdrawn abruptly) and prostatic hypertrophy.@N/A@No@@@@@N/A@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@No clinical data on label.@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTISKENAN@@@@@ACTISKENAN||||@Opioid Analgesic@@@@@Opioid Analgesic||||@N/A@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@14@1.1807@1.74@2.32@2.04@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@0.12@0.12@3.40E+12@CAPSULE@EURO@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922027@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive constant incremental dose increase of 50 mg/m2 per cohort. @@-@-@-@NEW YORK, NEW YORK@@@@@14922027@Advanced solid malignancies or B-cell lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00316511@46@-@-@@@-@@3/1/2006@-@C-726-05@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@Solid Tumours@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|Solid Tumours||||||@AROPLATIN@@@@@AROPLATIN||||@Platinum@@@@@Platinum||||@MAXIMUM TOLERATED DOSE@SAFETY@PHARMACOKINETICS@@@PHARMACOKINETICS@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916250@Onco@@@@@300f1015ntsdm@@@@@@N/A@@N02AA01@N02A@NO@NEW YORK, NEW YORK@@@@@14916250@Severe chronic pain and/or pain resistant to other analgesics, in particular pain associated with cancer.@@NO@Feb-00@@NO REVIEW@@@@65%@@@@N/A@Adults: Recommended dosage is one capsule twice daily, at 12-hourly intervals. Elderly: As with all narcotics, a reduction in dosage may be advisable in the elderly, as appropriate. Children: Not recommended.@@@1/3/2000@@@@Caution should be exercised:- in elderly subjects, in patients with impaired hepatic and/or renal functions, in patients with hypothyroidism or hypoadrenalism, in patients in a state of shock or with asthma. The dose should be reduced, or its use should be avoided in cases of hepatic or renal failure; and - in patients suffering from the following conditions: hypotension, convulsive disorders, dependence (severe withdrawal symptoms if withdrawn abruptly) and prostatic hypertrophy.@N/A@No@@@@@N/A@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@No clinical data on label.@@@@@@MORPHINE SULPHATE@@@@@MORPHINE SULPHATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@ACTISKENAN@@@@@ACTISKENAN||||@Opioid Analgesic@@@@@Opioid Analgesic||||@N/A@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@14@1.1807@3.12@4.09@3.42@@@@@@@@@@@@@@@@@@@@@@@@@@9/1/2017@0.22@0.22@3.40E+12@CAPSULE@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922484@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ZK-EPO in combination with prednisone for 6 cycles@@-@-@-@LEVERKUSEN, GERMANY@10/1/2008@@@@14922484@Androgen-Independent Prostate Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00350051@46@-@First Phase III trials planned for 2008.@@@-@@7/1/2006@-@91500, 307976@@-@-@@@II@II@@-@-@Completion due in October 2008. First Phase III trials planned for 2008.@-@@@@COMBO@SAGOPILONE@@@@@SAGOPILONE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ZK-EPO@ZK-219477@@@@ZK-EPO|ZK-219477|||@Epothilone@@@@@Epothilone||||@PSA@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922496@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Zactima (100mg or 300mg daily) with or without Xeloda@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14922496@Metastatic breast cancer previously treated with anthracycline and taxane therapy@@-@-@@NO REVIEW@@@@-@-@THIRD-LINE@NCT00034918@44@-@-@@@-@@5/1/2002@-@6474IL0002  @@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ZACTIMA@@@@@ZACTIMA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@N/A@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@FACTORIAL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922465@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@NEW YORK, NEW YORK@7/1/2008@@Tremelimumab is a fully human anti-CTLA4 (cytotoxic T-lymphocyte antigen 4) IgG2 monoclonal antibody developed by Pfizer for its potential therapeutic application in melanoma, non-small cell lung cancer (NSCLC) and colorectal cancer. CTLA4 is a CD28-family receptor expressed mainly on T-lymphocyte that acts to inhibit T-lymphocyte function.@@14922465@Disease progressed after treatment@@-@-@@NO REVIEW@@@@-@Medarex entitled to royalties@SECOND-LINE@NCT00313794@47@-@-@@@-@@5/1/2006@-@A3671014@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@TREMELIMUMAB@TICILIMUMAB@@@@TREMELIMUMAB|TICILIMUMAB|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@CP-675206@@@@@CP-675206||||@mAb@CTLA4 Receptor Antagonist@@@@mAb|CTLA4 Receptor Antagonist|||@RECIST@@@@@@@@@@METASTATIC@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919124@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@@@14919124@-@@-@-@@NO REVIEW@@@@-@In December 2007, GSK exercised its option to exclusively license XL-880, from an agreement signed in October 2002. It triggered a US$35 million payment, and Exelixis is to be paid royalties; it also has certain U.S. co-promotion rights.@-@NCT00742131@40@-@-@@@-@@@-@MET111647@@-@>> Histologically confirmed solid tumor which is metastatic or unresectable with no known effective treatment measures,    >> ECOG performance status of </= 2.     >> Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,@@@I@I@@-@-@Trial registered. [GSK, 26.08.2008]@-@@@@MONO@-@@@@@-||||@EXELIXIS@GSK@@@@EXELIXIS|GSK|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@GSK-1363089@XL-880@@@@GSK-1363089|XL-880|||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@MAXIMUM TOLERATED DOSE@SAFETY@TOLERABILITY@@@PHARMACOKINETICS@PHARMACODYNAMICS@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924665@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@PSMA ADC is designed to deliver the drug selectively to prostate cancer cells by targeting a surface protein, PSMA.@@14924665@HRPC following prior taxane chemotherapy@@-@-@@NO REVIEW@@@@-@Utilises auristatin drug-linker technology which has been in-licensed from Seattle Genetics.@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@>> Trial commenced. [Progenics, 08.09.2008]>> Trial delayed, but IND filing expected in H1 2008. [Progenics, 1 November 2007]>> Trial to commence in 2007. [Progenics, 25 May 2006]@-@@@@-@-@@@@@-||||@PROGENICS PHARMACEUTICALS@@@@@PROGENICS PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@PSMA@@@@@PSMA||||@mAb@Human@@@@mAb|Human|||@SAFETY@TOLERABILITY@@@@@@@@@METASTATIC@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923688@Onco@@@@@300f1008ntsdm@@@@@@Patients are assigned to a single-dose of 0.75 mg palonosetron group or a single-dose of 40 µg/kg granisetron hydrochloride with covariates of chemotherapy regimen, gender and age. A palonosetron group will receive IV of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of emetogenic chemotherapy. A granisetron hydrochloride group will be treated with palonosetron placebo and then IV 40µg/kg granisetron hydrochloride before a emetogenic chemotherapy.@@-@-@-@-@8/1/2007@@@@14923688@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00359567@1140@-@-@@@-@@7/1/2006@-@-@@-@-@@@III@III@@-@@RESULTS PENDING@-@@@@COMBO@-@@@@@-||||@TAIHO@@@@@TAIHO||||@@@@@@|||||||||@Supportive Care@CINV@@@@Supportive Care|CINV||||||||@PALO@@@@@PALO||||@5-HT3 Receptor Antagonist@@@@@5-HT3 Receptor Antagonist||||@COMPLETE RESPONSE@@@@@@@@@@-@@@@@PREVENTION@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14916167@Onco@@@@@@@@@@@Intermittent schedule.@@-@-@-@BASEL, SWITZERLAND@6/1/2010@@TKI258 is an oral TKI that has been demonstrated preclinically to target multiple growth-factor receptors: Fibroblast growth-factor receptor (FGFR), which plays a role in cell development, angiogenesis, and tumorigenesis1 VEGFR, which mediates angiogenesis and lymphangiogenesis2 PDGFR, which is associated with tumor progression and metastasis3 KIT, a receptor that induces cell proliferation and inhibits apoptosis4 Fms-like tyrosine kinase 3 (FLT-3), which mediates cell growth and survival and inhibits tumor-cell differentiation and apoptosis5 Due to its target profile, TKI258 exhibits both antitumor and antiangiogenic activity, and induces apoptosis in preclinical models of various cancers (acute myelogenous leukemia [AML], multiple myeloma, prostate, breast, colon, lung, renal, melanoma, bladder, and ovarian).@@14916167@TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00715182@81@-@-@@@-@@7/1/2008@-@TKI258A2107@@-@For phase I, confirmed advanced/ metastatic renal cell carcinoma for which no other therapeutic options exist. For phase II, must have been previously treated with VEGF receptor tyrosine kinase inhibitor (sunitinib and/or sorafenib); may have received one or both agents. @@@II@I@@-@-@Trial registered. [Novartis, 11.07.2008]@-@@@@MONO@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Kidney Cancer@Renal Cell Carcinoma@@@@Kidney Cancer|Renal Cell Carcinoma||||||||@TKI-258@@@@@TKI-258||||@TK Inhibitor@FGF@VEGF@@@TK Inhibitor|FGF|VEGF||@DOSE-LIMITING TOXICITY@RESPONSE RATE@@@@PHARMACOKINETICS@@@@@ADVANCED@METASTATIC@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15409682@Onco@@@@@@@@@@@Level 0, Other, Nintedanib low dose with docetaxelLevel 1, Other, Nintedanib medium dose with docetaxelLevel 2, Other, Nintedanib high dose with docetaxelLevel 3, Other, Nintedanib continuous high dose with docetaxel@@@@@@1/1/2018@@@@15409682@An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy@Both@@@@@Low Dose@@@@@@NCT02668393@30@@@@@@@2/1/2016@@1199.224@@@Patients with histologically/ cytologically confirmed locally advanced or metastatic lung adeno carcinoma after failure of first line platinum - based chemotherapy (patients with non-target lesion only are eligible). Prior immunotherapy is allowed.  Further inclusion criteria apply@@ADULTS@Phase 1@I@@@@@@@@@@DOCETAXEL@@@@@DOCETAXEL||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@-@@@@@-||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@Number of patients with Dose Limiting Toxicity (DLT) for nintedanib with weekly docetaxel during the first treatment cycle@Maximum Tolerated Dose (MTD) of nintedanib in association with weekly docetaxel.@@@@@@@@@@@@@@NON-RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923398@Onco@@@@@300f1012ntsdm@@@@@@-@@-@-@-@MAINZ, GERMANY@@@Ganymed has established advanced immunization technologies that can generate a broad range of highly effective and selective antibodies to the same target. Typically more than 100 are generated for each target. From this wealth of antibody diversity the best performers (imAbs) are selected. Because Ganymed proprietary cell surface cancer targets have unmatched tumor cell specificity, imAbs can efficiently kill tumor cells without harming normal tissues. Freed from concerns relating to toxicity in normal tissues, Ganymed's imAbs can fulfill the full potential of therapeutic antibodies by unleashing three separate but synergistic biological attacks specifically focused on the cancer cells alone: @@14923398@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@EMEA ORPHAN DRUG STATUS GRANTED FOR RENAL CELL CANCER IN MARCH 2007.@@@-@@@-@-@@-@-@@@I@I@@-@-@Trial to commence in Q408. [Ganymed, 18.11.2008]@-@@@@-@CLAUDIXIMAB@@@@@CLAUDIXIMAB||||@GANYMED PHARMACEUTICALS@@@@@GANYMED PHARMACEUTICALS||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IMAB-362@@@@@IMAB-362||||@mAb@@@@@mAb||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14924154@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AG-014699 in combination with temozolomide@@-@-@-@NEW YORK, NEW YORK@@@@@14924154@Combo with Temodal@@-@-@@NO REVIEW@@@@-@-@-@-@46@-@DISCONTINUED IN JUNE 2007 AFTER ENRICH TRIAL FAILED STATISTICAL SIGNIFICANCE.@@@-@@@-@-@@-@-@@@II@II@@-@-@Significant more myelosuppresion was seen versus Temodal monotherapy; 7 patients saw PR; endpoing met. SOURCE: Pfizer/ASCO, 6 June 2006@-@@@@COMBO@-@TEMOZOLOMIDE@@@@-|TEMOZOLOMIDE|||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@AG-14699@TEMODAL@@@@AG-14699|TEMODAL|||@PARP Inhibitor@@@@@PARP Inhibitor||||@RESPONSE RATE@@@@@@@@@@MALIGNANT@METASTATIC@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919020@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability inhibits the normal dynamic reorganisation of the microtubule network, which is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or bundles of microtubules throughout the cell cycle and multiple astersof microtubules during mitosis.@@14919020@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@-@@@-@N/A@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@-@PACLITAXEL@@@@@PACLITAXEL||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@SP-1010C-O@@@@@SP-1010C-O||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@N/A@@@@@@@@@@REFRACTORY@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922346@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity; versus Alimta alone@@-@-@-@NEW YORK, NEW YORK@12/1/2008@@@@14922346@Discontinued in Phase II trials in June 2007; advanced NSCLC, combo with Alimta@@-@-@@NO REVIEW@@@@-@In May 2005, Pfizer licensed global rights for NSCLC and breast cancer from Coley; Pfizer subsequently bought Coley in November 2007. @SECOND-LINE@NCT00321308@130@-@-@@@-@@9/1/2006@-@A8501004@@-@-@@@II@DISCONTINUED@@-@-@June 2007; interim analysis of Phase III data by DSMC showed no evdience of clinical efficacy over standard cytotoxic chemo alone; risk-benefit profile did not justify continuation.@-@@@@COMBO@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@PF-3512676@CPG-7909@@@@PF-3512676|CPG-7909|||@TLR-targeted@Immunotherapy@Vaccine@@@TLR-targeted|Immunotherapy|Vaccine||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922206@Onco@@@@@@@@@@@Treated with aflibercept dosed 4 mg/kg every 2 weeks. @@-@-@-@PARIS, FRANCE@12/1/2008@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. @@14922206@Advanced ovarian cancer with recurrent symptomatic malignant ascites@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@-@NCT00327444@54@-@-@@@-@@6/1/2006@-@AVE0005A@@-@-@@@II/III; EFC6125, @III@@-@-@8 out of the 10 evaluable patients achieved a repeat paracentesis response rate, the primary endpoint of the study, defined as at least a doubling of time to first paracentesis compared to baseline average. SOURCE: sanofi-aventis, 21 May 2008@Grade 3-4 adverse events included bowel obstruction, nausea, vomiting, anorexia, edema, general health deterioration, and one case of bowel perforation.@@@@MONO@AFLIBERCEPT@@@@@AFLIBERCEPT||||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@VEGF-TRAP@@@@@VEGF-TRAP||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@TIME TO REPEAT PARACENTESIS@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921827@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@12 cycles (of 28 days each); CC-4047 as a single agent or with prednisone@@-@-@-@SUMMIT, NEW JERSEY@3/1/2009@@Pomalidomide is a form of the drug thalidomide. It stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Pomalidomide is a type of angiogenesis inhibitor and a type of immunomodulatory agent.@@14921827@Myelofibrosis with myeloid metaplasia@@-@-@@NO REVIEW@@@@-@-@-@NCT00463385@80@-@-@@@-@@12/1/2006@-@CC-4047-MMM-001@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@BOTH@POMALIDOMIDE@@@@@POMALIDOMIDE||||@CELGENE@@@@@CELGENE||||@@@@@@|||||||||@Haematological Malignancy@@@@@Haematological Malignancy|||||||||@ACTIMID@CC-4047@@@@ACTIMID|CC-4047|||@Immunotherapy@IMiD@@@@Immunotherapy|IMiD|||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919289@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Xinlay 10mg@@-@-@-@UNITED STATES@@@@@14919289@HRPC@@-@-@@NO REVIEW@@@@-@-@-@NCT0012748@150@-@NDA FILED IN DECEMBER 2004; ODAC RECOMMENDED AGAINST APPROVAL IN SEPTEMBER 2005 CITING LACK OF EFFICACY DATA; DEVELOPMENT DISCONTINUED IN EARLY 2007.@@@-@@@-@M01-304  @@-@-@@@II/III; LONG-TERM SAFETY AND TOLERABILITY STUDY@III@@-@-@RESULTS PENDING@-@@@@MONO@ATRASENTAN@@@@@ATRASENTAN||||@ABBOTT@@@@@ABBOTT||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@XINLAY@@@@@XINLAY||||@Endothelin A Receptor Antagonist@@@@@Endothelin A Receptor Antagonist||||@SAFETY@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924343@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dosing range from 30 to 150MG@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@@@14924343@Health volunteers@@-@-@@NO REVIEW@@@@-@-@-@-@30@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@No adverse effects attributable to G4544 were observed in this study. Initial analysis of plasma samples of low doses showed that the active ingredient was absorbed after oral administration. Complete pharmacokinetic assessment of higher dose levels is pending further analyses. SOURCE: Genta, 15 November 2007@-@@@@MONO@GALLIUM NITRATE@@@@@GALLIUM NITRATE||||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Supportive Care@Bone Loss@@@@Supportive Care|Bone Loss||||||||@GANITE@G-4544@@@@GANITE|G-4544|||@Other@@@@@Other||||@SAFETY@PHARMACOKINETICS@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920987@Onco@@@@@@@@@@@84 mg octreotide implant (6 month implant) versus injections of Sandostatin LAR (dose range ~10-40 mg every 28 days) @@H01CB02@H01C@-@LEXINGTON, MASSACHUSSETTS@10/1/2009@@The octreotide implant is in development utilizing the company's patented Hydron Polymer Technology to deliver six months of octreotide, a long-acting octapeptide that mimics the natural hormone somatostatin to block production of growth hormone (GH), for the treatment of acromegaly.@@14920987@Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly@@-@-@@NO REVIEW@@@@-@-@-@NCT00765323@140@-@-@@@-@@9/1/2008@-@IP107-001@@-@>> Confirmed diagnosis of a growth hormone-secreting tumor      >> Received a stable dose of monthly octreotide depot injections for a minimum of 3 consecutive months immediately prior to screening     >> Must show a response to octreotide treatment with documented laboratory results at the screening visits defined as follows: IGF-1 < 20% above the upper limit of normal age and sex-adjusted levels and GH < 5.0 ng/mL@@@III@III@@-@-@Trial registered and commenced. [Indevus, 30.09.2008]@-@@@@-@OCTREOTIDE ACETATE@@@@@OCTREOTIDE ACETATE||||@INDEVUS PHARMACEUTICALS@@@@@INDEVUS PHARMACEUTICALS||||@@@@@@|||||||||@Acromegaly@@@@@Acromegaly|||||||||@-@@@@@-||||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@QUALITY OF LIFE@IGF-1@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@IMPLANT@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924711@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Two dosing schedules of MS-275@@-@-@-@-@11/1/2006@@Entinostat (SNDX-275) is a class I selective histone deacetylase inhibitor that has been evaluated in over 200 cancer patients. It has a long half-life and is orally bioavailable, which allows convenient once-weekly administration. No clinical trials are available at this time. In Phase 1 clinical trials, entinostat (SNDX-275) was associated with responses in both hematologic and solid tumors over a range of doses. In those studies, it was generally well tolerated at the dose and regimen selected for evaluation in Phase 2 clinical trials.@@14924711@-@@-@-@@NO REVIEW@@@@-@Global rights licensed from Bayer Schering [Syndax, February 2007]@MULTIPLE@-@-@-@-@@@-@@12/1/2004@-@-@@-@-@@@-@II@@-@-@Trials in colorectal cancer and lung cancer discontinued.@-@@@@MONO@ENTINOSTAT@@@@@ENTINOSTAT||||@SYNDAX PHARMACEUTICALS@@@@@SYNDAX PHARMACEUTICALS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@SNDX-275@MS-275@@@@SNDX-275|MS-275|||@HDAC@@@@@HDAC||||@RECIST@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916594@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Oral dose on day 1 followed by one week rest, then starting a 28 day course of daily dosing@@-@-@-@SAN DIEGO, CALIFORNIA@2/1/2009@@@@14916594@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00610194@60@-@-@@@-@@11/1/2007@-@RDEA119-101@@-@-@@@I@I@@-@-@RDEA119 demonstrated potential for once daily oral dosing in preliminary Phase 1 results. SOURCE: Ardea/AACR, 15 April 2008 Completed data to be reported in H2 2008. Phase II trial in advanced cancer to commence in H2 2008. SOURCE: Ardea, 24 March 2008@-@@@@MONO@-@@@@@-||||@ARDEA BIOSCIENCES@@@@@ARDEA BIOSCIENCES||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@RDEA-119@@@@@RDEA-119||||@MEK Inhibitor@@@@@MEK Inhibitor||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919069@Onco@@@@@300f1012ntsdm@@@@@@MT110 continuous IV infusion over 28 days with increasing doses@@-@-@-@-@12/1/2010@@MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. @@14919069@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00635596@30@-@Orphan drug for CLL@@@Orphan drug for CLL@@3/1/2008@-@MT110-101, @@-@-@@@EUDRACT No: 2007-004437-42; @I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@MICROMET@@@@@MICROMET||||@@@@@@|||||||||@Solid Tumours@Colorectal Cancer@SCLC@NSCLC@Stomach Cancer@Solid Tumours|Colorectal Cancer|SCLC|NSCLC|Stomach Cancer|||||@MT-110@@@@@MT-110||||@Other@@@@@Other||||@ADVERSE EVENTS@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14922146@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture. SOURCE: clinicaltrials.gov@@-@-@-@-@6/1/2009@@@@14922146@Cancer peptides plus GM-CSF and adjuvant for metastatic or high-risk breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00674791@21@-@-@@@-@@6/1/2007@-@BB-IND 12605B@@-@-@@@I@IV@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@IMMUNOTOPE@@@@@IMMUNOTOPE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CANCER PEPTIDES@@@@@CANCER PEPTIDES||||@Vaccine@@@@@Vaccine||||@SAFETY@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15412295@Onco@@@@@@@@@@@AFM13 + Pembrolizumab, Experimental, Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.@@@@@WHITEHOUSE STATION, NEW JERSEY@9/1/2017@@@@15412295@A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)@Both@@@@@@@@@@@NCT02665650@33@@@@@@@3/1/2016@@AFM13-103@@@1. Diagnosis of CD30+ classical Hodgkin lymphoma reconfirmed by histopathology. Note: where reconfirmation is not possible, patients will still be eligible where they have confirmation clearly documented in their medical records.  2. Relapsed or refractory disease after standard therapy including brentuximab vedotin (Adcetris®).  3. Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug which could interact with this trial not less than 4 weeks (or 5 half-lives of the drug, whichever occurs later) prior to first dose of study drug. Cessation of small molecule tyrosine kinase inhibitors must be at least 7 days prior to first dose of study drug.  4. Completion of, if applicable, an autologous stem cell transplantation (ASCT) at least 3 months prior to first dose of study drug.  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) <2.  Main@@ADULTS@Phase 1@I@@@@@@@@@@-@PEMBROLIZUMAB@@@@-|PEMBROLIZUMAB|||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Haematological Malignancy@Hodgkin's Lymphoma@@@@Haematological Malignancy|Hodgkin's Lymphoma||||||||@AFM13@KEYTRUDA@@@@AFM13|KEYTRUDA|||@Other@@@@@Other||||@Number of participants experiencing dose limiting toxicity (DLT) during combination treatment@@@@@Number and frequency of adverse events@@@@@@@@@@SAFETY/EFFICACY STUDY@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923982@Onco@@@@@300f1015ntsdm@@@@@@Uftoral/calcium folinate versus Mayo regimen/calcium folinate@@L01BC53@L01B@-@DARMSTADT, GERMANY@@@@@14923982@First-line treatment of metastatic colorectal cancer with calcium folinate.@@NO@6-Aug@@NO REVIEW@@@@100%@@@@1196@The dose of Uftoral is 300 mg/m2/day tegafur and 672 mg/m2/day uracil combined with 90 mg/day oral calcium folinate, given in three divided doses (preferably every 8 hours). Calcium folinate should be taken at the same time as Uftoral. Doses should be taken at least one hour before or one hour after meals for 28 consecutive days.@1-Feb@@@@@@@LABEL@No@@1196 [METASTATIC COLORECTAL CANCER]@@@III STUDY-011 AND STUDY-012@APPROVED@@FREE PRICE IN HOSPITAL@HAUTE AUTORITÉ DE SANTÉ@The median survival time was 12.4 months (95% CI: 11.2-13.6 months) and 13.4 months in the Uftoral/calcium folinate and the 5FU/calcium folinate treatment groups, respectively (Study-011). The median TTP was 3.4 months and 3.3 months respectively.@@@@@COMBO@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFT@MAYO REGIMEN@@@@UFT|MAYO REGIMEN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@@@@@21@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@3.40E+12@CAPSULE@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924127@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@ABI-008 every three weeks@@L01CD02@L01C@-@UNITED STATES@@@ABI-008 (nab-docetaxel) is a microtubule stabilizer and an albumin-bound chemotherapeutic, for the treatment of hormone refractory prostate and metastatic breast cancer.@@14924127@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@4/1/2007@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@DOCETAXEL NANOPARTICLE ALBUMIN-BOUND@@@@@DOCETAXEL NANOPARTICLE ALBUMIN-BOUND||||@ABRAXIS@@@@@ABRAXIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@ABI-008@@@@@ABI-008||||@Plant Alkaloid@Vinca Alkaloids@@@@Plant Alkaloid|Vinca Alkaloids|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@SINGLE-ARM@DOSE ESCALATION@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924691@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@AMSTERDAM, NETHERLANDS@@@@@14924691@GvHD intolerant or resistant to standard immunosuppressives@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@FDA orphan drug designation. SOURCE: Kiadis, 16 April 2008@4/16/2008@@FDA orphan drug designation. SOURCE: Kiadis, 16 April 2008@@@-@-@@-@-@@@I/II@II@@-@-@"The current preliminary clinical results demonstrate an ""excellent safety profile for Rhitol"" and evidence of efficacy in the alleviation of the symptoms associated with chronic Graft versus Host Disease. After the clinical study was closed for enrollment mid 2007 Kiadis allowed new patients to be treated under a compassionate protocol.  The successful completion of the Phase II clinical trial of Rhitol paves the way for a phase III study and Kiadis is planning to file for a phase III multi center clinical trial in the USA and Canada within the next few months. SOURCE: Kiadis, 31 January 2008"@-@@@@-@-@@@@@-||||@KIADIS PHARMA@@@@@KIADIS PHARMA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@RHITOL@@@@@RHITOL||||@Other@@@@@Other||||@SAFETY@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921613@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV administered twice a week for 2 weeks@@-@-@-@LONDON, UNITED KINGDOM@7/1/2008@@@@14921613@Cell cycle inhibitor@@-@-@@NO REVIEW@@@@-@-@-@NCT00471367@30@-@-@@@-@@4/1/2007@-@D2782C00006@@-@-@@@I@I@@-@-@MTD was 11mg on twice-weekly schedule of 1hour infusion on days 1,4,8 and 11 in a 3-week cycle. DLT was neutropaenia without anaemia or thrombocytopaenia. 1 patient with DLBCL had partial response. SOURCE: AstraZeneca/ASCO, 2 June 2008@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-4877@@@@@AZD-4877||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921487@Onco@@@@@@@@@@@Lapatinib with paclitaxel versus paclitaxel/placebo@@-@-@-@BRENTFORD, UNITED KINGDOM@7/1/2010@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14921487@ErbB2-over-expressing study with Tykerb and paclitaxel@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00281658@424@-@Registrational study for first-line setting@@@-@@1/1/2006@-@EGF104535@@-@-@@@III@III@@-@-@Endpoint over 2 weeks.@-@@@@COMBO@LAPATINIB@PACLITAXEL@@@@LAPATINIB|PACLITAXEL|||@GSK@@@@@GSK||||@China@@@@@China|||||||||@Breast Cancer@HER2+@@@@Breast Cancer|HER2+||||||||@TYKERB@@@@@TYKERB||||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921603@Onco@@@@@@@@@@@Faslodex 250mg with Arimidex 1mg@@L02BA03@L02B@-@LONDON, UNITED KINGDOM@@@Fulvestrant is an oestrogen receptor antagonist and binds to oestrogen receptors in a competitive manner with an affinity comparable with that of oestradiol. Fulvestrant blocks the trophic actions of oestrogens without itself having any partial agonist (oestrogen-like) activity. The mode of action is associated with down-regulation of oestrogen receptor (ER) protein. Clinical trials in postmenopausal women with primary breast cancer have shown that fulvestrant significantly down-regulates ER protein in ER positive tumours compared with placebo. There was also a significant decrease in progesterone receptor expression consistent with a lack of intrinsic oestrogen agonist effects.@@14921603@ER-positive advanced breast cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00327769@250@-@-@@@-@@12/1/2005@-@D6997L00004@@-@-@@@III@III@@-@-@RESULTS PENDING (recruiting)@-@@@@COMBO@FULVESTRANT@ANASTROZOLE@@@@FULVESTRANT|ANASTROZOLE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@China@@@@@China|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FASLODEX@ARIMIDEX@@@@FASLODEX|ARIMIDEX|||@Hormone Antagonist@@@@@Hormone Antagonist||||@TIME TO PROGRESSION@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922533@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Given daily on a 7 days on / 7 days off schedule @@-@-@-@MONTREAL, CANADA@6/1/2009@@@@14922533@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00679133@60@-@-@@@-@@4/1/2008@-@265-102@@-@Patients with advanced metastatic or unresectable malignancy that is refractory to standard therapy and/or existing therapies are not likely to achieve clinical benefit. The patient's disease must be histologically confirmed;@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@METHYLGENE@@@@@METHYLGENE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@MGCD-265@@@@@MGCD-265||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@SAFETY@TOLERABILITY@@@@PHARMACOKINETICS@PHARMACODYNAMICS@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919032@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Bexarotene 400mg/m2/d and cisplatin 100mg/m2 Q4 weeks and vinorelbine (25mg/m2 Qwk) IV or cisplatin/vinorelbine alone.@@L01XX25@L01X@-@TOKYO, JAPAN@@@@@14919032@NSCLC@@-@-@@NO REVIEW@@@@-@Global rights licensed by Eisai from Ligand in September 2006. Cephalon acquired European rights through takeover of Zeneus in December 2005.@FIRST-LINE@-@623@-@-@@@-@@@-@N/A@@2016@-@@@III@III@@-@-@ASCO 2005 final results; OS were not different with medians of 260 and 297 days; 2--year survival was 13% and 16%. No overall improvement in OS.@-@@@@COMBO@BEXAROTENE@CISPLATIN@@@@BEXAROTENE|CISPLATIN|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@TARGRETIN@@@@@TARGRETIN||||@Retinoid@@@@@Retinoid||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918935@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@BETHESA, MARYLAND@@@DCVax products are being developed to activate all aspects of the immune response, both cellular and antibody, thus potentially providing a broader and longer lasting immune and clinical response. Northwest Biotherapeutics' products are deigned as pure, activated DC loaded with the immunogen as would naturally occur, and that are capable of migrating to lymph nodes. The intended result is a very robust, and full immune response consisting of both a specific cellular T cell response and a specific antibody response against the cancer associated antigen.@@14918935@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@FDA cleared for this trial. SOURCE: Northwest@-@@@@-@-@@@@@-||||@NORTHWEST BIOTHERAPEUTICS@@@@@NORTHWEST BIOTHERAPEUTICS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@DCVAX@@@@@DCVAX||||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@RESPONSE RATE@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921917@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Brivanib 400MG based on day 1 pharmacokinetics, QD, until progression@@-@-@-@NEW YORK, NEW YORK@11/1/2008@@@@14921917@Liver cancer patients with mild, moderate or severe liver dysfuntion@@-@-@@NO REVIEW@@@@-@-@-@NCT00437424@54@-@-@@@-@@7/1/2007@-@CA182-015@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@BRIVANIB ALANINATE@@@@@BRIVANIB ALANINATE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@BMS-582664@@@@@BMS-582664||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916440@Onco@@@@@300f1012ntsdm@@@@@@SBG versus placebo@@-@-@-@TROMSO, NORWAY@7/1/2006@@@@14916440@Oral mucositis in head and neck cancer patients@@-@-@@NO REVIEW@@@@-@-@-@NCT00289003@40@-@Orphan drug in Europe.@@@Orphan drug in Europe.@@10/1/2003@-@SMR-907-SBG-1-02-HN@@-@-@@@II@II@@-@-@September 2006; patients with SBG experience significantly lower mucusitis.@-@@@@MONO@-@@@@@-||||@BIOTEC PHARMACON@@@@@BIOTEC PHARMACON||||@@@@@@|||||||||@Supportive Care@Mucositis@Head & Neck Cancer@@@Supportive Care|Mucositis|Head & Neck Cancer|||||||@SBG@@@@@SBG||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14921621@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AZD-7762 administered either alone or with Camptosar@@-@-@-@LONDON, UNITED KINGDOM@3/1/2010@@@@14921621@CHK1 Inhibitor@@-@-@@NO REVIEW@@@@-@-@-@NCT00473616@60@-@-@@@-@@5/1/2007@-@D1040C00004@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@BOTH@-@IRINOTECAN@@@@-|IRINOTECAN|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-7762@CAMPTOSAR@@@@AZD-7762|CAMPTOSAR|||@Other@@@@@Other||||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INTRAVENOUS INFUSION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924288@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01XA03@L01X@-@PARIS, FRANCE@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14924288@-@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@SECOND-LINE@NCT00525915@76@-@-@@@-@@4/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Oesophageal Cancer@@@@@Oesophageal Cancer|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921483@Onco@@@@@@@@@@@Lapatinib combo with concurrent radiotherapy and cisplatin versus cisplatin-radiotherapy alone@@-@-@-@BRENTFORD, UNITED KINGDOM@8/1/2013@@Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM, respectively) with a dissociation half-life of =300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.@@14921483@Stage III, IVA, B SCCHN@@-@-@@NO REVIEW@@@@-@-@-@NCT00387127@100@-@-@@@-@@10/1/2006@-@EGF105884@@17-Jul@-@@@II@II@@-@-@Trial registered. [GSK, 10.10.2006]@-@@@@COMBO@LAPATINIB@CISPLATIN@@@@LAPATINIB|CISPLATIN|||@GSK@@@@@GSK||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@TYKERB@@@@@TYKERB||||@TK Inhibitor@HER2@EGFR@@@TK Inhibitor|HER2|EGFR||@RECIST@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
15398311@Onco@@@@@300f1008ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@15398311@Radical unresectable medullary thyroid cancer@@NA@26-Nov-15@11/26/2015@NO REVIEW@@@@REIMBURSEMENT RANGES FROM 100% TO 70% DEPENDING ON SUB-POPULATIONS@@@@@300 MG once daily@MHLW, 28 September 2015@9/28/2015@@Yes@@@@@No@@@ADULT@@@APPROVED@@@NHI@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@UNRESECTABLE@METASTATIC@@@@@@@@@1@1@18310362.5@@@30.5@month@30.5 month@18310362.5@18310362.5@19737.63@1@0.0091@6579.21@7758.5@@@@@@@@@@@65.79@1@@mg@300@1@@@@@@@@@@@8/30/2017@6579.21@6579.21@4291041F1029@TABLET@YEN@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14923024@Onco@@@@@@@@@@@-@@L1A@L1A@-@RIDGEFIELD PARK, NEW JERSEY@@@Glufosfamide combines the active part of an approved alkylator, a member of a widely used class of chemotherapy drugs, with a glucose molecule. The linkage between glucose and the alkylator is cleaved to release the active drug. With glucose as the side product, glufosfamide has fewer side effects than other drugs in its class, which are known to cause hemorrhagic cystitis, a serious condition characterized by severe bladder bleeding.@@14923024@Second-line therapy @@-@-@@NO REVIEW@@@-@-@-@-@-@300@-@-@@@EC grants orphan drug designation status in Europe [Eleison, 28 April 2011, http://eleison-pharma.com/yahoo_site_admin/assets/docs/eleison_news_release_4-28-11_eu_orphan_designation_v1.11772335.pdf ] @@@-@-@@-@-@@@III@III@@-@-@Threshold Pharmaceuticals reported overall survival in the glufosfamide arm was 18% higher compared to those in best supportive care alone. But as result was not statistically significant, the trial was closed to enrollment.@-@@@@MONO@GLUFOSFAMIDE@@@@@GLUFOSFAMIDE||||@THRESHOLD PHARMACEUTICALS@@@@@THRESHOLD PHARMACEUTICALS||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@-@@@@@-||||@Alkylating Agent@@@@@Alkylating Agent||||@OVERALL SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922588@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Ultralow dose IRX-2 with cyclophosphamide, indomethacin and zinc@@-@-@-@-@@@IRX-2 is a stimulant of the TH1-specific cellular immune system and comprised of a uniform set of naturally-derived cytokines. @@14922588@Resectable/operable head and neck cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00210470@27@-@-@@@-@@7/1/2005@-@2005-A@@-@-@@@II@II@@-@-@The preoperative IRX-2 regimen was associated with significant changes in immune cells consistent with an anti-tumor immune response, with some patients showing tumor shrinkageafter treatment. At 18 months of follow-up in the Stage IVa cohort, thirteen of sixteen patients, 81%, of IRX-2 treated patients were alive. The IRX-2 regimen was well tolerated by all patients and had a good safety profile. SOURCE: IRX/American Head and Neck Society, 22 July 2008@-@@@@COMBO@CITOPLURIKIN@CYLCOPHOSPHAMIDE@@@@CITOPLURIKIN|CYLCOPHOSPHAMIDE|||@IRX THERAPEUTICS@@@@@IRX THERAPEUTICS||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@IRX-2@@@@@IRX-2||||@Immunotherapy@@@@@Immunotherapy||||@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924720@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@SPI-1620 in escalating doses from 0.5 µg/m2 intravenous over sixty seconds @@-@-@-@IRVINE, CALIFORNIA@1/1/2009@@@@14924720@Adjunt to cancer chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@NCT00613691@36@-@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@2/14/2006@@EMEA COMP recommended for orphan drug status for multiple myeloma; early granted orphan drug designation for CLL and Hodgkin's lymphoma. SOURCE: GPC Biotech, 14 February 2006@@1/1/2008@-@-@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@ADJUVANT@-@@@@@-||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Other@@@@@Other|||||||||@SPI-1620@@@@@SPI-1620||||@Chemopotentiator@@@@@Chemopotentiator||||@MAXIMUM TOLERATED DOSE@SAFETY@TOLERABILITY@@@TOLERABILITY@@@@@-@@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922747@Onco@@@@@300f1008ntsdm@@@@@@The first part of the study is a Phase I design to evaluate the maximum tolerated dose of S-3304 when given in combination with radiation and paclitaxel/carboplatin chemotherapy that is appropriate for further evaluation. The second part of the study is a randomized Phase II design to evaluate the efficacy of recommended S-3304 dose in combination with chemo-radiation.@@-@-@-@-@@@@@14922747@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00078390@90@-@-@@@-@@2/1/2003@-@0207P1421@@-@-@@@II@DISCONTINUED@@-@@RESULTS PENDING@-@@@@COMBO@-@PACLITAXEL@CARBOPLATIN@@@-|PACLITAXEL|CARBOPLATIN||@SHIONOGI@@@@@SHIONOGI||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@S-3304@@@@@S-3304||||@Other@@@@@Other||||@SAFETY@PHARMACOKINETICS@@@@@@@@@LOCALLY ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14919008@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@QUEBEC, QUEBEC@@@@@14919008@Hormone refractory prostate cancer and SCLC@@-@-@@NO REVIEW@@@@-@Available for licensing on a worldwide basis.@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Results to date: the Phase I trial tested in patients with various solid tumors the subcutaneous injection, up to the highest dose level tested RC- 3095 was tolerated without clinically relevant side effects; systemic tolerability of RC-3095 was very good. Although tumor response was not a primary endpoint in Phase I, patients with different tumor types showed clinical response. In addition, a patient with hormone-refractory prostate cancer with rapidly rising PSA showed a drop in serum PSA as a biochemical indicator of tumor response. Finally, a patient with a thyroid cancer who was treated at the low dosage of 32 µg/kg once daily showed a transient decrease in the size of a cervical lymph node and qualified for a minor remission.@-@@@@-@-@@@@@-||||@AETERNA ZENTARIS@@@@@AETERNA ZENTARIS||||@@@@@@|||||||||@Prostate Cancer@SCLC@@@@Prostate Cancer|SCLC||||||||@RC-3095@@@@@RC-3095||||@TK Inhibitor@HER2@VEGF@@@TK Inhibitor|HER2|VEGF||@-@@@@@@@@@@REFRACTORY@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14925008@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients with recurrent disease receive the HSPPC-96 vaccine between 2-8 weeks after surgery. The HSPPC-96 vaccine is administered intradermally every 1-3 weeks for 4 doses and then every 2-3 weeks thereafter.@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14925008@Recurrent or progressive glioma@@-@-@@NO REVIEW@@@@-@-@-@NCT00293423@50@-@-@@@-@@@-@5103@@-@-@@@I/II@III@@-@-@RESULTS PENDING@-@@@@MONO@VITESPAN@@@@@VITESPAN||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@MAXIMUM TOLERATED DOSE@OVERALL SURVIVAL@RESPONSE RATE@TIME TO PROGRESSION@@RESPONSE RATE@TIME TO PROGRESSION@@@@RELAPSED@REFRACTORY@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921810@Onco@@@@@@@@@@@DFS measured at 5 years.@@L02BG04@L02B@-@BASEL, SWITZERLAND@@@The elimination of oestrogen-mediated stimulatory effects is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone (E1) and oestradiol (E2). The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues.@@14921810@Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer @@-@-@@NO REVIEW@@@@-@-@-@NCT00248170@4000@-@-@@@-@@12/1/2005@-@CFEM345D2411@@-@-@@@III@III@@-@-@Trial registered. [Novartis, 26.06.2005]@-@@@@ADJUVANT@LETROZOLE@ANASTROZOLE@@@@LETROZOLE|ANASTROZOLE|||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FEMARA@ARIMIDEX@@@@FEMARA|ARIMIDEX|||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917900@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@@@NO@NEW YORK, NEW YORK@@@@@14917900@Recommended as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women when hormonal therapy is indicated. It may also be used in women who were diagnosed as having had disseminated breast carcinoma when premenopausal, in whom ovarian function has been subsequently terminated. It was found to be effective in approximately 15% of patients with advanced or disseminated mammary cancer evaluated according to the following criteria: 1) those with a measurable decrease in size of all demonstrable tumour masses; 2) those in whom more than 50% of non-osseous lesions decreased in size although all bone lesions remained static; and 3) those in whom more than 50% of total lesions improved while the remainder were static.@@@temporary authorization in France@@NO REVIEW@@@@@@@@@The recommended oral dose is 250 mg qid. In order to evaluate the response, therapy with testolactone should be continued for a minimum of three months unless there is active progression of the disease.@@@@@@@NONE@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@TESTOLACTONE@@@@@TESTOLACTONE||||@BMS@@@@@BMS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@FLUDESTRIN@@@@@FLUDESTRIN||||@Hormone Antagonist@Aromatase Inhibitor@@@@Hormone Antagonist|Aromatase Inhibitor|||@@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14923936@Onco@@@@@@@@@@@Docetaxel, Cisplatin and Fluorouracil Combination@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14923936@Neoadjuvant treatment of locally advanced gastric carcinoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00343239@57@-@-@@@-@@4/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@NEOADJUVANT@DOCETAXEL@CISPLATIN@FLUOROURACIL@@@DOCETAXEL|CISPLATIN|FLUOROURACIL||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@Turkey@@@@@Turkey|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESECTION RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924281@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Eloxatin and Docetaxel@@L01XA03@L01X@-@PARIS, FRANCE@12/1/2007@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14924281@First-line therapy of stage IV or IIIb Unresectable NSCLC@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed U.S. and European rights from Debiopharm.@FIRST-LINE@NCT00145418@48@-@-@@@-@@2/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@OXALIPLATIN@@@@@OXALIPLATIN||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@ELOXATIN@@@@@ELOXATIN||||@Platinum@@@@@Platinum||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919122@Onco@@@@@@@@@@@160mg PI-88 vs control@@-@-@-@QUEENSLAND, AUSTRALIA@6/1/2008@@@@14919122@HCC adjuvant@@-@-@@NO REVIEW@@@@-@-@-@NCT00247728@343@-@EMEA Orphan DrugFDA Fast-Track (and SPA subsequently abandoned). SOURCE: Progen, 2 November 2007@11/2/2007@@EMEA Orphan DrugFDA Fast-Track (and SPA subsequently abandoned). SOURCE: Progen, 2 November 2007@@6/1/2004@-@MG 002,  @@-@-@-@@II; PR88204;@II@@-@-@A subgroup analysis of data from Taiwanese Phase II trials showed patients with high risk of recurrence within 12-month period had a doubling in time to recurrence with 160mg PI-88 vs controls (48 vs 24 weeks, p=0.0107). Previous data had shown a 25% improvement on the primary endpoint of DFS for patients receiving 160mg PI-88 vs those receiving standard care. 48-week data showed PI-88 160MG improved disease-free rate 25% and prolonged disease-free survival from 27 to 48 weeks (78%).@-@@@@ADJUVANT@-@@@@@-||||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@Taiwan@@@@@Taiwan|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@PI-88@@@@@PI-88||||@Angiogenesis Inhibitor@VEGF@TK Inhibitor@@@Angiogenesis Inhibitor|VEGF|TK Inhibitor||@DISEASE-FREE SURVIVAL@SAFETY@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14923263@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@N01AH01@N01A@@BUFFALO GROVE, ILLINOIS@@@Fentanyl is a synthetic opiate with a clinical potency of 50 to 100 times that of morphine. Its onset of action is rapid and its duration of action is short. In man, a single iv dose of 0.5-1 mg/70 kg body weight immediately produces a pronounced state of surgical analgesia, respiratory depression, bradycardia and other typical morphine-like effects. The duration of action of the peak effects is about 30 minutes. All potent morphine-like drugs produce relief from pain, ventilatory depression, emesis, constipation, physical dependence, certain vagal effects and varying degrees of sedation. Fentanyl, however, differs from morphine not only by its short duration of action but also by its lack of emetic effect and minimal hypotensive activity in animals.@@14923263@Management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain@@@@@NO REVIEW@@@@@@@@@@FDA, 19 February 1968@2/19/1968@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@FENTANYL CITRATE@@@@@FENTANYL CITRATE||||@AKORN@@@@@AKORN||||@@@@@@|||||||||@Supportive Care@Cancer Pain@@@@Supportive Care|Cancer Pain||||||||@SUBLIMAZE@@@@@SUBLIMAZE||||@Opioid Analgesic@@@@@Opioid Analgesic||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@5@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@17478-0030-20@INJECTION - 20 ML@US$@@@@@@@@1000@MCG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924871@Onco@@@@@@@@@@@Patients will be randomized (1:1) to oral deforolimus or progestin. SOURCE: Ariad@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@Deforolimus is a novel small-molecule inhibitor of the protein mTOR, a “master switch” in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. @@14924871@Advanced endometrial cancer@@-@-@@NO REVIEW@@@@-@Merck licensed the drug in July 2007 for US$75 mil. upfront, up to US$452 mil. in milestone payments and up to US$200 mil. in sales-related bonus. Merck will cover half development costs@-@-@150@-@-@@@-@@8/1/2008@-@-@@-@-@@@II@II@@-@-@Trial started. Enrollment due to be completed in H2 2009. SOURCE: Ariad, 6 August 2008@-@@@@MONO@RIDAFOROLIMUS@@@@@RIDAFOROLIMUS||||@ARIAD PHARMACEUTICALS@MERCK & CO@@@@ARIAD PHARMACEUTICALS|MERCK & CO|||@@@@@@|||||||||@Endometrial Cancer@@@@@Endometrial Cancer|||||||||@AP-23573@@@@@AP-23573||||@mTOR Inhibitor@@@@@mTOR Inhibitor||||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916078@Onco@@@@@300f1018ntsdm@@@@@@Gardasil 0.5ML injection as 3 dose-regimen versus V505 0.5ML 3-dose regimen (6 months) or V505 (0.5ML 1Pbo dose regimen (6 monhts)@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@12/1/2010@@@@14916078@Women aged 16-26@@-@-@@NO REVIEW@@@@-@extra-Australia rights licensed from CSL@-@NCT00520598@500@-@-@@@-@@10/1/2007@-@V505-001@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@V-505@@@@@V-505||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@23@Australia@@@@@@@@
14924675@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@OSAKA, JAPAN@@@@@14924675@Clearance of HPV infection on cervarix@@-@-@@NO REVIEW@@@@-@Fully licensed from 3M@-@NCT00312286@480@N/A@-@@@-@@4/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@R-851@851B GEL@@@@R-851|851B GEL|||@Immunotherapy@@@@@Immunotherapy||||@REGRESSION OF HIGH RISK@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TOPICAL AGENT@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924442@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@Octreotide is a synthetic octapeptide analog of naturally occurring somatostatin with similar pharmacological effects, but with a longer duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the gastroenteropancreatic (GEP) endocrine system, stomach, intestine and pancreas (for example, gastrin, insulin and glucagon). @@14924442@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@QLT is submitting information to the FDA and expects to enter the clinic in H1 2007. SOURCE: QLT, 22 February 2007@-@@@@-@OCTREOTIDE ACETATE@@@@@OCTREOTIDE ACETATE||||@QLT@@@@@QLT||||@@@@@@|||||||||@Acromegaly@@@@@Acromegaly|||||||||@GHRP-1@ATRIGEL@@@@GHRP-1|ATRIGEL|||@Somatostatin Analogue@@@@@Somatostatin Analogue||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ONE-MONTH FORMULATION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918944@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14918944@-@@-@-@@NO REVIEW@@@@-@">> Roche reaches a friendly agreement to purchase the latter's outstanding shares at a price of US$95 per share. The transaction will be valued at US$46.8 billion. [Genentech, 12 March 2009]>> Roche has made a formal announcement of cash tender offer for all outstanding shares of Genentech at US$86.50 per share for the 44.2% of Genentech not already held by Roche. Genentech's special committee, on the other hand, has responded to the offer by urging its shareholders ""to take no action at this time"". [Genentech, 10.02.2009]          >> Genentech rejects the acquisition bid. [Genentech, 14.08.2008]        >> Licensing deal signed through which Piramed receives milestone payments and future royalties; Genentech is solely responsible for clinical development"@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Drug has reached the clinic. [Piramed, 17 March 2008]@-@@@@-@-@@@@@-||||@GENENTECH@ROCHE@@@@GENENTECH|ROCHE|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@GDC-0941@@@@@GDC-0941||||@P13 kinase inhibitor@@@@@P13 kinase inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924119@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW YORK, NEW YORK@@@@@14924119@-@@-@-@@NO REVIEW@@@@-@Genzyme and Callisto amended their licensing agreement for the drug in January 2008; all milestone payments owed to Genzyme were exchanged for an upfront payment; Genzyme is eligibly for a reduced royalty rate of single digits. Callisto originally license@-@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@ATIPRIMOD@@@@@ATIPRIMOD||||@CALLISTO@@@@@CALLISTO||||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@-@@@@@-||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@120@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918916@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Dosing of BIIB-021 with frequency and duration@@-@-@-@CAMBRIDGE, MASSACHUSSETTS@@@@@14918916@-@@-@-@@NO REVIEW@@@@-@-@-@-@34@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@Preliminary results: well-tolerated at doses up to 800MG twice-weekly for solid tumours and 50MG daily for 3 weeks in CLL. No dose-limiting toxicities or Grade 4 adverse events were seen. SOURCE: AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics, 22-26 October 2007@-@@@@MONO@-@@@@@-||||@BIOGEN IDEC@@@@@BIOGEN IDEC||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@Solid Tumours@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|Solid Tumours|||||||@BIIB-021@@@@@BIIB-021||||@HSP90 Inhibitor@HER2@@@@HSP90 Inhibitor|HER2|||@MAXIMUM TOLERATED DOSE@SAFETY@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916312@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Increasing doses of the compound, administered every three weeks, are to be evaluated in new cohorts of patients with solid tumors until the maximum tolerated dose (MTD) is established and the dose-limiting toxicities are identified. Once the MTD is established, enrollment will be limited to patients with tumors that are melanomas, sarcomas or those carcinomas that characteristically express the relevant integrin target. SOURCE: Immunogen@@-@-@-@-@@@IMGN388 consists of the Company's DM4 cell-killing agent attached to an antibody that binds specifically to an integrin expressed on a wide range of solid tumors - melanomas, sarcomas and many carcinomas, including lung, bladder, renal cell and thyroid carcinomas.@@14916312@Solid tumours@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@STUDY 201@@-@-@@@I@I@@-@-@Trial started. IND filed in mid-May 2008 and approved in mid-June 2008. SOURCE: Immunogen, 7 July 2008@-@@@@MONO@-@@@@@-||||@IMMUNOGEN@@@@@IMMUNOGEN||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IMGN-388@@@@@IMGN-388||||@mAb@@@@@mAb||||@TOLERABILITY@RESPONSE RATE@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918763@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MUMBAI, INDIA@@@@@14918763@-@@-@-@@NO REVIEW@@@@-@Licensed from Ribozyme/Sirna and Chiron@-@-@-@-@APPROVAL IS EXPECTED IN INDIA IN 2007 AND EUROPE IN 2008.@@@-@@@-@NA@@-@-@@@IIB@II@@-@-@Study results have not been released.@-@@@@-@RIBOZYME MOLECULE@@@@@RIBOZYME MOLECULE||||@ACTIS BIOLOGICS@@@@@ACTIS BIOLOGICS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ACONC-001@@@@@ACONC-001||||@Gene Therapy@@@@@Gene Therapy||||@-@@@@@@@@@@-@@@@@NOT AVAILABLE@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921127@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@50, 82.5, 125, 175, 225, 275 or 300 mg/M2, sterile suspension of nanoparticulate paclitaxel administered intraperitoneally on Day 1 of each 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops. SOURCE: clinicaltrials.gov@@-@-@-@LAWRENCE, KANSAS@7/1/2010@@@@14921127@Peritoneal cancers@@-@-@@NO REVIEW@@@@-@-@-@NCT00666991@20@-@-@@@-@@6/1/2008@-@HSC#11140@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@PACLITAXEL, NANOPARTICLE@@@@@PACLITAXEL, NANOPARTICLE||||@CRITITECH INC@@@@@CRITITECH INC||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@-@@@@@-||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@DOSE-LIMITING TOXICITY@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917974@Onco@@@@@300f1020ntsdm@@@@@@Foscan alone@@L01XD05@L01X@NO@EAST LONGMEADOW, MASSACHUSSETTS@@@@@14917974@Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.@@YES@10.10.2005@@NO REVIEW@@@@0%@-@-@-@147@The dose is 0.15mg/kg body weight.@EMA, 24 October 2001@10/24/2001@@-@@@Special care must be taken to prevent extravasation at the injection site. If extravasation occurs, protect the area from light for at least 3 months. There is no known benefit from injecting the extravasation site with another substance.@-@No@-@-@@@III: ADVANCED H&N CANCER@APPROVED@@Classification H. Post-marketing monitoring system: centres utilising the drug must compile records of usage indicating the eligibility of the patients for follow-up. [AIFA]@@Median duration of tumour response was 57 days for overall responseand 84 days for complete response.@-@@@@MONO@TEMOPORFIN@@@@@TEMOPORFIN||||@BIOLITEC@@@@@BIOLITEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@FOSCAN@@@@@FOSCAN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@5773.71@9479.09@6032.23@@@@@@@@@@288.69@@@@@@@@@@@@@@@@6/7/2017@5773.71@5773.71@36433023@INJECTABLE SOLUTION VIAL, 5 ML@EURO@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14922028@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Aroplatin given to subjects refractory to 5-FU/leucovorin or capecitabine, and irinotecan therapies.@@-@-@-@NEW YORK, NEW YORK@@@@@14922028@Advanced colorectal cancer resistant to standard therapies@@-@-@@NO REVIEW@@@@-@-@-@NCT00043199@40@-@-@@@-@@@-@C-726-01@@-@-@@@II@II@@-@-@ECCO 2003; one out of the 15 evaluable patients demonstrated a partial clinical response and two experienced disease stabilization. Aroplatin appeared well tolerated in the trial. Antigenics' confirmation, data analysis and finalisation of results reported by study investigators are ongoing.@-@@@@MONO@-@@@@@-||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Colorectal Cancer@B-Cell Lymphoma@@@@Colorectal Cancer|B-Cell Lymphoma||||||||@AROPLATIN@@@@@AROPLATIN||||@Platinum@@@@@Platinum||||@COMPLETE RESPONSE@PARTIAL RESPONSE@DURATION OF RESPONSE@@@DURATION OF RESPONSE@@@@@REFRACTORY@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924881@Onco@@@@@@@@@@@Multikine plus standard of care (surgery + radiotherapy or surgery + concurrent chemoradiotherapy) versus standard of care only@@-@-@-@VIENNA, VIRGINIA@@@@@14924881@Primary Squamous Cell Carcinoma of the Oral Cavity.@@-@-@@NO REVIEW@@@@-@>> Orient Europharma has expanded its exclusive licensing agreement for Multikine. Orient will now have rights to South Korea, Philippines, Australia, and New Zealand in addition to Taiwan, Hong Kong, Singapore and Malaysia. Orient has invested US$500,000 in Cel-Sci and will fund part of 2009's global Phase III trial. [Cel-Sci, 4.11.2008]     >> Teva licenses rights to Israel and Turkey for Multine for head and neck cancer only. [Teva, 20 August 2008]@-@-@800@-@ORPHAN DRUG STATUS GRANTED IN JUNE 2007 FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK@@@ORPHAN DRUG STATUS GRANTED IN JUNE 2007 FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK@@@-@-@@-@-@@@III@III@@-@-@Trial to commence in Q4 08.@-@@@@COMBO@-@@@@@-||||@CEL-SCI@@@@@CEL-SCI||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@MULTIKINE@@@@@MULTIKINE||||@Immunotherapy@@@@@Immunotherapy||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@OPEN-LABEL@RANDOMISED@MULTI-CENTRE@PIVOTAL@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924840@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01BC06 @L01B@-@BASEL, SWITZERLAND@@@Xeloda is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered prodrug of 5'dexoxy-5-fluorouridine which is converted to 5-FU.@@14924840@Biliary tract and gallbladder cancer@@-@-@@NO REVIEW@@@@-@Roche announces US$43.7 billion proposal to assume full control of Genentech. SOURCE: Roche, 21 July 2008@-@NCT00142480@26@-@-@@@-@@12/1/2004@-@-@@-@-@@@III@II@@-@-@RESULTS PENDING@-@@@@COMBO@CAPECITABINE@@@@@CAPECITABINE||||@ROCHE@GENENTECH@SANOFI-AVENTIS@@@ROCHE|GENENTECH|SANOFI-AVENTIS||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@XELODA@@@@@XELODA||||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@PROGRESSION-FREE SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921304@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented. SOURCE: clinicaltrials.gov@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@@@14921304@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00054808@40@-@-@@@-@@6/1/2002@-@GENTA GGN202@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@GALLIUM NITRATE@@@@@GALLIUM NITRATE||||@GENTA@@@@@GENTA||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@@@@Haematological Malignancy|Non-Hodgkin's Lymphoma||||||||@GANITE@@@@@GANITE||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919064@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NOV-002 with doxorubicin and cyclophosphamide followed by docetaxel@@-@-@-@-@5/1/2011@@@@14919064@Early stage (IIB-IIIC), newly diagnosed; neodjuvant trial@@-@-@@NO REVIEW@@@@-@-@-@NCT00499122@46@-@Approved in Russia.@@@-@@5/1/2007@-@MUSC-101072@@-@-@@@II@II@@-@-@16 women have been enrolled with four pathologic complete responses in the first 8 women that have both completed chemotherapy and undergone surgery. Detailed results will be submitted for presentation at the San Antonio Breast Cancer Symposium in December 2008. Full enrollment of 46 patients is expected mid-2009, with trial conclusion in early 2010. SOURCE: Novelos, 12 May 2008@NOV-002 was associated with decreased hematologic toxicities and with decreased use of growth factors relative to historical experience.@@@@ADJUVANT@-@@@@@-||||@NOVELOS THERAPEUTICS@@@@@NOVELOS THERAPEUTICS||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@NOV-002@GLUTOXIM@@@@NOV-002|GLUTOXIM|||@Interleukin@Immunotherapy@@@@Interleukin|Immunotherapy|||@COMPLETE RESPONSE@@@@@@@@@@-@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@8 CYCLES@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16074364@Onco@@@@@@@@@@@Dose level 1, Active Comparator, 0,2 mg/KgDose level 2, Active Comparator, 2,0 mg/KgDose level 3, Active Comparator, 20 mg/Kg@@@@@@6/1/2001@@5-ALA is a natural biochemical precursor of heme that is metabolised in a series of enzymatic reactions to fluorescent porphyrins, particularly PPIX. 5-ALA synthesis is regulated by an intracellular pool of free heme via a negative feedback mechanism.@@16074364@Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas@Both@@@@@@@@@@@NCT02755142@21@@@@@@@2/1/2000@@MC-ALS.8-I/GLI@@@Radiological suspicion of a malignant glioma with distinct ring- or garland shaped, contrast agent-enhancing tumour structures and a core area of reduced intensity in the MRI (tumour necrosis)  -  Indication for surgical tumour resection  -  First operation of the tumour, no other tumour-specific pre-treatment  -  Karnofsky Performance Scale 70%  -  Patient's written informed consent  -  Age 18-75 years@MONO@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@@5-AMINOLEVULINIC ACID (5-ALA)@@@@@5-AMINOLEVULINIC ACID (5-ALA)||||@MEDAC@@@@@MEDAC||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@GLIOLAN@@@@@GLIOLAN||||@Other@@@@@Other||||@Detection of a dose-efficacy relationship between the dose levels and the extent and quality of fluorescence in the tumour core@@@@@@@@@@MALIGNANT@@@@@RANDOMIZED@PARALLEL ASSIGNMENT@DOUBLE-BLIND@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14917981@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@@@@IRVINE, CALIFORNIA@@@Fusilev is a novel folate analog available in 50-mg vials of freeze-dried powder. It is the pharmacologically active isomer of leucovorin. Fusilev rescue is indicated after high-dose methotrexate therapy in osteosarcoma, and is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.@@14917981@Combo with 5-FU as a palliative treatment@@@@@NO REVIEW@@@@@Acquired through takeover of oncology assets of Targent, which licensed it from Merck KGaA in 2004, in March 2006.@@@@@FDA, 29 April 2011@4/29/2011@@@@@@@No@@@@@@APPROVED@@@@@@@@@@LEVOLEUCOVORIN@@@@@LEVOLEUCOVORIN||||@SPECTRUM PHARMACEUTICALS@@@@@SPECTRUM PHARMACEUTICALS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@FUSILEV@(ISO-VORIN)@@@@FUSILEV|(ISO-VORIN)|||@Detoxifying Agent@@@@@Detoxifying Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@50@MG@50 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916627@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Ortataxel alone@@-@-@-@LEVERKUSEN, GERMANY@@@@@14916627@Taxane-resistant@@-@-@@NO REVIEW@@@@-@-@-@NCT00044525@84@-@-@@@-@@4/1/2002@-@Protocol No. 10654@@-@-@@@II@DISCONTINUED@@-@-@ASCO 2003; results from 24 evaluable patients showed that 4 patients (17%) had a partial response and 10 had stable disease. 9 patients had progressive disease. Adverse effects included nausea, vomiting, neuropathy, myalgia, neutropenia and anemia. Discontinued in December 2004.@-@@@@MONO@ORTATAXEL@@@@@ORTATAXEL||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@BAY-598862@@@@@BAY-598862||||@Taxane@@@@@Taxane||||@RESPONSE RATE@SAFETY@@@@@@@@@METASTATIC@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924799@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients will receive a single dose of MIP-1072 or MIP-1095, followed by a single dose of the alternate candidate compound 14 days later. SOURCE: MIP@@-@-@-@-@@@MIP-1072 and MIP-1095 are radiolabeled small molecules developed by Molecular Insight that target PSMA, a protein that is highly expressed by prostate cancer cells. PSMA is well established as a molecular target for prostate cancer and coupling it with an imaging radionuclide enables a rapid, non-invasive way to detect the location of metastatic cancer.@@14924799@N/R@@-@-@@NO REVIEW@@@@-@-@-@-@12@-@-@@@-@@@-@-@@-@Patients diagnosed with prostate cancer who have evidence of recurrent metastatic disease@@@I@I@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@MOLECULAR INSIGHT PHARMACEUTICALS@@@@@MOLECULAR INSIGHT PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TROFEX@@@@@TROFEX||||@Radiolabeled@@@@@Radiolabeled||||@PHARMACOKINETICS@DOSIMETRY@@@@EXCRETION@METABOLISM@SAFETY@@@-@METASTATIC@@@@SINGLE-BLIND@RANDOMISED@CROSSOVER@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918761@Onco@@@@@@@@@@@Not available@@-@-@-@DALLAS, TEXAS@@@@@14918761@Platinum-sensitive ovarian cancer@@-@-@@NO REVIEW@@@STARTED IN JUNE 2006@-@Jiangsu Aosaikang Pharmaceutical licensed rights to manufacture, develop and commercialize Access's proprietary product ProLindac for the Greater China Region. ASK will pay Access an upfront fee and subsequent milestone payments along with a double digit royalty upon commercialization of ProLindac. In addition, in cooperation with Access, ASK has committed to fund and execute two Phase 2 studies for ProLindac in colorectal cancer and one other indication to be determined by the Parties. These major Phase 2 studies would cost up to $20 million if conducted in the US or Europe. ASK has also committed to become a second source for the manufacturing of ProLindac. ASK will be responsible for obtaining the necessary regulatory approvals for ProLindac and commercializing the product in the Greater China Region. SOURCE: Access, 4 June 2008@SECOND-LINE@-@40@-@-@@@-@@@-@NA@@-@-@@@II@II@@-@-@>>66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. [Access 5 March 2009]>>Interim results are expected in 2007.@No patient in any dose group exhibited any signs of acute neurotoxicity.; well-tolerated [Access 5 March 2009]@@@@MONO@DACH PLATINUM, NANOPARTICLE PRODRUG@@@@@DACH PLATINUM, NANOPARTICLE PRODRUG||||@ACCESS PHARMACEUTICALS@@@@@ACCESS PHARMACEUTICALS||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@PROLINDAC@AP-5346@@@@PROLINDAC|AP-5346|||@Platinum@@@@@Platinum||||@-@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921585@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive DX-8951f IV over 30 minutes daily for 5 days. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for survival.@@-@-@-@TOKYO, JAPAN@@@@@14921585@Biliary cancer@@-@-@@NO REVIEW@@@@-@-@-@NCT00005938@37@-@-@@@-@@3/1/2000@-@DAIICHI-8951A-PRT020@@-@-@@@MDA-ID-99379, MSKCC-99110, SACI-IDD-99-31, UCHSC-00892, UTHSC-9905011256; @II@@-@-@RESULTS PENDING@-@@@@MONO@EXATECAN MESYLATE@@@@@EXATECAN MESYLATE||||@DAIICHI SANKYO@@@@@DAIICHI SANKYO||||@@@@@@|||||||||@Bladder Cancer@Liver Cancer@@@@Bladder Cancer|Liver Cancer||||||||@DX-8951F@@@@@DX-8951F||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@TUMOUR RESPONSE@@@@@@@@@@-@@@@@INTERVENTIONAL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922987@Onco@@@@@@@@@@@-@@-@-@-@PARIS, FRANCE@@@DTS-108 is a prodrug of SN38, the active metabolite of widely-used anti-cancer chemotherapy drug irinotecan. DTS-108 is based on Diatos' Vectocell technology platform. DTS-108 aims at improving the bioavailability and biodistribution of SN38 in comparison with that of irinotecan. In turn, DTS-108 aims at increasing the efficacy of SN38 while reducing the toxic effects of irinotecan. Irinotecan is a chemotherapy drug widely used in the treatment of colon cancer. It is a soluble prodrug of SN38, which is an insoluble and potent inhibitor of topoisomerase, an enzyme involved in cancer cell proliferation. The rate of conversion of irinotecan into SN38 in the liver is low and highly variable among individuals. Consequently, very high doses of irinotecan need to be administered to be effective and patients typically experience adverse side effects, including severe, potentially life-threatening diarrhea and myelosuppression. By applying Vectocell to SN38, Diatos has shown in non-clinical models that it can deliver high doses of SN38, whilst avoiding the gastrointestinal toxicity observed with irinotecan.@@14922987@Advanced or metastatic solid tumours@@-@-@@NO REVIEW@@@-@-@Diatos and Drais enter global co-development agreement for DTS-108, which is in Phase I trials for solid tumours. Diatos will receive an upfront payment, milestones and royalties in a US$46.9 million deal. [Diatos, 22.12.2008]@-@-@-@-@-@@@-@@@-@-@@-@-@@@N/A@I@@-@-@Trial commenced. [Diatos, 22.12.2008]@-@@@@MONO@SN38@@@@@SN38||||@DIATOS@DRAIS PHARMACEUTICALS@@@@DIATOS|DRAIS PHARMACEUTICALS|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@DTS-108@@@@@DTS-108||||@Plant Alkaloid@@@@@Plant Alkaloid||||@MAXIMUM TOLERATED DOSE@@@@@PHARMACOKINETICS@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924818@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PARIS, FRANCE@@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. @@14924818@-@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@II@@-@-@-@-@@@@-@AFLIBERCEPT@@@@@AFLIBERCEPT||||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@VEGF-TRAP@@@@@VEGF-TRAP||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921202@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1, and BSI-201 IV over 1 hour twice weekly beginning on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@BRISBANE, CALIFORNIA@12/1/2010@@@@14921202@Stage III or IV uterine cancer; uterine carcinosarcoma@@-@-@@NO REVIEW@@@@-@Sanofi-Aventis acquires Bi-Par [Sanofi-Aventis 15 April 2009 http://en.sanofi-aventis.com/binaries/20090415_bipar_acquisition_en_tcm28-24863.pdf ]@-@NCT00588744@45@-@-@@@-@@2/1/2008@-@GOG-0232C@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@PACLITAXEL@@@@-|PACLITAXEL|||@BIPAR SCIENCES@SANOFI-AVENTIS@@@@BIPAR SCIENCES|SANOFI-AVENTIS|||@@@@@@|||||||||@Sarcoma@Endometrial Cancer@@@@Sarcoma|Endometrial Cancer||||||||@BSI-201@@@@@BSI-201||||@PARP Inhibitor@@@@@PARP Inhibitor||||@DOSE-LIMITING TOXICITY@@@@@@@@@@RELAPSED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16791367@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791367@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NO@@@NO REVIEW@@@@100%@@@@16@@EMA, 16 December 2016@12/16/2016@@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NHS@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@3733.333296@@@8@week@8 week@3733.33@3733.33@66.67@30@1.299@5000@@@@@@@@@@@@0.56@1@@mg/m²@100@1@@@@@@@@@@@7/28/2017@166.67@166.67@2.04E+16@FILM-COATED TABLET@GB£@@@@@@@@300@MG@300 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14918962@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Starting dose of 650MG/M2 administered as weekly 1-hour IV infusions@@-@-@-@MADRID, SPAIN@@@Kahalalide F is a depsipeptide derived from the sea slug Elysia rufescens. Kahalalide F alters the function of the lysosomal membranes inducing cell death by oncosis. Antitumour-activity independent of MDR (Multi Drug Resistance) and p53 status and to correlate with basal ErbB3 expression. @@14918962@Irresectable HCC@@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@FIRST-LINE@-@22@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Stable disease was reported in ten patients (seven lasting more than three months and four lasting more than six months). A 50% decrease in the tumor marker alpha-fetoprotein, AFP (considered to be an indicator of improvement) was observed in two patients. SOURCE: PharmaMar/ESMO, 29 September 2006@-@@@@MONO@-@@@@@-||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@KAHALALIDE F@@@@@KAHALALIDE F||||@Depsipeptide@@@@@Depsipeptide||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916136@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide. @@-@-@-@BRENTFORD, UNITED KINGDOM@10/1/2010@@@@14916136@Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide@@-@-@@NO REVIEW@@@@-@The GSK-Ligand collaboration began in 1997 to utilize Ligand's expertise and technology to discover small-molecule drugs to control hematopoieses and treat patients with cancer, anemia or platelet deficiencies. The research phase of the collaboration ende@-@NCT00358540@48@-@-@@@-@@6/1/2006@-@TRC105499@@-@Prior history of =grade 2 thrombocytopenia (platelet nadir = 75,000/microliters)@@@I@I@@-@-@Trial registered [GSK, 28 July 2006]@-@@@@MONO@ELTROMBOPAG@@@@@ELTROMBOPAG||||@GSK@@@@@GSK||||@@@@@@|||||||||@Supportive Care@Thrombocytopaenia@Sarcoma@@@Supportive Care|Thrombocytopaenia|Sarcoma|||||||@PROMACTA@@@@@PROMACTA||||@Thrombopoietin Agonist@@@@@Thrombopoietin Agonist||||@SAFETY@TOLERABILITY@@@@DOSING@PHARMACOKINETICS@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924853@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEW BRUNSWICK, NEW JERSEY@@@A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.@@14924853@Elderly patients who are not candidates for standard chemotherapy@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Johnson & Johnson will not file for the AML indication. SOURCE: Johnson & Johnson, 17 July 2007FDA non-approvable letter based on Phase II trial. SOURCE: Johnson & Johnson, 30 June 2005Orphan drug and Fast-track designation; refused accelerated approval by ODAC. SOURCE: Johnson & Johnson, 6 May 2005FDA NDA filing. SOURCE: Johnson & Johnson, 24 January 2005@5/6/2005@@-@@@-@-@@-@-@ELDERLY@@-@FILED@@-@-@RESULTS PENDING@-@@@@-@TIPIFARNIB@@@@@TIPIFARNIB||||@JOHNSON & JOHNSON@@@@@JOHNSON & JOHNSON||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@ZARNESTRA@@@@@ZARNESTRA||||@Farnesyltransferase Inhibitor@@@@@Farnesyltransferase Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922140@Onco@@@@@@@@@@@Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks. SOURCE: clinicaltrials.gov@@-@-@-@JERUSALEM, ISRAEL@1/1/2009@@@@14922140@Superficial bladder cancer@@-@-@@NO REVIEW@@@@-@Pro-Pharmaceuticals and BioCancell formed partnership to target destruction of H19 genes in cancer cells by delivering siRNA through IV administration of Davanat and BC-819. SOURCE: Pro-Pharmaceuticals, 19 May 2008@-@NCT00595088@33@-@-@@@-@@1/1/2008@-@BC-07-01.CTIL@@-@-@@@IIB@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@BIOCANCELL THERAPEUTICS@@@@@BIOCANCELL THERAPEUTICS||||@Israel@@@@@Israel|||||||||@Bladder Cancer@@@@@Bladder Cancer|||||||||@BC-819@@@@@BC-819||||@Other@@@@@Other||||@COMPLETE RESPONSE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924676@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@OSAKA, JAPAN@8/1/2006@@@@14924676@Clearance of HPV infection on cervarix@@-@-@@NO REVIEW@@@@-@Fully licensed from 3M@-@NCT00117884@240@N/A@-@@@-@@6/1/2005@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@TAKEDA PHARMACEUTICAL@@@@@TAKEDA PHARMACEUTICAL||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@R-851@851B GEL@@@@R-851|851B GEL|||@Immunotherapy@@@@@Immunotherapy||||@-@@@@@@@@@@-@@@@@DIAGNOSTIC@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TOPICAL AGENT@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924753@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Taxoprexin 500MG/M2 weekly for first 5 weeks of a 6-week cycle@@L01CD01@L01C@-@TOKYO, JAPAN@@@Taxoprexin is a conjugate of paclitaxel and the fatty acid docosahexaenoic acid (DHA). Preclinical studies have shown increased activity and an improved therapeutic ratio relative to paclitaxel. @@14924753@Advanced skin melanoma@@-@-@@NO REVIEW@@@@-@Luitpold is a subsidiary of Daiichi Sankyo.@SECOND-LINE@NCT00249262@30@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Study completed in April 2007, results pending.@-@@@@MONO@PACLITAXEL, DHI@@@@@PACLITAXEL, DHI||||@DAIICHI SANKYO@LUITPOLD PHARMACEUTICALS@@@@DAIICHI SANKYO|LUITPOLD PHARMACEUTICALS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAXOPREXIN@@@@@TAXOPREXIN||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916604@Onco@@@@@@@@@@@-@@-@-@-@OXFORD, UNITED KINGDOM@@@TroVax is Oxford BioMedica's novel therapeutic cancer vaccine, which is being developed in collaboration with sanofi-aventis. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient?s body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4 antigen. @@14916604@Stage II/III colorectal cancer who have had surgical resection of their primary tumours and been treated with adjuvant chemotherapy.@@-@-@@NO REVIEW@@@@-@sanofi-aventis licensed global rights for TroVax in March 2007; co-fund Phase III trials and sanofi-aventis all future research and marketing@-@-@3000@-@SPA agreement from FDA. SOURCE: Cell Genesys, November 2006@@@-@@@-@QUASAR V@@Bavarian Nordic re-files patent infringement case against Oxford BioMedica. [Bavarian Nordic, 27.01.2009]@-@@@III@III@@-@-@Trial is still on track to commence despite TRIST findings. SOURCE: Oxford BioMedica, 14 July 2008@-@@@@ADJUVANT@-@@@@@-||||@OXFORD BIOMEDICA@SANOFI-AVENTIS@@@@OXFORD BIOMEDICA|SANOFI-AVENTIS|||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@TROVAX@MVA-5T4@@@@TROVAX|MVA-5T4|||@Immunotherapy@Vaccine@@@@Immunotherapy|Vaccine|||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@-@@@@RANDOMISED@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919027@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@MONTREAL, CANADA@@@@@14919027@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@Orphan drug agreement with FDA for gastric cancer. SOURCE: Supratek, 31 March 2008SPA agreement with FDA. SOURCE: Supratek, 28 November 2008@3/31/2008@@-@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@-@-@@@@@-||||@SUPRATEK PHARMA@@@@@SUPRATEK PHARMA||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@SP-MET-X1@@@@@SP-MET-X1||||@Other@@@@@Other||||@N/A@@@@@@@@@@MALIGNANT@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919070@Onco@@@@@300f1012ntsdm@@@@@@MT-103 15µg/m2/24h,30µg/m2/24h, or 60µg/m2/24h continuous intravenous (CIV) over 4 weeks, up to 10 cycles or progression or unacceptable toxicity@@-@-@-@-@10/1/2010@@"The BiTE antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful ""killer cells"" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc."@@14919070@-@@-@-@@NO REVIEW@@@@-@>> AstraZeneca acquires MedImmune in US$15 billion deal. [AstraZeneca, 23.04.2007]@-@NCT00560794@21@-@Orphan drug for CLL@@@Orphan drug for CLL@@10/1/2007@-@MT103-202@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@BLINATUMOMAB@@@@@BLINATUMOMAB||||@MICROMET@MEDIMMUNE@ASTRAZENECA@@@MICROMET|MEDIMMUNE|ASTRAZENECA||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@MT-103@MEDI-538@@@@MT-103|MEDI-538|||@mAb@@@@@mAb||||@MINIMAL RESIDUAL DISEASE@@@@@@@@@@-@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14916666@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Administered every three weeks intravenously over 30 minutes@@-@-@-@MADRID, SPAIN@@@PM02734 is a novel chemical entity resulting from PharmaMar's internal research program for derivatives of marine natural compounds. Produced synthetically in-house by PharmaMar, PM02734 is a new depsipeptide of the kahalalides family. Preliminary in vitro in-house studies identified PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others. PM02734 has been selected for clinical development based on its in vivo activity in xenografted human tumors, as well as an acceptable non-clinical toxicology profile. @@14916666@-@@-@-@@NO REVIEW@@@@-@PharmaMar is part of the Zeltia Group.@-@NCT00404521@35@-@-@@@-@@8/1/2005@-@PM2734-A-001-05@@-@-@@@I@I@@-@-@Trial registered [PharmaMar, 27.11.2006]@-@@@@MONO@-@@@@@-||||@PHARMAMAR@ZELTIA GROUP@@@@PHARMAMAR|ZELTIA GROUP|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@IRVALEC@PM-02734@@@@IRVALEC|PM-02734|||@Depsipeptide@@@@@Depsipeptide||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@MALIGNANT@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916471@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Combo with Gemzar versus placebo and Gemzar@@-@-@-@-@@@@@14916471@-@@-@-@@NO REVIEW@@@@-@Licensed from AVI in April 2000@FIRST-LINE@NCT00113256@30@-@Nov-97@@@-@@2/1/2005@-@SGI-RUB-048@@-@-@@@II/III@DISCONTINUED@@-@-@RESULTS PENDING@-@@@@-@RUBITECAN@GEMCITABINE@@@@RUBITECAN|GEMCITABINE|||@SUPERGEN@@@@@SUPERGEN||||@@@@@@|||||||||@Pancreatic Cancer@@@@@Pancreatic Cancer|||||||||@ORATHECIN@GEMZAR@@@@ORATHECIN|GEMZAR|||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922247@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Asentar or placebo with Taxotere@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@12/1/2005@@@@14922247@Androgen-independent prostate cancer (AIPC)@@-@-@@NO REVIEW@@@@-@Schering-Plough dropped out of licensing agreement with all rights returning to Novacea. SOURCE: Novacea, 9 April 2008In May 2007, Schering-Plough licensed global rights for US$60 million, common stock purchase, milestone payments of up to US$380 millio@-@NCT00043576@250@-@-@@@-@@8/1/2002@-@ASCENT@@-@-@@@II/III DN101-002; @DISCONTINUED@@-@-@>> FDA lifts clinical hold, but Novacea has decided against further development. [Novacea, 12.09.2008]@-@@@@COMBO@CALCITRIOL, HIGH-DOSE ORAL@@@@@CALCITRIOL, HIGH-DOSE ORAL||||@NOVACEA@@@@@NOVACEA||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@ASENTAR@DN-1010@@@@ASENTAR|DN-1010|||@Vitamin D Analogue@@@@@Vitamin D Analogue||||@TIME TO PROGRESSION@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922603@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@IV MK-517@@A04AD12@A04A@-@WHITEHOUSE STATION, NEW JERSEY@@@@@14922603@Prevention of PONV@@-@-@@NO REVIEW@@@@-@Japanese rights with Ono.@-@NCT00231777@200@-@-@@@-@@8/1/2005@-@2005_074  @@JANUARY 2011; JUNE 2012 (EMESIS)@-@@@III@III@@-@-@RESULTS PENDING@-@@@@MONO@FOSAPREPITANT MEGLUMINE@@@@@FOSAPREPITANT MEGLUMINE||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Supportive Care@PONV@@@@Supportive Care|PONV||||||||@EMEND FOR INJECTION@@@@@EMEND FOR INJECTION||||@NK1 Antagonist@@@@@NK1 Antagonist||||@SAFETY@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@1@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@115@MG@115 MG@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924616@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@240 patients receive OncoVex and 120 patients receive control (subcutaneous GM-CSF)@@-@-@-@WOBURN, MASSACHUSSETTS@@@@@14924616@Previously treated patients with metastatic melanoma@@-@-@@NO REVIEW@@@@-@-@-@-@360@-@SPA agreement with FDA. SOURCE: BioVex, 22 April 2008@4/22/2008@@-@@@-@-@@-@-@@@III@III@@-@-@Trial to start in Q1 2009. SOURCE: BioVex, 22 April 2008@-@@@@MONO@-@@@@@-||||@BIOVEX@@@@@BIOVEX||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ONCOVEX@@@@@ONCOVEX||||@Gene Therapy@Immunotherapy@@@@Gene Therapy|Immunotherapy|||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922454@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive CP-751871 IV over 5 hours on days 1 and 22 and undergo magnetic resonance spectroscopy on days 8 and 29. Patients may also undergo surgery between days 29-43 for tumor sample removal to analyzed the presence of markers related to the IGR-1R pathway. SOURCE: clinicaltrials.gov@@-@-@-@NEW YORK, NEW YORK@6/1/2011@@CP-751,871, a fully human monoclonal antibody, is a highly specific inhibitor of the IGF-1R pathway. The IGF-1R pathway is one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumour cells. @@14922454@Early stage resectable breast cancer@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Pharmacia Corp.@-@NCT00635245@19@-@-@@@-@@3/1/2007@-@A4021012@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@NEOADJUVANT@FIGITUMUMAB@@@@@FIGITUMUMAB||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@CP-751,871@@@@@CP-751,871||||@mAb@Human@@@@mAb|Human|||@TUMOUR TOTAL CHOLINE@@@@@@@@@@EARLY@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921815@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@BASEL, SWITZERLAND@@@Patupilone (EPO906, epothilone B) is a novel non-taxane-related microtubule-stabilizing natural compound that retains full activity in multidrug-resistant tumors and is clinically less toxic than paclitaxel.@@14921815@Advanced unresectable and/or metastatic HCC@@-@-@@NO REVIEW@@@@-@-@-@NCT00273312@65@-@-@@@-@@1/1/2006@-@CEPO906A2213@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PATUPILONE@@@@@PATUPILONE||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Liver Cancer@Hepatocellular Carcinoma@@@@Liver Cancer|Hepatocellular Carcinoma||||||||@EPO-906@@@@@EPO-906||||@Epothilone@@@@@Epothilone||||@RECIST@@@@@@@@@@METASTATIC@ADVANCED@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16066632@Onco@@@@@@@@@@@Part 1: Dose Escalation and Expansion, Experimental, BMS-986178 at specified doses at specified intervalsPart 2: Dose Escalation and Expansion, Experimental, BMS-986178 in combination with Nivolumab at specified doses at specified intervalsPart 3: Dose Escalation and Expansion, Experimental, BMS-986178 in combination with Ipilimumab at specified doses at specified intervals@@-@-@@@2/1/2019@@@@16066632@A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab or Ipilimumab in Advanced Solid Tumors@Both@@@@@@@@@@@NCT02737475@212@@@@@@@6/1/2016@@CA012-004@@@Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting  -  ECOG (Eastern Cooperative Oncology Group) 0-1  -  Men and women 18 years old or older  -  At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1@@ADULTS@Phase 1/Phase 2@I/II@@@@@@@@@BOTH@-@NIVOLUMAB@IPILIMUMAB@@@-|NIVOLUMAB|IPILIMUMAB||@BRISTOL-MYERS SQUIBB@@@@@BRISTOL-MYERS SQUIBB||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@BMS-986178@OPDIVO@YERVOY@@@BMS-986178|OPDIVO|YERVOY||@Other@@@@@Other||||@Incidence of adverse events and serious adverse events@@@@@Cmax (maximum observed serum concentration)@Tmax (time of maximum observed concentration)@@@@ADVANCED@@@@@RANDOMIZED@SAFETY/EFFICACY STUDY@PARALLEL ASSIGNMENT@OPEN LABEL@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916142@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Tariquidar or placebo with paclitaxel and carboplatin@@-@-@-@-@@@@@14916142@Combo with paclitaxel and carboplatin@@-@-@@NO REVIEW@@@@-@QLT in-licensed the drug from Xenova in North America in August 2001.@FIRST-LINE@NCT00042302@540@-@FDA fast-track status@@@-@@6/1/2002@-@TQD LUNG 001@@-@-@@@III@DISCONTINUED@@-@-@Trial discontinued. SOURCE: QLT, 12 May 2003Trial placed on hold by IDSMC amid safety concerns. SOURCE: QLT, 26 February 2003@-@@@@ADJUVANT@TARIQUIDAR@@@@@TARIQUIDAR||||@QLT@XENOVA@@@@QLT|XENOVA|||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@XR-9576@@@@@XR-9576||||@Anthracycline@@@@@Anthracycline||||@OVERALL SURVIVAL@@@@@@@@@@-@@@@@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920910@Onco@@@@@300f1010ntsdm@@@@@@AZD-2281 with Hycamtin IV infusion@@-@-@-@LONDON, UNITED KINGDOM@3/1/2008@@A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. PARP inhibitor AZD2281 selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.@@14920910@-@@-@-@@NO REVIEW@@@@-@Acquired through takeover of KuDOS in January 2007@-@NCT00516438@48@-@-@@@-@@7/1/2007@-@KU36-93, @@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@TOPOTECAN HYDROCHLORIDE@@@@-|TOPOTECAN HYDROCHLORIDE|||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-2281@HYCAMTIN@@@@AZD-2281|HYCAMTIN|||@PARP Inhibitor@@@@@PARP Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CAPSULE@GB£@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14919861@Onco@@@@@300f1010ntsdm@@@@@@@@L02BB03@L02B@NO@@@@@@14919861@Indicated for use in combination therapy with an LH-RH analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.@@NO@@@NO REVIEW@@@@100%@@FIRST-LINE@@@Adult males including the elderly: one tablet (50mg) once a day. Treatment with 'Casodex' should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration.@MHRA, 16 September 2008@9/16/2008@@@@@Rare cases of death or hospitalisation due to severe liver injury have been reported in post-marketing in association with Casdoex use.@@No@@@@@@APPROVED@@@NHS@@@@@@COMBO@BICALUTAMIDE@@@@@BICALUTAMIDE||||@MPX INTERNATIONAL@@@@@MPX INTERNATIONAL||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@Anti-androgen@@@@Hormone Antagonist|Anti-androgen|||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@@1.299@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@TABLET@GB£@@@@@@@@20@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14916527@Onco@@@@@300f1012ntsdm@@@@@@AP-12009 10MG versus standard chemotherapy@@-@-@-@-@@@TGF-beta 2 inhibitor@@14916527@Anaplastic astrocytoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00761280@132@-@-@@@-@@12/1/2008@-@SAPPHIRE@@-@-@@@III@III@@-@-@">> Trial registered. [Antisense, 26.09.2008]     >> The 24-month survival rate was accepted by the Scientific Advice Working Party (SAWP) at the EMEA as the primary endpoint for the upcoming Phase III study in recurrent or refractory anaplastic astrocytoma patients. Furthermore, 14-month progression rate was accepted as the endpoint for conditional approval. [Antisense, 3 June 2008]"@Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies. @@@@MONO@TRABEDERSEN@@@@@TRABEDERSEN||||@ANTISENSE PHARMA@@@@@ANTISENSE PHARMA||||@@@@@@|||||||||@Astrocytoma@@@@@Astrocytoma|||||||||@AP-12009@@@@@AP-12009||||@Other@@@@@Other||||@OVERALL SURVIVAL@@@@@@@@@@RELAPSED@REFRACTORY@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14920208@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BA01@L02B@YES@@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920208@@@NO@@@NO REVIEW@@@@@@@@@@@@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@MCKESSON@@@@@MCKESSON||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@100@1@47.83@@@@@@@@@@@@0.05@@@@@@@@@@@@@@@@8/2/2017@0.48@0.48@63739-0269-10@TABLET@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922351@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts). If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle. @@-@-@-@NEW YORK, NEW YORK@10/1/2009@@@@14922351@with Gemzar@@-@-@@NO REVIEW@@@@-@-@-@NCT00437203@50@-@-@@@-@@12/1/2006@-@A8211001@@-@-@@@I@I@@-@-@Endpoint over 2 years@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PF-477736@@@@@PF-477736||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924514@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PASADENA, CALIFORNIA@@@@@14924514@-@@YES@-@@NO REVIEW@@@@-@Arrowhead merged its two subsidiaries Calando and Insert Therapeutics in February 2008; now known as Calando Pharmaceuticals.@SECOND-LINE@-@-@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@Insert filed for Phase II trial. [Insert, 17 April 2008]@-@@@@COMBO@-@@@@@-||||@CALANDO PHARMACEUTICALS@INSERT THERAPEUTICS@@@@CALANDO PHARMACEUTICALS|INSERT THERAPEUTICS|||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@IT-101@@@@@IT-101||||@Camptothecin@@@@@Camptothecin||||@TIME TO PROGRESSION@@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16791366@Onco@@@@@300f1010ntsdm@@@@@@@@L01XE12@L01X@@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.@@16791366@Paediatric patients aged 5 to 18 with unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC)@Both@NO@@@NO REVIEW@@@@100%@@@@16@@EMA, 16 December 2016@12/16/2016@@Yes@@@@@No@@@PAEDIATRIC@PAEDIATRIC@I/II@APPROVED@@@NHS@@@@@@MONO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Thyroid Cancer@@@@@Thyroid Cancer|||||||||@CAPRELSA@@@@@CAPRELSA||||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@@@@@@@@@@@LOCALLY ADVANCED@METASTATIC@@@@@@@@@1.2@m²@5599.999944@@@8@week@8 week@5600@5600@100@30@1.299@2500@@@@@@@@@@@@0.83@1@@mg/m²@100@1@@@@@@@@@@@7/28/2017@83.33@83.33@2.04E+16@FILM-COATED TABLET@GB£@@@@@@@@100@MG@100 MG@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14916414@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@N/A@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@12/1/2009@@@@14916414@Untreated AML in patients older than 60@@-@-@@NO REVIEW@@@@-@-@FIRST-LINE@NCT00607997@55@-@-@@@-@@2/1/2008@-@SPO-0014@@-@-@@@II@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@SUNESIS PHARMACEUTICALS@@@@@SUNESIS PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@SNS-314@@@@@SNS-314||||@Aurora Kinase Inhibitor@@@@@Aurora Kinase Inhibitor||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921819@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. SOURCE: clinicaltrials.gov@@-@-@-@LONDON, UNITED KINGDOM@9/1/2008@@AZD0530 is an orally available, dual-specific, Src/Abl kinase inhibitor that is being evaluated to determine its effects as an anti-invasive agent. AZD0530 is being studied in a variety of clinical settings in solid tumors and leukemias.@@14921819@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00513071@40@-@-@@@-@@8/1/2007@-@CCC-PHII-79@@-@-@@@CHNMC-PHII-79; @II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@AZD-0530@@@@@AZD-0530||||@TK Inhibitor@@@@@TK Inhibitor||||@PSA@@@@@@@@@@REFRACTORY@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919038@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01DB01@L01D@-@COLUMBIA, MARYLAND@@@Celsion has encapsulated doxorubicin in its heat-activated liposome to create ThermoDox. @@14919038@-@@-@-@@NO REVIEW@@@@-@Yakult and Celsion to collaborate on development in Japan. SOURCE: Yakult, 20 August 2008@-@-@100@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@Trial to start in H2 2008. SOURCE: Celsion, January 2008.@-@@@@-@DOXORUBICIN, HEAT-ACTIVATED LIPOSOME@@@@@DOXORUBICIN, HEAT-ACTIVATED LIPOSOME||||@CELSION@@@@@CELSION||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@THERMODOX@@@@@THERMODOX||||@Other@@@@@Other||||@-@@@@@@@@@@RELAPSED@@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921512@Onco@@@@@300f1015ntsdm@@@@@@Intron A (18 months) versus PEG-Intron (36 months) adjuvant @@-@-@-@KENILWORTH, NEW JERSEY@@@@@14921512@Cutaneous melanoma@@-@-@@NO REVIEW@@@@-@Merck & Co and Schering-Plough have announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Based on the closing price of Merck stock on March 6, 2009, the consideration to be received by Schering-Plough shareholders is valued at $23.61 per share, or $41.1 billion in the aggregate. [Merck & Co, 9 March 2009]@-@NCT00221702@1190@-@-@@@-@@@-@EADO 2002CMII@@-@-@@@9267-01; 2001-034 / @III@@-@-@RESULTS PENDING (recruiting).@-@@@@MONO@PEG-INTERFERON@@@@@PEG-INTERFERON||||@SCHERING-PLOUGH@MERCK & CO@@@@SCHERING-PLOUGH|MERCK & CO|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@PEG-INTRON@@@@@PEG-INTRON||||@Interferon@@@@@Interferon||||@DISEASE-FREE SURVIVAL@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922475@Onco@@@@@300f1020ntsdm@@@@@@Gemzar/docetaxel (weekly and tri-weekly) versus Gemzar/paclitaxel (weekly and tri-weekly).@@L01BC05@L01B@-@INDIANAPOLIS, INDIANA@@@Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. In vitro the cytotoxic action of gemcitabine is both concentration and time dependent.@@14922475@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00236899@360@-@-@@@-@@@-@9846B9E-IT-S376@@-@-@@@III@III@@-@-@Completion expected in July 2010.@-@@@@COMBO@GEMCITABINE HYDROCHLORIDE@DOCETAXEL@@@@GEMCITABINE HYDROCHLORIDE|DOCETAXEL|||@LILLY@@@@@LILLY||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GEMZAR@TAXOTERE@@@@GEMZAR|TAXOTERE|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@TIME TO PROGRESSION@@@@@@@@@@METASTATIC@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@FACTORIAL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924752@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Weekly Taxoprexin@@L01CD01@L01C@-@TOKYO, JAPAN@@@Taxoprexin is a conjugate of paclitaxel and the fatty acid docosahexaenoic acid (DHA). Preclinical studies have shown increased activity and an improved therapeutic ratio relative to paclitaxel. @@14924752@Metastatic skin/mucosal (non-choroidal) melanoma@@-@-@@NO REVIEW@@@@-@Luitpold is a subsidiary of Daiichi Sankyo.@FIRST-LINE@NCT00411918@30@-@-@@@-@@@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@PACLITAXEL, DHI@@@@@PACLITAXEL, DHI||||@DAIICHI SANKYO@LUITPOLD PHARMACEUTICALS@@@@DAIICHI SANKYO|LUITPOLD PHARMACEUTICALS|||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@TAXOPREXIN@@@@@TAXOPREXIN||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919018@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@21-day cycle; SGX-523 twice daily for 14 days followed by 7 days off.@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14919018@-@@-@-@@NO REVIEW@@@@-@Lilly completes US$64 million acquisition of SGX. SOURCE: SGX, 21 August 2008@-@-@-@-@-@@@-@@@-@N/A@@-@-@@@I@I@@-@-@SGX observed dose limiting toxicity earlier than anticipated. The toxicity is of a nature that was not anticipated based on the preclinical profile of SGX523. The interrupted dosing trial started at a higher dose than the continuous dosing trial and no patients are currently receiving treatment on the interrupted dosing trial. SOURCE: SGX, 27 March 2008Trial has started. SOURCE: SGX, January 2008.@-@@@@MONO@-@@@@@-||||@SGX PHARMACEUTICALS@LILLY@@@@SGX PHARMACEUTICALS|LILLY|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@SGX-523@@@@@SGX-523||||@TK Inhibitor@@@@@TK Inhibitor||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@-@@@@@OPEN-LABEL@DOSE ESCALATION@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922980@Onco@@@@@@@@@@@36 patients received 130mg/m2 (MTD) on days one and 8 of a 3-week cycle@@-@-@-@LONDON, UNITED KINGDOM@@@@@14922980@Chemotherapy-naïve patients with advanced and/or metastatic gastric cancer@@-@-@@NO REVIEW@@@-@-@BTG reacquired global commercial rights from AstraZeneca in July 2003.@-@-@55@-@June 2007; FDA granted it orphan drug status for ovarian and gastric cancer.@@@June 2007; FDA granted it orphan drug status for ovarian and gastric cancer.@@@-@-@@-@-@@@I/II; EUROPEAN TRIAL@II@@-@-@January 2007; 5 of 28 patients evaluable for efficacy response at the 130 mg/m2 dose of plevitrexed had a partial response (17.9% response rate) and a further 15 patients (53.6%) had stable disease (overall disease control rate of 71.4%). One patient given 65 mg/m2 plevitrexed achieved a complete response and five patients given 165 mg/m2 of the agent achieved stable disease.@-@@@@MONO@PLEVITREXED@@@@@PLEVITREXED||||@BTG@@@@@BTG||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@BGC-9331@ZD-9331@@@@BGC-9331|ZD-9331|||@TS Inhibitor@@@@@TS Inhibitor||||@RESPONSE RATE@@@@@@@@@@ADVANCED@METASTATIC@@@@NON-COMPARATIVE@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919067@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@852A administered subcutaneously twice a week for 12 weeks@@-@-@-@NEW YORK, NEW YORK@@@@@14919067@-@@-@-@@NO REVIEW@@@@-@Pfizer has completed acquisition of Coley Pharmaceutical@-@NCT00319748@40@-@-@@@-@@4/1/2006@-@MT2006-02@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@COLEY PHARMACEUTICAL@@@@PFIZER|COLEY PHARMACEUTICAL|||@@@@@@|||||||||@Breast Cancer@Ovarian Cancer@Endometrial Cancer@Cervical Cancer@@Breast Cancer|Ovarian Cancer|Endometrial Cancer|Cervical Cancer||||||@852A@@@@@852A||||@Other@@@@@Other||||@RECIST@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924463@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Stereotactic biopsy and AdV-tk injection on day 0, prodrug for days 1-14, radiotherapy started on day 2-3.@@-@-@-@BOSTON, MASSACHUSETTS@@@@@14924463@Untreated, inoperable GBM@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ADVANTAGENE@@@@@ADVANTAGENE||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@GLIATAK@@@@@GLIATAK||||@Immunotherapy@@@@@Immunotherapy||||@SAFETY@RESPONSE RATE@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919109@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Arm 1: odanacatib 50 mg tablet once weekly; one time zoledronic acid 4 mg IV infusion. Arm 2: odanacatib 50 mg tablet once weekly; one time zoledronic acid Pbo IV infusion. Arm 3: odanacatib Pbo tablet once weekly; one time zoledronic acid 4 mg IV infusion.Arm 4: odanacatib Pbo tablet once weekly; one time zoledronic acid Pbo IV infusion.@@-@-@-@WHITEHOUSE STATION, NEW JERSEY@12/1/2007@@Odanacatib is a highly selective, potent inhibitor of the cathepsin K enzyme.  Cathepsin K enzyme plays a key role in breaking down the protein in bone.  In cancer that has spread to the bones, tumor cells speed up the normal process of bone breakdown and formation, which in turn results in further tumor growth and bone destruction.  By inhibiting cathepsin K activity, odanacatib represents a potential novel therapeutic approach for metastatic bone disease that works differently from other commonly used medicines.@@14919109@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00399802@45@-@-@@@-@@11/1/2006@-@MK0822-016@@-@-@@@II@II@@-@-@Endpoint over 4 weeks.@-@@@@MONO@ODANACATIB@@@@@ODANACATIB||||@MERCK & CO@@@@@MERCK & CO||||@@@@@@|||||||||@Bone Metastases@Breast Cancer@@@@Bone Metastases|Breast Cancer||||||||@MK-822@@@@@MK-822||||@Other@@@@@Other||||@URINARY N-TELOPEPTIDE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918845@Onco@@@@@300f1012ntsdm@@@@@@Continuous daily treatment with 2x250MG or 2x150MG until disease progression.@@-@-@-@INGELHEIM, GERMANY@@@@@14918845@Advanced or metastatic@@-@-@@NO REVIEW@@@@-@-@-@-@73@-@-@@@-@@@-@N/A@@-@-@@@EU-20631, CRUK-BIBF1120, BOEHRINGER-CRUK-1199.9, EUDRACT-2005-002427-14; @II@@-@-@Interim results; subset of 57 patients with ECOG 0 or 1 had median PFS, overall survial and stable disease of 2.9 months, 9.5 months and 59% respectively versus placebo. Side effects were tolerable. The overall population of 73 patients (ECOG 0-2) has PFS of 1.7 months. SOURCE: Boehringer, 25 April 2008ASCO 2007; results showed that the agent was well tolerated with a stable disease rate of 59%. Patients with ECOG performance status of 0 or 1 (n=57) had a median PFS of 2.9 months and a 3.5-month PFS rate of 46% and 31%, respectively, without any difference between treatment arms. The most common side effects were gastrointestinal; 12% of patients discontinued treatment due to adverse events.@-@@@@MONO@-@@@@@-||||@BOEHRINGER INGELHEIM@@@@@BOEHRINGER INGELHEIM||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@VARGATEF@BIBF-1120@@@@VARGATEF|BIBF-1120|||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@STABLE DISEASE@PROGRESSION-FREE SURVIVAL@@@@@@@@@ADVANCED@METASTATIC@@@@DOUBLE-BLIND@MULTI-CENTRE@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14921031@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@168mg/m2 of huC242-DM4 given once every three weeks. SOURCE: Immunogen@@-@-@-@-@5/1/2009@@@@14921031@Metastatic or locally-advanced stomach or gastroesopagael cancer who have failed front-line therapy@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00620607@40@-@-@@@-@@5/1/2007@-@IMGN 102@@-@40 patients who have failed front-line chemotherapy@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@IMMUNOGEN@@@@@IMMUNOGEN||||@@@@@@|||||||||@Stomach Cancer@@@@@Stomach Cancer|||||||||@HUC242-DM4@@@@@HUC242-DM4||||@mAb@Humanised@@@@mAb|Humanised|||@RESPONSE RATE@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916165@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@-@12/1/2009@@Lipotecan is a drug product of TLC388 HCl, which is a potent camptothecin analog with cytotoxic activities against a variety of human tumor cell lines in vitro and anti-tumor activities in several xenograft models with human tumor cell lines. Structurally, TLC388 HCl is related to other camptothecins, but it has been chemically modified to improve stability and potency, and to minimize toxicities.@@14916165@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00747474@40@-@-@@@-@@9/1/2008@-@TLC388-101@@-@Pathologically confirmed advanced solid tumors for which standard therapy proven to provide clinical benefit does not exist or is no longer effective @@@I@I@@-@-@Trial registered. [TLC, 03.09.2008]@-@@@@-@-@@@@@-||||@TAIWAN LIPOSOME COMPANY@@@@@TAIWAN LIPOSOME COMPANY||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LIPOTECAN@TLC-388@@@@LIPOTECAN|TLC-388|||@Camptothecin@@@@@Camptothecin||||@SAFETY@PHARMACOKINETICS@@@@RESPONSE RATE@@@@@ADVANCED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920205@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L02BA01@L02B@YES@PETACH TIKVA, ISRAEL@@@Tamoxifen is a non-steroidal, triphenylethylene-based drug which displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10–20%. Tamoxifen does not adversely affect bone mineral density.@@14920205@@@NO@@@NO REVIEW@@@@@Via takeover of Ivax@@@@@@@@@@@@@No@@@@@@APPROVED@@@MEDICARE@RESULTS PENDING@@@@@@TAMOXIFEN CITRATE@@@@@TAMOXIFEN CITRATE||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@GENERIC@@@@@GENERIC||||@Hormone Antagonist@SERMs@@@@Hormone Antagonist|SERMs|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1000@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@00093-0784-10@FILM-COATED TABLET@US$@@@@@@@@10@MG@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921514@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@E7974 in a Day 1 of 21-day cycle @@-@-@-@TOKYO, JAPAN@@@@@14921514@Advanced solid tumours@@-@-@@NO REVIEW@@@@-@-@-@NCT00165802@40@-@-@@@-@@5/1/2006@-@E7974-A001-103@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@E-7974@@@@@E-7974||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@RECIST@@@@@@@@@ADVANCED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916634@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@The aim of the lead-in phase is to establish the maximum tolerated dose (MTD) of PI-88 administered either 4 days/week or 7 days/week) in combination with fixed doses of docetaxel (75 mg/m^2 every 21 days) and prednisone (5 mg twice daily). In the randomized phase II component, patients will receive PI-88 at the MTD, either 4 days/week or 7 days/week, in combination with docetaxel and prednisone. The patients will receive up to 10 treatment cycles of the combination therapy.@@-@-@-@QUEENSLAND, AUSTRALIA@8/1/2007@@@@14916634@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00268593@82@-@-@@@-@@8/1/2005@-@PROPIT,@@-@-@@@II PR88206@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@DOCETAXEL@@@@-|DOCETAXEL|||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@PI-88@TAXOTERE@@@@PI-88|TAXOTERE|||@Angiogenesis Inhibitor@VEGF@TK Inhibitor@@@Angiogenesis Inhibitor|VEGF|TK Inhibitor||@PSA@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916742@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@CA4P in escalating doses with Avastin@@-@-@-@WALTHAM, MASSACHUSSETTS@@@@@14916742@Combo with Avastin@@-@-@@NO REVIEW@@@@-@-@-@NCT00395434@20@-@-@@@-@@9/1/2006@-@OXC4P1-105@@-@-@@@I@I@@-@-@Based on results from the first two of three dose cohorts in the study, in which a total of six patients were evaluable, the ZYBRESTAT-bevacizumab combination appeared safe and well-tolerated, resulted in significantly enhanced tumor blood-flow reductions as measured by DCE-MRI imaging, and demonstrated early evidence of clinical activity in the absence of concurrent cytotoxic chemotherapy. SOURCE: Oxigene, 5 October 2007@-@@@@COMBO@COMBRETASTATIN A4 PRODRUG@BEVACIZUMAB@@@@COMBRETASTATIN A4 PRODRUG|BEVACIZUMAB|||@OXIGENE@@@@@OXIGENE||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@ZYBRESTAT@AVASTIN@@@@ZYBRESTAT|AVASTIN|||@Vascular Disrupting Agent@@@@@Vascular Disrupting Agent||||@ADVERSE EVENTS@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917984@Onco@@@@@300f1015ntsdm@@@@@@@@J06BA02@J06B@@DEERFIELD, ILLINOIS@@@@@14917984@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@YES@4-Dec@@NO REVIEW@@@@100%@@@@@@Jul-99@@7/1/1999@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD@@@@@GAMMAGARD||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@275@@@@@@@@@@@@0.06@@@@@@@@@@@@@@@@8/2/2017@275@275@9199078R@POWDER AND SOLVANT FOR SOLUTION FOR PERFUSION@EURO@@@@@@@@5000@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14921610@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AZD-6918 liquid suspension daily oral dose alone and with Gemzar or Alimta. [AstraZeneca]@@-@-@-@LONDON, UNITED KINGDOM@6/1/2010@@@@14921610@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00733031@75@-@-@@@-@@8/1/2008@-@D2785C00002@@-@>> Advanced solid tumors for which standard treatment does not exist or is no longer effective.     >> For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.@@@I@I@@-@-@Trial registered. [AstraZeneca, 08.08.2008]@-@@@@MONO@-@GEMCITABINE@PEMETREXED@@@-|GEMCITABINE|PEMETREXED||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@AZD-6918@GEMZAR@ALIMTA@@@AZD-6918|GEMZAR|ALIMTA||@Other@@@@@Other||||@ADVERSE EVENTS@MAXIMUM TOLERATED DOSE@@@@PHARMACOKINETICS@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922078@Onco@@@@@300f1020ntsdm@@@@@@Patients received Oncophage alone@@-@-@-@NEW YORK, NEW YORK@@@Based on proprietary heat shock protein technology, the Oncophage vaccine is designed to capture the particular cancer's ‘fingerprint.' This fingerprint contains unique antigens (substances that can provoke an immune response) that are present only on that particular patient's specific cancer cells. Injection of the vaccine is intended to stimulate the patient's immune system to recognize and attack any cells bearing the specific cancer fingerpri@@14922078@Metastatic melanoma@@-@-@@NO REVIEW@@@@-@-@-@-@39@-@-@@@-@@@-@C-100-06@@-@-@@@II@II@@-@-@ASCO 2002; 14 patients reacted favourably to Oncophage treatment, including 2 with complete disease regression, three with disease stabilization of more than 5 months, and 4 who remained disease-free for up to 22 months. Almost half of the patients evaluated for immune response demonstrated a significant increase in melanoma-specific T cells. No toxicity was observed with Oncophage treatment.@-@@@@MONO@VITESPAN@@@@@VITESPAN||||@ANTIGENICS@@@@@ANTIGENICS||||@@@@@@|||||||||@Melanoma / Skin Cancer@@@@@Melanoma / Skin Cancer|||||||||@ONCOPHAGE@@@@@ONCOPHAGE||||@Vaccine@@@@@Vaccine||||@COMPLETE RESPONSE@STABLE DISEASE@@@@@@@@@METASTATIC@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@1.0543@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924627@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@orbBec or placebo at start of their conditioning regimen.@@-@-@-@EWING, NEW JERSEY@@@orBec (oral beclomethasone dipropionate) is a potent,locally-acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD) as well as other gastrointestinal disorders characterized by severe inflammation. @@14924627@Prevention of gastrointestinal graft-versus-host disease.@@-@-@@NO REVIEW@@@@-@IDIS licenses supply and distribution rights in Europe for orBec via a named patient programme. SOURCE: Dor, 16 July 2008@FIRST-LINE@-@138@-@-@@@-@@7/1/2007@-@-@@-@138 PATIENTS; 92 IN ORBEC ARM AND 46 IN PLACEBO.@@@II@II@@-@-@Patient enrolment due to complete in Q2 2008.@-@@@@MONO@BECLOMETHASONE DIPROPIONATE@@@@@BECLOMETHASONE DIPROPIONATE||||@DOR BIOPHARMA@@@@@DOR BIOPHARMA||||@@@@@@|||||||||@Supportive Care@@@@@Supportive Care|||||||||@ORBEC@@@@@ORBEC||||@Corticosteroid@@@@@Corticosteroid||||@PREVENT GVHD@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916649@Onco@@@@@@@@@@@Patients were randomised in a ratio of 2:1 to receive either IL13-PE38QQR via CED or Gliadel Wafers.@@-@-@-@-@@@@@14916649@GBM@@-@-@@NO REVIEW@@@@-@NeoPharm and Nippon Kayaku terminated an agreement to develop the drug in Japan. SOURCE: Nippon Kayaku, 14 September 2007@SECOND-LINE@NCT00076986@300@-@IN MARCH 2007, THE FDA'S OFFICE OF ONCOLOGY RECOMMENDED ANOTHER PHASE III TRIAL BEFORE FILING.@@@-@@3/1/2004@-@PRECISE@@-@-@@@III@III@@-@-@December 2006; did not meet the efficacy endpoint at 215 deaths, which was a statistically significant difference, or separation, in the overall survival curves versus Gliadel Wafer Median cintredekin survival was 36.4 weeks whilst those on Gliadel was 35.3 weeks. In June 2006, it had passed interim criteria at 160 deaths.@-@@@@MONO@CINTREDEKIN BESUDOTOX@@@@@CINTREDEKIN BESUDOTOX||||@NEOPHARM@@@@@NEOPHARM||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@IL13-PE38QQR@@@@@IL13-PE38QQR||||@Interleukin@@@@@Interleukin||||@OVERALL SURVIVAL@@@@@@@@@@MALIGNANT@RELAPSED@@@@RANDOMISED@CONTROLLED@MULTI-CENTRE@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@CONVECTION-ENHANCED DELIVERY@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921126@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@CGC-11047 300mg IV over 60 minutes weekly for 3 weeks followed by one rest week (4weeks=1cycle) @@-@-@-@QUEENSLAND, AUSTRALIA@11/1/2007@@@@14921126@-@@-@-@@NO REVIEW@@@@-@Progen closed acquisition of Cellgate in February 2008@-@NCT00585416@23@-@-@@@-@@6/1/2006@-@HSC2006-0099@@-@-@@@II@I@@-@-@Trial enrolment resumed. SOURCE: Progen, 15 MaySuspended until further evaluation of Phase I dosing@-@@@@MONO@-@@@@@-||||@PROGEN PHARMACEUTICALS@@@@@PROGEN PHARMACEUTICALS||||@@@@@@|||||||||@Prostate Cancer@HRPC@@@@Prostate Cancer|HRPC||||||||@PG-11047@CGC-11047@@@@PG-11047|CGC-11047|||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@METASTATIC@@@@@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924964@Onco@@@@@300f1008ntsdm@@@@@@2 doses of gadobutrol 1.0 Molar and Gadoteridol (ProHance) with corresponding blinded image evaluation following multiple injections of 0.1 Mmol/kg bw of Gadobutrol and Gadoteridol. SOURCE: clinicaltrials.gov@@-@-@-@LEVERKUSEN, GERMANY@@@@@14924964@Known or suspected brain metastasis@@-@-@@NO REVIEW@@@@-@-@-@NCT00522951@160@-@First Phase III trials planned for 2008.@@@-@@8/1/2007@-@310864@@-@-@@@II/III@III@@-@@RESULTS PENDING@-@@@@MONO@GADOBUTROL@@@@@GADOBUTROL||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Brain Cancer@@@@@Brain Cancer|||||||||@PROHANCE@@@@@PROHANCE||||@Imaging@@@@@Imaging||||@DIAGNOSTIC@@@@@@@@@@-@@@@@RANDOMISED@SINGLE-BLIND@DOSE COMPARISON@CROSSOVER@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14924243@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@-@@@CPX-351 is a liposomal formulation of cytarabine and daunorubicin delivered in a 5:1 molar ratio shown to be strongly synergistic in preclinical studies. CPX-351 was developed using Celator's proprietary CombiPlex technology platform. @@14924243@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@FDA orphan drug for AML. [Celator, 04.09.2008]@@@-@-@@-@-@@@II@II@@-@-@Trial to start in Q4 2008. [Celator, 04.09.2008]@-@@@@MONO@DAUNORUBICIN, LIPOSOMAL@@@@@DAUNORUBICIN, LIPOSOMAL||||@CELATOR PHARMACEUTICALS@@@@@CELATOR PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@CPX-351@@@@@CPX-351||||@Other@@@@@Other||||@@@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924820@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PARIS, FRANCE@@@Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis. @@14924820@-@@-@-@@NO REVIEW@@@@-@sanofi-aventis holds worldwide licensed including (since January 2006) Japan. Bayer Schering holds eye disease rights.@-@-@-@-@-@@@-@@@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@AFLIBERCEPT@@@@@AFLIBERCEPT||||@SANOFI-AVENTIS@REGENERON PHARMACEUTICALS@@@@SANOFI-AVENTIS|REGENERON PHARMACEUTICALS|||@@@@@@|||||||||@Solid Tumours@Pancreatic Cancer@@@@Solid Tumours|Pancreatic Cancer||||||||@VEGF-TRAP@@@@@VEGF-TRAP||||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916474@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Single agent SGN-40@@-@-@-@SEATTLE, WASHINGTON@@@@@14916474@Diffuse large B-cell lymphoma@@-@-@@NO REVIEW@@@@-@Genentech licensed the drug from Seattle Genetics in January 2007@-@NCT00435916@35@-@-@@@-@@12/1/2006@-@SG040-0004@@-@-@@@II@II@@-@-@Enrolment ongoing (SOURCE: Genentech Q3 07 SEC).@-@@@@MONO@DACETUZUMAB@@@@@DACETUZUMAB||||@SEATTLE GENETICS@@@@@SEATTLE GENETICS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@B-Cell Lymphoma@DLBCL@@Haematological Malignancy|Non-Hodgkin's Lymphoma|B-Cell Lymphoma|DLBCL||||||@SGN-40@ANTI-CD40@@@@SGN-40|ANTI-CD40|||@mAb@Humanised@CD40@@@mAb|Humanised|CD40||@DURATION OF RESPONSE@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924761@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@L01CD02@L01C@-@PARIS, FRANCE@@@Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. The binding of docetaxel to microtubules does not alter the number of protofilaments. Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions. Docetaxel was found to be cytotoxic in vitro against various murine and human tumour cell lines and against freshly excised human tumour cells in clonogenic assays. Docetaxel achieves high intracellular concentrations with a long cell residence time. In addition, docetaxel was found to be active on some but not all cell lines over expressing the p-glycoprotein which is encoded by the multidrug resistance gene. In vivo, docetaxel is schedule independent and has a broad spectrum of experimental antitumour activity against advanced murine and human grafted tumours.@@14924761@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@III@@-@-@RESULTS PENDING@-@@@@-@DOCETAXEL@@@@@DOCETAXEL||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@TAXOTERE@@@@@TAXOTERE||||@Plant Alkaloid@Taxane@@@@Plant Alkaloid|Taxane|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
16511010@Onco@@@@@@@@@@@"MIK665, Experimental, "@@@@@BASEL, SWITZERLAND@4/1/2019@@Mcl-1 Inhibitor@@16511010@Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma@Both@@@@@@@@@@SECOND-LINE@NCT02992483@67@@@@@@@2/1/2017@@CMIK665X2101@@@-  Age ≥ 18 years.  -  Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that is relapsed and/or refractory.  -  Other Inclusion Criteria May Apply.@@ADULTS@Phase 1@I@@@@@@@@@MONO@-@@@@@-||||@NOVARTIS@@@@@NOVARTIS||||@Australia@France@Germany@Italy@Japan@Australia|France|Germany|Italy|Japan|South Korea|Spain|United States||@Myeloma@B-Cell Lymphoma@@@@Myeloma|B-Cell Lymphoma||||||||@MIK665@@@@@MIK665||||@Other@@@@@Other||||@Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs and ECGs.@Incidence of DLTs during the first cycle of treatment with single agent MIK665 during the dose escalation phase only@Tolerability: Dose interruptions@@@Best Overall response (BOR) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma@Area Under Curve (AUC)@@@@REFRACTORY@RELAPSED@@@@Safety/Efficacy Study@Single Group Assignment@Open Label@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919191@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@CANONSBURG, PENNSYLVANIA@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919191@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks.@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@@OXALIPLATIN@@@@@OXALIPLATIN||||@ACTAVIS@@@@@ACTAVIS||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@METASTATIC@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9319720T@POWDER FOR SOLUTION FOR PERFUSION, 20 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14920195@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01DB07@L01D@@NEW DELHI, INDIA@@@Although its mechanism of action has not been determined, mitoxantrone is a DNA-reactive agent. It has a cytocidal effect on proliferating and non-proliferating cultured human cells, suggesting activity against rapidly proliferating and slow-growing neoplasms.@@14920195@@@@@@NO REVIEW@@@@@Dabur Pharma will change its name to Fresenius Kabi Oncology. [Dabur, 29.10.2008]@@@@@FDA, 19 May 2008@5/19/2008@@@@@@@No@@@@@@APPROVED@@@@@@@@@COMBO@MITOXANTRONE@@@@@MITOXANTRONE||||@DABUR PHARMA@FRESENIUS KABI ONCOLOGY@@@@DABUR PHARMA|FRESENIUS KABI ONCOLOGY|||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@GENERIC@@@@@GENERIC||||@Cytotoxic Antibiotic@Anthracycline@Topoisomerase II Inhibitor@@@Cytotoxic Antibiotic|Anthracycline|Topoisomerase II Inhibitor||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@INJECTION@US$@@@@@@@@25@MG@2 MG/ML@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14919072@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients receive oral AZD0530 on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also complete a medication diary. Patients undergo urine and blood sample collection periodically for correlative and pharmacokinetic studies. Samples are analyzed for circulating tumor cells; urine N-telopeptide cross links (NTx) via enzyme-linked immunosorbent assay; NTx concentration via spectrophotometry; and AZD0530 plasma concentrations. After completion of study treatment, patients are followed for 4 weeks. SOURCE: clinicaltrials.gov@@-@-@-@LONDON, UNITED KINGDOM@@@AZD0530 is an orally available, dual-specific, Src/Abl kinase inhibitor that is being evaluated to determine its effects as an anti-invasive agent. AZD0530 is being studied in a variety of clinical settings in solid tumors and leukemias.@@14919072@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00559507@41@-@-@@@-@@10/1/2007@-@MSKCC-07112@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@AZD-0530@@@@@AZD-0530||||@TK Inhibitor@@@@@TK Inhibitor||||@RESPONSE RATE@@@@@@@@@@METASTATIC@LOCALLY ADVANCED@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15413479@Onco@@@@@@@@@@@Drug: Rociletinib Phase 1: Rociletinib will be administered in escalating dosages in a period of 21-day cyclesPhase 2: Rociletinib will be administered daily.@@@@@@6/1/2016@@@@15413479@Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral Rociletinib in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)@Both@@@@@@@1553@@@SECOND-LINE@NCT01526928@605@@@@@@@3/1/2012@@CO-1686-008@@@All patients must meet the following inclusion criteria: 1.Metastatic or unresectable locally advanced NSCLC/2.Evidence of a tumor with one or more EGFR mutations excluding exon 20 insertion/3.Biopsy of either primary or metastatic tumor tissue within 60 days of dosing/4.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1/5.Minimum age of 18 years/6.Adequate hematological and biological function/7.Written consent on an IRB/IEC-approved Informed Consent Form (ICF) prior to any study-specific evaluation@@ADULTS@Phase 1/2@I/II@@@@@@@@@MONO@ROCILETINIB@@@@@ROCILETINIB||||@CLOVIS ONCOLOGY@@@@@CLOVIS ONCOLOGY||||@United States@Australia@France@Poland@@United States|Australia|France|Poland||||||@NSCLC@@@@@NSCLC|||||||||@CO-1686@@@@@CO-1686||||@Other@@@@@Other||||@Objective response rate@DURATION OF RESPONSE@@@@PROGRESSION-FREE SURVIVAL@@@@@ADVANCED@METASTATIC@@@@SINGLE GROUP ASSIGNMENT@OPEN LABEL@@@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924249@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Seliciclib administered at 1,600mg for 4 days every weeks with docetaxel (administered once every three weeks).@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@Seliciclib is an orally available molecule that selectively inhibits multiple enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been evaluated to date in approximately 380 patients and is currently being evaluated in a randomized Phase 2 trial in patients with previously treated nasopharyngeal cancer.@@14924249@-@@-@-@@NO REVIEW@@@@-@All rights@SECOND-LINE@-@7@-@-@@@-@@@-@-@@-@7 PATIENTS WITH ADVANCED NSCLC WHO HAD ONE PRIOR CHEMO@@@II@DISCONTINUED@@-@-@Discontinued in June 2007 due to slow accrual. There were 2 patients with PR and 1 with SD in the combination of seliciclib plus docetaxel. @-@@@@COMBO@SELICICLIB@DOCETAXEL@@@@SELICICLIB|DOCETAXEL|||@CYCLACEL PHARMACEUTICALS@@@@@CYCLACEL PHARMACEUTICALS||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@CYC-202@TAXOTERE@@@@CYC-202|TAXOTERE|||@Purine Analogue@@@@@Purine Analogue||||@PARTIAL RESPONSE@STABLE DISEASE@@@@@@@@@ADVANCED@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922485@Onco@@@@@300f1012ntsdm@@@@@@ZK-EPO in combination with carboplatin for 6 cycles@@-@-@-@LEVERKUSEN, GERMANY@9/1/2008@@@@14922485@Recurrent ovarian cancer in patients who previously have had a good response with cisplatin or carboplatin@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00325351@N/A@-@First Phase III trials planned for 2008.@@@-@@7/1/2006@-@91476, 307979@@-@-@@@II@II@@-@-@"ASCO 2007; results from a 63-patient trial of platinum-resistant ovarian cancer taking sagopilone monotherapy (16MG/M2 30 minute or 3 hour infusions every three weeks) showed ""confirmed antitumor response"". Responses were observed at both dose schedules, with 52.2% and 60.0% of patients in the 30 minute and 3 hour arms respectively showing a partial response or disease stabilisation. The agent was well tolerated in both treatment arms; sensory neuropathy was the most common adverse event. No significant myelosuppression or diarrhea were observed. Completion due in September 2008. First Phase III trials planned for 2008."@-@@@@COMBO@SAGOPILONE@@@@@SAGOPILONE||||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@ZK-EPO@ZK-219477@@@@ZK-EPO|ZK-219477|||@Epothilone@@@@@Epothilone||||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Incorrect Average Duration of Use (Unit)@@@6@cycles@6 cycles@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14919078@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours followed by carboplatin at AUC4 administered by intravenous infusion over 1 hour; combination given once every 2 weeks for 6 week cycles.@@-@-@-@SALT LAKE CITY, UTAH@3/1/2009@@@@14919078@-@@-@-@@NO REVIEW@@@@-@-@SECOND-LINE@NCT00635557@30@-@-@@@-@@3/1/2008@-@MPC-6827-07-004,@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@CARBOPLATIN@@@@-|CARBOPLATIN|||@MYRIAD GENETICS@@@@@MYRIAD GENETICS||||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@MPC-6827@@@@@MPC-6827||||@Other@@@@@Other||||@MAXIMUM TOLERATED DOSE@@@@@@@@@@REFRACTORY@RELAPSED@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916014@Onco@@@@@@@@@@@15 MG/KG INTRAVENOUSLY (IV) ON DAY 1 OF EACH 3-WEEK CYCLE@@L01XC07@L01X@@BASEL, SWITZERLAND@7/1/2014@@@@14916014@A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTICENTER PHASE III STUDY COMPARING BEVACIZUMAB PLUS CARBOPLATIN/PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN / PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY@@@@@@@@@@@@NCT01364012@270@@@@@@@5/1/2011@@YO25404@@@LOCALLY ADVANCED (STAGE IIIB NOT AMENABLE FOR COMBINED MODALITY TREATMENT), METASTATIC (STAGE IV) OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)  -  EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS 0-1  -  ADEQUATE HAEMATOLOGICAL, RENAL AND LIVER FUNCTION@@@III@III@@@@Trial registered [Roche 27 May 2011]@@@@@COMBO@BEVACIZUMAB@@@@@BEVACIZUMAB||||@ROCHE@@@@@ROCHE||||@China@@@@@China|||||||||@NSCLC@@@@@NSCLC|||||||||@AVASTIN@@@@@AVASTIN||||@mAb@Humanised@TK Inhibitor@VEGF@@mAb|Humanised|TK Inhibitor|VEGF|@PROGRESSION-FREE SURVIVAL (PFS), TUMOUR ASSESSMENTS ACCORDING TO RECIST CRITERIA@@@@@OVERALL SURVIVAL (OS)@1-YEAR SURVIVAL RATE@@@@ADVANCED@@@@@RANDOMISED@SAFETY@PARALLEL ASSIGNMENT@DOUBLE BLIND@@@@Invalid Factory Price@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14921723@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Abiterone and prednisone@@-@-@-@NEW BRUNSWICK, NEW JERSEY@6/1/2013@@@@14921723@Patients who failed androgen deprivation and docetaxel-based chemo@@-@-@@NO REVIEW@@@@-@J&J acquired Cougar in 2009.[J&J May 21 2009 http://www.jnj.com/connect/news/all/20090521_160000 ]@SECOND-LINE@NCT00485303@10@-@-@@@-@@6/1/2007@-@COU-AA-004@@-@-@@@II@II@@-@-@Abiraterone was well tolerated in 10 evaluable patients with advanced prostate cancer who failed androgen derivation and docetaxel-based chemotherapy and reduced PSA levels by >50% in 4 patients. In 5 patients with measurable tumour lesions, 1 patient had a partial radiological response. @-@@@@COMBO@ABIRATERONE ACETATE@PREDNISONE@@@@ABIRATERONE ACETATE|PREDNISONE|||@JOHNSON & JOHNSON@COUGAR BIOTECHNOLOGY@@@@JOHNSON & JOHNSON|COUGAR BIOTECHNOLOGY|||@@@@@@|||||||||@Prostate Cancer@@@@@Prostate Cancer|||||||||@CB-7630@@@@@CB-7630||||@Other@@@@@Other||||@SAFETY@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924970@Onco@@@@@@@@@@@Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil. Patients will be stratified by age; 374 women aged 18-26, 334 women aged 27-35 and 334 women aged 36-45.@@J07BM01@J07B@-@BRENTFORD, UNITED KINGDOM@@@Cervarix is a non-infectious recombinant vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral immune response. HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers across all regions worldwide.@@14924970@Cervarix head-to-head with Gardasil@@NO@-@@NO REVIEW@@@@-@-@-@NCT00423046@1042@-@"GSK received a ""complete response letter"" from the U.S. FDA; the FDA has completed its review of the application but has unanswered questions, which GSK need to address prior to being granted marketing approval. SOURCE: GSK December 2007BLA submitted with FDA in March 2007. SOURCE: GSK 30 March 2007"@3/30/2007@@-@@1/1/2007@-@108933@@FIRST PATENT EXPIRES IN 2017.@-@@@III@III@@-@-@Results are expected 1 year after completion of patient enrolment.@-@@@@MONO@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@GSK@@@@@GSK||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@CERVARIX@@@@@CERVARIX||||@Vaccine@@@@@Vaccine||||@IMMUNE RESPONSE@@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916406@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@-@@-@-@-@BASEL, SWITZERLAND@9/1/2004@@@@14916406@-@@-@-@@NO REVIEW@@@@-@Worldwide rights licensed to Novartis in 2003@-@NCT00032903@59@-@-@@@-@@3/1/2002@-@ST-01-402@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@MONO@GIMATECAN@@@@@GIMATECAN||||@NOVARTIS@SIGMA TAU@@@@NOVARTIS|SIGMA TAU|||@@@@@@|||||||||@Brain Cancer@Glioblastoma Multiforme@@@@Brain Cancer|Glioblastoma Multiforme||||||||@LBQ-707@@@@@LBQ-707||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@MAXIMUM TOLERATED DOSE@@@@@@@@@@MALIGNANT@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921608@Onco@@@@@@@@@@@Zactima with FOLFIRI versus FOLFIRI alone@@-@-@-@LONDON, UNITED KINGDOM@@@An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. @@14921608@Combo with FOLFIRI@@-@-@@NO REVIEW@@@@-@-@-@NCT00454116@-@-@-@@@-@@@-@D4200C00048  @@-@PATIENTS WHO HAVE FAILED OXALIPLATIN AND FLUOROPYRIMIDINE-CONTAINING REGIMEN@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@VANDETANIB@@@@@VANDETANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@ZACTIMA@FOLFIRI@@@@ZACTIMA|FOLFIRI|||@TK Inhibitor@VEGF@EGFR@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|EGFR|Angiogenesis Inhibitor|@RESPONSE RATE@SAFETY@@@@@@@@@-@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916797@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@Drug: NPI-0052 IV injection, three times every 28 days, escalating dosing cohorts Drug: NPI-0052 IV injection, three times every 28 day cycle SOURCE: clinicaltrials.gov@@-@-@-@SAN DIEGO, CALIFORNIA@@@@@14916797@Advanced solid tumours or refractory lymphoma@@-@-@@NO REVIEW@@@@-@-@-@NCT00396864@50@-@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@3/18/2008@@FDA orphan drug designation for multiple myeloma. SOURCE: Immunomedics press release, 18 March 2008@@5/1/2006@-@NPI-0052-100@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@NEREUS PHARMACEUTICALS@@@@@NEREUS PHARMACEUTICALS||||@@@@@@|||||||||@Haematological Malignancy@Non-Hodgkin's Lymphoma@Hodgkin's Lymphoma@Solid Tumours@@Haematological Malignancy|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Solid Tumours||||||@NPI-0052@@@@@NPI-0052||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@MAXIMUM TOLERATED DOSE@PHARMACOKINETICS@@@@@@@@@ADVANCED@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@DOSE COMPARISON@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918912@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@SOUTH SAN FRANCISCO, CALIFORNIA@@@@@14918912@-@@-@-@@NO REVIEW@@@@-@Novacea licensed exclusive worldwide rights from KuDOS, which was acquired by AstraZeneca, and BTG.@-@-@56@-@-@@@-@@10/1/2007@-@N/A@@-@-@@@II@II@@-@-@Discontinued as part of scale back in development of AQ4N due to shift in resources following failure of ASCENT-2. SOURCE: Novacea, 3 January 2008@-@@@@MONO@BANOXANTRONE@@@@@BANOXANTRONE||||@NOVACEA@@@@@NOVACEA||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@@@@Haematological Malignancy|Acute Lymphocytic Leukaemia||||||||@AQ4N@@@@@AQ4N||||@Topoisomerase II Inhibitor@@@@@Topoisomerase II Inhibitor||||@COMPLETE RESPONSE@@@@@@@@@@RELAPSED@REFRACTORY@@@@MULTI-CENTRE@SINGLE-ARM@OPEN-LABEL@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917977@Onco@@@@@300f1010ntsdm@@@@@@Foscan alone@@L01XD05@L01X@NO@EAST LONGMEADOW, MASSACHUSSETTS@@@@@14917977@Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.@@NO@@@NO REVIEW@@@@100%@Licensed from QLT@@@147@The dose is 0.15mg/kg body weight.@EMA, 24 October 2001@10/24/2001@@@@@Special care must be taken to prevent extravasation at the injection site. If extravasation occurs, protect the area from light for at least 3 months. There is no known benefit from injecting the extravasation site with another substance.@LABEL@No@@@@@III@APPROVED@@The SMC advised in May 2004 that temoporfin is not recommended for the palliative treatment of advanced head and neck cancer.@NHS@Median duration of tumour response was 57 days for overall responseand 84 days for complete response.@@@@@MONO@TEMOPORFIN@@@@@TEMOPORFIN||||@BIOLITEC@@@@@BIOLITEC||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@FOSCAN@@@@@FOSCAN||||@Other@@@@@Other||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.299@1575@@1800@@@@@@@@@@525@@@@@@@@@@@@@@@@7/28/2017@1575@1575@UK_BNF_1074957639@SOLUTION FOR INJECTION - 3 ML@GB£@@@@@@@@3@MG@@@@@@@@@@@@@@@@@@@@@@@@@243@United Kingdom@@@@@@@@
14920134@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01AA01@L01A@@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14920134@@@@@@NO REVIEW@@@@@@@@@@FDA, 21 May 2008@5/21/2008@@@@@@@No@@@@@@APPROVED@@@MEDICARE@@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Breast Cancer@Ovarian Cancer@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Breast Cancer|Ovarian Cancer||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@1465@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@1465@1465@10019-0957-01@LYOPHILISATE FOR SOLUTION FOR INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14917973@Onco@@@@@300f1015ntsdm@@@@@@@@J06BA02@J06B@@DEERFIELD, ILLINOIS@@@@@14917973@Indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia (CCL), for the prevention of coronary artery aneurysms associated with Kawasaki Syndrome and to induce rapid rise in platelet count when needed to prevent and/or to control bleeding in a patient with Idiopathic Thrombocytopenic Purpura (ITP).@@YES@4-Dec@@NO REVIEW@@@@100%@@@@@@Jul-99@@7/1/1999@@@@@@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@RESULTS PENDING@@@@@@IMMUNOGLOBULIN (HUMAN)@@@@@IMMUNOGLOBULIN (HUMAN)||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@B-Cell Lymphoma@Supportive Care@@Haematological Malignancy|Chronic Lymphocytic Leukaemia|B-Cell Lymphoma|Supportive Care||||||@GAMMAGARD@@@@@GAMMAGARD||||@Other@@@@@Other||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@550@@@@@@@@@@@@0.06@@@@@@@@@@@@@@@@8/2/2017@550@550@9199055R@POWDER AND SOLVANT FOR SOLUTION FOR PERFUSION@EURO@@@@@@@@10000@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14924209@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@-@-@-@-@@@Immunogen created AVE1642 and licensed it to sanofi-aventis, who advanced it into clinical testing in October 2006. AVE1642 is a “naked” (non-conjugated) antibody that binds to the IGF-1 receptor, to block a pathway used by cancer cells to survive exposure to chemotherapy agents. Thus, it is expected that AVE1642 will be used in combination with chemotherapeutic agents@@14924209@-@@-@-@@NO REVIEW@@@@-@AVE1642 is an anticancer compound that was developed by ImmunoGen and licensed to sanofi-aventis as part of a broader collaboration between the companies. ImmunoGen and sanofi-aventis have an ongoing collaboration to discover, develop, and commercialize novel anticancer products using ImmunoGen's antibody expertise as well as the Company's Tumor-Activated Prodrug (TAP) technology.@-@-@-@-@-@@@-@@@-@-@@-@-@@@-@I@@-@-@RESULTS PENDING@-@@@@COMBO@-@BORTEZOMIB@@@@-|BORTEZOMIB|||@SANOFI-AVENTIS@IMMUNOGEN@@@@SANOFI-AVENTIS|IMMUNOGEN|||@@@@@@|||||||||@Haematological Malignancy@Myeloma@@@@Haematological Malignancy|Myeloma||||||||@AVE-1642@VELCADE@@@@AVE-1642|VELCADE|||@mAb@CD33@@@@mAb|CD33|||@DOSE-LIMITING TOXICITY@MAXIMUM TOLERATED DOSE@@@@@@@@@RELAPSED@REFRACTORY@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924231@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@J07BM01@J07B@-@BRENTFORD, UNITED KINGDOM@@@Cervarix is a non-infectious recombinant vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral immune response. HPV-16 and HPV-18 are responsible for approximately 70% of cervical cancers across all regions worldwide.@@14924231@-@@NO@-@@NO REVIEW@@@@-@-@-@-@18644@-@-@@@-@@@-@-@@FIRST PATENT EXPIRES IN 2017.@18,644 WOMEN AGED 15-25@@@III@III@@-@-@June 2007; interim data; 100% protection against precancerous lesions caused by HPV types 16 and 18.@-@@@@-@HUMAN PAPILLOMAVIRUS@@@@@HUMAN PAPILLOMAVIRUS||||@GSK@@@@@GSK||||@@@@@@|||||||||@Cervical Cancer@@@@@Cervical Cancer|||||||||@CERVARIX@@@@@CERVARIX||||@Vaccine@@@@@Vaccine||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921781@Onco@@@@@300f1008ntsdm@@@@@@Gimatecan oral dose twice per week in Japanese patients@@-@-@-@BASEL, SWITZERLAND@@@@@14921781@-@@-@-@@NO REVIEW@@@@-@Worldwide rights licensed to Novartis in 2003@-@NCT00487058@28@-@-@@@-@@5/1/2007@-@CLBQ707A1103@@-@-@@@I@I@@-@@RESULTS PENDING@-@@@@MONO@GIMATECAN@@@@@GIMATECAN||||@NOVARTIS@SIGMA TAU@@@@NOVARTIS|SIGMA TAU|||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@LBQ-707@@@@@LBQ-707||||@Plant Alkaloid@Topoisomerase I Inhibitor@@@@Plant Alkaloid|Topoisomerase I Inhibitor|||@RECIST@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14924554@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@-@-@-@-@@@@@14924554@Lymphoseek and vital blue dye as lymphoid tissue targeting agents in patients with known head and neck cancer who are undergoing lymph node mapping@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@EMEA PDCO recommended product-specific waiver. SOURCE: EMEA PDCO, January 2008Orphan designation was granted by the European Commission for panobinostat lactate for the treatment of cutaneous T cell lymphoma. [There is discussion of current treatments, the numbers or persons affected with this condition in the EU, and the mode of action & state of development of panobinostat lactate for the treatment of this condition. Panobinostat lactate was not authorised anywhere in the world for cutaneous T-cell lymphoma, or designated as orphan medicinal product elsewhere for this condition, at the time of submission. Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.] SOURCE: EMEA COMP, 6 November 2007@11/6/2007@@-@@@-@-@@-@-@@@III@III@@-@-@Trial awaiting final regulatory clearance. SOURCE: Neoprobe, 9 June 2008@-@@@@MONO@-@@@@@-||||@NEOPROBE@@@@@NEOPROBE||||@@@@@@|||||||||@Head & Neck Cancer@@@@@Head & Neck Cancer|||||||||@LYMPHOSEEK@@@@@LYMPHOSEEK||||@Other@@@@@Other||||@@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14923988@Onco@@@@@300f1020ntsdm@@@@@@Uftoral/calcium folinate versus Mayo regimen/calcium folinate@@-@-@-@DARMSTADT, GERMANY@@@@@14923988@First-line treatment of metastatic colorectal cancer with calcium folinate.@@YES@-@@NO REVIEW@@@@100%@-@-@-@1196@The dose of Uftoral is 300 mg/m2/day tegafur and 672 mg/m2/day uracil combined with 90 mg/day oral calcium folinate, given in three divided doses (preferably every 8 hours). Calcium folinate should be taken at the same time as Uftoral. Doses should be taken at least one hour before or one hour after meals for 28 consecutive days.@N/A@@@-@@@-@LABEL@@-@1196 [METASTATIC COLORECTAL CANCER]@@@III STUDY-011 AND STUDY-012@APPROVED@@1@SSN@The median survival time was 12.4 months (95% CI: 11.2-13.6 months) and 13.4 months in the Uftoral/calcium folinate and the 5FU/calcium folinate treatment groups, respectively (Study-011). The median TTP was 3.4 months and 3.3 months respectively.@-@@@@COMBO@TEGAFUR / URACIL@@@@@TEGAFUR / URACIL||||@MERCK SERONO@@@@@MERCK SERONO||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UFT@MAYO REGIMEN@@@@UFT|MAYO REGIMEN|||@Anti-metabolite@Pyrimidine Analogue@@@@Anti-metabolite|Pyrimidine Analogue|||@OVERALL SURVIVAL@@@@@@@@@@METASTATIC@@@@@RANDOMISED@@@@@@@Invalid Factory Price@@@@@@@@@21@1.1229@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@CAPSULE@EURO@@@@@@@@@@100 MG|224 MG@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
14924608@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@NEWTOWN, PENNSYLVANIA@@@ON 013105 is initially being evaluated as a novel approach to treat a particularly deadly type of non-Hodgkin's lymphoma: Mantle Cell Lymphoma (MCL). ON 013105 selectively kills solid tumor and blood cancer cells and shrinks human MCL tumors implanted in mice by disabling several regulatory proteins, most importantly cyclin D1, an essential protein that is over-expressed in many types of cancer cells.  Treatment of MCL by targeting cyclin D1 protein provides a first clinical test for this strategy. Other potential applications of ON 013105 are in multiple myeloma, myelodysplastic syndrome (MDS) and certain solid tumors that also employ similar mechanisms.@@14924608@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@-@@@-@@@-@-@@-@-@@@I@I@@-@-@IND to be fialed in Q4 08. [Onconova, 28 April 2008]@-@@@@MONO@-@@@@@-||||@ONCONOVA@@@@@ONCONOVA||||@@@@@@|||||||||@Haematological Malignancy@Chronic Myeloid Leukaemia@@@@Haematological Malignancy|Chronic Myeloid Leukaemia||||||||@ON-013105@@@@@ON-013105||||@Other@@@@@Other||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14920135@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@@@L01AA01@L01A@@DEERFIELD, ILLINOIS@@@Cyclophosphamide is an antineoplastic agent which is converted in the body to an active alkylating metabolite. It also possesses marked immunosuppressant properties. The principal site of cyclophosphamide activation is the liver. The chemotherapeutic and immunosuppressant activity of cyclophosphamide is thought to be mediated by the cytotoxic intermediates produced by activation by mixed function oxidases in hepatic microsomes. Non-enzymatic cleavage, possibly taking place in the tumour cells, results in the formulation of highly cytotoxic forms of the drug.@@14920135@@@@@@NO REVIEW@@@@@@@@@@FDA, 21 May 2008@5/21/2008@@@@@@@No@@@@@@APPROVED@@@MEDICARE@@@@@@@CYCLOPHOSPHAMIDE@@@@@CYCLOPHOSPHAMIDE||||@BAXTER HEALTHCARE@@@@@BAXTER HEALTHCARE||||@@@@@@|||||||||@Haematological Malignancy@Acute Lymphocytic Leukaemia@Breast Cancer@Ovarian Cancer@@Haematological Malignancy|Acute Lymphocytic Leukaemia|Breast Cancer|Ovarian Cancer||||||@GENERIC@@@@@GENERIC||||@Alkylating Agent@@@@@Alkylating Agent||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1@732.5@@@@@@@@@@@@@@@@@@@@@@@@@@@@8/2/2017@732.5@732.5@10019-0956-01@LYOPHILISATE FOR SOLUTION FOR INJECTION@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924806@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@N/A@@-@-@-@SAN FRANCISCO, CALIFORNIA@@@@@14924806@-@@-@February 1998 (FDA)@@NO REVIEW@@@@-@Licensed from Bayer as part of ACT's creation through financing from NGN Capital. SOURCE: NGN, 7 May 2008@-@-@-@-@On 5 September 2007 AGI Dermatics announced that T4N5 (DIMERICINE) has been granted Fast Track status by the US FDA for the treatment of solar and ultraviolet photosensitivity in patients with xeroderma pigmentosum (XP).@9/5/2007@@-@@@-@-@@-@-@@@II@II@@-@-@N/A@-@@@@-@-@@@@@-||||@ACT BIOTECH@@@@@ACT BIOTECH||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@UNNAMED@@@@@UNNAMED||||@TK Inhibitor@VEGF@Angiogenesis Inhibitor@@@TK Inhibitor|VEGF|Angiogenesis Inhibitor||@PSA@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922237@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@AT-101 in combination with topotecan@@-@-@-@MALVERN, PENNSYLVANIA@11/1/2008@@@@14922237@Combo with topotecan in relapsed or refractory SCLC@@-@-@@NO REVIEW@@@@-@Partnering opportunity@-@NCT00397293@94@-@-@@@-@@11/1/2006@-@AT-101-CS-101@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@TOPOTECAN HYDROCHLORIDE@@@@-|TOPOTECAN HYDROCHLORIDE|||@ASCENTA THERAPEUTICS@@@@@ASCENTA THERAPEUTICS||||@@@@@@|||||||||@SCLC@@@@@SCLC|||||||||@AT-101@HYCAMTIN@@@@AT-101|HYCAMTIN|||@Bcl-2 Inhibitor@@@@@Bcl-2 Inhibitor||||@SAFETY@RESPONSE RATE@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14916598@Onco@@@@@@@@@@@RAD-001 as monotherapy@@-@-@-@BASEL, SWITZERLAND@@@The active substance in Afinitor, everolimus, is an anticancer medicine, which acts by blocking a protein called ‘mammalian target of rapamycin' (mTOR). In the body, everolimus attaches to a protein that is found inside cells to make a ‘complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of kidney cancer.@@14916598@Advanced and Metastatic Silent Neuro-Endocrine Tumors@@-@-@@NO REVIEW@@@October 2008-@-@-@FIRST-LINE@NCT00688623@60@-@-@@@@@@-@RAMSETE/CDE16@@-@Patients with advanced (unresectable or metastatic) biopsy proven non-syndromic neuro-endocrine carcinoma, low or intermediate grade@@@II@II@@-@-@RESULTS PENDING@-@@@@MONO@EVEROLIMUS@@@@@EVEROLIMUS||||@NOVARTIS@@@@@NOVARTIS||||@@@@@@|||||||||@Carcinoid / Neuroendocrine Tumour@@@@@Carcinoid / Neuroendocrine Tumour|||||||||@AFINITOR@RAD-001@@@@AFINITOR|RAD-001|||@Immunotherapy@Immunosuppressive@mTOR Inhibitor@@@Immunotherapy|Immunosuppressive|mTOR Inhibitor||@RECIST@@@@@@@@@@ADVANCED@METASTATIC@@@@OPEN-LABEL@SINGLE-ARM@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14916611@Onco@@@@@300f1224ntsdm@300f1225ntsdm@300f1226ntsdm@300f1227ntsdm@300f1228ntsdm@@IV push twice weekly for 3 weeks in a 28-day cycle. A maximum of 12 cycles will be administered. @@-@-@-@SAN FRANCISCO, CALIFORNIA@11/1/2009@@@@14916611@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00531284@200@-@-@@@FDA orphan drug for multiple myeloma and Waldenstrom's macroglobulinaemia. SOURCE: Proteolix, 2 April 2008@@9/1/2007@-@PX-171-007@@-@-@@@I/II@II@@-@-@Phase II portion started. SOURCE: Proteolix, 1 May 2008@-@@@@MONO@CARFILZOMIB@@@@@CARFILZOMIB||||@ONYX@@@@@ONYX||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@PR-171@@@@@PR-171||||@Proteasome Inhibitor@@@@@Proteasome Inhibitor||||@RESPONSE RATE@@@@@@@@@@RELAPSED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14918857@Onco@@@@@300f1008ntsdm@@@@@@Patients received tesetaxel 27mg/m2 or 35mg/m2 every 3 weeks; 8 patients subsequently received docetaxel as a monotherapy@@-@-@-@BERKELEY HEIGHTS, NEW JERSEY@@@@@14918857@Anthracycline-pretreated advanced breast cancer@@-@-@@NO REVIEW@@@@-@Genta entered into an exclusive worldwide licensing agreement with Daiichi-Sankyo for the development and commercialisation of the drug. SOURCE: Genta, 7 March 2008@-@-@33@-@-@@@-@@@-@N/A@@-@-@@@II@CLINICAL HOLD@@-@@"After discussions with FDA, clinical development will continue with licensee Genta. SOURCE: Genta, 7 March 2008Abandoned by Daiichi Sankyo. SOURCE: Daiichi Sankyo, 21 February 200818th EORTC-NCI-AACR November 2006; 7 confirmed PRs, 17 had SD, 2 withdrew consent and 7 discontinued due to toxicity. Of those treated with docetaxel, PR and SD was 63% and 13% respectively. Embolisms occurred in 35mg/m2 and 27mg/m2 dosing is recommended."@-@@@@MONO@TESETAXEL@@@@@TESETAXEL||||@GENTA@DAIICHI SANKYO@@@@GENTA|DAIICHI SANKYO|||@@@@@@|||||||||@Breast Cancer@@@@@Breast Cancer|||||||||@DJ-927@@@@@DJ-927||||@Taxane@@@@@Taxane||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@N/A@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@YEN@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@2017-09-15T09:28:17.5370353Z@121@Japan@@@@@@@@
14922122@Onco@@@@@@@@@@@Omnitarg in combination with carboplatin-based chemotherapy versus carboplatin-based therapy alone on treatment response in patients with platinum-sensitive recurrent ovarian cancer@@-@-@-@BASEL, SWITZERLAND@@@Pertuzumab is a humanized antibody and the first in a new class of agents known as HER dimerization inhibitors (HDIs). HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members (HER1/EGFR, HER3, and HER4). In cancer cells, interfering with HER2's ability to collaborate with other HER family receptors blocks cell signaling and may ultimately lead to cancer cell growth inhibition and death of the cancer cell. HDIs, because of their unique mode of action, have the potential to work in a wide variety of tumors, including those that do not overexpress HER2@@14922122@Platinum-sensitive ovarian cancer@@-@-@@NO REVIEW@@@@-@-@-@-@140@-@-@@@-@@@-@BO17931@@-@-@@@II@II@@-@-@Enrolment completed in 2007; results should be seen in early 2008 (SOURCE: Genentech Q307 SEC).@-@@@@COMBO@PERTUZUMAB@@@@@PERTUZUMAB||||@ROCHE@@@@@ROCHE||||@Poland@@@@@Poland|||||||||@Ovarian Cancer@@@@@Ovarian Cancer|||||||||@OMNITARG / R-1273@R-1273@@@@OMNITARG / R-1273|R-1273|||@mAb@Humanised@HER2@@@mAb|Humanised|HER2||@RECIST@@@@@@@@@@-@@@@@RANDOMISED@OPEN-LABEL@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14919055@Onco@@@@@@@@@@@Enzastaurin with pemetrexed and carboplatin@@-@-@-@INDIANAPOLIS, INDIANA@@@Enzastaurin is an oral, serine threonine kinase inhibitor which selectively targets the PKCBeta and PI3/AKTsignaling pathways. By blocking these key pathways frequently over-expressed in a wide variety of cancers, enzastaurin suppresses tumor cell proliferation, induces tumor cell death and inhibits tumor-induced angiogenesis. Treatment has been well tolerated with minimal drug-related toxicity. Enzastaurin administration is associated with fatigue, diarrhea, nausea, decreased platelets, cough, vomiting, transaminase elevation, dyspnea, peripheral edema, and dizziness. Further testing in Phase III versus a placebo will provide us with a more complete look at the side effect profile for enzastaurin. In addition to DLBCL, enzastaurin is also being studied in other tumor types including breast, colon, lung, ovarian and prostate cancers@@14919055@-@@-@-@@NO REVIEW@@@@-@-@-@-@210@-@-@@@-@@@-@N/A@@-@-@@@II@II@@-@-@RESULTS PENDING; previous PII trial for advanced/metastatic NSCLC in 53 patients showed PFS of 1.84 months and 34% SD. @-@@@@COMBO@ENZASTAURIN@PEMETREXED@CARBOPLATIN@@@ENZASTAURIN|PEMETREXED|CARBOPLATIN||@LILLY@@@@@LILLY||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@LY-317615@ALIMTA@@@@LY-317615|ALIMTA|||@Angiogenesis Inhibitor@@@@@Angiogenesis Inhibitor||||@SAFETY@RESPONSE RATE@@@@@@@@@ADVANCED@@@@@RANDOMISED@OPEN-LABEL@ACTIVE CONTROL@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@ORAL @-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922600@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Patients are given DepoCyt and temozolomide@@-@-@-@BRIDGEWATER, NEW JERSEY@@@@@14922600@Neoplastic meningitis from solid tumours and systemic lymphoma@@-@-@@NO REVIEW@@@@-@Enzon will spin-off its novel biotechnology business from Enzon in a transaction that will result in two independent and highly focused public companies. Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including PEG-Intron, Cimzia and Hematide, and the manufacturing facility in Indianapolis. SOURCE: Enzon, 7 May 2008Marketed by Enzon in U.S., Mundipharma in Europe@-@NCT00515788@70@-@-@@@-@@2/1/2006@-@2005-0135@@-@-@@@I/II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@TEMOZOLOMIDE@@@@-|TEMOZOLOMIDE|||@ENZON@@@@@ENZON||||@@@@@@|||||||||@Lymphomatous Meningitis@@@@@Lymphomatous Meningitis|||||||||@DEPOCYT@TEMODAL@@@@DEPOCYT|TEMODAL|||@Anti-metabolite@@@@@Anti-metabolite||||@SAFETY@TOLERABILITY@MAXIMUM TOLERATED DOSE@@@MAXIMUM TOLERATED DOSE@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924492@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@IRVINE, CALIFORNIA@@@@@14924492@Stage IIIB/IV or recurrent NSCLC in HLA-A2-positive patients@@-@-@@NO REVIEW@@@@-@-@-@-@63@-@-@@@-@@@-@-@@-@63 PATIENTS WITH HLA-A2-POSITIVE NSCLC@@@II@II@@-@-@One-year survival was 60% versus 49% in HLA-A2-positive verus HLA-A2-negative groups. SOURCE: IDM/ASCO, 3 June 2008Updated Phase II data in 63 evaluable patients showed that median survival times for those treated with IDM-2101 was 17.3 months vs 12 months for the comparator group. The comparator group was 72 patients with HLA-A2-negative NSCLC who were not enrolled in the study and could receive any treatment they wanted. Previous results reported that 60% of patients were alive at one year vs 49% of patients in the control arm; median survival of 583 days. SOURCE: IDM, November 2007@-@@@@-@-@@@@@-||||@IDM PHARMA@@@@@IDM PHARMA||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@IDM-2101 @@@@@IDM-2101 ||||@Synthetic Peptide@@@@@Synthetic Peptide||||@OVERALL SURVIVAL@IMMUNE RESPONSE@SAFETY@@@SAFETY@@@@@METASTATIC@ADVANCED@@@@OPEN-LABEL@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14921600@Onco@@@@@300f1012ntsdm@@@@@@AZD-2171 multiple ascending doses of 20, 30 or 45 mg with or without AZD-0530 multiple ascending doses 125mg or 175mg.@@-@-@-@LONDON, UNITED KINGDOM@6/1/2008@@Cediranib (Recentin AZD2171) is a highly potent inhibitor of the tyrosine kinase activity associated with all three vascular endothelial growth factor (VEGF) receptors and is currently in Phase II/III clinical trials. Preclinically, cediranib inhibits VEGF signaling and angiogenesis in vivo and impedes solid tumor growth significantly. @@14921600@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00475956@56@-@-@@@-@@5/1/2007@-@D8480C00014, @@-@-@@@EuDract #2006-003505-55; @I@@-@-@RESULTS PENDING@-@@@@COMBO@CEDIRANIB@@@@@CEDIRANIB||||@ASTRAZENECA@@@@@ASTRAZENECA||||@@@@@@|||||||||@Solid Tumours@@@@@Solid Tumours|||||||||@RECENTIN@AZD-2171@AZD-0530@@@RECENTIN|AZD-2171|AZD-0530||@TK Inhibitor@VEGF@@@@TK Inhibitor|VEGF|||@SAFETY@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@UNCONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@TABLET@EURO@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@92@Germany@@@@@@@@
14919159@Onco@@@@@300f1015ntsdm@@@@@@NO LABELLED TRIAL@@L01XA03@L01X@YES@@@@Eloxatin is an antineoplastic agent which is an organoplatinum complex in which the platinum atom is complexed with 1,2-DACH and with an oxalate ligand as a leaving group. It undergoes non-enzymatic conversion in physiologic solutions to active derivatives via displacement of the labil oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.@@14919159@Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. • Treatment of metastatic colorectal cancer.@@YES@@@No ASMR rating.@@@@@@@@@The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months).@@@@@@@Hypersensitivity and anaphylactic / anaphylactoid reactions to Eloxatin have been reported. Eloxatin may cause fetal harm when administered to a pregnant woman.@NO LABELLED TRIAL@No@@@@@@APPROVED@@@HAUTE AUTORITÉ DE SANTÉ@NO LABELLED TRIAL@@@@@ADJUVANT@OXALIPLATIN@@@@@OXALIPLATIN||||@EBEWE PHARMA@@@@@EBEWE PHARMA||||@@@@@@|||||||||@Colorectal Cancer@@@@@Colorectal Cancer|||||||||@GENERIC@@@@@GENERIC||||@Platinum@@@@@Platinum||||@@@@@@@@@@@@@@@@@@@@@@@Invalid Factory Price@@@@@@@@@1@1.1511@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9301393T@POWDER FOR SOLUTION FOR PERFUSION, 20 ML@EURO@@@@@@@@100@MG@@@@@@@@@@@@@@@@@@@@@@@@@85@France@@@@@@@@
14922438@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily. @@-@-@-@NEW YORK, NEW YORK@6/1/2008@@@@14922438@-@@-@-@@NO REVIEW@@@@-@-@-@NCT00147550@310@-@-@@@-@@2/1/2004@-@A4581001@@-@-@@@I@I@@-@-@RESULTS PENDING@-@@@@MONO@-@@@@@-||||@PFIZER@@@@@PFIZER||||@@@@@@|||||||||@Breast Cancer@Colorectal Cancer@Melanoma / Skin Cancer@@@Breast Cancer|Colorectal Cancer|Melanoma / Skin Cancer|||||||@PD-325901@@@@@PD-325901||||@MEK Inhibitor@@@@@MEK Inhibitor||||@RESPONSE RATE@@@@@@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14924272@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@E-7820 plus Erbitux@@-@-@-@TOKYO, JAPAN@@@@@14924272@Combo with Erbitux@@-@-@@NO REVIEW@@@@-@Acquired through takeover of Morphotek in April 2007; Ludwig Institute@-@NCT00309179@99@-@FILING EXPECTED IN FY2011/12@@@-@@8/1/2006@-@-@@-@-@@@II@II@@-@-@RESULTS PENDING (recruiting).@-@@@@COMBO@-@CETUXIMAB@@@@-|CETUXIMAB|||@EISAI@@@@@EISAI||||@@@@@@|||||||||@Solid Tumours@Colorectal Cancer@@@@Solid Tumours|Colorectal Cancer||||||||@E-7820@ERBITUX@@@@E-7820|ERBITUX|||@TK Inhibitor@Angiogenesis Inhibitor@VEGF@FGF@@TK Inhibitor|Angiogenesis Inhibitor|VEGF|FGF|@COMPLETE RESPONSE@PARTIAL RESPONSE@RECIST@@@RECIST@@@@@ADVANCED@@@@@NON-RANDOMISED@OPEN-LABEL@HISTORICAL CONTROL@SINGLE-ARM@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
14922357@Onco@@@@@@@@@@@Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent. [clinicaltrials.gov]@@-@-@-@NEW YORK, NEW YORK@4/1/2009@@This is an irreversible pan-ERBB inhibitor. PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo. Additionally, PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers. @@14922357@Phase 1/2 Trial To Determine The Recommended Phase 2 Dose And Evaluate The Efficacy Of Pf 00299804 In Patients In Korea With Kras Wild Type Advanced NSCLC Which Is Refractory To Chemotherapy And Erlotinib Or Gefitinib@@-@-@@NO REVIEW@@@@-@-@-@NCT00553254@80@-@-@@@-@@1/1/2008@-@A7471003@@-@>> Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib. Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment. @@@I/II@II@@-@-@Trial registered. [Pfizer, 02.11.2008]@-@@@@MONO@DACOMITINIB@@@@@DACOMITINIB||||@PFIZER@@@@@PFIZER||||@South Korea@@@@@South Korea|||||||||@NSCLC@@@@@NSCLC|||||||||@PF-299804@@@@@PF-299804||||@TK Inhibitor@EGFR@@@@TK Inhibitor|EGFR|||@RECIST@MAXIMUM TOLERATED DOSE@@@@PROGRESSION-FREE SURVIVAL@OVERALL SURVIVAL@SAFETY@@@KRAS WILD-TYPE@REFRACTORY@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14924982@Onco@@@@@@@@@@@Gemcitabine (1250mg/m2 IV), cisplatin (75mg/m2 IV) +/- Nexavar (400mg po bid)@@L01XE05@L01X@-@LEVERKUSEN, GERMANY@@@Sorafenib is a multikinase inhibitor that decreases tumour cell proliferation in vitro. Sorafenib inhibits tumour growth of a broad spectrum of human tumour xenografts in athymic mice accompanied by a reduction of tumour angiogenesis. Sorafenib inhibits the activity of targets present in the tumour cell (CRAF, BRAF, V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature (CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß). RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases. @@14924982@Stage IIIb with effusion and Stage IV NSCLC@@-@-@@NO REVIEW@@@@-@Bayer Schering and Onyx have global co-development rights for Nexavar except Japan, where Bayer Schering has exclusive rights.@FIRST-LINE@NCT00449033@350@-@-@@@-@@2/1/2007@-@12006@@DECEMBER 2010 (NCE); DECEMBER 2012 (ORPHAN); JUNE 2022 (EXTENSION)@-@@@EUDRACT 2006-002688-26 / @III@@-@-@RESULTS PENDING (recruiting)@-@@@@COMBO@SORAFENIB TOSYLATE@GEMCITABINE@CISPLATIN@@@SORAFENIB TOSYLATE|GEMCITABINE|CISPLATIN||@BAYER HEALTHCARE@@@@@BAYER HEALTHCARE||||@@@@@@|||||||||@NSCLC@@@@@NSCLC|||||||||@NEXAVAR@GEMZAR@@@@NEXAVAR|GEMZAR|||@TK Inhibitor@VEGF@PDGF@Angiogenesis Inhibitor@@TK Inhibitor|VEGF|PDGF|Angiogenesis Inhibitor|@PROGRESSION-FREE SURVIVAL@@@@@@@@@@ADVANCED@@@@@RANDOMISED@DOUBLE-BLIND@PLACEBO-CONTROLLED@PARALLEL ASSIGNMENT@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
14922474@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@NRX 195183 30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation with Arsenic Trioxide 0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles. @@-@-@-@-@5/1/2011@@@@14922474@Previously untreated APL@@-@-@@NO REVIEW@@@@-@-@-@NCT00670150@45@-@@@@EMEA'S COMP issues positive opinion to grant ORPHAN DRUG status for CLL treatment@@5/1/2008@-@9L-07-12@@-@-@@@II@II@@-@-@RESULTS PENDING@-@@@@COMBO@-@ARSENIC TRIOXIDE@@@@-|ARSENIC TRIOXIDE|||@NURX@@@@@NURX||||@@@@@@|||||||||@Haematological Malignancy@Acute Myeloid Leukaemia@@@@Haematological Malignancy|Acute Myeloid Leukaemia||||||||@NRX-195183@TRISENOX@@@@NRX-195183|TRISENOX|||@Retinoid@@@@@Retinoid||||@RESPONSE RATE@@@@@@@@@@-@@@@@NON-RANDOMISED@OPEN-LABEL@SINGLE-ARM@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
15046566@Onco@@@@@300f1020ntsdm@@@@@@-@@L03AA14@L03A@-@PETACH TIKVA, ISRAEL@@@Lonquex (lipegfilgrastim) is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) based on novel GlycoPEGylation technology. Lipegfilgrastim is a novel, pegylated and glycosylated long-acting form of filgrastim, intended for once-per-cycle fixed dose, subcutaneous injection for neutrophil support in patients receiving myelosuppressive chemotherapy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). [Teva]@@15046566@-@@NO@-@@NO REVIEW@@@@100%@-@-@-@-@-@EMA, 8 August 2013@8/8/2013@@-@@@-@-@No@-@-@@@-@APPROVED@@@SSN@NO LABELLED TRIAL@-@@@@-@LIPEGFILGRASTIM@@@@@LIPEGFILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@LONQUEX@@@@@LONQUEX||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1229@820.37@1353.94@857.3@@@@@@@@@@136.73@@@@@@@@@@@@@@@@6/7/2017@820.37@820.37@42919011@INJECTION SOLUTION PREFILLED SYRINGE - 0.6 ML@EURO@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@119@Italy@@@@@@@@
15046565@Onco@@@@@300f1037ntsdm@@@@@@@@L03AA14@L03A@@PETACH TIKVA, ISRAEL@@@Lonquex (lipegfilgrastim) is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) based on novel GlycoPEGylation technology. Lipegfilgrastim is a novel, pegylated and glycosylated long-acting form of filgrastim, intended for once-per-cycle fixed dose, subcutaneous injection for neutrophil support in patients receiving myelosuppressive chemotherapy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). [Teva]@@15046565@@@YES@@@NO REVIEW@@@@@@@@@@EMA, 8 August 2013@8/8/2013@8/1/2014@@@@@@No@@@@@@APPROVED@@@SNS@NO LABELLED TRIAL@@@@@@LIPEGFILGRASTIM@@@@@LIPEGFILGRASTIM||||@TEVA PHARMACEUTICAL@@@@@TEVA PHARMACEUTICAL||||@@@@@@|||||||||@Supportive Care@Neutropaenia@@@@Supportive Care|Neutropaenia||||||||@LONQUEX@@@@@LONQUEX||||@Immunotherapy@G-CSF@@@@Immunotherapy|G-CSF|||@@@@@@@@@@@@@@@@@@@@@@@Invalid Dosage Value Phase 1@@@@@@@@@1@1.1511@772@861.03@779.54@@@@@@@@@@128.67@@@@@@@@@@@@@@@@8/4/2017@772@772@699375@INJECTION SOLUTION PREFILLED SYRINGE - 0.6 ML@EURO@@@@@@@@6@MG@@@@@@@@@@@@@@@@@@@@@@@@@217@Spain@@@@@@@@
14924482@Onco@@@@@300f1228ntsdm@300f1226ntsdm@300f1224ntsdm@300f1230ntsdm@300f1223ntsdm@@-@@-@-@-@PARIS, FRANCE@@@@@14924482@-@@-@-@@NO REVIEW@@@@-@-@-@-@-@-@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@EMEA issued positive opinion on Orphan Drug designation for alvocidib@@@-@-@@-@-@@@III@III@@-@-@RESULTS PENDING@-@@@@-@ALVOCIDIB@@@@@ALVOCIDIB||||@SANOFI-AVENTIS@@@@@SANOFI-AVENTIS||||@@@@@@|||||||||@Haematological Malignancy@Chronic Lymphocytic Leukaemia@@@@Haematological Malignancy|Chronic Lymphocytic Leukaemia||||||||@HMR-1275@@@@@HMR-1275||||@TK Inhibitor@@@@@TK Inhibitor||||@-@@@@@@@@@@-@@@@@-@@@@@@@Invalid Factory Price@@@@@-@-@@@@-@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@-@@@-@US$@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@244@United States@@@@@@@@
